

DESCRIPTION

TITLE OF INVENTION

TIM PROTEIN-BOUND CARRIER, METHODS FOR OBTAINING, REMOVING
5 AND DETECTING EXTRACELLULAR MEMBRANE VESICLES AND VIRUSES
USING SAID CARRIER, AND KIT INCLUDING SAID CARRIER

TECHNICAL FIELD

[0001]

10 The present invention relates to a Tim protein-binding carrier, a method for obtaining, removing and detecting extracellular membrane vesicles and viruses using the carrier, as well as a kit comprising the carrier.

BACKGROUND ART

15 [0002]

It has been known that the extracellular membrane vesicles contain proteins or nucleic acids, such as microRNAs, and the like, inside of the particles, and are responsible for transferring substances between cells. The extracellular membrane vesicles are secreted also into body fluids, such as blood, and the like,
20 and proteins, microRNAs, and the like, in the extracellular membrane vesicles have been noticed as diagnostic markers for diseases. In addition, application of the extracellular membrane vesicles as a delivery tool of nucleic acid medicines has also been noticed.

[0003]

25 In addition, there are many enveloped viruses covered with a membrane-like envelope on the surface of the viruses. Many enveloped viruses, such as influenza virus, human immunodeficiency virus, and the like, have been noticed as research subjects, since they cause diseases. In addition, the enveloped viruses are detoxified and utilized for vaccines, vectors, and the like,

and they have been applied in prevention and treatment of diseases.

[0004]

In this way, a process for obtaining the extracellular membrane vesicles or the enveloped viruses in high purity is indispensable, in the utilization of the extracellular membrane vesicles for diagnosis and medicines, in the utilization of the enveloped viruses as the vaccines and the vectors, and in carrying out basic research, or the like, of functional analysis, or the like, of the extracellular membrane vesicles or the enveloped viruses, and thus a means for obtaining the extracellular membrane vesicles or the enveloped viruses easily and conveniently, as well as in high purity has long been awaited. In addition, development of a method for efficiently removing the extracellular membrane vesicles or the enveloped viruses from materials derived from body fluid to be used has been expected, to prevent contamination of the extracellular membrane vesicles or the enveloped viruses derived from living organisms. Furthermore, a method for detecting the obtained extracellular membrane vesicles or the enveloped viruses, or the extracellular membrane vesicles or the enveloped viruses in a specimen in high sensitivity has also long been awaited.

[0005]

As a method for obtaining the extracellular membrane vesicles, there has been known, as the most common method, a method in which a sample is subjected to ultracentrifugal separation treatment to obtain the extracellular membrane vesicles as a precipitate fraction (NON-PATENT LITERATURE 1). However, with this method, it is difficult to obtain the highly pure extracellular membrane vesicles, because protein complexes or aggregates, lipoproteins, such as HDL, and the like, contained in a sample are also co-precipitated, other than the extracellular membrane vesicles. Although it is possible to separate the protein complexes or the aggregates by density fractionation of the precipitate fraction obtained by the ultracentrifugal separation treatment by a sucrose density gradient method, it is difficult to separate them from the HDL having the same

density. In addition, it is difficult to process multiple samples at the same time, since this method requires ultracentrifugal separation treatment. In addition, expensive equipment is required for ultracentrifugal separation treatment.

[0006]

5 In addition, there is also a method for obtaining the extracellular membrane vesicles, as a precipitated fraction, by centrifugal separation treatment by the addition of a commercial reagent, represented by ExoQuick (produced by System Biosciences Co., Ltd.) or Total Exosome Isolation Reagent (produced by Thermo Fisher Scientific Co., Ltd.) (NON-PATENT LITERATURE 1), however, there is a
10 problem that purity of the resulting extracellular membrane vesicles is further lower as compared with a method by the ultra-centrifugal separation treatment.

[0007]

In addition to these conventional methods, there are methods for obtaining the extracellular membrane vesicles by affinity of a surface antigenic protein and
15 an antibody, using the antibody against the surface antigenic protein of the extracellular membrane vesicles (an anti-CD63 antibody immobilization method, Exosome-Human CD63 Isolation/Detection (produced by Thermo Fisher Scientific, Inc.), and the like.) (NON-PATENT LITERATURE 1). These methods have such problems that only the extracellular membrane vesicles having the
20 surface antigenic protein for the antibody can be obtained; yield of the extracellular membrane vesicles is small; it is difficult to obtain the extracellular membrane vesicles in an intact state (that is, while maintaining an original state of function of the extracellular membrane vesicles) because it is necessary to use a surfactant, an acidic buffer, or the like, in order to elute the extracellular membrane
25 vesicles from the antibody; and the like, although the high purity extracellular membrane vesicles can be obtained.

[0008]

As a method for obtaining the viruses, there has been known, as the most general method, a method for subjecting a sample to ultracentrifugal separation

treatment to obtain the viruses, as the precipitate fraction (NON-PATENT LITERATURE 1). However, in this method, it is difficult to obtain the high purity viruses, because the protein complexes and the aggregates, the lipoproteins, such as HDL, and the like, contained in the sample are co-precipitated other than the viruses. Although it is possible to separate the protein complexes or the aggregates by density fractionation of the precipitate fraction obtained by the ultracentrifugal separation treatment, by a sucrose density gradient method, it is difficult to separate them from the aggregates having the same density. In addition, there is also a problem that activity of the viruses is lowered by the ultracentrifugal separation treatment (NON-PATENT LITERATURE 2). In addition, this method is difficult to process multiple specimens at the same time, because it requires the ultracentrifugal separation treatment. In addition, an expensive machine is required for the ultracentrifugal separation treatment.

[0009]

Other than these methods, there has been known a method for purifying the viruses by ion-exchange chromatography, (NON-PATENT LITERATURE 3). However, this method requires setting optimum condition for each of the viruses. In addition, condition setting may be difficult, in some cases, and thus it is difficult to apply it to purification of all viruses.

[0010]

As a method for removing the extracellular membrane vesicles, there has been known, as the most general method, a method for subjecting the sample to the ultra-centrifugal separation treatment to precipitation fractionate the extracellular membrane vesicles to obtain the supernatant fraction as a removal sample. However, this method has difficulty in complete removal of the extracellular membrane vesicles, thus resulting in remaining of the extracellular membrane vesicles not completely removed, in the sample.

[0011]

Furthermore, there is also a method for precipitation fractioning the

extracellular membrane vesicles, by the centrifugal separation treatment and the addition of a commercial reagent, represented by ExoQuick (produced by System Biosciences Co., Ltd.) or Total Exosome Isolation Reagent (produced by Thermo Fisher Scientific Co., Ltd.) to obtain the supernatant fraction as the removal sample. However, in also this method, there was difficulty to completely remove the extracellular membrane vesicles, due to remaining of the extracellular membrane vesicles not completely removed, in the sample. In addition, there was the case of inducing a problem on bioactivity, or the like, of the extracellular membrane vesicles, by the reagent, because of contamination of the reagent added into the sample.

There has been known the same method also as a method for removing the viruses and there was the same problem as in the method for removing the extracellular membrane vesicles.

[0012]

As a method for detecting the extracellular membrane vesicles, there has been known, as a general method, a sandwich ELISA using the antibody against the surface antigen of the extracellular membrane vesicles. However, the minimum detection sensitivity of the sandwich ELISA system using the antibody that detects an ordinary color development signal has been reported to be about 3 µg in purified exosomes, and sufficient sensitivity for measuring a body fluid sample, such as serum, has not been obtained (NON-PATENT LITERATURE 4). The same method has been known, also as the method for detecting the viruses, and sufficient sensitivity for detection of the viruses has also not been obtained.

[0013]

In addition, as the other method for detecting the extracellular membrane vesicles, a flow cytometry method has been known. However, in the usual method for capturing the extracellular membrane vesicles using a carrier to which the antibody against the surface antigen of the extracellular membrane vesicles was immobilized, sufficient sensitivity has not been obtained; and thus direct

detection from the sample, such as culture supernatant or body fluid, has been difficult, and the detection from the sample after concentrating or purifying the extracellular membrane vesicles has been required.

5 CITATION LIST

NON-PATENT LITERATURE

[0014]

[NON-PATENT LITERATURE 1] Kenneth W. Witwer et al. Journal of Extracellular Vesicles, 2013 May 27; 2. doi: 10.3402

10 [NON-PATENT LITERATURE 2] G.Y. Chen et al. Biotechnol. Prog. 25 (2009), 1669

[NON-PATENT LITERATURE 3] Petra Gerster et al. Journal of Chromatography A, 1290 (2013), 36-45

[NON-PATENT LITERATURE 4] Mariantonia Logozzi et al. PLoS ONE 4 (2009) ,
15 5219

SUMMARY OF INVENTION

TECHNICAL PROBLEM

[0015]

20 As described above, the conventional methods for obtaining the extracellular membrane vesicles or the viruses have difficulty in obtaining the highly pure extracellular membrane vesicles or the viruses in an intact state, simply and conveniently, as well as efficiently. In addition, with the conventional methods for removing the extracellular membrane vesicles or the viruses, it is
25 difficult to efficiently remove the extracellular membrane vesicles or the viruses in the sample. Furthermore, the conventional methods for detecting the extracellular membrane vesicles or the viruses have not achieved sufficient sensitivity.

[0016]

Therefore, an object of the present invention is to obtain or remove the extracellular membrane vesicles or the viruses present in the sample in high purity, and in an intact state, simply and conveniently, as well as efficiently, and detect the extracellular membrane vesicles or the viruses in high sensitivity.

5

SOLUTION TO PROBLEM

[0017]

The present invention has been made to solve the problems, and has the following constitution:

- 10 1. A carrier (a Tim carrier) on which a protein (a Tim protein) selected from a T-cell immunoglobulin and mucin domain-containing molecule-4 (a Tim-4) protein, a T-cell immunoglobulin and mucin domain-containing molecule-3 (a Tim-3) protein, and a T-cell immunoglobulin and mucin domain-containing molecule-1 (a Tim-1) protein, is bound.
- 15 2. A method for obtaining an extracellular membrane vesicle or a virus in a sample, comprising the following steps:
 - (1) a step for forming a complex of the Tim protein bound to the carrier, and the extracellular membrane vesicle or the virus in the sample, in the presence of a calcium ion (complex formation step),
 - 20 (2) a step for separating the complex from the sample (complex separation step),
 - (3) a step for separating the extracellular membrane vesicle or the virus from the complex to obtain the extracellular membrane vesicle or the virus (obtaining step).
3. A method for removing an extracellular membrane vesicle or a virus in a sample, comprising the following steps:
 - 25 (1) a step for forming the complex of the Tim protein bound to the carrier, and the extracellular membrane vesicle or the virus in the sample in the presence of the calcium ion (complex formation step),
 - (2) a step for separating the complex and the sample (complex separation step).
4. A method for detecting an extracellular membrane vesicle or a virus in the

sample, comprising the following steps:

(1) a step for forming the complex of the Tim protein bound to the carrier, and the extracellular membrane vesicle or the virus in the sample, in the presence of the calcium ion (complex formation step),

5 (2) a step for detecting the complex (detection step).

5. A kit for capturing an extracellular membrane vesicle or a virus comprising the Tim carrier.

6. A kit for capturing an extracellular membrane vesicle or a virus comprising a reagent containing the Tim protein and a reagent containing the carrier.

10 [0018]

In view of the above circumstances, the present inventors have discovered, as a result of intensive studies, that the extracellular membrane vesicles or the viruses having phosphatidylserine on the surface can be obtained in high purity, that the extracellular membrane vesicles or the viruses can be obtained in an
15 intact state, that the extracellular membrane vesicles or the viruses can be efficiently removed, and that they can be detected in high sensitivity, by using at least one kind of a protein selected from the Tim-1 protein, the Tim-3 protein and the Tim-4 protein, and have thus completed the present invention.

[0019]

20

Phosphatidylserine, which is a phospholipid, is present (exposed) on the surface of the extracellular membrane vesicles. As a protein having binding capability to phosphatidylserine (hereinafter it may be abbreviated as “the phosphatidylserine-binding protein” or “the PS proteins”, in some cases), there has been known, for example, Annexin V, MFG-E8, the Tim-1 (the T-cell immunoglobulin and mucin domain-containing molecule-1, the T-cell immunoglobulin-mucin-domain 1), the Tim-1 (the T-cell immunoglobulin and mucin domain-containing molecule-1, the T-cell immunoglobulin-mucin-domain-1) protein, the Tim-3 (the T-cell immunoglobulin and mucin domain-containing molecule-3, the T-cell immunoglobulin-mucin-domain-3) protein, the Tim-4 (the
25

T-cell immunoglobulin and mucin domain-containing molecule-4, the T-cell immunoglobulin-mucin-domain-4) protein, or the like (The Journal of Biochemistry 265, 4923-4928 (25 March, 1990), Nature 417, 182-187 (9 May, 2002), Nature 450, 435-439 (15 November, 2007).

5 However, it has been revealed that it is difficult to obtain, remove or detect the extracellular membrane vesicles or the viruses, when the PS proteins other than the Tim-1 protein, the Tim-3 protein and the Tim-4 protein are used, among these PS proteins.

10 ADVANTAGEOUS EFFECTS OF INVENTION

[0020]

 According to the present invention, the extracellular membrane vesicles or the viruses present in the sample can be obtained or removed in high purity, or in an intact state, simply and conveniently, as well as efficiently, and can be detected
15 in high sensitivity.

BRIEF DESCRIPTION OF DRAWINGS

[0021]

Fig. 1 is an electropherogram for confirming whether the extracellular membrane
20 vesicles were obtained or not, by Western blotting, in Examples 1 to 8.

Fig. 2 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 9 to 16.

Fig. 3 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 17 to 18.

25 Fig. 4-A is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 19 to 20, and Comparative Examples 1 to 3, and Fig. 4-B is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by silver staining, in Examples 19 to 20, and Comparative Examples 1 to 3.

Fig. 5 is a drawing where the extracellular membrane vesicles, obtained by the method of the present invention, were observed using an electron microscope, in Example 21.

Fig. 6 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 22 to 25.

Fig. 7 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by silver staining, in Examples 26 to 27, and Comparative Examples 4 to 9.

Fig. 8 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 28 to 33.

Fig. 9 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 34 to 35, and Comparative Examples 10 to 13.

Fig. 10 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 36 to 38.

Fig. 11 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 39 to 40.

Fig. 12 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained (removed) or not, by Western blotting, in Examples 41 to 47.

Fig. 13 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained (removed) or not, by Western blotting, in Examples 48 to 55.

Fig. 14 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 56 to 67, and Comparative Examples 14 to 15.

Fig. 15 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 68 to 79.

Fig. 16 is an electropherogram for confirming whether the extracellular membrane

vesicles were obtained or not, by Western blotting, in Examples 80 to 83, and Comparative Examples 16 to 19.

Fig. 17 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 84 to 95, and Comparative Examples 20 to 21.

Fig. 18 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 96 to 99, and Comparative Examples 22 to 25.

Fig. 19 is detection result of the extracellular membrane vesicles by an ELISA method, in Examples 100 to 105, and Comparative Examples 26 to 33.

Fig. 20 is detection result of the extracellular membrane vesicles by the ELISA method, in Examples 106 to 109.

Fig. 21 is detection result of the extracellular membrane vesicles by the ELISA method, in Examples 110 to 115, and Comparative Examples 34 to 39.

Fig. 22 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 116 to 119.

Fig. 23 is detection result of the extracellular membrane vesicles by a flow cytometry method, in Examples 120 to 121, and Comparative Examples 40 to 41.

Fig. 24 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 122 to 123, and Comparative Examples 42 to 43

Fig. 25 is an electropherogram for confirming whether the extracellular membrane vesicles were obtained or not, by Western blotting, in Examples 124 to 125, and Comparative Examples 44 to 45.

DESCRIPTION OF EMBODIMENTS

[0022]

<1. Extracellular membrane vesicle pertaining to the present invention>

The extracellular membrane vesicle pertaining to the present invention is the small-sized membrane vesicle secreted from in vivo cells or cultured cells, composed of a lipid bilayer membrane, and having phosphatidylserine on the membrane surface thereof. Diameter of the vesicle is usually 20 nm to 1000 nm, preferably 50 nm to 500 nm, and more preferably 50 nm to 200 nm.

[0023]

The extracellular membrane vesicle pertaining to the present invention include those classified variously depending on origin of its generation and size of the small-sized membrane vesicle, and the like, as described in Nature Reviews Immunology 9, 581-593 (August, 2009), "Obesity Study" Vol. 13, No. 2, 2007, topics by Naoto Aoki et al. Specifically, there are included Exosomes, micro-vesicles, Ectosomes, Membrane particles, Exosome-like vesicles, Apoptotic vesicles, Adiposome, and the like.

[0024]

Exosome is the small-sized membrane vesicle derived from late endosome composed of the lipid bilayer membrane, and having phosphatidylserine on the membrane surface thereof. Diameter of the vesicle is usually 50 nm to 200 nm, preferably 50 nm to 150 nm, and more preferably 50 nm to 100 nm. Exosome is known to contain proteins, such as tetraspanins, CD 63, CD 9, and the like, Alix, TSG 101, Lamp-1, Flotillin, and the like.

[0025]

The micro-vesicle is the small-sized membrane vesicle derived from a cell membrane (plasma membrane), composed of the lipid bilayer membrane, and having phosphatidylserine on the membrane surface thereof. The micro-vesicle is usually 100 nm to 1000 nm, preferably 100 nm to 800 nm, and more preferably 100 nm to 500 nm. The micro-vesicle is known to contain proteins, such as integrin, selectin, CD40 ligands, and the like.

[0026]

Ectosome is the small-sized membrane vesicle derived from the cell

membrane (plasma membrane), composed of the lipid bilayer membrane, and having phosphatidylserine on the membrane surface thereof. Ectosome is usually 50 nm to 200 nm, preferably 50 nm to 150 nm, and more preferably 50 nm to 100 nm. Ectosome is known to contain CR1, a proteolytic enzyme, but does not contain CD63.

[0027]

The membrane particle is the small-sized membrane vesicle derived from the cell membrane (plasma membrane), composed of the lipid bilayer membrane, and having phosphatidylserine on the membrane surface thereof. The membrane particle is usually 50 nm to 80 nm. It is known that the membrane particle contains CD133 but does not contain CD63.

[0028]

The exosome-like vesicle is the small-sized membrane vesicle derived from the early endosome, composed of the lipid bilayer, and having phosphatidylserine on the membrane surface thereof. The exosome-like vesicle is usually 20 nm to 50 nm. The exosome-like vesicle is known to contain TNFRI.

[0029]

The apoptotic vesicle is the small-sized membrane vesicle derived from the apoptotic cell, composed of the lipid bilayer, and having phosphatidylserine on the membrane surface thereof. The apoptotic vesicle is usually 50 nm to 500 nm, preferably 50 nm to 300 nm, and more preferably 50 nm to 200 nm. The apoptotic vesicle is known to contain histones.

[0030]

Adiposome is the small-sized membrane vesicle derived from the adipocyte, composed of the lipid bilayer membrane, and having phosphatidylserine on the membrane surface thereof. The adiposome is usually 100 nm to 1000 nm, preferably 100 nm to 800 nm, and more preferably 100 nm to 500 nm. The adiposome is known to contain MFG-E8 (milk fat globule-EGF factor 8).

[0031]

< 2. Virus pertaining to the present invention >

The virus pertaining to the present invention has an envelope composed of the lipid bilayer membrane derived from a cell membrane, a nuclear membrane, a Golgi apparatus, an endoplasmic reticulum, or the like, of a host cell as a capsid (outer shell) of the virus, and has phosphatidylserine on the surface of the envelope (hereinafter referred to as “the enveloped virus”). Diameter of the virus pertaining to the present invention is usually 20 nm to 320 nm. The enveloped virus pertaining to the present invention includes the virus having an envelope, belonging to a family described in the Biochemical Dictionary 2nd edition, Tokyo Kagaku Dojin, 1990, 1503p-1505p. Specifically, there are included Poxviridae, Baculoviridae, Rhabdoviridae, Bunyaviridae, Togaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae, Retroviridae, Arenaviridae, Coronaviridae, and the like.

[0032]

< 3. Tim protein pertaining to the present invention >

The Tim protein pertaining to the present invention is at least one kind of the Tim protein selected from the T-cell immunoglobulin and mucin domain-containing molecule-1 (the Tim-1) protein pertaining to the present invention (hereinafter it may be abbreviated as “the Tim-1 protein pertaining to the present invention”, in some cases), the T-cell immunoglobulin and mucin domain-containing molecule-3 (the Tim-3) protein pertaining to the present invention (hereinafter it may be abbreviated as “the Tim-3 protein pertaining to the present invention”, in some cases), and the T-cell immunoglobulin and mucin domain-containing molecule-4 (the Tim-4) protein pertaining to the present invention (hereinafter it may be abbreviated as “the Tim-4 protein pertaining to the present invention”, in some cases).

[0033]

The Tim-4 (the T-cell immunoglobulin and mucin domain-containing

molecule-4) protein pertaining to the present invention may be any protein capable of binding to the extracellular membrane vesicles or the viruses pertaining to the present invention, and the Tim-4 protein derived from an animal is preferable. Among these, the Tim-4 protein of human or a mouse is preferable
5 (hereinafter, the Tim-4 protein of human may be abbreviated as “the human-derived Tim-4 protein”, and the Tim-4 protein of mouse may be abbreviated as “the mouse-derived Tim-4 protein”, in some cases).

More specifically, it may be the one, as long as having at least an amino acid sequence of the binding domain (IgV domain) for phosphatidylserine, and it
10 may be the one having a full-length amino acid sequence of the Tim-4 protein, or a part of the amino acid sequence of the Tim-4 protein.

The amino acid sequence of the binding domain (IgV domain) for phosphatidylserine includes, for example, SEQ ID NO: 1 (N-terminal 22 to 135 amino acid region (RefSeq NP_848874.3) of the mouse-derived Tim-4 protein),
15 SEQ ID NO: 2 (N-terminal 25 to 137 amino acid region (RefSeq NP_612388.2) of the human-derived Tim-4 protein), or the like.

The full-length amino acid sequence of the Tim-4 protein includes SEQ ID NO: 3 (full-length sequence of the mouse-derived Tim-4 protein 1 to 343 amino acid region (RefSeq NP_848874.3)), SEQ ID NO: 4 (full length sequence of the
20 human-derived Tim-4 protein 1 to 378 amino acid region (RefSeq NP_612388.2)), or the like.

A part of the Tim-4 protein includes those having the amino acid sequence of the binding domain (IgV domain) for phosphatidylserine and the mucin domain, such as SEQ ID NO: 5 (N-terminal 22 to 273 amino acid region of the
25 mouse-derived Tim-4 protein (RefSeq NP_848874.3)), SEQ ID NO: 6 (N-terminal 22 to 279 amino acid region of the mouse-derived Tim-4 protein (RefSeq NP_848874.3)), SEQ ID NO: 7 (N-terminal 25 to 315 amino acid region of the human-derived Tim-4 protein (RefSeq NP_612388.2)), or the like. These sequences may have a signal sequence, as needed.

[0034]

The Tim-1 (the T-cell immunoglobulin and mucin domain-containing molecule-1) protein pertaining to the present invention may be any protein, as long as capable of binding to the extracellular membrane vesicles or the viruses
5 pertaining to the present invention, and the Tim-1 protein derived from an animal is preferable. Among these, the Tim-1 protein of human or mouse is preferable (hereinafter, sometimes the Tim-1 protein of human is abbreviated as “the human-derived Tim-1 protein” and the Tim-1 protein of mouse is abbreviated as “the mouse-derived Tim-1 protein”).

10 More specifically, it may be the one, as long as having at least the amino acid sequence of the binding domain (IgV domain) for phosphatidylserine, and it may be the one having a full-length amino acid sequence of the Tim-1 protein, or a part of the Tim-1 protein.

The amino acid sequence of the binding domain (IgV domain) for
15 phosphatidylserine include, for example, SEQ ID NO: 8 (N-terminal 22 to 131 amino acid region (RefSeq NP_001160104.1) of the mouse-derived Tim-1 protein, SEQ ID NO: 9 (N-terminal 21 to 130 amino acid region (RefSeq NP_036338.2), or the like.

The full-length amino acid sequence of the Tim-1 protein includes SEQ ID
20 NO: 10 (full-length sequence 1 to 282 amino acid region of the mouse-derived Tim-1 protein (RefSeq NP_001160104.1)), SEQ ID NO: 11 (full length sequence of the human-derived Tim-1 protein 1 to 364 amino acid region (RefSeq NP_036338.2)), or the like.

A part of the Tim-1 protein includes those having the amino acid sequence
25 of the binding domain (IgV domain) for phosphatidylserine and the mucin domain, such as SEQ ID NO: 12 (N-terminal 22 to 212 amino acid region of the mouse-derived Tim-1 protein (RefSeq NP_001160104.1)), SEQ ID NO: 13 (N-terminal 21 to 295 amino acid region of the human-derived Tim-1 protein (RefSeq NP_612388.2), or the like. These sequences may have the signal

sequence, as needed.

[0035]

The Tim-3 (the T-cell immunoglobulin and mucin domain-containing molecule-3) protein pertaining to the present invention may be any protein, as long as capable of binding to the extracellular membrane vesicles or the viruses pertaining to the present invention, and the Tim-3 protein derived from an animal is preferable. Among these, the Tim-3 protein of human or mouse is preferable (hereinafter, the Tim-3 protein of human is abbreviated as “the human-derived Tim-3 protein”, and the Tim-3 protein of mouse is abbreviated as “the mouse-derived Tim-3 protein”, in some cases).

More specifically, it may be the one, as long as having at least the amino acid sequence of the binding domain (IgV domain) for phosphatidylserine, and it may be the one having a full-length amino acid sequence of the Tim-3 protein, or a part of the Tim-3 protein.

The amino acid sequence of the binding domain (IgV domain) for phosphatidylserine include, for example, SEQ ID NO: 14 (N-terminal 22 to 134 amino acid region (RefSeq NP_599011.2) of the mouse-derived Tim-3 protein), SEQ ID NO: 15 (N-terminal 22 to 135 amino acid region (RefSeq NP_116171.3) of the human-derived Tim-3 protein), or the like.

The full-length amino acid sequence of the Tim-3 protein includes SEQ ID NO: 16 (full-length sequence 1 to 281 amino acid region of the mouse-derived Tim-3 protein (RefSeq NP_599011.2)), SEQ ID NO: 17 (full length sequence of the human-derived Tim-3 protein 1 to 301 amino acid region (RefSeq NP_116171.3)), or the like.

A part of the Tim-3 protein includes those having the amino acid sequence of the binding domain (IgV domain) for phosphatidylserine and the mucin domain, such as SEQ ID NO: 18 (N-terminal 22 to 189 amino acid region of the mouse-derived Tim-3 protein (RefSeq NP_599011.2)), SEQ ID NO: 19 (N-terminal 22 to 200 amino acid region of the human-derived Tim-3 protein

(RefSeq NP_116171.3), or the like. These sequences may have the signal sequence, as needed.

[0036]

In addition, the Tim protein pertaining to the present invention may be a mutant of the above amino acid sequences, in which one or more amino acids are deleted, substituted, inserted and/or added, as long as it is capable of binding to the extracellular membrane vesicles or the viruses pertaining to the present invention.

[0037]

The Tim protein pertaining to the present invention may be the one, as long as having properties as described above, and may be the one extracted from cells (for example, immune cells, such as macrophages) or tissues of living organisms having the Tim protein, such as animals including the mouse and the human, or plants, and the like, and the one prepared by genetic recombination technology based on this, or the like, and any of them can be used.

[0038]

In using the Tim protein pertaining to the present invention prepared by genetic recombination technology, those having one or more affinity tags are preferable, from the viewpoint of simplicity of purification.

[0039]

The affinity tags may be any tags, as long as being used in preparation of a protein by genetic recombination technology, and include the affinity tags, for example, Fc tag, FLAG tag, His tag, GST tag, MBP tag, HA tag, Myc tag, Strep (II) tag, PA tag, and the like.

[0040]

The affinity tags are fused to the C-terminal side of the Tim protein pertaining to the present invention.

[0041]

Therefore, the Tim protein pertaining to the present invention includes not

only a protein consisting only of the amino acid sequence of the Tim protein (full length or partial sequence) but also a protein having the amino acid sequence (full length or partial sequence) of the Tim protein and the amino acid sequence of the affinity tag, as described above.

5 In addition, the affinity tag and the Tim protein may be bound directly to each other, or may be bound via a spacer as described in "Protein Expression using a cell-free protein synthesis reagent kit, Transdirect insect cell, derived from insect cultured cells", Toru Ezure, Takashi Suzuki, Masaaki Ito, Masamitsu Shikata (Shimadzu Seisakusho, Analytical Measurement Division), publication date
10 2008/6/9: Protein Science Foundation Archive, 1, e005 (2008)", or the like. Therefore, the Tim protein pertaining to the present invention also includes a protein having the amino acid sequence (full length or partial sequence) of the Tim protein, and the amino acid sequence of the affinity tag as described above, and the amino acid sequence of the spacer.

15 [0042]

<4. Preparation method for Tim protein pertaining to the present invention>

The Tim protein pertaining to the present invention can be produced by a general chemical production method, in accordance with the amino acid sequence thereof. The Tim protein pertaining to the present invention can be
20 obtained by a usual chemical production method (chemical synthesis method), for example, a fluorenylmethyloxycarbonyl method (Fmoc method), a t-butyloxycarbonyl method (t-Boc method), or the like. In addition, it can be chemically synthesized also, using a commercially available peptide synthesizer.

[0043]

25 Furthermore, the Tim protein pertaining to the present invention can also be obtained by a well-known method using the genetic recombination technique, such that a nucleic acid molecule encoding the Tim protein pertaining to the present invention is incorporated into an expression vector, such as an appropriate plasmid or phage, the host cell is transformed (transduced) using the

recombinant expression vector, and the resulting host cell is proliferated to secrete the Tim protein inside of the cell or outside of the cell.

[0044]

Explanation will be given below on the preparation method for the Tim protein pertaining to the present invention, for the case of preparation by the genetic recombination technology.

[0045]

< Expression vector pertaining to the present invention >

The expression vector for expressing the Tim protein pertaining to the present invention (hereinafter, it is referred to as the expression vector pertaining to the present invention) may be any one, as long as it contains the nucleic acid sequence encoding the Tim protein pertaining to the present invention (hereinafter, it may be abbreviated as "Tim coding sequence pertaining to the present invention", in some cases).

15 [0046]

Among the Tim coding sequences pertaining to the present invention, the nucleic acid sequence encoding the Tim-4 protein includes, for example, SEQ ID NO: 20 (the nucleotide sequence of cDNA encoding the full-length sequence 1 to 343 amino acid region of the mouse-derived Tim-4 protein (RefSeq No. NM_178759.4), and containing a stop codon (tga) at the terminal 3 nucleotides), SEQ ID NO: 21 (nucleotide sequence of cDNA encoding the full-length sequence 1 to 378 amino acid region of the human-derived Tim-4 protein (RefSeq No. NM_138379.2), and containing the stop codon (taa) at the terminal 3 nucleotides), or the like.

25 The nucleic acid sequence encoding the Tim-1 protein pertaining to the present invention includes, for example, SEQ ID NO: 22 (the nucleotide sequence of cDNA encoding the full-length sequence 1 to 282 amino acid region of the mouse-derived Tim-1 protein (RefSeq No. NM_001166632.1), containing the stop codon (tga) at the terminal 3 nucleotides), SEQ ID NO: 23 (the nucleotide

sequence of cDNA encoding the full-length sequence 1 to 364 amino acid region of the human-derived Tim-1 protein (RefSeq No. NM_012206.3), containing the stop codon (taa) at the terminal 3 nucleotides), or the like.

The nucleic acid sequence encoding the Tim-3 protein pertaining to the present invention includes, for example, SEQ ID NO: 24 (the nucleotide sequence of cDNA encoding the full-length sequence 1 to 281 amino acid region of the mouse-derived Tim-3 protein (RefSeq No. NM_134250.2), containing the stop codon (tga) at the terminal 3 nucleotides), SEQ ID NO: 25 (the nucleotide sequence of the cDNA encoding the full-length sequence 1 to 301 the amino acid region of the human derived Tim-3 protein (RefSeq No. NM_032782.4), containing the stop codon (tag) at the terminal 3 nucleotides), or the like.

[0047]

For the expression vector pertaining to the present invention, the Tim-coding sequence pertaining to the present invention may be gene introduced into a commercially available vector, according to a conventional cloning method. The expression vector pertaining to the present invention includes, for example, an expression vector, such as a commercially available pCAG-Neo vector (produced by Wako Pure Chemical Industries, Ltd.), or the like, into which is incorporated SEQ ID NO: 26 (cDNA encoding the N-terminal 1 to 273 amino acid region of the mouse-derived Tim-4 protein, containing the stop codon (tga) at the terminal 3 nucleotides), SEQ ID NO: 27 (cDNA encoding the N-terminal 1 to 279 amino acid region of the mouse-derived Tim-4 protein, containing the stop codon (tga) at the terminal 3 nucleotides), SEQ ID NO: 28 (cDNA encoding the N-terminal 1 to 315 amino acid region of the human-derived Tim-4 protein, containing the stop codon (tga) at the terminal 3 nucleotides), SEQ ID NO: 29 (cDNA encoding the N terminal 1 to 212 amino acid region of the mouse-derived Tim-1 protein, containing the stop codon (tga) at the terminal 3 nucleotides), SEQ ID NO: 30 (cDNA encoding the N-terminal 1 to 295 amino acid region of the human-derived Tim-1 protein, containing the stop codon (tga) at the terminal 3

nucleotides), SEQ ID NO: 31 (cDNA encoding N-terminal 1 to 189 amino acid region of the mouse-derived Tim-3 protein, containing the stop codon (tga) at the terminal 3 nucleotides), or SEQ ID NO: 32 (cDNA encoding N-terminal 1 to 200 amino acid region of the human-derived Tim-3 protein, containing the stop codon (tga) at the terminal 3 nucleotides), in accordance with the conventional cloning technique. As the vector into which the Tim coding sequence is gene introduced, any vector may be used, as long as it has function of expressing and producing the Tim protein pertaining to the present invention in the host cell, and it is convenient to use commercially available vectors. The commercially available vectors used for this purpose include pCAG-Neo vector, pcDNA vector, and the like, when the host is an animal cell.

[0048]

<Host>

As the host, anyone can be used, as long as it is capable of expressing the Tim protein pertaining to the present invention, and includes Escherichia coli, insect cells, mammalian cells, plant cells, yeast cells, or the like, and the mammalian cells are preferable. The mammalian cells include, for example, HEK 293T cell, COS-7 cell, CHO-K1 cell, CHO-S cell, and the like.

[0049]

<Introduction of gene into host>

The expression vector pertaining to the present invention is gene introduced into the host, according to a usual method of the technique of gene introducing the vector into the host, described in "Protein expression protocol that can be selected depending on each purpose, Chapter 3, Protein expression protocol, ISBN 978-4-7581-0175-2, Yodosha Co., Ltd.", or the like.

[0050]

< Culture of host>

The host after carrying out gene introduction is cultured, according to a usual method for culturing the host. Culture condition varies depending on the

host into which the gene has been introduced, but may be in accordance with a usual method for each host. For example, when it is an animal cell, the cell may be cultured for 1 day to 10 days, and preferably 3 days to 4 days, under conditions of usually 5 to 10% CO₂, preferably 5 to 8% CO₂, usually at 36°C to 38°C, preferably at 36.5°C to 37.5°C. It should be noted that, the Tim protein pertaining to the present invention is expressed and secreted in the culture supernatant, since it does not contain a transmembrane domain and an intracellular domain.

[0051]

< Purification of Tim Protein pertaining to the present invention >

A culture supernatant filtrate may be obtained by subsequently subjecting a culture solution of the resulting gene-introduced host to centrifugal separation treatment (usually at 200 to 400 × G for 3 minutes to 10 minutes, and preferably at 300 × G for 3 minutes to 6 minutes) to recover a culture supernatant, and subjecting, as needed, the recovered culture supernatant to (i) centrifugal separation treatment usually at 1000 to 2000 × G for 20 minutes to 60 minutes, and preferably at 1200 × G for 20 minutes to 40 minutes, and/or to (ii) filtration treatment to separate impurities.

Further, a concentrated culture supernatant filtrate may be obtained by concentration of the resulting culture supernatant filtrate usually 5 times to 20 times, and preferably 8 times to 12 times, according to a usual method, such as ultrafiltration, or the like, as needed.

Next, when the Tim protein pertaining to the present invention has the affinity tag, the Tim protein (a fusion protein of the Tim protein and the affinity tag) pertaining to the present invention may be purified from the resulting culture supernatant, from the resulting culture supernatant filtrate, or from the resulting concentrated solution of the culture supernatant filtrate, according to a usual method for protein purification utilizing the affinity tag (for example, a method for using a carrier on which a substance having affinity to the affinity tag is immobilized) for each tag, described in "Protein expression protocol that can be

selected depending on each purpose, Chapter 3 Protein expression protocol, Section 6, Purification of protein purification by a tag, ISBN 978-4-7581-0175-2, Yodosha Co., Ltd.”, or the like.

When the Tim protein pertaining to the present invention does not have the affinity tag, the Tim protein pertaining to the present invention may be purified by various kinds of chromatography, from the resulting culture supernatant, from the resulting culture supernatant filtrate, or from the resulting concentrated solution of the culture supernatant filtrate, according to a usual method of protein purification, described in “Protein expression protocol that can be selected depending on each purpose, Chapter 3, Protein expression protocol, Section 6, Purification of protein Purification by chromatography, ISBN 978-4-7581-0175 -2, Yodosha Co., Ltd.”, or the like.

Purification may be carried out by appropriately combining the above purification methods.

[0052]

<Specific preparation method for Tim protein pertaining to the present invention>

As a specific preparation method for the Tim protein pertaining to the present invention, for example, when a Fc tag is used as the affinity tag, the following method is included. First, according to a usual method, the Tim coding sequence pertaining to the present invention is incorporated into a pEF-Fc vector or a commercially available vector to construct the expression vector pertaining to the present invention. Subsequently, the expression vector pertaining to the present invention is gene introduced into the host cell, according to a usual method to culture for 1 day to 10 days, and preferably 3 days to 4 days, under conditions of usually 5 to 10% CO₂, preferably 5 to 8% CO₂, at 36°C to 38°C, preferably 36.5°C to 37.5°C. The culture supernatant filtrate is obtained by subsequently subjecting the resulting culture solution of the gene-introduced host to a centrifugal separation treatment (usually at 200 to 400 × G for 3 minutes to 10 minutes, and preferably at 300 × G for 3 minutes to 6 minutes) to recover the

culture supernatant, and by subjecting, as needed, the recovered culture supernatant to (i) centrifugal separation treatment usually at 1000 to 2000 × G for 20 minutes to 60 minutes, and preferably at 1200 × G for 20 minutes to 40 minutes, and/or to (ii) filtration treatment to separate impurities. Further, the concentrated solution of the culture supernatant filtrate is obtained by concentration, as needed, of the resulting culture supernatant filtrate usually 5 times to 20 times, and preferably 8 times to 12 times, according to a usual method, such as ultrafiltration, or the like. After that, when the Tim protein pertaining to the present invention has the affinity tag, the Tim protein pertaining to the present invention can be obtained by purifying the Tim protein pertaining to the present invention from the resulting culture supernatant, the resulting culture supernatant filtrate, or the resulting concentrated solution of the culture supernatant filtrate, in accordance with a usual method for purification utilizing affinity of respective affinity tags.

[0053]

<5. Tim carrier of the present invention>

A carrier on which the Tim protein of the present invention is bound (hereafter it may be abbreviated as “the Tim carrier of the present invention”, in some cases) is the one where the Tim protein pertaining to the present invention is bound on the carrier pertaining to the present invention.

Specifically, the Tim carrier of the present invention includes a carrier on which the Tim-1 protein pertaining to the present invention is bound (hereafter it may be abbreviated as “the Tim-1 carrier of the present invention”, in some cases), a carrier on which the Tim-3 protein pertaining to the present invention is bound (hereafter it may be abbreviated as “the Tim-3 carrier of the present invention”, in some cases), a carrier on which the Tim-4 protein pertaining to the present invention is bound (hereafter it may be abbreviated as “the Tim-4 carrier of the present invention”, in some cases), or the like. In addition, a carrier on which two or more kinds of proteins selected from the Tim-1 protein pertaining to the present

invention, Tim-3 protein pertaining to the present invention, and Tim-4 protein pertaining to the present invention are bound is also encompassed in the Tim carrier of the present invention.

As the Tim carrier of the present invention, the Tim-4 carrier of the present invention is particularly preferable.

[0054]

<Carrier pertaining to the present invention>

As the carrier pertaining to the present invention, any carrier can be used as long as it is an insoluble carrier used in usual immunological assay, and includes an organic substance, such as, polystyrene, polyacrylic acid, polymethacrylic acid, polymethyl methacrylate, polyacryl amide, polyglycidyl methacrylate, polypropylene, polyolefin, polyimide, polyurethane, polyester, polyvinyl chloride, polyethylene, polychlorocarbonate, a silicone resin, silicone rubber, agarose, dextran, an ethylene-maleic anhydride copolymer, or the like; an inorganic substance, such as glass, silicon oxide, diatomaceous earth, porous glass, obscured glass, alumina, silica gel, a metal oxide, or the like; a magnetic substance, such as iron, cobalt, nickel, magnetite, chromite, or the like; and those prepared using alloys of these magnetic substances as raw materials. In addition, these carriers may be used in a wide variety of forms, such as a microplate, a tube, a disk-like piece, particles (the beads), and the like.

It should be noted that it is preferable to use as particles (the beads), when used in the obtaining method of the present invention, and the removing method of the present invention, to be described later, and particle size is not especially limited, however, there is included the one having usually 10 nm to 100 μ m, and preferably 100 nm to 10 μ m, according to objects and the applications.

In addition, the particles (the beads) or the microplate are preferable when used in the detection method of the present invention, to be described later, and particle size is not especially limited and includes the one having usually 10 nm to 100 μ m, and preferably 100 nm to 10 μ m, according to the objects and the

applications. In addition, number and size of a well of the microplate are not especially limited, and include the one having usually 12 holes to 1536 holes, and preferably 96 holes to 384 holes, according to the objects and the applications.

[0055]

- 5 <Binding method for Tim protein pertaining to the present invention and carrier pertaining to the present invention>

The binding method for the Tim protein pertaining to the present invention and the carrier pertaining to the present invention may be in accordance with a method known per se for binding a protein to a carrier, and the method includes,
10 for example, a binding method by affinity binding; a binding method by chemical binding (for example, a method described in JP No. 3269554, WO 2012/039395); a binding method by physical adsorption (for example, a method described in JP-B-05-41946), or the like, and the binding method by affinity binding and the binding method by physical adsorption are preferable.

- 15 It should be noted that the binding method by affinity binding is preferable, when used in the obtaining method and the removing method of the present invention to be described later. In addition, the binding method by the affinity binding, or physical adsorption is preferable, when used in the detection method of the present invention, to be described later.

20 [0056]

<Binding form of Tim protein pertaining to the present invention and carrier pertaining to the present invention>

- Binding form of the Tim protein pertaining to the present invention and the carrier pertaining to the present invention is not limited, as long as the carrier
25 pertaining to the present invention and the Tim protein pertaining to the present invention are bound, however, the one in which the carrier pertaining to the present invention binds to an SH group of the Tim protein pertaining to the present invention is preferable. In addition, the Tim protein pertaining to the present invention and the carrier pertaining to the present invention may be bound either

by direct binding, or indirect binding via a chemical linker, an affinity substance [for example, a substance having affinity to an affinity-tag (to be described later), an antibody against the Tim protein pertaining to the present invention, biotins (to be described later), avidins (to be described later), an antibody, or the like], or the like.

[0057]

<Method for binding by affinity binding>

The method for binding by affinity binding may be any one, as long as it is a method for binding by utilization of affinity binding (affinity) between substances, and includes, for example, the following (a) to (c):

(a) Method for binding by affinity binding of biotins and avidins.

The Tim protein pertaining to the present invention and the carrier pertaining to the present invention can be bound, via the affinity substances, by using two or more kinds of substances (affinity substances) having affinity each other, comprising a combination of, for example, biotins (biotin, iminobiotin, desthiobiotin, biocytin, biotin sulfoxide, and the like) and avidins (avidin, tamavidin, tamavidin 2, and the like), and the like.

It should be noted that either one of the affinity substances may be bound to the Tim protein pertaining to the present invention, and the remaining one may be bound to the carrier pertaining to the present invention, however, it is general, for example, that the avidins are bound to the carrier pertaining to the present invention, and biotins are bound to the Tim protein pertaining to the present invention, when biotins and avidins are used.

(b) Method for binding by affinity binding of the affinity tag and a substance having affinity to the affinity tag.

The Tim protein pertaining to the present invention and the carrier pertaining to the present invention can be bound, via the affinity substance by using the substance having affinity to the Tim protein pertaining to the present invention (the affinity substance), for example, the substance having affinity to the

affinity tag (Protein A, Protein G, or the like).

It should be noted that the affinity substance is generally bound to the carrier pertaining to the present invention.

(c) Method for binding by affinity binding of the antibody against the Tim protein of
5 the present invention and the Tim protein of the present invention.

The Tim protein pertaining to the present invention and the carrier
pertaining to the present invention can be bound, via the affinity substance, by
using the substance which has affinity to the Tim protein pertaining to the present
invention (the affinity substance), for example, an antibody against the Tim protein
10 pertaining to the present invention (an antibody against the affinity tag, such as an
anti-FLAG tag antibody, an anti-His tag antibody, an anti-HA tag antibody, an
anti-Myc tag antibody, an anti-MBP tag antibody, an anti-GST tag antibody, an
anti-Strep (II) tag antibody, or the like; and an anti-Tim 4 antibody (clone RMT
4-54) (produced by LifeSpan Biosciences Inc.), or the like), or the like.

15 It should be noted that the affinity substance is generally bound to the
carrier pertaining to the present invention.

[0058]

It should be noted that also as for a method for binding the Tim protein
pertaining to the present invention and/or the carrier pertaining to the present
20 invention, and the affinity substance, in the above method, a method for binding
by physical adsorption, or a method for binding by chemical bonding, known per
se, can be used, and the binding may be carried out directly or indirectly via a
linker, or the like.

[0059]

25 < Amount of Tim protein pertaining to the present invention to be bound on carrier
pertaining to the present invention >

Amount of the Tim protein pertaining to the present invention to be bound
on the carrier pertaining to the present invention is, for example, when the carrier
pertaining to the present invention is the beads, usually 0.1 µg to 50 µg, preferably

0.5 µg to 30 µg, and more preferably 1.0 µg to 20 µg, relative to 1 mg of the carrier.

In addition, when the carrier pertaining to the present invention is the microplate, it is usually 0.1 µg to 10 µg, preferably 0.2 µg to 5 µg, and more preferably 0.5 µg to 2 µg, relative to 1 well.

[0060]

<Specific preparation methods for Tim carrier of the present invention>

Explanation will be given below on specific preparation methods for the Tim carrier of the present invention, taking the cases of preparation of the Tim carrier of the present invention, by the methods (a) to (c), as examples.

[0061]

< (a) Method for binding by affinity binding of biotins and avidins >

First of all, in the method (a), the Tim protein pertaining to the present invention is prepared, according to the preparation method for the Tim protein pertaining to the present invention. Next, the Tim protein pertaining to the present invention-biotins complex is formed by binding the Tim protein pertaining to the present invention and biotins (hereinafter, it may be abbreviated as “biotin labelling” or “biotinylation”, in some cases). On the other hand, the carrier pertaining to the present invention-avidins complex is formed, by binding avidins to the carrier pertaining to the present invention (hereinafter, it may be abbreviated as “the carrier pertaining to the present invention bound with avidins”, in some cases). The Tim carrier of the present invention is obtained, by bringing into contacted the resulting Tim protein pertaining to the present invention-biotins complex, and the carrier pertaining to the present invention-avidins complex, to bind biotins in the Tim protein pertaining to the present invention-biotins complex, and avidins in the carrier pertaining to the present invention-avidins complex.

[0062]

-Binding of Tim protein pertaining to the present invention and biotins (Biotin labelling)-

In the method (a), binding of the Tim protein pertaining to the present invention and biotins may be carried out by using a commercially available biotin labelling-kit, or according to a usual method of biotin labelling of a protein, by appropriately adjusting reagents required. A method for using the commercially available biotin labelling-kit of the protein (Biotinylation kit) may be in accordance with a method described in a protocol attached to Biotin Labeling Kit-SH (manufactured by Dojindo Molecular Technologies, Inc.), or Biotin Labeling Kit-NH₂ (manufactured by Dojindo Molecular Technologies, Inc.).

[0063]

Amount of biotins to be bound with 1μg of the Tim protein pertaining to the present invention is usually 10 ng to 1.0 μg, preferably 20 ng to 200 ng, and more preferably 30 ng to 150 ng.

[0064]

A site for binding biotins to the Tim protein pertaining to the present invention is preferably an SH group of the Tim protein pertaining to the present invention.

[0065]

- Carrier pertaining to the present invention-avidins complex (carrier of the present invention bound with avidins)-

As the carrier pertaining to the present invention-avidins complex (the carrier pertaining to the present invention bound with avidins), in the method (a), commercially available one may be used, or it may be prepared in accordance with a usual method by appropriately adjusting reagents required. The carrier pertaining to the present invention-avidins complex includes, for example, the beads or the microplate bound with avidin; the beads or the microplate bound with tamavidin; the beads or the microplate bound with tamavidin 2; the beads or the microplate bound with streptavidin, or the like; and the commercially available one includes Dynabeads M-270 Streptavidin C1 (manufactured by Thermo Fisher Scientific, Inc.), FGbeads Streptavidin (manufactured by Tamagawa Seiki Co.,

Ltd.), Avidin plate (manufactured by Sumitom Bakelite Co., Ltd.), or the like.

[0066]

Amount of avidins to be brought into contacted with 1 mg of the carrier pertaining to the present invention is usually 5.0 to 150 μg , preferably 10 to 100 μg , and more preferably 20 to 50 μg , when the carrier pertaining to the present invention is, for example, the beads, in binding of the carrier pertaining to the present invention and avidins. Amount of avidins to be brought into contacted to 1 well is usually 0.1 μg to 10 μg , preferably 0.2 μg to 5 μg , and more preferably 0.5 μg to 2 μg , when the carrier pertaining to the present invention is, for example, the microplate.

[0067]

-Binding of carrier pertaining to the present invention-avidins complex, and Tim protein pertaining to the present invention-biotins complex -

To obtain the Tim carrier of the present invention (by binding the carrier pertaining to the present invention-avidins complex, and the Tim protein pertaining to the present invention-biotins complex), in the method (a), usually 0.1 mg to 10 mg, preferably 0.3 mg to 5.0 mg, and more preferably 0.5 to 3.0 mg of the carrier pertaining to the present invention-avidins complex, and usually 1.0 to 50 μg , preferably 1.0 to 30 μg , and more preferably 1.0 to 20 μg of the Tim protein pertaining to the present invention-biotins complex, relative to 1 mg of the carrier pertaining to the present invention-avidins complex, may be brought into contacted, when the carrier pertaining to the present invention is, for example, the beads; in addition, the carrier pertaining to the present invention-avidins complex, relative to 1 well, and usually 1.0 to 10 μg , preferably 1.0 to 5.0 μg , and more preferably 1.0 to 2.0 μg of the Tim protein pertaining to the present invention-biotins complex may be brought into contacted, when the carrier pertaining to the present invention is the microplate, and then subjected to a reaction at usually 4.0 $^{\circ}\text{C}$ to 37 $^{\circ}\text{C}$, preferably 11 $^{\circ}\text{C}$ to 30 $^{\circ}\text{C}$, and more preferably 20 $^{\circ}\text{C}$ to 25 $^{\circ}\text{C}$, for usually 0.5 hour to 24 hours, preferably 0.5 hour to 8.0 hours,

and more preferably 0.5 hour to 2.0 hours to bind avidins and biotins. In this way, the carrier pertaining to the present invention-avidins complex, and the Tim protein pertaining to the present invention-biotins complex are bound to obtain the Tim carrier of the present invention.

5 [0068]

It should be noted that contact of the carrier pertaining to the present invention-avidins complex, and the Tim protein pertaining to the present invention-avidins complex is generally carried out by bringing into contacted a solution containing the Tim protein pertaining to the present invention-biotins complex, and the carrier pertaining to the present invention-avidins complex.

[0069]

The solution for containing the Tim protein pertaining to the present invention-biotins complex may be any solution, as long as it is capable of dissolving the Tim protein pertaining to the present invention-biotins complex in a stable state, and includes for example, purified water, a buffer solution which has buffer action, for example, at pH 7.0 to 8.0, and preferably 7.2 to 7.6 (for example, PBS, TBS, HBS or the like). In addition, buffer agent concentration in these buffer solutions is appropriately selected from a range of usually 5.0 to 50 mM, and preferably 10 to 30 mM, and NaCl concentration is appropriately selected from a range of usually 100 to 200 mM, and preferably 140 to 160 mM. In addition, for example, saccharides, salts, such as NaCl, and the like, a surfactant, a preservative, a protein, or the like, may be contained in this solution, as long as in such an amount that does not inhibit binding of the carrier pertaining to the present invention-avidins complex, and the Tim protein pertaining to the present invention-biotins complex, after contacting the carrier pertaining to the present invention-avidins complex, and the solution containing the Tim protein pertaining to the present invention-biotins complex. The surfactant includes, for example, Tween 20, or the like, and surfactant concentration in the solution for containing the Tim protein pertaining to the present invention-biotins complex is usually

0.00001 to 0.2 %, and preferably 0.0005 to 0.1 %. It should be noted that the solution dissolving the Tim protein pertaining to the present invention-biotins complex in these solvents may be abbreviated as "the Tim protein pertaining to the present invention-biotins complex-containing solution", in some cases.

5 [0070]

- Specific preparation method for Tim carrier of the present invention by method (a) -

A specific preparation method for the Tim carrier of the present invention by the method (a) may be carried out, for example, by the following method.

10 First of all, the Tim protein pertaining to the present invention is prepared, according to the preparation method for the Tim protein pertaining to the present invention. Next, the Tim protein pertaining to the present invention-biotins complex is formed by binding biotins to the Tim protein pertaining to the present invention, according to an attached protocol in the Biotin Labeling Kit-SH
15 (manufactured by Dojindo Molecular Technologies, Inc.), the Biotin Labeling Kit-NH₂ (manufactured by Dojindo Molecular Technologies, Inc.), or a usual method in biotin labelling of the protein.

After that, when the carrier pertaining to the present invention is the beads, the Tim carrier of the present invention is obtained, by bringing into contacted
20 usually 0.1 mg to 10 mg, preferably 0.3 mg to 5.0 mg, and more preferably 0.5 to 3.0 mg of the carrier pertaining to the present invention-avidins complex, and usually 50 μ L to 1500 μ L, preferably 100 μ L to 1000 μ L, and more preferably 200 μ L to 500 μ L of a solution containing usually 1.0 to 50 μ g, preferably 1.0 to 30 μ g, and more preferably 1.0 to 20 μ g of the Tim protein pertaining to the present
25 invention-biotins complex (a solution containing the Tim protein pertaining to the present invention-biotins complex, for example, in purified water, or in buffer solution, or the like, which has buffer action at pH 7.0 to 8.0, and preferably 7.2 to 7.6), relative to 1 mg of the carrier pertaining to the present invention-avidins complex, and then subjecting them to a reaction at usually 4.0°C to 37°C,

preferably 11 °C to 30 °C, and more preferably 20 °C to 25 °C, for usually 0.5 hour to 24 hours, preferably 0.5 hour to 8.0 hours, and more preferably 0.5 hour to 2.0 hours, to bind avidins in the carrier pertaining to the present invention-avidins complex, and biotins in the Tim protein pertaining to the present invention-biotins complex.

When the carrier pertaining to the present invention is the microplate, the Tim carrier of the present invention is obtained by bringing into contacted the carrier pertaining to the present invention-avidins complex, relative to 1 well, and usually 50μL to 300μL, preferably 50 μL to 200 μL, more preferably 100 μL to 200 μL of a solution containing usually 1.0 to 10 μg, preferably 1.0 to 5.0 μg, and more preferably 1.0 to 2.0 μg of the Tim protein pertaining to the present invention-biotins complex (a solution containing the Tim protein pertaining to the present invention-biotins complex, for example, in purified water, or in a buffer solution, or the like, which has buffer action at pH 7.0 to 8.0, and preferably 7.2 to 7.6), and then subjecting them to a reaction at usually 4.0°C to 37°C, preferably 11 °C to 30 °C, and more preferably 20 °C to 25 °C, usually for 0.5 hour to 24 hours, preferably 0.5 hour to 8.0 hours, and more preferably 0.5 hour to 2.0 hours, to bind avidins in the carrier pertaining to the present invention-avidins complex, and biotins in the Tim protein pertaining to the present invention-biotins complex.

[0071]

< (b) Method for binding by affinity binding of affinity-tag, and substance having affinity to affinity-tag >

In the method of (b), first of all, the Tim protein pertaining to the present invention having the affinity-tag is prepared, according to the preparation method for the Tim protein pertaining to the present invention. On the other hand, the carrier pertaining to the present invention-the affinity substance complex (hereinafter, it may be abbreviated as “the carrier pertaining to the present invention bound with the affinity substance”, in some cases) is formed, by binding the substance having affinity to the affinity-tag (the affinity substance) to the carrier

pertaining to the present invention. The Tim carrier of the present invention is obtained by bringing into contacted the resulting carrier pertaining to the present invention-affinity substance complex, and the Tim protein pertaining to the present invention having the affinity-tag to bind the affinity substance in the carrier
5 pertaining to the present invention-the affinity substance complex, and the affinity-tag in the Tim protein pertaining to the present invention having the affinity-tag, and to bind the carrier pertaining to the present invention-affinity substance complex, and the Tim protein pertaining to the present invention having the affinity-tag.

10 [0072]

- Carrier pertaining to the present invention-affinity substance complex -

As the carrier pertaining to the present invention-the affinity substance complex in the method (b), the commercially available one may be used, or it may be prepared, according to a usual method by appropriately adjusting reagents
15 required. The carrier pertaining to the present invention-the affinity substance complex includes, for example, the beads or the microplate bound with Protein G, the beads or the microplate bound with Protein A, or the like, and the commercially available one includes, Dynabeads Protein G (manufactured by Thermo Fisher Scientific Co.), Dynabeads Protein A (manufactured by Thermo
20 Fisher Scientific Co.), FG beads Protein G (manufactured by Tamagawaseiki Co. Ltd.), FG beads Protein A (manufactured by Tamagawaseiki Co. Ltd.), or the like.

[0073]

Amount of the affinity substance to be brought into contacted with 1 mg of the carrier pertaining to the present invention, in binding of the carrier pertaining to
25 the present invention and the affinity substance, is usually 5.0 to 50 μ g, preferably 10 to 50 μ g, and more preferably 20 to 50 μ g, when the carrier pertaining to the present invention is the beads. Amount of the affinity substance to be brought into contacted with 1 well is usually 0.1 μ g to 10 μ g, preferably 0.2 μ g to 5 μ g, and more preferably 0.5 μ g to 2 μ g, when the carrier pertaining to the present

invention is the microplate.

[0074]

- Binding of carrier pertaining to the present invention-affinity substance complex, and Tim protein pertaining to the present invention having affinity-tag -

5 In the method (b), for example, the following method may be carried out to obtain the Tim carrier of the present invention (by binding the carrier pertaining to the present invention-affinity substance complex, and the Tim protein pertaining to the present invention having the affinity-tag). The Tim carrier of the present invention is obtained by bringing into contacted usually 0.1 mg to 10 mg, preferably 0.3 mg to 5.0 mg, and more preferably 0.5 to 3.0 mg of the carrier
10 pertaining to the present invention-affinity substance complex, and usually 1.0 to 50 µg, preferably 1.0 to 30 µg, and more preferably 1.0 to 20 µg of the Tim protein pertaining to the present invention having the affinity-tag, relative to 1mg of the carrier pertaining to the present invention-affinity substance complex, when the
15 carrier pertaining to the present invention is the beads; and by bringing into contacted the carrier pertaining to the present invention-affinity substance complex, relative to 1 well, and usually 1.0 to 10 µg, preferably, 1.0 to 5.0 µg, and more preferably 1.0 to 2.0 µg of the Tim protein pertaining to the present invention having the affinity-tag, when the carrier pertaining to the present invention is the
20 microplate, and by subjecting them to a reaction at usually 4.0°C to 37°C, preferably 11°C to 30°C, more preferably 20°C to 25°C, for usually 0.5 hour to 24 hours, preferably 0.5 hour to 8.0 hours, more preferably 0.5 hour to 2.0 hours, to bind the carrier pertaining to the present invention-affinity substance complex, and the Tim protein pertaining to the present invention having the affinity-tag.

25 [0075]

 It should be noted that contact of the carrier pertaining to the present invention-the affinity substance complex, and the Tim protein pertaining to the present invention having the affinity-tag, in the method (b), is generally carried out by bringing into contacted the carrier pertaining to the present invention-the affinity

substance complex, and a solution containing the Tim protein pertaining to the present invention having the affinity-tag.

[0076]

The solution for containing the Tim protein pertaining to the present invention having the affinity tag may be any solution, as long as capable of dissolving the Tim protein pertaining to the present invention having the affinity-tag, in a stable state, and includes for example, purified water, or a buffer solution which has buffer action, for example, at pH 7.0 to 8.0, and preferably 7.2 to 7.6 (for example, PBS, TBS, HBS or the like). In addition, buffer agent concentration in these buffer solutions is appropriately selected from a range of usually 5.0 to 50 mM, and preferably 10 to 30 mM, and NaCl concentration is appropriately selected from a range of usually 100 to 200 mM, and preferably 140 to 160 mM.

In addition, for example, saccharides, salts, such as NaCl, and the like, a surfactant, a preservative, a protein, or the like, may be contained in this solution, as long as in such an amount that does not inhibit binding of the Tim protein pertaining to the present invention having the affinity-tag, and the carrier pertaining to the present invention-the affinity-substance complex, after contacting the solution containing the Tim protein pertaining to the present invention having the affinity-tag, and the carrier pertaining to the present invention-the affinity substance complex. The surfactant includes, for example, Tween 20, or the like, and surfactant concentration in the solution for containing the Tim protein pertaining to the present invention having the affinity-tag, is usually 0.00001 to 0.2 %, and preferably 0.0005 to 0.1 %. It should be noted that the solution dissolving the Tim protein pertaining to the present invention having the affinity-tag, in these solutions, may be abbreviated as “the Tim protein pertaining to the present invention having the affinity-tag-containing solution”, in some cases.

[0077]

-Specific preparation method for Tim carrier of the present invention by method (b)

-

A specific preparation method for the Tim carrier of the present invention in the method (b) may be carried out, for example, by the following method.

First of all, the Tim protein pertaining to the present invention having the affinity-tag is prepared, according to the preparation method for the Tim protein
5 pertaining to the present invention.

Next, when the carrier pertaining to the present invention is the beads, the Tim carrier of the present invention is obtained by bringing into contacted usually 0.1 mg to 10 mg, preferably 0.3 mg to 5.0 mg, and more preferably 0.5 to 3.0 mg of the carrier pertaining to the present invention-the affinity substance complex,
10 and usually 50 μ L to 1500 μ L, preferably 100 μ L to 1000 μ L, and more preferably 200 μ L to 500 μ L of the solution containing usually 1.0 to 50 μ g, preferably 1.0 to 30 μ g, and more preferably 1.0 to 20 μ g of the Tim protein pertaining to the present invention having the affinity-tag (the solution containing the Tim protein pertaining to the present invention having the affinity-tag, for example, in purified
15 water, or in the buffer solution at pH 7.0 to 8.0, or the like), relative to 1 mg of the carrier pertaining to the present invention-the affinity substance complex, and are subjected them to a reaction at usually 4.0°C to 37°C, preferably 11°C to 30°C, and more preferably 20°C to 25°C, for usually 0.5 hour to 24 hours, preferably 0.5 hour to 8.0 hours, and more preferably 0.5 hour to 2.0 hours, to bind the affinity
20 substance in the carrier pertaining to the present invention-the affinity substance complex, and the affinity-tag in the Tim protein pertaining to the present invention having the affinity-tag.

When the carrier pertaining to the present invention is the microplate, the Tim carrier of the present invention is obtained by bringing into contacted the
25 carrier pertaining to the present invention-the affinity substance complex, relative to 1 well, and usually 50 μ L to 300 μ L, preferably 50 μ L to 200 μ L, and more preferably 100 μ L to 200 μ L of the solution containing 1.0 to 10 μ g, preferably 1.0 to 5.0 μ g, and more preferably 1.0 to 2.0 μ g of the Tim protein pertaining to the present invention having the affinity-tag pertaining to the present invention (the

solution containing the Tim protein pertaining to the present invention-biotins complex, for example, in purified water, or the buffer solution, or the like, which has buffer action at pH 7.0 to 8.0, and preferably 7.2 to 7.6), and are subjected them to a reaction at usually 4.0°C to 37°C, preferably 11°C to 30°C, and more preferably 20°C to 25°C, for usually 0.5 hour to 24 hours, preferably 0.5 hour to 8.0 hours, and more preferably 0.5 hour to 2.0 hours, to bind the affinity substance in the carrier pertaining to the present invention-the affinity substance complex, and the affinity-tag in the Tim protein pertaining to the present invention having the affinity-tag.

10 [0078]

<(C) Method for binding by affinity binding of antibody against Tim protein of the present invention and Tim protein of the present invention>

[0079]

First of all, the Tim protein pertaining to the present invention is prepared, according to the preparation method for the Tim protein pertaining to the present invention. On the other hand, an antibody against the Tim protein pertaining to the present invention (hereinafter it may be abbreviated as “the anti-Tim antibody”, in some cases) is bound to the carrier pertaining to the present invention to form a carrier pertaining to the present invention-anti-Tim antibody complex. The Tim carrier of the present invention is obtained by bringing into contacted the resulting carrier pertaining to the present invention-anti-Tim antibody complex, and the Tim protein pertaining to the present invention to bind the antibody against the Tim protein in the carrier pertaining to the present invention-anti-Tim antibody complex, and the Tim protein pertaining to the present invention.

25 It should be noted that, in the above description, when the Tim protein having the affinity tag (a protein having the amino acid sequence of the Tim protein and the amino acid sequence of the affinity tag) is used as the Tim protein pertaining to the present invention, as the anti-Tim antibody, either an antibody recognizing the Tim protein (an antibody recognizing a protein portion, based on

the amino acid sequence of the Tim protein), or an antibody recognizing the affinity tag (an antibody recognizing a protein portion, based on the amino acid sequence of the affinity tag) may be used. In addition, when the Tim protein not having the affinity tag (a protein consisting only of the amino acid sequence of the Tim protein) is used as the Tim protein pertaining to the present invention, as the anti-Tim antibody, an antibody that recognizes the Tim protein (an antibody that recognizes a protein portion, based on the amino acid sequence of the Tim protein) may be used.

[0080]

- 10 - Carrier pertaining to the present invention-anti-Tim antibody complex (the carrier pertaining to the present invention to which antibody is bound) -

In the method (c), as the carrier pertaining to the present invention-anti-Tim antibody complex, a commercially available one may be used, or it may be prepared, according to a usual method by arranging necessary reagents appropriately. The carrier pertaining to the present invention-anti-Tim antibody complex includes, for example, the beads or the microplates to which an anti-Fc tag antibody is bound, the beads or the microplates to which an anti-FLAG tag antibody is bound, the beads or the microplates to which an anti-His tag antibody is bound, the beads or the microplates to which an anti-GST tag is bound, the beads or the microplates to which an anti-MBP tag is bound, the beads or the microplates to which an anti-HA tag is bound, the beads or the microplates to which an anti-Myc tag is bound, the beads or the microplates to which an anti-Strep (II) tag is bound, the beads or the microplates to which an antibody against an anti-Tim protein is bound, or the like, and as a commercially available one, the anti-DYKDDDDK tag antibody magnetic beads (produced by Wako Pure Chemical Industries, Ltd.), or the like, is included.

[0081]

The origin of the anti-Tim antibody is not especially limited. In addition, either polyclonal antibodies or monoclonal antibodies may be used, and the

monoclonal antibodies are preferable. In addition, as the anti-Tim antibody, a commercially available one may be used, or it may be prepared according to a usual method by arranging necessary reagents appropriately. Specific examples of the anti-Tim antibody are as described above.

5 [0082]

Amount of the antibody, relative to the Tim protein pertaining to the present invention, to be brought into contacted with 1 mg of the carrier pertaining to the present invention, is usually 5.0 to 50 μ g, preferably 10 to 50 μ g, and more preferably 20 μ g to 50 μ g, when the obtaining method of the present invention and
10 the removing method of the present invention are used, when the carrier pertaining to the present invention is the beads, in binding of the carrier pertaining to the present invention and the anti-Tim antibody. When the carrier pertaining to the present invention is the microplate, it is usually 0.1 μ g to 10 μ g, preferably 0.2 μ g to 5 μ g, and more preferably 0.5 μ g to 2 μ g, relative to 1 well.

15 [0083]

-Binding of carrier pertaining to the present invention-anti-Tim antibody complex and Tim protein pertaining to the present invention

A method for obtaining the Tim carrier of the present invention, by binding of the carrier pertaining to the present invention-the anti-Tim antibody complex,
20 and the Tim protein pertaining to the present invention, in the method (c), includes, for example, the following methods. That is, when the carrier pertaining to the present invention is the beads, the Tim carrier of the present invention is obtained by bringing into contacted usually 0.1 mg to 10 mg, preferably 0.3 mg to 5.0 mg, and more preferably 0.5 to 3.0 mg of the carrier pertaining to the present
25 invention-the anti-Tim antibody complex, and usually 1.0 to 50 μ g, preferably 1.0 to 30 μ g, and more preferably 1.0 to 20 μ g of the Tim protein pertaining to the present invention, relative to 1 mg of the carrier pertaining to the present invention-the anti-Tim antibody complex; and when the carrier pertaining to the present invention is the microplate, by bringing into contacted the carrier

pertaining to the present invention-the anti-Tim antibody complex, relative to 1 well, and usually 1.0 to 10 µg, preferably 1.0 to 5.0 µg, and more preferably 1.0 to 2.0 µg of the Tim protein pertaining to the present invention, and by subjecting them to a reaction at usually 4.0°C to 37°C, preferably 11°C to 30°C, and more preferably 20°C to 25°C, for usually 0.5 hour to 24 hours, preferably 0.5 hour to 8.0 hours, and more preferably 0.5 hour to 2.0 hours to bind the anti-Tim antibody in the carrier pertaining to the present invention-the anti-Tim antibody complex, and the Tim protein pertaining to the present invention.

[0084]

It should be noted that contact between the carrier pertaining to the present invention-the anti-Tim antibody complex, and the Tim protein pertaining to the present invention, in the method (c), is carried out generally by bringing into contacted the carrier pertaining to the present invention-the anti-Tim antibody complex, and a solution containing the Tim protein pertaining to the present invention.

[0085]

The solution for containing the Tim protein pertaining to the present invention may be any one, as long as it dissolves the Tim protein pertaining to the present invention in a stable state, and includes, for example, purified water, or the buffer solution which has buffer action, for example, at pH 7.0 to 8.0, and preferably 7.2 to 7.6 (for example, PBS, TBS, HBC or the like). In addition, buffer agent concentration in these buffer solutions is appropriately selected from a range of usually 5 to 50 mM, and preferably 10 to 30 mM, and NaCl concentration is appropriately selected from a range of usually 100 to 200 mM, and preferably 140 to 160 mM. In addition, for example, saccharides, salts, such as NaCl, and the like, a surfactant, a preservative, a protein, or the like, may be contained in this solution, as long as in such an amount that does not inhibit binding of the Tim protein pertaining to the present invention and the carrier pertaining to the present invention-the anti-Tim antibody complex, after contacting the solution containing to

Tim protein pertaining to the present invention, and the carrier pertaining to the present invention-the anti-Tim antibody complex. The surfactant includes, for example, Tween 20, or the like, and surfactant concentration in the solution containing the Tim protein pertaining to the present invention is usually 0.00001 to 0.2 %, and preferably 0.0005 to 0.1 %. It should be noted that the solution dissolving the Tim protein pertaining to the present invention in these solutions may be abbreviated as “the Tim protein pertaining to the present invention-containing solution”, in some cases.

[0086]

- 10 - Specific preparation method for Tim carrier of the present invention by method (c) -

A specific preparation method for the Tim carrier of the present invention in the method (c) may be carried out, for example, by the following method.

- 15 First of all, the Tim protein pertaining to the present invention is prepared, according to the preparation method for the Tim protein pertaining to the present invention. Next, when the carrier pertaining to the present invention is the beads, the Tim carrier of the present invention is obtained, by bringing into contacted usually 0.1 mg to 10 mg, preferably 0.3 mg to 5.0 mg, and more preferably 0.5 mg to 3.0 mg of the carrier pertaining to the present invention-the anti-Tim antibody complex, and usually 100 to 1000 μ L, and preferably 200 to 500 μ L of the solution containing usually 1.0 to 50 μ g, preferably 1.0 to 30 μ g, and more preferably 1.0 to 20 μ g of the Tim protein pertaining to the present invention, relative to 1 mg of the carrier pertaining to the present invention-anti-Tim antibody complex (for example, the solution containing the Tim protein pertaining to the present invention, for example, in purified water, or the buffer solution, for example, at pH 7.0 to 8.0), and by subjecting them to a reaction at usually 4°C to 37°C, preferably 11°C to 30°C, and more preferably 20°C to 25°C, for usually 0.5 hour to 24 hours, preferably 0.5 hour to 8.0 hours, and more preferably 0.5 hour to 2.0 hours to bind the antibody against the Tim protein pertaining to the present invention in the
- 20
- 25

carrier pertaining to the present invention—the anti-Tim antibody complex, and the Tim protein pertaining to the present invention. When the carrier pertaining to the present invention is the microplate, the Tim carrier of the present invention is obtained by bringing into contacted the carrier pertaining to the present invention-the anti-Tim antibody complex, relative to 1 well, and usually 50 μ L to 300 μ L, preferably 50 μ L to 200 μ L, and more preferably 100 μ L to 200 μ L of the solution containing 1.0 to 10 μ g, preferably 1.0 to 5.0 μ g, and more preferably 1.0 to 2.0 μ g of the Tim protein pertaining to the present invention (the solution containing the Tim protein pertaining to the present invention-biotins complex, for example, in purified water, or the buffer solution having buffer action at pH 7.0 to 8.0, and preferably 7.2 to 7.6), and by subjecting them to a reaction at usually 4.0°C to 37°C, preferably 11°C to 30°C, and more preferably 20°C to 25°C, for usually 0.5 hour to 24 hours, preferably 0.5 hour to 8.0 hours, and more preferably 0.5 hour to 2.0 hours to bind the affinity substance in the carrier pertaining to the present invention-the affinity substance complex, and the affinity-tag in the Tim protein pertaining to the present invention having the affinity-tag.

[0087]

<Method for binding by physical adsorption>

As the method for binding the Tim protein pertaining to the present invention and the carrier pertaining to the present invention by physical adsorption, the Tim protein pertaining to the present invention and the carrier pertaining to the present invention may be brought into contacted under condition where the Tim protein pertaining to the present invention and the carrier pertaining to the present invention bind, according to a known method per se.

[0088]

Reaction temperature of the Tim protein pertaining to the present invention and the carrier pertaining to the present invention is usually 2°C to 37°C, and preferably 4°C to 11°C.

[0089]

Reaction time of the Tim protein pertaining to the present invention and the carrier pertaining to the present invention is usually 4 hours to 48 hours, and preferably 12 hours to 24 hours.

[0090]

5 Amount of the Tim protein pertaining to the present invention to be brought into contacted with 1 mg of the carrier pertaining to the present invention is usually 5.0 to 50 μ g, preferably 10 to 50 μ g, and more preferably 20 to 50 μ g, when the carrier pertaining to the present invention is the beads. Amount of the Tim protein pertaining to the present invention to be brought into contacted with 1 well
10 is usually 0.1 μ g to 10 μ g, preferably 0.2 μ g to 5 μ g, and more preferably 0.5 μ g to 2 μ g, when the carrier pertaining to the present invention is the microplate.

[0091]

It should be noted that physical adsorption of the Tim protein pertaining to the present invention and the carrier pertaining to the present invention may be
15 carried out generally by bringing into contacted the solution containing the Tim protein pertaining to the present invention, and the carrier pertaining to the present invention.

[0092]

The solution for containing the Tim protein pertaining to the present
20 invention may be any solution, as long as being capable of dissolving the Tim protein pertaining to the present invention in a stable state, and includes for example, purified water, or a buffer solution which has buffer action, for example, at pH 6.0 to 9.5, and preferably 7.0 to 8.0 (for example, a Good's buffer solution, such as MOPS, or the like, a carbonate buffer solution, PBS, TBS, HBS or the
25 like). In addition, buffer agent concentration in these buffer solutions is appropriately selected from a range of usually 5 to 100 mM, and preferably 10 to 50 mM, and NaCl concentration, if added, is appropriately selected from a range of usually 100 to 200 mM, and preferably 140 to 160 mM. In addition, for example, saccharides, salts, such as NaCl, and the like, a surfactant, a

preservative, a protein, or the like, may be contained in this solution, as long as in such an amount that does not inhibit binding of the carrier of the present invention and the extracellular membrane vesicles or the viruses, after contacting the solution containing the Tim protein pertaining to the present invention, and the carrier pertaining to the present invention. It should be noted that the solution dissolving the Tim protein pertaining to the present invention in these solutions may be abbreviated as “the Tim protein pertaining to the present invention-containing solution”, in some cases.

[0093]

Specific examples of the binding method by physical adsorption, in the binding method for the Tim protein pertaining to the present invention and the carrier pertaining to the present invention, include, for example, the following methods.

First of all, the Tim protein pertaining to the present invention is prepared, according to a preparation method for the Tim protein pertaining to the present invention. Next, the Tim carrier of the present invention is obtained by bringing into contacted usually 50 μ L to 300 μ L, preferably 50 μ L to 200 μ L, and more preferably 50 μ L to 100 μ L of the solution containing usually 5.0 to 50 μ g, preferably 10 to 50 μ g, and more preferably 20 to 50 μ g of the Tim protein (the solution containing the Tim protein pertaining to the present invention, for example, in purified water, or in a buffer solution of, for example, pH 7.0 to 8.0, or the like), to 1 mg of the carrier pertaining to the present invention when the carrier pertaining to the present invention is the beads; or by bringing into contacted usually 50 μ L to 300 μ L, preferably 50 μ L to 200 μ L, and more preferably 50 μ L to 100 μ L of a solution containing usually 0.1 μ g to 10 μ g, preferably 0.2 μ g to 5 μ g, and more preferably 0.5 μ g to 2 μ g of the Tim protein (the solution containing the Tim protein pertaining to the present invention, for example, in purified water, or in a buffer solution of, for example, pH 7.0 to 8.0, or the like), to 1 well when the carrier pertaining to the present invention is the microplate

; and by subjecting them to a reaction at usually 2°C to 37°C, and preferably 4°C to 11°C, for usually 4 hours to 48 hours, and preferably 12 hours to 24 hours to bind the carrier pertaining to the present invention and the Tim protein pertaining to the present invention.

5 [0094]

<Treatment of Tim carrier of the present invention>

The resulting Tim carrier of the present invention as above may be subjected to blocking treatment usually carried out in this field.

[0095]

10 The resulting Tim carrier of the present invention as above may be subjected to purification treatment usually carried out in this field, as needed. Purification treatment is not especially limited, as long as impurities adhered on the carrier surface can be removed, and includes, for example, a method for washing the Tim carrier of the present invention with a washing solution (hereafter
15 it may be abbreviated as “washing operation”, in some cases).

[0096]

Explanation will be given on an example by taking the case of using the magnetic particles, as the carrier pertaining to the present invention.

First of all, a container, containing the solution containing the resulting Tim
20 carrier of the present invention as described above, is installed in a magnet stand, to collect the Tim carrier of the present invention on a tube wall using magnetic force, and the solution in the container is discarded. Next, the washing solution is added in the container, and stirred. After that, the container is installed in the magnet stand, the same as the above, to collect the Tim carrier of the present
25 invention on the tube wall by using magnetic force, and the solution in the container is discarded. The washing operation may be repeated several times, as necessary. The washing solution to be used in the washing operation may be any solution, as long as it does not affect binding of the Tim protein pertaining to the present invention in the Tim carrier of the present invention, and the carrier of

the present invention, and includes, for example, purified water or the buffer solution which has buffer action, for example, at pH 7.0 to 8.0, and preferably 7.2 to 7.6 (for example, PBS, TBS, HBC, or the like). In addition, buffer agent concentration in these solutions is appropriately selected from a range of usually 5 to 50 mM, and preferably 10 to 30 mM, and NaCl concentration is appropriately selected from a range of usually 100 to 200 mM, and preferably 140 to 160 mM. This solution may contain, for example, saccharides, salts, such as NaCl, and the like, a surfactant, a preservative, a protein, or the like, as long as in such an amount that does not inhibit binding of the Tim protein pertaining to the present invention and the carrier pertaining to the present invention.

The surfactant includes, for example, Tween 20, or the like, and surfactant concentration in the washing solution is usually 0.00001 to 0.2 %, and preferably 0.0005 to 0.1 %.

[0097]

The extracellular membrane vesicles or the viruses can be obtained efficiently, and the extracellular membrane vesicles or the viruses in the sample can be obtained in high purity, by using the Tim carrier of the present invention. In addition, the extracellular membrane vesicles or the viruses in the sample can also be removed efficiently. Further, the extracellular membrane vesicles or the viruses in the sample can also be detected in high sensitivity.

[0098]

<6. Obtaining method for extracellular membrane vesicles or the viruses in sample>

A method for obtaining the extracellular membrane vesicle or the virus of the present invention (hereafter it may be abbreviated as “the obtaining method of the present invention”, in some cases) is characterized by comprising the following steps:

(1) A step for forming a complex of the Tim protein bound to the carrier, and the extracellular membrane vesicle or the virus in the sample, in the presence of the

calcium ion (hereafter it may be abbreviated as “the complex formation step”, in some cases).

(2) A step for separating the complex and the sample (hereafter it may be abbreviated as “the complex separation step”, in some cases).

- 5 (3) A step for separating the extracellular membrane vesicle or the virus from the complex to obtain the extracellular membrane vesicles or the viruses (hereafter it may be abbreviated as “the obtaining step”, in some cases).

[0099]

<6-1. Complex formation step>

- 10 The complex formation step is a step for forming the complex of the Tim protein, the carrier, and the extracellular membrane vesicle or the virus in the sample, in the presence of the calcium ion.

[0100]

<Sample pertaining to the present invention>

- 15 The sample pertaining to the present invention may be either of the one containing the extracellular membrane vesicle or the virus pertaining to the present invention in liquid, or the one possibly containing the extracellular membrane vesicle or the virus pertaining to the present invention. The sample pertaining to the present invention may be either of the one derived from a living
20 organism or may be the one where the extracellular membrane vesicle or the virus pertaining to the present invention is dissolved or suspended in a solution, such as a medium or a buffer solution, or the like. Specific examples of the sample pertaining to the present invention include body fluids, such as blood, saliva, urine, milk, amniotic fluid, ascites, and the like, cell culture supernatant,
25 and the like.

The solution for containing (dissolving or suspending) the extracellular membrane vesicle or the virus pertaining to the present invention may be any one, as long as it dissolves or suspends the extracellular membrane vesicle or the virus pertaining to the present invention in a stable state, and does not inhibit binding of

the complex of the Tim protein bound to the carrier, and the extracellular membrane vesicle or the virus in the sample, and includes, for example, water, a buffer solution having buffering action at pH 7.0 to pH 8.0, and preferably pH 7.2 to pH 7.6 (for example, TBS, HBS, or the like), or the like. It should be noted that, a phosphate buffer is not preferable because it binds with calcium and causes precipitation. In addition, concentration of the buffering agents in these buffer solutions is appropriately selected usually from a range of 5 to 50 mM, and preferably 10 to 30 mM, and NaCl concentration is appropriately selected from a range of usually 100 to 200 mM, and preferably 140 to 160 mM.

This solution may contain, for example, saccharides, salts, such as NaCl, and the like, a surfactant, an antiseptic agent, a protein, or the like, as long as in such an amount that does not inhibit binding of the complex of the Tim protein bound to the carrier and the extracellular membrane vesicle or the virus in the sample. Examples of the surfactant include Tween 20, or the like, and concentration of the surfactant in the solution, for containing the extracellular membrane vesicles or the viruses pertaining to the present invention, is usually 0.00001 to 0.2%, and preferably it is usually 0.0005 to 0.1%.

[0101]

<Calcium ion concentration and origin of calcium ion>

In the present invention, the calcium ion is present in formation of the complex of the Tim protein pertaining to the present invention, the carrier, and the extracellular membrane vesicle or the virus in the sample. More specifically, the calcium ion is present in bringing into contacted the Tim protein pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample.

[0102]

Calcium ion concentration, in bringing into contacted the Tim protein pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample pertaining to the present invention, is usually 0.5 to 100 mM,

preferably 1.0 to 10 mM, and more preferably 2.0 to 5.0 mM. It should be noted that it is not without saying that the calcium ion of the concentration as above is necessary, in the solution containing the complex, until the complex of the Tim protein pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample pertaining to the present invention is formed, and up to carrying out the obtaining step, that is, until the complex is subjected to the separation step.

[0103]

In addition, source of the calcium ion is not especially limited, and includes, for example, calcium chloride, calcium hydroxide, calcium hydrogen carbonate, calcium iodide, calcium bromide, calcium acetate, or the like; preferably calcium chloride, calcium hydrogen carbonate, and calcium iodide; and more preferably calcium chloride, and calcium hydrogen carbonate.

[0104]

It should be noted that, as the method for the calcium ion to be present, when the Tim protein pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample is brought into contacted, generally, the calcium ion as described above may be contained in the solution containing the Tim carrier of the present invention, the solution containing the sample and the solution containing the Tim protein pertaining to the present invention, and/or the solution containing the carrier pertaining to the present invention, in such an amount that attains calcium ion concentration in a range described above, when the Tim protein pertaining to the present invention, the carrier pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample is brought into contacted. In addition, using a solution containing the calcium ion, in such an amount that attains calcium ion concentration in a range described above, when the Tim protein pertaining to the present invention, the carrier pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample is brought into contacted, this solution, the solution

containing the Tim protein of the present invention, the solution containing the sample and the solution containing the Tim protein pertaining to the present invention, and/or the carrier pertaining to the present invention may be mixed.

The solution for containing the calcium ion is the same as the solution for containing (dissolving or suspending) the extracellular membrane vesicle or the virus pertaining to the present invention, and specific examples, and the like, are also the same.

[0105]

<Amount of sample>

Amount of the sample to be brought into contacted with 1 μ g of the Tim protein of the present invention, in the complex formation step, is usually 0.1 to 100 mL, preferably 0.1 to 10 mL, and more preferably 0.1 to 1.0 mL.

[0106]

<Temperature>

Temperature in bringing into contacted the Tim protein of the present invention, with the extracellular membrane vesicles or the viruses in the sample, in the complex formation step, is usually 4° to 37°C, preferably 4 to 25°C, and more preferably 4 to 11°C.

[0107]

<Time>

Contacting time of the Tim protein pertaining to the present invention and the sample, in the complex formation step, is usually 0.5 to 24 hours, preferably 0.5 to 8 hours, and more preferably 0.5 to 4 hours.

[0108]

The complex formation step is classified into two cases of (1-A) where the Tim carrier of the present invention, prepared in advance, is used (that is, the case where the carrier on which the Tim protein pertaining to the present invention is bound is used), and (1-B) where the Tim protein pertaining to the present invention and the carrier pertaining to the present invention are used separately.

[0109]

< (1-A) >

(1-A) is a method for forming the complex of the Tim protein bound to the carrier pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample (hereafter it may be abbreviated as "the complex pertaining to the present invention", in some cases), by bringing into contacted the Tim carrier of the present invention, and the extracellular membrane vesicle or the virus in the sample, in the presence of the calcium ion. In (1-A), the calcium ion may be present, when the Tim carrier of the present invention and the extracellular membrane vesicle or the virus in the sample is brought into contacted. Specifically, the solution containing the carrier on which the Tim protein pertaining to the present invention is bound and containing the calcium ion and/or the solution containing the sample and the calcium ion may be used, or the solution containing the carrier on which the Tim protein pertaining to the present invention is bound, and the solution containing the sample and the calcium ion may be used.

[0110]

-Amount of sample pertaining to the present invention-

Amount of the sample to be brought into contacted with 1 mg of the Tim carrier of the present invention, in (1-A), is usually 0.1 to 100 mL, preferably 0.1 to 10 mL, and more preferably 0.1 to 1.0 mL.

[0111]

-Contacting temperature-

Temperature when the Tim carrier of the present invention, and the sample are brought into contacted, in (1-A), is usually 4.0 to 37°C, preferably 4.0 to 25°C, and more preferably 4.0 to 11°C.

[0112]

-Contacting time-

Contacting time of the Tim carrier of the present invention, and the sample

(the extracellular membrane vesicles or the viruses), in (1-A), is usually 0.5 to 24 hours, preferably 0.5 to 8.0 hours, and more preferably 0.5 to 4.0 hours.

[0113]

-Amount of Tim carrier of the present invention-

5 Amount of the Tim carrier of the present invention, in (1-A), is usually 0.1 to 20 mg, preferably 0.3 to 10 mg, and more preferably 0.5 to 6.0 mg, relative to 1 mL of the solution in forming the complex pertaining to the present invention.

[0114]

-Specific example of 1-A-

10 (1-A) may be carried out, for example, by the following method. That is, the complex of the Tim protein bound to the carrier pertaining to the present invention, and the extracellular membrane vesicles or the viruses in the sample is formed by bringing into contacted usually 0.1 to 20 mg, preferably 0.3 to 10 mg, and more preferably 0.5 to 6.0 mg of the Tim carrier of the present invention,
15 relative to 1 mL of the solution after mixing of the Tim carrier of the present invention, and the solution containing the sample and the solution containing the calcium ion (the solution in forming the complex pertaining to the present invention), with the solution containing the calcium ion, in an amount to attain a calcium ion concentration of usually 0.5 to 100 mM, preferably 1.0 to 10 mM, and
20 more preferably 2.0 to 5.0 mM, in the solution in forming the complex pertaining to the present invention, and usually 0.1 to 100 mL, preferably 0.1 to 10 mL, and more preferably 0.1 to 1.0 mL of the sample, relative to 1 mg of the Tim carrier of the present invention, at usually 4.0 to 37°C, preferably 4.0 to 25°C, and more preferably 4.0 to 11°C, for usually 0.5 to 24 hours, preferably 0.5 to 8.0 hours, and
25 more preferably 0.5 to 4.0 hours.

[0115]

<(1-B)>

(1-B) is a method for using the Tim protein of the present invention, and the carrier pertaining to the present invention separately. For example, when the Tim

protein pertaining to the present invention and the carrier pertaining to the present invention are bound, utilizing affinity binding, it may be carried out as the following (1-B-i), (1-B-ii), or (1-B-iii).

[0116]

5 (1-B-i)

The complex pertaining to the present invention is formed by bringing into contacted the Tim protein of the present invention, the carrier pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample, at the same time, in the presence of the calcium ion.

10 [0117]

(1-B-ii)

The complex pertaining to the present invention is formed by forming the complex of the Tim protein of the present invention, and the extracellular membrane vesicle or the virus by bringing into contacted the Tim protein of the present invention, and the extracellular membrane vesicle or the virus in the sample, in the presence of the calcium ion, and then by further bringing into contacted the complex and the carrier pertaining to the present invention.

[0118]

(1-B-iii)

20 The complex pertaining to the present invention is formed by bringing into contacted the carrier of the present invention, and the extracellular membrane vesicle or the virus in the sample, and then by further bringing into contacted the Tim protein of the present invention, in the presence of the calcium ion.

[0119]

25 - (1-B-i)-

(1-B-i) is a method for forming the complex pertaining to the present invention composed of [the extracellular membrane vesicle or the virus-(the Tim protein pertaining to the present invention)-the affinity substance-(the carrier pertaining to the present invention)], by bringing into contacted the Tim protein

pertaining to the present invention, the carrier pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample, at the same time, in the presence of the calcium ion.

Specifically, for example, in using two or more kinds of substances having
5 affinity each other, as the affinity substance, the complex pertaining to the present invention composed of [the extracellular membrane vesicle or the virus in the sample-(the Tim protein pertaining to the present invention)-the affinity substance-(the carrier pertaining to the present invention)] is formed by bringing into contacted the Tim protein pertaining to the present invention bound with either
10 of the affinity substances (the affinity substance-binding Tim protein), and the carrier bound with the remaining affinity substances (the affinity substance-binding carrier), and the extracellular membrane vesicle or the virus in the sample, at the same time, in the presence of the calcium ion, to bind the Tim protein pertaining to the present invention in the affinity substance-binding Tim protein, and the
15 extracellular membrane vesicle or the virus, as well as to bind the affinity substance in the affinity substance-binding Tim protein, and the affinity substance in the affinity substance-binding carrier.

In (1-B-i), the calcium ion may be present in bringing into contacted the Tim protein pertaining to the present invention, the carrier pertaining to the present
20 invention, and the extracellular membrane vesicle or the virus in the sample, at the same time. Specifically, it may be carried out either by using the solution containing the Tim protein pertaining to the present invention, the solution containing the carrier pertaining to the present invention, and the sample, which the calcium ion contained in at least one more kinds of the solutions, or by
25 bringing into contacted the solution containing the Tim protein pertaining to the present invention, the solution containing the carrier pertaining to the present invention, and the solution containing the sample and the calcium ion.

[0120]

-Amount of sample pertaining to the present invention-

In (1-B-i), an amount of the sample to be brought into contacted with 1 μ g of the Tim protein pertaining to the present invention is usually 0.1 to 100 mL, preferably 0.1 to 10 mL, and more preferably 0.1 to 1.0 mL.

[0121]

5 -Amount of Tim protein pertaining to the present invention-

In (1-B-i), an amount of the Tim protein pertaining to the present invention is usually 0.01 to 200 μ g, preferably 0.15 to 50 μ g, and more preferably 0.5 to 24 μ g, relative to 1 mL of the solution in forming the complex pertaining to the present invention.

10 [0122]

-Amount of carrier pertaining to the present invention-

In (1-B-i), an amount of the carrier pertaining to the present invention is usually 1 to 20 mg, preferably 0.3 to 10 mg, and more preferably 0.5 to 6.0 mg, relative to 1 mL of the solution in forming the complex pertaining to the present invention.

15 [0123]

-Contacting temperature-

In (1-B-i), temperature in bringing into contacted the Tim protein of the present invention, the carrier pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample, is usually 4 to 37°C, preferably 4 to 25°C, and more preferably 4 to 11°C.

20 [0124]

-Contacting time-

Contacting time in bringing into contacted the Tim protein of the present invention, the carrier pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample, is usually 0.5 to 24 hours, preferably 0.5 to 8.0 hours, and more preferably 0.5 to 4.0 hours.

25 [0125]

It should be noted that contact of the Tim protein of the present invention,

the carrier pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample is carried out usually by bringing into contacted the solution containing the Tim protein of the present invention, the carrier pertaining to the present invention, the extracellular membrane vesicle or the virus
5 in the sample, and the solution containing the calcium ion.

[0126]

The solution for containing the Tim protein pertaining to the present invention may be any solution which is capable of dissolving the Tim protein pertaining to the present invention in a stable state, and does not inhibit binding of
10 the Tim protein pertaining to the present invention, the carrier pertaining to the present invention and the extracellular membrane vesicle or the virus, and includes for example, purified water, or a buffer solution which has buffer action, for example, at pH 7.0 to 8.0, and preferably 7.2 to 7.6 (for example, PBS, TBS, HBS or the like). In addition, buffer agent concentration in these buffer solutions
15 is appropriately selected from a range of usually 5 to 50 mM, and preferably 10 to 30 mM, and NaCl concentration is appropriately selected from a range of usually 100 to 200 mM, and preferably 140 to 160 mM. For example, saccharides, salts, such as NaCl, and the like, a surfactant, a preservative, a protein, or the like, may be contained in this solution, as long as in such an amount that dissolves the Tim
20 protein pertaining to the present invention in a stable state, and does not inhibit binding of the Tim protein pertaining to the present invention, the carrier pertaining to the present invention and the extracellular membrane vesicle or the virus. The surfactant includes, for example, Tween 20, or the like, and surfactant concentration in the solution for containing the Tim protein pertaining to the
25 present invention is usually 0.00001 to 0.2 %, and preferably 0.0005 to 0.1 %.

[0127]

The solution for containing the calcium ion is the same as the solution for containing (dissolving or suspending) the extracellular membrane vesicle or the virus pertaining to the present invention, and the specific example, or the like, is

also the same.

The solution containing the calcium ion is the solution containing such amount of the calcium ion that attains a calcium ion concentration of usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM in the solution in forming the complex pertaining to the present invention, among the solutions containing the calcium ion.

[0128]

-Specific example of (1-B-i)-

(1-B-i) may be carried out, for example, by the following method. That is, the complex pertaining to the present invention is formed by bringing into contact usually 0.5 μ L to 1 ml, preferably 0.5 μ L to 100 μ L, and more preferably 0.5 μ L to 10 μ L of the solution containing usually 0.01 to 200 μ g, preferably 0.15 to 50 μ g, and more preferably 0.5 to 24 μ g of the Tim protein pertaining to the present invention (for example, the solution containing the Tim protein of the present invention, for example, in purified water or, in the buffer solution which has buffer action at pH 7.0 to 8.0, and preferably 7.2 to 7.6), relative to 1 mL of the solution in forming the complex pertaining to the present invention; usually 0.1 to 100 ml, preferably 0.1 to 10 ml, and more preferably 0.1 to 1 ml of the sample, relative to 1 μ g of the Tim protein pertaining to the present invention; the solution containing the calcium ion in such an amount that attains a concentration of the calcium ion of usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM, in the solution in forming the complex pertaining to the present invention; and usually 0.1 to 20 mg, preferably 0.3 to 10 mg, and more preferably 0.5 to 6 mg of the carrier pertaining to the present invention, relative to 1 mL of a solution after mixing the solution containing the Tim protein pertaining to the present invention, the solution containing the sample and the calcium ion, and the solution containing the carrier pertaining to the present invention (the solution in forming the complex pertaining to the present invention), for usually 0.5 to 24 hours, preferably 0.5 to 8 hours, and more preferably 0.5 to 4 hours.

[0129]

-(1-B-ii)-

(1-B-ii) is a method for forming the complex of the Tim protein of the present invention, and the extracellular membrane vesicle or the virus, by bringing
5 into contacted the Tim protein of the present invention, and the extracellular membrane vesicle or the virus in the sample, in the presence of the calcium ion, and further by bringing into contacted the complex and the carrier pertaining to the present invention to form the complex composed of [the extracellular membrane vesicle or the virus-(the Tim protein pertaining to the present invention)-the affinity
10 substance-(the carrier pertaining to the present invention)].

Specifically, for example, in using two or more kinds of substances having affinity each other, as the affinity substances, the complex of [the extracellular membrane vesicle or the virus-(the Tim protein pertaining to the present invention)-the affinity substance] is formed by bringing into contacted the Tim
15 protein bound with either of the affinity substances (the affinity substance-binding Tim protein), and the extracellular membrane vesicle or the virus in the sample, in the presence of the calcium ion to bind the Tim protein in the affinity substance-binding Tim protein, and the extracellular membrane vesicle. Next, [the extracellular membrane vesicle or the virus-(the Tim protein pertaining to the present invention-the affinity substance)-(the affinity substance-the carrier
20 pertaining to the present invention)] is formed by bringing into contacted the [the extracellular membrane vesicle-(the Tim protein pertaining to the present invention-the affinity substance)] complex, and the carrier bound with the other affinity substance (the affinity substance-binding carrier) to bind the affinity
25 substance in [the extracellular membrane vesicle or the virus-(the Tim protein pertaining to the present invention-the affinity substance)] complex, and the affinity substance in the affinity substance-binding carrier.

In addition, for example, in using a substance having affinity to an affinity tag or an anti-Tim antibody, as the affinity substance, [the extracellular membrane

vesicle or the virus-the Tim protein pertaining to the present invention] complex is formed, by bringing into contacted the Tim protein pertaining to the present invention and the extracellular membrane vesicle or the virus in the sample, in the presence of the calcium ion to bind the Tim protein pertaining to the present invention and the extracellular membrane vesicle or the virus. Next, [the extracellular membrane vesicle or the virus-the Tim protein pertaining to the present invention-(the affinity substance-the carrier pertaining to the present invention)] complex is formed, by bringing into contacted [the extracellular membrane vesicle or the virus-the Tim protein pertaining to the present invention] complex, and the carrier bound with the affinity substance (the affinity substance-binding carrier) to bind the Tim protein pertaining to the present invention in [the extracellular membrane vesicle or the virus-the Tim protein pertaining to the present invention] complex, and the affinity substance in the affinity substance-binding carrier.

In (1-B-ii), the calcium ion may be present in bringing into contacted the Tim protein pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample. Specifically, the solution containing the Tim protein pertaining to the present invention and/or the sample, which is containing the calcium ion may be used, or the solution containing the Tim protein pertaining to the present invention, the sample, and the solution containing the calcium ion may be used.

[0130]

- Amount of sample pertaining to the present invention-

An amount of the sample to be brought into contacted with 1 μ g of the Tim protein pertaining to the present invention in (1-B-ii), is usually 0.1 to 100 ml, preferably 0.1 to 10 ml, and more preferably 0.1 to 1.0 ml.

[0131]

-Amount of Tim protein pertaining to the present invention-

An amount of the Tim protein pertaining to the present invention in (1-B-ii)

is usually 0.01 to 200 µg, preferably 0.15 to 50 µg, and more preferably 0.5 to 24 µg, relative to 1 mL of the solution in forming the complex pertaining to the present invention.

[0132]

5 -Amount of carrier pertaining to the present invention-

An amount of the carrier pertaining to the present invention in (1-B-ii) is usually 0.1 to 20 mg, preferably 0.3 to 10 mg, and more preferably 0.5 to 6 mg, relative to 1mL of the solution in forming the complex pertaining to the present invention.

10 [0133]

- Contacting temperature-

Temperature in bringing into contacted the Tim protein of the present invention, and the extracellular membrane vesicles or the viruses in the sample in (1-B-ii), is usually 4 to 37 °C, preferably 4 to 25 °C, and more preferably 4 to 11 °C.

[0134]

After forming the complex of the Tim protein of the present invention and extracellular membrane vesicle or the virus in (1-B-ii), temperature in further bringing into contacted the complex and the carrier pertaining to the present invention is usually 4 to 37°C, preferably 4 to 25°C, and more preferably 4 to 11°C.

[0135]

- Contacting time-

Contacting time of the Tim protein of the present invention, the carrier pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample pertaining to present invention in (1-B-ii), is usually 0.5 to 24 hours, preferably 0.5 to 8 hours, and more preferably 0.5 to 4 hours.

[0136]

After forming the complex of the Tim protein of the present invention and extracellular membrane vesicle or the virus in (1-B-ii), time for further bringing into

contacted the complex and the carrier pertaining to the present invention is usually 0.5 to 24 hours, preferably 0.5 to 8 hours, and more preferably 0.5 to 4 hours.

[0137]

5 It should be noted that contact of the Tim protein pertaining to the present invention and the extracellular membrane vesicle or the virus in the sample is usually carried out by bringing into contacted the solution containing the Tim protein pertaining to the present invention, the sample and the solution containing the calcium ion.

10 [0138]

 The solution for containing the Tim protein pertaining to the present invention may be any solution, as long as it is capable of dissolving the Tim protein pertaining to the present invention in a stable state, and dose not inhibit binding of the Tim protein pertaining to the present invention, the carrier pertaining to the present invention and the extracellular membrane vesicle or the virus pertaining to the present invention, and includes for example, purified water, or a buffer solution which has buffer action, for example, at pH 7.0 to 8.0, and preferably 7.2 to 7.6 (for example, TBS, HBS or the like). In addition, buffer agent concentration in these buffer solutions is appropriately selected from a range of usually 5 to 50 mM, and preferably 10 to 30 mM, and NaCl concentration is appropriately selected from a range of usually 100 to 200 mM, and preferably 140 to 160 mM. For example, saccharides, salts, such as NaCl, and the like, a surfactant, a preservative, a protein, or the like, may be contained in this solution, as long as in such an amount that dissolves the Tim protein pertaining to the present invention in a stable state, and dose not inhibit binding of the Tim protein pertaining to the present invention, the carrier pertaining to the present invention, and the extracellular membrane vesicle or the virus. The surfactant includes, for example, Tween 20, or the like, and surfactant concentration in the solution for containing the Tim protein pertaining to the present invention is usually 0.00001 to

0.2 %, and preferably 0.0005 to 0.1 %.

[0139]

The solution for containing the calcium ion is the same as the solution for containing (dissolving or suspending) the extracellular membrane vesicle or the virus pertaining to the present invention. The specific example, or the like, is also the same.

The solution containing the calcium ion is the solution containing such an amount of the calcium ion that attains a calcium ion concentration of usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM, in the solution in forming the complex pertaining to the present invention.

[0140]

-Specific example of (1-B-ii)-

(1-B-ii) may be carried out, for example, by the following method. That is, the complex of the Tim protein of the present invention and the extracellular membrane vesicles or the viruses is formed, by bringing into contacted usually 0.5 μ L to 1 mL, preferably 0.5 μ L to 100 μ L, and more preferably 0.5 μ L to 10 μ L of the solution containing usually 0.01 to 200 μ g, preferably 0.15 to 50 μ g, and more preferably 0.5 to 24 μ g of the Tim protein pertaining to the present invention (the solution containing the Tim protein pertaining to the present invention, for example, in purified water, or in the buffer solution, having buffering action, for example, at pH 7.0 to 8.0, and preferably 7.2 to 7.6), relative to 1 mL of the solution in forming the complex pertaining to the present invention; usually 0.1 to 100 mL, preferably 0.1 to 10 mL, and more preferably 0.1 to 1 mL of the sample, relative to 1 μ g of the Tim protein pertaining to the present invention; and the solution containing the calcium ion, in such an amount that attains a calcium ion concentration of usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM, in a solution mixed with the sample, the solution containing the calcium ion, and the solution containing the Tim protein pertaining to the present invention, and further in a solution after bringing into contacted the mixed solution and the carrier

pertaining to the present invention; at usually 4 to 37°C, preferably 4 to 25°C, and more preferably 4 to 11°C, for usually 0.5 to 24 hours, preferably 0.5 to 8 hours, and more preferably 0.5 to 4 hours, and after that, the complex pertaining to the present invention is formed, by the further addition of usually 0.1 to 20 mg, preferably 0.3 to 10 mg, and more preferably 0.5 to 6 mg of the carrier pertaining to the present invention, relative to 1 mL of the solution in formation of the complex pertaining to the present invention, and by bringing into contacted the resulting complex of the Tim protein of the present invention and the extracellular membrane vesicles or the viruses, and the carrier pertaining to the present invention, at usually 4 to 37°C, preferably 4 to 25°C, and more preferably 4 to 11°C, for usually 0.5 to 24 hours, preferably 0.5 to 8 hours, and more preferably 0.5 to 4 hours.

[0141]

-(1-B-iii)-

(1-B-iii) is a method for forming the complex pertaining to the present invention composed of [the extracellular membrane vesicle or the virus-(the Tim protein pertaining to the present invention)-the affinity substance-(the carrier pertaining to the present invention)], by bringing into contacted the carrier of the present invention, and the extracellular membrane vesicle or the virus in the sample, and after that by further bringing into contacted the Tim protein of the present invention, in the presence of the calcium ion.

Specifically, for example, in using two or more kinds of substances having affinity each other as the affinity substance, [the extracellular membrane vesicle or the virus-(the Tim protein pertaining to the present invention-the affinity substance)-(the affinity substance-the carrier pertaining to the present invention)] complex is formed by bringing into contacted the carrier bound with either of the affinity substances (the affinity substance-binding carrier), and the extracellular membrane vesicle or the virus in the sample, and next by bringing into contacted with the Tim protein bound with the other affinity substance (the affinity

substance-binding Tim protein), at the same time, in the presence of the calcium ion to bind the Tim protein in the affinity substance-binding Tim protein, and the extracellular membrane vesicle or the virus, as well as to bind the affinity substance in the affinity substance-binding Tim protein, and the affinity substance
5 in the affinity substance-binding carrier.

In addition, in using, for example, a substance having affinity to the affinity tag or an anti-Tim antibody, as the affinity substance, [the extracellular membrane vesicle or the virus-the Tim protein pertaining to the present invention-(the affinity substance-the carrier pertaining to the present invention)] complex is formed, by
10 bringing into contacted the carrier bound with the affinity substance (the affinity substance-binding carrier), and the extracellular membrane vesicle or the virus in the sample, and next by bringing into contacted with the Tim protein pertaining to the present invention, at the same time, in the presence of the calcium ion to bind the Tim protein pertaining to the present invention and the extracellular membrane
15 vesicle or the virus, as well as to bind the Tim protein pertaining to the present invention, and the affinity substance in the affinity substance-binding carrier.

In (1-B-iii), the calcium ion may be present in bringing into contacted the Tim protein pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample. Specifically, either the solution containing the
20 Tim protein pertaining to the present invention, and/or the solution containing the calcium ion in the extracellular membrane vesicle or the virus in the sample may be used, or the solution containing the Tim-4 protein pertaining to the present invention, and the solution containing the extracellular membrane vesicle or the virus in the sample and the calcium ion may be used.

25 [0142]

-Amount of sample pertaining to the present invention-

An amount of the sample to be brought into contacted with 1 μ g of the Tim protein pertaining to the present invention in (1-B-iii), is usually 0.1 to 100ml, preferably 0.1 to 10ml, and more preferably 0.1 to 1 ml.

[0143]

- Amount of Tim protein pertaining to the present invention-

An amount of the Tim protein pertaining to the present invention in (1-B-iii) is usually 0.01 to 200 µg, preferably 0.15 to 50 µg, and more preferably 0.5 to 24 µg, relative to 1 mL of the solution in forming the complex pertaining to the present invention.

[0144]

-Amount of carrier pertaining to the present invention-

An amount of the carrier pertaining to the present invention in (1-B-iii) is usually 0.1 to 20 mg, preferably 0.3 to 10 mg, and more preferably 0.5 to 6 mg, relative to 1 mL of the solution in forming the complex pertaining to the present invention.

[0145]

- Contacting temperature-

Temperature in bringing into contacted the carrier pertaining to the present invention and the extracellular membrane vesicle or the virus in the sample in (1-B-iii), is usually 4 to 37°C, preferably 4 to 25°C, and more preferably 4 to 11°C.

[0146]

Temperature in further bringing into contacted the Tim protein of the present invention, after bringing into contacted the carrier of the present invention, and the extracellular membrane vesicle or the virus in the sample, in (1-B-iii), is usually 4 to 37°C, preferably 4 to 25°C, and more preferably 4 to 11°C.

[0147]

- Contacting time-

Contacting time in bringing into contacted the carrier pertaining to the present invention and the sample in (1-B-iii), is usually 0.5 to 24 hours, preferably 0.5 to 8 hours, and more preferably 0.5 to 4 hours.

[0148]

Contacting time in further bringing into contacted the Tim protein pertaining

to the present invention, after bringing into contacted the carrier of the present invention and the extracellular membrane vesicle or the virus in the sample in (1-B-iii), is usually 0.5 to 24 hours, preferably 0.5 to 8 hours, and more preferably 0.5 to 4 hours.

5 [0149]

It should be noted that further contact with the Tim protein pertaining to the present invention, after bringing into contacted the carrier of the present invention, and the extracellular membrane vesicle or the virus in the sample, is generally carried out by using the solution containing the Tim protein pertaining to the present invention, and the solution containing the calcium ion.

[0150]

The solution for containing the Tim protein pertaining to the present invention may be any solution, as long as it is capable of dissolving the Tim protein pertaining to the present invention in a stable state, and dose not inhibit binding of the Tim protein pertaining to the present invention, the carrier pertaining to the present invention and the extracellular membrane vesicle or the virus, and includes for example, purified water, or the buffer solution which has buffer action, for example, at pH 7.0 to 8.0, and preferably 7.2 to 7.6 (for example, PBS, TBS, HBS or the like). In addition, buffer agent concentration in these buffer solutions is appropriately selected from a range of usually 5 to 50 mM, and preferably 10 to 30 mM, and NaCl concentration is appropriately selected from a range of usually 100 to 200 mM, and preferably 140 to 160 mM. For example, saccharides, salts, such as NaCl, and the like, a surfactant, a preservative, a protein, or the like, may be contained in this solution, as long as in such an amount that dissolves the Tim-4 protein pertaining to the present invention in a stable state, and dose not inhibit binding of the Tim protein pertaining to the present invention, the carrier pertaining to the present invention and the extracellular membrane vesicle or the virus. The surfactant includes, for example, Tween 20, or the like, and surfactant concentration in the solution for containing the Tim protein pertaining to the

present invention is usually 0.00001 to 0.2 %, and preferably 0.0005 to 0.1 %.

[0151]

The solution for containing the calcium ion is the same as the solution for containing (dissolving or suspending) the extracellular membrane vesicle or the virus pertaining to the present invention, and the specific examples are also the same.

The solution containing the calcium ion is the solution having such an amount of the calcium ion that attains a calcium ion concentration of usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM, in the solution in forming the complex pertaining to the present invention.

[0152]

-Specific example of (1-B-iii)-

(1-B-iii) may be carried out, for example, by the following method. That is, the complex pertaining to the present invention is formed by bringing into contacted usually 0.1 to 100 ml, preferably 0.1 to 10 ml, and more preferably 0.1 to 1 ml of the sample pertaining to the present invention, relative to 1 µg of the Tim protein pertaining to the present invention, and usually 0.1 to 20 mg, preferably 0.3 to 10 mg, and more preferably 0.5 to 6 mg of the carrier pertaining to the present invention, relative to 1 mL of the solution in forming the complex pertaining to the present invention, at usually 4 to 37°C, preferably 4 to 25°C, and more preferably 4 to 11°C, for usually 0.5 to 24 hours, preferably 0.5 to 8 hours, and more preferably 0.5 to 4 hours, and after that, by the addition of the solution containing such amount of the calcium ion that attains a calcium ion concentration of usually 0.5 to 100 mM, preferably 1.0 to 10 mM, and more preferably 2 to 5 mM, in the solution obtained by bringing into contacted the solution containing the sample pertaining to the present invention and the calcium ion, and the carrier pertaining to the present invention, and further by bringing into contacted the solution containing the Tim protein pertaining to the present invention; and usually 0.5 µL to 1 mL, preferably 0.5 µL to 100 µL, and more preferably 0.5 µL to 10 µL of

the solution containing usually 0.01 to 200 µg, preferably 0.15 to 50 µg, and more preferably 0.5 to 24 µg of the Tim protein pertaining to the present invention (the solution containing the Tim protein pertaining to the present invention, for example, in purified water or in the buffer solution, which has buffer action, for example, at pH 7.0 to 8.0, and preferably 7.2 to 7.6), relative to 1 mL of the solution in forming the complex pertaining to the present invention, to bring into contacted at usually 4 to 37°C, preferably 4 to 25°C, and more preferably 4 to 11°C, for usually 0.5 to 24 hours, preferably 0.5 to 8 hours, and more preferably 0.5 to 4 hours.

[0153]

10 <6-2. Complex separation step >

The complex separation step in the obtaining method of the present invention is an obtaining step of the separated complex pertaining to the present invention, after the complex formation step, by separation of the complex of the Tim protein bound to the resulting carrier pertaining to the present invention (the Tim carrier of the present invention), and the extracellular membrane vesicle or the virus in the sample (the complex pertaining to the present invention), and the sample.

[0154]

20 The complex separation step in the obtaining method of the present invention may be any method, as long as it is capable of obtaining the complex pertaining to the present invention, by separation of the complex pertaining to the present invention, and the sample, and includes, for example, the following methods.

[0155]

25 (1) When a magnetic carrier is used as the carrier pertaining to the present invention, a method for installing a container, used in the complex formation step, in the magnet stand as needed, collecting the complex pertaining to the present invention on the tube wall by using magnetic force and removing the supernatant sample to separate them.

(2) When the carrier of the present invention is beads-like, a method for subjecting the container, used in the complex formation step, to centrifugal separation treatment to collect the complex pertaining to the present invention as precipitate, and to remove the supernatant sample to separate them.

5 (3) When the carrier of the present invention in a form of a non-beads-like plate, or the like, is used, a method for separating these by removing only the sample.

(4) A method for separating the complex pertaining to the present invention, and the sample by filtration.

After separation of the complex of the present invention and the sample, in
10 this way, the separated complex of the present invention may be obtained (recovered) by a method known per se.

[0156]

-Specific example of complex separation step -

When the magnetic carrier is used as the carrier pertaining to the present
15 invention, the container used in the complex formation step is installed in the magnet stand, as needed, and the complex pertaining to the present invention is collected on the tube wall by using magnetic force to remove the supernatant sample.

[0157]

20 <6-3. Washing operation>

After the complex formation step and the complex separation step, the resulting complex pertaining to the present invention may be washed, as needed, using the calcium ion-containing washing solution (hereinafter, it may be optionally abbreviated as "washing operation"). Impurities in the sample pertaining to the
25 present invention, such as components originated from the cell attached on the surface of the carrier pertaining to the present invention, and the like, can be removed by the washing operation. A washing method usually practiced in this field can be used, except for using the washing solution containing the calcium ion, as described above, as the washing method. The calcium ion-containing

washing solution, to be used in the washing operation, may be any solution, as long as it contains usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM of the calcium ion, and does not influence binding of the extracellular membrane vesicle or the virus pertaining to the present invention in the complex, the Tim-4 protein pertaining to the present invention, and the carrier of the present invention, and includes, for example, the buffer solution containing usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM of the calcium ion, and having buffer action at pH 7.0 to 8.0, and preferably 7.2 to 7.6, and not precipitating calcium (for example, TBS, HBS). It should be noted that the phosphate buffer is not preferable, because it precipitates by binding with calcium. In addition, buffer agent concentration in these buffer solutions is selected from a range of usually 5 to 50 mM, and preferably 10 to 30 mM, and NaCl concentration is selected from a range of usually 100 to 200mM, and preferably 140 to 160 mM. This solution may contain, for example, saccharides, salts, such as NaCl, and the like, a surfactant, a preservative, a protein, or the like, as long as in such an amount that does not inhibit binding of the extracellular membrane vesicle or the virus pertaining to the present invention in the complex, the Tim protein pertaining to the present invention, and the carrier of the present invention. The surfactant includes, for example, Tween 20 (produced by Wako Pure Chemical Industries Co.), or the like, and surfactant concentration in the washing solution is usually 0.00001 to 0.2 %, and preferably 0.0005 to 0.1%.

[0158]

Explanation will be given on an example by taking the case of using the magnetic particles, as the carrier pertaining to the present invention. First of all, the calcium ion-containing washing solution is added in the container containing the resulting complex pertaining to the present invention by the complex separation step, and is stirred. After that, the container is installed in the magnet stand, to collect the complex on the tube wall by using magnetic force, and the solution in the container is discarded. The washing operation may be repeated

several times, as needed.

[0159]

- Specific example of washing operation-

First of all, the calcium ion-containing washing solution (for example, the
5 buffer solution containing usually 0.5 to 100 mM, preferably 1 to 10 mM, and more
preferably 2 to 5 mM of the calcium ion, having buffer action at pH 7.0 to 8.0, and
preferably 7.2 to 7.6, and not precipitation calcium. However, the phosphate buffer
is not preferable because it precipitates by binding with calcium) is added into the
container containing the resulting complex pertaining to the present invention by
10 the complex separation step, and is stirred. After that, the container is installed in
the magnet stand, to collect the complex on the tube wall by using magnetic force,
and solution in the container is discarded. The washing operation may be
repeated several times, as needed.

[0160]

15 <6-4. Obtaining step>

The obtaining step is a step for obtaining the extracellular membrane
vesicle or the virus pertaining to the present invention, after carrying out the
complex formation step, the complex separation step, and carrying out the
washing step (washing operation), as needed, to separate the extracellular
20 membrane vesicle or the virus from the complex of the Tim protein bound to the
resulting carrier pertaining to the present invention, and the extracellular
membrane vesicle or the virus in the sample.

In this way, the extracellular membrane vesicle or the virus pertaining to the
present invention can be obtained in high purity.

25 [0161]

Specific examples of the obtaining step include, for example, the following
(2-A) and (2-B).

(2-A) A method for using a protein denaturing agent.

(2-B) A method for decreasing calcium ion concentration.

[0162]

< (2-A) : Method for using protein denaturing agent >

(2-A) is a step for separating the extracellular membrane vesicle or the virus from the complex pertaining to the present invention, after carrying out the complex formation step, the complex separation step, and carrying out the washing operation, as needed, to make acting the protein denaturing agent on the resulting complex pertaining to the present invention, to denature the Tim protein pertaining to the present invention in the complex pertaining to the present invention. In this way, the extracellular membrane vesicle or the virus pertaining to the present invention can be obtained in high purity.

[0163]

- Protein denaturing agent-

The protein denaturing agent to be used in (2-A) may be any one, as long as it is generally used in this field, as a compound to denature the protein, and includes an anionic surfactant, for example, SDS (sodium dodecyl sulfate), N-lauroyl sarcosine, or the like; an amphoteric surfactant, such as CHAPS (3-(3-cholamidopropyl)dimethylamino-1-propane sulfonate salt), Zwittergent 3-12 (N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate), or the like; a non-ionic surfactant, such as Brij 35 (produced by Takara Bio Inc.), dodecyl- β -D-maltoside(n-dodecyl- β -D-maltoside), Nonidet P-40, octyl- β -D-glucoside (octyl- β -D-glucoside), Triton X-100 (polyoxyethylene (10) octylphenol), Tween 20 (polyoxyethylene (20) sorbitan monolaurate), or the like; a chaotropic agent, such as urea, formamide, guanidine, or the like, and the anionic surfactant is preferable, and SDS is particularly preferable.

[0164]

Action of these protein denaturing agents on the complex pertaining to the present invention, in (2-A), is generally carried out by bringing into contact the solution containing the protein denaturing agent (hereinafter, it may be abbreviated as "the protein denaturing agent-containing solution", in some cases),

and the complex of the Tim protein bound to the carrier pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample to make acted the protein denaturing agent-containing solution on the complex pertaining to the present invention.

5 It should be noted that the contacting of the protein denaturing agent-containing solution and the complex pertaining to the present invention can be carried out, for example, by a method for suspending the complex in the solution (when the carrier is the beads, and the like); a method for dipping the complex into the solution (when the carrier is a disc-like piece, a tube, or the like);
10 a method for the addition of the solution to the complex (the carrier), (when the carrier is the microplate, the tube, or the like) .

[0165]

- Solution for containing protein denaturing agent-

 The solution for containing the protein denaturing agent, in (2-A), includes
15 purified water, the buffer solution which is capable of dissolving the protein denaturing agent, or the like. The buffer solution includes the buffer solution having buffer action at usually pH 6 to 9, preferably 7 to 8 (for example, Tris, HEPES, or the like). In addition, buffer agent concentration in these solutions is appropriately selected from a range of usually 5 to 100 mM, and preferably 10 to
20 50 mM.

[0166]

- Protein denaturing agent-containing solution -

 The protein denaturing agent-containing solution has a pH of usually 6.0 to 9.0, and preferably 7.0 to 8.0, in (2-A). Concentration of the protein denaturing
25 agent in the protein denaturing agent-containing solution is different depending on kind of the protein denaturing agent, and generally, may be within a concentration range to be used in this field, and for example, when using SDS, it is usually 0.1 to 10 %, preferably 0.3 to 4 %, and more preferably 0.5 to 2%. In addition, the protein denaturing agent-containing solution may contain, for example,

saccharides, salts, such as NaCl, and the like, a preservative, a protein, or the like. Usually 10 μ L to 500 μ L, preferably 20 μ L to 200 μ L, and more preferably 50 μ L to 100 μ L of the protein denaturing agent-containing solution, relative to 1 mg of the Tim carrier of the present invention is used, in (2-A).

5 [0167]

- Action (contact) condition -

Temperature or time for bringing into acted (contacted) the protein denaturing agent on the complex, in (2-A), is at usually 4.0 to 37 °C, preferably 10 to 30 °C, and more preferably 20 to 30°C, for usually 5.0 to 60 seconds, preferably
10 10 to 30 seconds, and more preferably 10 to 20 seconds.

[0168]

- Tim protein-

As the Tim protein pertaining to the present invention in obtaining the extracellular membrane vesicle, in bringing into acted (contacted) the protein
15 denaturing agent (that is, in the (2-A)), any one may be used, as long as it is the Tim protein pertaining to the present invention, and, the Tim-4 protein pertaining to the present invention and the Tim-1 protein pertaining to the present invention are preferable, and the Tim-4 protein pertaining to the present invention is particularly preferable, and in obtaining the virus, the Tim-4 protein pertaining to the present
20 invention and the Tim-3 protein pertaining to the present invention are particularly preferable.

[0169]

-Specific example of (2-A)-

(2-A) may be carried out, for example, by the following method. That is,
25 the extracellular membrane vesicles or the viruses are separated from the complex pertaining to the present invention, after carrying out the complex formation step, the complex separation step, and carrying out the washing operation, as needed, by the addition of usually 10 μ L to 500 μ L, preferably 20 μ L to 200 μ L, and more preferably 50 μ L to 100 μ L, relative to 1 mg of the Tim carrier

of the present invention, of the solution containing usually 0.1 to 10 %, preferably 0.3 to 4.0 %, and more preferably 0.5 to 2.0 % of the protein denaturing agent (the solution containing the protein denaturing agent in purified water, or the buffer solution which has buffer action at usually pH 6 to 9, and preferably 7 to 8), to the resulting complex pertaining to the present invention, and by subjecting them to a reaction at usually 4 to 37°C, preferably 10 to 30°C, and more preferably 20 to 30°C, for usually 5 to 60 seconds, preferably 10 to 30 seconds, and more preferably 10 to 20 seconds, while stirring by using a vortex mixer, or the like, so as to make acted by bringing into contacted the Tim protein pertaining to the present invention in the complex pertaining to the present invention, and the protein denaturing agent.

[0170]

< (2-B) : Method for decreasing calcium ion concentration >

(2-B) is a method for separating the extracellular membrane vesicle or the virus pertaining to the present invention from the complex pertaining to the present invention, by decreasing calcium ion concentration bound to the resulting complex pertaining to the present invention, and the calcium ion in the solution containing the complex, after carrying out the complex formation step, the complex separation step, and carrying out the washing operation, as needed.

In this way, the extracellular membrane vesicle or the virus pertaining to the present invention can be obtained in high purity and in an intact state.

[0171]

By the way, it has been known that the calcium ion is intermediated in binding of the Tim protein and phosphatidyl serine (Immunity 2007 December; 27 (6): 941-951). Co-presence of the calcium ion is required also for the resulting complex pertaining to the present invention, after carrying out the complex formation step, and the complex separation step, and the washing operation, as needed, to maintain binding of the Tim protein pertaining to the present invention in the complex pertaining to the present invention, and the extracellular

membrane vesicle or the virus in the sample. It is necessary to maintain 0.5 mM or more of the calcium ion in the solution of the complex pertaining to the present invention, for example, when the complex pertaining to the present invention is made co-present in the solution. Here, a pellet state carrier, after carrying out the complex formation step, the complex separation step, and the washing operation, as needed, is also encompassed, when the complex pertaining to the present invention is made co-present in the solution.

It should be noted that the calcium ion never elutes from the complex unless the obtaining step is carried out, even if the complex pertaining to the present invention is dried, after carrying out the complex formation step, the complex separation step, and the washing operation, as needed, and thus binding of the carrier of the present invention and the extracellular membrane vesicle or the virus is maintained.

[0172]

It is possible, in (2-B), to separate the extracellular membrane vesicle or the virus pertaining to the present invention from the complex pertaining to the present invention, by decreasing concentration of the calcium ion, entrained from the calcium ion bound to the complex pertaining to the present invention, to lower than required concentration (effective concentration) to maintain binding of the Tim protein pertaining to the present invention and the extracellular membrane vesicle or the virus, as described above.

Specifically, calcium ion concentration in the solution containing the complex pertaining to the present invention may be set usually lower than 0.5 mM, preferably lower than 0.4 mM, and more preferably lower than 0.2 mM.

[0173]

The method for decreasing (effective) concentration of the calcium ion includes, for example, the following (2-B-i), (2-B-ii), or the like.

[0174]

(2-B-i) Method for using calcium ion chelating agent.

(2-B-ii) Method for using solution not containing calcium ion.

[0175]

- (2-B-i) Method for using calcium ion chelating agent. -

(2-B-i) is a method for separating the extracellular membrane vesicle or the virus from the complex pertaining to the present invention, after carrying out the complex formation step, the complex separation step, and the washing operation, as needed, and after making acted the calcium ion chelating agent on the calcium ion bound to the resulting complex pertaining to the present invention, and the calcium ion entrained from the solution containing the complex, by decreasing (effective) concentration of the calcium ion bound to the complex pertaining to the present invention, and the calcium ion entrained from the solution containing the complex.

In this way, the extracellular membrane vesicle or the virus pertaining to the present invention can be obtained in high purity and in an intact state.

15 [0176]

-Calcium ion chelating agent-

The calcium ion chelating agent may be any compound, as long as it is capable of chelating the calcium ion, and includes, for example, EDTA (ethylenediamine tetraacetate), NTA (nitrilotriacetate), DTPA (diethylenetriamine pentaacetate), GLDA (L-glutamic acid diacetate), HEDTA (hydroxyethylethylenediamine triacetate), GEDTA (ethyleneglycol bis(β -aminoethyl ether)-N,N,N,N-tetraacetate), TTHA (triethylenetetramine-N,N,N',N'',N''',N''''-hexaacetate), HIDA (2-hydroxyethyliminodiacetic acid), DHEG (N,N-bis(2-hydroxyethyl)glycin), CyDTA (trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid monohydrate), or the like, and EDTA, GEDTA, and CyDTA are preferable. The solution containing the calcium ion chelating agents (hereinafter it may be abbreviated as "the calcium ion chelating agent-containing solution", in some cases) is generally brought into contacted with the pellet-like complex pertaining to the present invention, then the

calcium ion bound to the complex pertaining to the present invention, and the calcium ion chelating agent in the calcium ion chelating agent-containing solution are subjected to a reaction, to make acted these calcium ion chelating agents to the calcium ion bound to the complex pertaining to the present invention.

5 It should be noted that contacting of the calcium ion chelating agent-containing solution and the complex pertaining to the present invention can be carried out, for example, by a method for suspending the complex in the solution (when the carrier is the beads, and the like); a method for dipping the complex in the solution (when the carrier is disc-like piece, a tube, or the like); a
10 method for the addition of the solution to the complex (carrier) (when the carrier is the microplate, the tube, or the like), or the like.

[0177]

- Calcium ion chelating agent-containing solution-

 The solution for containing the calcium ion chelating agent, in (2-B-i), may
15 be any one, as long as it dissolves the calcium ion chelating agent, and includes for example, purified water, a buffer solution, or the like. As the buffer solution, the one which has buffer action at usually pH 7.0 to 8.0, preferably 7.2 to 7.6 (for example, PBS, TBS, HBS or the like) is preferable. In addition, buffer agent concentration in these buffer solutions is appropriately selected from a range of
20 usually 5 to 50 mM, and preferably 10 to 30 mM, and NaCl concentration is appropriately selected from a range of usually 100 to 200 mM, and preferably 140 to 160 mM. For example, saccharides, salts, such as NaCl, and the like, a surfactant, a preservative, a protein, or the like, may be contained in the calcium ion chelating agent-containing solution.

25 [0178]

 Concentration of the calcium ion chelating agent in the calcium ion chelating agent-containing solution, in (2-B-i), is usually 0.5 to 500 mM, preferably 0.5 to 100 mM, and more preferably 0.5 to 50 mM.

[0179]

The calcium ion chelating agent-containing solution, in (2-B-i), has a pH of usually 6.0 to 9.0, preferably 7.0 to 8.0, and more preferably 7.2 to 7.6.

[0180]

Amount of the calcium ion chelating agent-containing solution to be mixed
5 in the reaction solution, in (2-B-i), may be such amount that concentration of the calcium ion in the reaction solution attains lower than effective concentration, and the extracellular membrane vesicle or the virus can be separated from the complex pertaining to the present invention.

[0181]

10 - Acting (contacting) condition-

Temperature or time of bringing into acted (contacted) the calcium ion chelating agent on the complex, in (2-B-i), is usually 4.0 to 37°C, preferably 10 to 30°C, more preferably 20 to 30°C, and usually 5 to 60 seconds, preferably 10 to 30 seconds, and more preferably 10 to 20 seconds.

15 [0182]

-Tim carrier-

Binding form of the Tim protein pertaining to the present invention and the carrier pertaining to the present invention, in (2-B-i), is not limited, as long as the carrier pertaining to the present invention and the Tim protein pertaining to the
20 present invention are bound. The one in which the carrier pertaining to the present invention binds to the SH group of the Tim protein pertaining to the present invention is preferable, and the one in which the carrier pertaining to the present invention binds to the SH group of the Tim-4 protein pertaining to the present invention is particularly preferable, when the extracellular membrane
25 vesicle or the virus is eluted by using the calcium ion chelating agent (that is, in (2-B-i)), because many extracellular membrane vesicle or virus can be obtained.

[0183]

-Specific example of (2-B-i)-

(2-B-i) may be carried out, for example, by the following method. That is,

the extracellular membrane vesicle or the virus is separated from the complex pertaining to the present invention, after carrying out the complex formation step, the complex separation step, and carrying out the washing operation, as needed, by the addition of usually 10 μ L to 500 μ L, preferably 20 μ L to 200 μ L, and more preferably 50 μ L to 100 μ L of the solution containing usually 0.5 to 500 mM, preferably 0.5 to 100 mM, and more preferably 0.5 to 50 mM of the calcium ion chelating agent (a solution containing the calcium ion chelating agent, in purified water, or the buffer solution which has buffer action at usually pH 7.0 to 8.0, preferably 7.2 to 7.6), to the resulting complex pertaining to the present invention, relative to 1 mg of the Tim carrier of the present invention, and by subjecting them to a reaction at usually 4.0 to 37°C, preferably 10 to 30°C, and more preferably 20 to 30°C, for usually 5 to 60 seconds, preferably 10 to 30 seconds, and more preferably 10 to 20 seconds, while stirring by using a vortex mixer, or the like.

[0184]

- (2-B-ii) Method for using solution not containing calcium ion-

(2-B-ii) is a method for separating the extracellular membrane vesicle or the virus from the complex pertaining to the present invention, after carrying out the complex formation step, the complex separation step, and the washing operation, as needed, by bringing into contacted the resulting complex pertaining to the present invention to the solution not containing the calcium ion to decrease (dilute) (effective) concentration of the calcium ion bound to the complex pertaining to the present invention.

[0185]

That is, the extracellular membrane vesicle can be separated from the complex pertaining to the present invention, by decreasing (diluting) (effective) concentration of the calcium ion, which is required to maintain binding of the Tim protein pertaining to the present invention in the complex pertaining to the present invention, and the extracellular membrane vesicle or the virus in the sample, by bringing into contacted the solution not containing the calcium ion to the complex

pertaining to the present invention.

It should be noted that contact of the solution not containing the calcium ion and the complex pertaining to the present invention can be carried out, for example, by a method for suspending the complex in the solution (when the carrier is the beads, or the like); a method for dipping the complex in the solution (when the carrier is a disc-like piece, a tube, or the like); a method for the addition of the solution to the complex (carrier) (when the carrier is the microplate, the tube, or the like), or the like.

[0186]

10 -Solution not containing calcium ion -

The solution not containing the calcium ion to be added to the resulting complex pertaining to the present invention, in (2-B-ii), may be any one, as long as not denaturing the extracellular membrane vesicle or the virus, and includes for example, purified water, the buffer solution, or the like. As the buffer solution, the one which has buffer action at usually pH 7.0 to 8.0, preferably 7.2 to 7.6 (for example, PBS, TBS, HBS or the like) is preferable. In addition, buffer agent concentration in these buffer solutions is appropriately selected from a range of usually 5 to 50 mM, and preferably 10 to 30 mM, and NaCl concentration is appropriately selected from a range of usually 100 to 200 mM, and preferably 140 to 160 mM. For example, saccharides, salts, such as NaCl, and the like, a surfactant, a preservative, a protein, or the like, may be contained in the solvent not containing the calcium ion.

[0187]

Amount of the solution not containing the calcium ion to be added to the resulting complex pertaining to the present invention, in (2-B-ii), may be any amount, as long as it is capable of making calcium ion concentration lower than the effective concentration.

[0188]

-Specific example of (2-B-ii)-

(2-B-ii) is carried out by the addition of the solution not containing the calcium ion to the resulting complex pertaining to the present invention, after carrying out the complex formation step, the complex separation step, and as needed, after carrying out the washing operation, in such an amount that attains a calcium ion concentration of usually lower than 0.5 mM, preferably lower than 0.1 mM, more preferably lower than 0.01 mM, in the solution containing the complex pertaining to the present invention.

[0189]

It should be noted that, the solution containing the calcium ion may be replaced to the solution not containing the calcium ion and/or diluted by the solution not containing the calcium ion, after carrying out the complex formation step, the complex separation step, and after carrying out the washing operation, as needed, so as to attain the final concentration of the calcium ion to lower than the effective concentration, when the resulting complex pertaining to the present invention is present in the solution containing the calcium ion (for example, a reaction solution after carrying out the complex formation step, or a calcium ion-containing washing solution).

[0190]

(2-B-i) is preferable, because amount (volume increase) of the solution containing the resulting extracellular membrane vesicle by the obtaining step is more in (2-B-ii) than in (2-B-i).

[0191]

In the above description, the solution brought into contacted and interacted with the complex (the protein denaturing agent-containing solution, the calcium ion chelating agent-containing solution, the solution not containing the calcium ion) results in to contain the carrier and extracellular membrane vesicle or the virus separated (released) from the carrier (complex). Therefore, the solution containing the extracellular membrane vesicle or the virus can be obtained by removing the carrier from the solution, and recovering only the solution.

[0192]

The extracellular membrane vesicle or the virus can be efficiently removed from the sample, therefore, the sample with less contaminants can be obtained by using the Tim carrier of the present invention.

5 [0193]

The removing method of the present invention is capable of removing the extracellular membrane vesicle or the virus in the sample in good precision and efficiently, which cannot be removed completely by conventional methods, such as ultracentrifugal separation method, polymer sedimentation treatment, and the
10 like.

[0194]

<7. Removing method of extracellular membrane vesicle or the virus in sample>

The method for obtaining the extracellular membrane vesicle or the virus of the present invention (hereinafter it may be abbreviated as “the removing method
15 of the present invention”, in some cases) is characterized by including the following steps.

(1) The step for forming the complex of the Tim protein bound to the carrier, and the extracellular membrane vesicle or the virus in the sample, in the presence of the calcium ion (hereinafter, it may be abbreviated as “the complex formation step”,
20 in some cases).

(2) The step for separating the complex and the sample (hereinafter, it may be abbreviated as “the complex separation step”, in some cases).

[0195]

<7-1. Complex formation step>

25 The complex formation step in the removing method of the present invention is the same as the complex formation step in the obtaining step of the present invention, and various kinds of preferable conditions are also the same.

[0196]

<7-2. Complex separation step>

The complex separation step in the removing method of the present invention is a step for separating the resulting complex of the Tim protein bound to the carrier pertaining to the present invention (the Tim carrier of the present invention), and the extracellular membrane vesicle or the virus in the sample (the complex pertaining to the present invention), and the sample, after carrying out
5 the complex formation step, to obtain the separated sample.

By carrying out this step, the sample from where the extracellular membrane vesicle or the virus is removed can be obtained.

[0197]

10 The complex separation step in the removing method of the present invention may be any method, as long as it is capable of removing the complex pertaining to the present invention from the sample, and includes the same method as the complex separation step in the obtaining method of the present invention. After separating the complex of the present invention and the sample
15 in this way, the separated sample may be obtained (recovered) by a method known per se.

[0198]

In this way, the extracellular membrane vesicle or the virus in the sample can be removed in good precision and efficiently, which cannot be removed
20 completely by a conventional method, such as the ultracentrifugal separation method or a polymer precipitation treatment, or the like.

[0199]

In addition, removal of the extracellular membrane vesicle or the virus from the sample can be carried out more efficiently, by repeating the complex formation
25 step and the complex separation step multiple times. Either a new carrier may be used, or a carrier after use may also be re-utilized, in carrying out the complex formation step and the complex separation step repeatedly. In re-utilization of the carrier, the complex pertaining to the present invention, which was removed at the complex separation step in the removing method of the present invention, may

be subjected to the same treatment as the obtaining step of the obtaining method of the present invention ((2-B) a method for decreasing calcium ion concentration) using the solution containing the calcium ion chelating agent, or the solution not containing the calcium ion. In this way, the Tim carrier of the present invention and the extracellular membrane vesicle or the virus can be separated from the complex pertaining to the present invention. That is, removal of the extracellular membrane vesicle or the virus in the sample can be carried out in good precision and efficiently, by re-utilization of the Tim carrier of the present invention, because the Tim carrier of the present invention can be used again in the removing method of the present invention.

[0200]

The extracellular membrane vesicle or the virus in the sample can be detected in good precision and in high sensitivity, by using the Tim carrier of the present invention.

[0201]

<8. Method for detecting extracellular membrane vesicle or the virus in sample>

A method for detecting the extracellular membrane vesicle or the virus of the present invention (hereafter it may be abbreviated as “the detection method of the present invention”, in some cases) is characterized by comprising the following steps:

(1) A step for forming the complex of the Tim protein bound to the carrier, and the extracellular membrane vesicle or the virus in the sample, in the presence of the calcium ion (complex formation step).

(2) A step for detecting the complex (detection step).

[0202]

<8-1. Complex formation step>

The complex formation step in the detection method of the present invention is a step for forming the complex of the Tim carrier of the present invention, and the extracellular membrane vesicle or the virus in the sample, in the

presence of the calcium ion.

[0203]

-Sample pertaining to the present invention-

The sample pertaining to the present invention is the same as the sample
5 in the obtaining method of the present invention.

[0204]

-Calcium ion concentration and origin of calcium ion-

In the detection method of the present invention, the calcium ion is present
in forming the complex of the Tim carrier pertaining to the present invention, and
10 the extracellular membrane vesicle or the virus in the sample (the complex
pertaining to the present invention).

[0205]

In the detection method of the present invention, calcium ion concentration,
in bringing into contacted the Tim carrier pertaining to the present invention, and
15 the extracellular membrane vesicle or the virus in the sample pertaining to the
present invention, is usually 0.5 to 100 mM, preferably 1 to 10 mM, and more
preferably 2 to 5 mM. It should be noted that it is not without saying that the
calcium ion of such concentration as described above is necessary in the solution
containing the complex, until the complex of the Tim carrier pertaining to the
20 present invention, and the extracellular membrane vesicle or the virus in the
sample pertaining to the present invention is formed and the detection step is
carried out, that is, until the complex is subjected to the detection step.

[0206]

In addition, origin of the calcium ion is not especially limited, and includes
25 the same as specific example as origin of the calcium ion in the obtaining method
of the present invention.

[0207]

It should be noted that as a method for the calcium ion to be present in
bringing into contacted the Tim carrier of the present invention, and the

extracellular membrane vesicle or the virus in the sample, generally the calcium ion as described above may be contained in the sample, in such an amount that attains a calcium ion concentration of the above range, in bringing into contacted the Tim carrier of the present invention, and the extracellular membrane vesicle or the virus in the sample.

The solution for containing the calcium ion is the same as the solution for containing (dissolving or suspending) the extracellular membrane vesicle or the virus pertaining to the present invention, and specific examples, and the like, are also the same.

[0208]

-Amount of sample-

Amount of the sample, in the complex formation step of the detection method of the present invention, is usually 0.1 to 1000 mL, preferably 0.1 to 500 mL, and more preferably 0.1 to 100 mL, relative to 1 mg of the Tim carrier of the present invention, in using the beads as the carrier pertaining to the present invention, and is usually 50 μ L to 300 μ L, and preferably 100 μ L to 200 μ L, relative to 1 well, in using the microplate as the carrier pertaining to the present invention.

[0209]

-Temperature-

In the complex formation step of the detection method of the present invention, temperature in bringing into contacted the Tim carrier of the present invention, and the extracellular membrane vesicle or the virus in the sample, is usually 2 to 37°C, and preferably 2 to 30°C.

[0210]

-Time-

In the complex formation step of the detection method of the present invention, contacting time of the Tim protein pertaining to the present invention and the sample is usually 0.5 to 24 hours, preferably 1 to 20 hours, and more preferably 1 to 12 hours.

[0211]

-Tim protein-

As the Tim protein pertaining to the present invention in the detection method of the present invention, any one may be used, as long as being the Tim protein pertaining to the present invention, however, the Tim-4 protein pertaining to the present invention is particularly preferable.

[0212]

-Tim carrier-

Binding form of the Tim protein pertaining to the present invention and the carrier pertaining to the present invention is not especially limited, as long as the carrier pertaining to the present invention and the Tim protein pertaining to the present invention are bound, and, the one where the carrier pertaining to the present invention is bound to the SH group of the Tim protein pertaining to the present invention is preferable, and the one where the carrier pertaining to the present invention is bound to the SH group of the Tim-4 protein pertaining to the present invention is particularly preferable, because they are capable of detecting the extracellular membrane vesicles or the viruses in high sensitivity.

[0213]

-Specific example of complex formation step in detection method of the present invention-

The complex formation step in the detection method of the present invention may be carried out, for example, by the following method.

That is, in using the beads as the carrier pertaining to the present invention, the complex of the Tim protein bound to the carrier pertaining to the present invention, and the extracellular membrane vesicles or the viruses in the sample is formed, by bringing into contacted usually 0.001 to 20 mg, preferably 0.005 to 10 mg, and more preferably 0.01 to 6.0 mg of the Tim carrier of the present invention, relative to 1 mL of the solution after mixing the Tim carrier of the present invention, and the solution containing the sample and the calcium ion (the solution in forming

the complex pertaining to the present invention); the solution containing the calcium ion, in such an amount that attains a concentration of the calcium ion of usually 0.5 to 100 mM, preferably 1.0 to 10 mM, and more preferably 2.0 to 5.0 mM, in the solution in forming the complex pertaining to the present invention; and
5 usually 0.1 to 1000 mL, preferably 0.1 to 500 mL, and more preferably 0.1 to 100 mL of the sample, relative to 1 mg of the Tim carrier of the present invention; at usually 2 to 37°C, and preferably 2 to 30°C, for usually 0.5 to 24 hours, preferably 1 to 20 hours, and more preferably 1 to 12 hours.

In using the microplate as the carrier pertaining to the present invention,
10 the complex of the Tim carrier of the present invention, and the extracellular membrane vesicles or the viruses in the sample (the complex pertaining to the present invention) is formed by the addition of the solution containing the calcium ion, in such an amount that attains a calcium ion concentration of usually 0.5 to 100 mM, preferably 1.0 to 10 mM, and more preferably 2.0 to 5.0 mM, in the
15 solution in forming the complex pertaining to the present invention, and usually 50 μ L to 300 μ L, and preferably 100 μ L to 200 μ L of the sample pertaining to the present invention, relative to 1 well, to each well of the microplate on which the Tim protein is immobilized (the Tim carrier of the present invention) to be subjected to a reaction at usually 2°C to 37°C, and preferably 2°C to 30°C, for
20 usually 0.5 hour to 24 hours, preferably 1 hour to 20 hours, and more preferably 1 to 12 hours.

[0214]

<8-2. Detection step in detection method of the present invention>

The detection step in the detection method of the present invention is a
25 step for detecting the complex of the Tim carrier of the present invention, and the extracellular membrane vesicle or the virus in the sample (the complex pertaining to the present invention), by carrying out the complex separation step of the sample, as needed, after carrying out the complex formation step, and after carrying out the washing operation, as needed.

[0215]

-Complex separation step-

The complex separation step in the detection method of the present invention is, after the complex formation step, a step for removing the sample from
5 the resulting complex of the Tim protein bound to the carrier pertaining to the present invention (the Tim carrier of the present invention), and the extracellular membrane vesicle or the virus in the sample (the complex pertaining to the present invention), as needed.

[0216]

10 The complex separation step in the detection method of the present invention may be any method, as long as it is capable of separating the complex pertaining to the present invention and the sample, in other words, is capable of what is called B/F separation, and the B/F separation method usually used in this field can be used. Such a method includes the same one as the complex
15 separation step in the obtaining method of the present invention.

[0217]

-Specific example of complex separation step –

The complex separation step in the detection method of the present invention may be carried out, according to a usual method in this field, and, in
20 using the magnetic beads as the carrier pertaining to the present invention, for example, a container used in the complex formation step is placed on a magnet stand, as needed, to collect the complex pertaining to the present invention on the tube wall using magnetic force, to remove the sample of the supernatant.

In using the microplate as the carrier pertaining to the present invention,
25 the sample is removed using a micropipette or a plate washer, as need, for example, from the microplate after carrying out the complex formation step.

[0218]

<8.3. Washing operation>

After the complex formation step, and carrying out the complex separation

step, as needed, the resulting complex pertaining to the present invention may be washed further using a washing solution containing the calcium ion (hereafter it may be abbreviated as “washing operation”, in some cases), as needed. Impurities in the sample pertaining to the present invention, such as cell-derived components, and the like, adhered at the carrier surface pertaining to the present invention can be removed by the washing operation. Various conditions of the washing method, and the like, are the same as those in the washing operation in the obtaining method of the present invention.

[0219]

10 - Specific example of washing operation-

In carrying out the washing operation in a tube having a volume of 1.5 mL, using the magnetic beads as the carrier pertaining to the present invention, firstly, usually 100 μ L to 1500 μ L, and preferably 200 μ L to 1000 μ L of the washing solution containing the calcium ion (a buffer solution, containing, for example, usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM of the calcium ion, and having buffering action at pH 7.0 to 8.0, and preferably 7.2 to 7.6, and not precipitating calcium. However, the phosphate buffer is not preferable because it precipitates by binding with calcium.) is added into a container containing the resulting complex pertaining to the present invention by the complex separation step, and stirred. After that, the container is placed at the magnet stand to collect the complex on the tube wall, using magnetic force, and the solution in the container is discarded. The washing operation may be carried out repeatedly several times, as needed.

In using the microplate as the carrier pertaining to the present invention, firstly, usually 100 μ L to 300 μ L, and preferably 200 μ L to 300 μ L of the calcium ion-containing washing solution (for example, the buffer solution containing usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2.0 to 5.0 mM of the calcium ion, and having buffering action at pH 7.0 to 8.0, and preferably 7.2 to 7.6, and not precipitating calcium. However, the phosphate buffer is not

preferable because it precipitates by binding with calcium.) is added in a well containing the resulting complex pertaining to the present invention by the complex separation step, and then the added washing solution is removed. The washing operation may be carried out repeatedly several times, as needed.

5 [0220]

<8-4. Detection step>

The detection step in the detection method of the present invention may be any method, as long as it is a method capable of detecting presence or absence and/or amount of the complex pertaining to the present invention, and any method
10 known per se to be used for immunological measurement can be used.

The detection step of the present invention is not especially limited, except for using the Tim carrier of the present invention prepared by the method as described above. Such an immunological measurement method includes all of, for example, a measurement method utilizing an agglutination reaction, such as a
15 reversed passive agglutination reaction method (“(sequel) Biochemical Experimental Course 5, Immuno-biochemical Research Method” p.36-37, Tokyo Kagaku Dojin Co., Ltd.; “Kanai’s Manual of Clinical Laboratory Medicine”, 30th edition, p.844-845, Kanehara Publishing Co., Ltd., or the like.), for example, an optical measurement method applying the agglutination reaction, such as
20 nephelometry (“Kanai’s Manual of Clinical Laboratory Medicine”, 30th edition, p.851-853, Kanehara Publishing Co., Ltd., or the like.), immunoturbidimetry (“Kanai’s Manual of Clinical Laboratory Medicine”, 30th edition, p.853-854, Kanehara Publishing Co., Ltd., or the like.), radioimmunoassay (RIA) (“(sequel) Biochemical Experimental Course 5, Immuno-biochemical Research Method”
25 p.57-61, Tokyo Kagaku Dojin Co., Ltd.; “Kanai’s Manual of Clinical Laboratory Medicine”, 30th edition, p.856-862, Kanehara Publishing Co., Ltd., or the like.), immune-radiometric assay (IRMA) (“Kanai’s Manual of Clinical Laboratory Medicine”, 30th edition, p.856-862, Kanehara Publishing Co., Ltd., or the like.), enzyme immunoassay (EIA) (“(sequel) Biochemical Experimental Course 5

Immuno-biochemical Research Method" p.62-65, Tokyo Kagaku Dojin Co., Ltd.; "Kanai's Manual of Clinical Laboratory Medicine", 30th edition, p.862-865, Kanehara Publishing Co., Ltd.; JP-A-56-106154; JP-A-58-23796, or the like.), solid phase enzyme immunoassay (ELISA) ("Kanai's Manual of Clinical Laboratory Medicine", 30th edition, p.1145-1149, Kanehara Publishing Co., Ltd., or the like.), fluorescence/luminescence immunoassay ("Kanai's Manual of Clinical Laboratory Medicine", 30th edition, p.865-867, Kanehara Publishing Co., Ltd., or the like.), the flow cytometry method, or the like, and the solid phase enzyme immunoassay (ELISA) or the flow cytometry is preferable.

10 [0221]

When the detection step of the present invention is carried out by the solid phase enzyme immunoassay (ELISA) or the flow cytometry, it may be carried out, according to a method known per se, as long as the complex pertaining to the present invention is a detection object. There is included, for example, a method for using a labeled primary antibody which is a primary antibody labeled with a labelling substance, such as an anti-extracellular membrane vesicle antibody or an anti-virus antibody capable of binding with the extracellular membrane vesicle or the virus, or a method for using the primary antibody and a labeled secondary antibody that binds to the primary antibody. Any labeled primary antibody and labeled secondary antibody may be used, as long as they are used for a labeled antibody of the ELISA method or the flow cytometry method, and includes, for example, a fluorescent labeled antibody labeled with a fluorescent substance, such as Cy3, Cy5, FITC, rhodamine, PE or the like, an enzyme labeled antibody labeled with an enzyme, such as a peroxidase, an alkaline phosphatase, or the like, the magnetic beads labeled antibody, an infrared labeled antibody, or the like. Fluorescence, or the like, pertaining to these labeled antibodies may be measured by a method known per se, corresponding to the labeling method (labeling substance) of the labeled antibody.

[0222]

-Diluent of labelled antibody-

A diluent of the labelled primary antibody, or the primary antibody and the labelled secondary antibody to be subjected to a reaction with the complex pertaining to the present invention, in the detection method of the present invention, may be any one, as long as it does not inhibit binding of the complex of the Tim protein and the extracellular membrane vesicle or the virus in the sample, and the antibody, except for containing the calcium ion, and includes, for example, water, or the buffer solution which has buffer action at pH 7.0 to 8.0, and preferably 7.2 to 7.6 (for example, TBS, HBS or the like), or the like. It should be noted that the phosphate buffer is not preferable, because it precipitates by binding with calcium. In addition, buffer concentration in these buffer solutions is appropriately selected from a range of usually 5 to 50 mM, and preferably 10 to 30 mM, and NaCl concentration is appropriately selected from a range of usually 100 to 200 mM, and preferably 140 to 160mM. For example, saccharides, salts such as NaCl, and the like, a surfactant, a preservative, a protein, or the like, may be contained in these solutions, as long as in such amount that does not inhibit binding of the complex of the Tim carrier pertaining to the present invention and the extracellular membrane vesicle or the virus in the sample. The surfactant includes, for example, Tween 20, and surfactant concentration in the solution for containing the extracellular membrane vesicle or the virus relevant to the present invention is usually 0.00001 % to 0.2 %, and preferably 0.0005% to 0.1%. In addition, concentration of the calcium ion contained in the diluent is usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM.

[0223]

In the detection method of the present invention, dilution degree of the labeled primary antibody or the primary antibody and the labeled secondary antibody to be subjected to a reaction with the complex pertaining to the present invention, is different depending on activity or concentration of the antibody, however, it is usually 10-fold to 1000000-fold, and preferably 1000-fold to

100000-fold.

[0224]

In the detection method of the present invention, amount of the diluent of the labeled primary antibody, or the primary antibody and the labeled secondary antibody to be subjected to a reaction with the complex pertaining to the present invention, is usually 0.1 mL to 1000 mL, preferably 0.1 mL to 500 mL, and more preferably 0.1 mL to 100 mL, relative to 1 mg of the carrier pertaining to the present invention, when the carrier pertaining to the present invention is the beads; and it is usually 50 μ L to 300 μ L, preferably 50 μ L to 200 μ L, and more preferably 50 μ L to 100 μ L, relative to 1 well, when the carrier pertaining to the present invention is the microplate.

[0225]

- Reaction (contacting) temperature-

In the detection method of the present invention, reaction temperature of the complex pertaining to the present invention, and the labelled primary antibody, or the primary antibody and the labelled secondary antibody, is usually 2 to 37°C, preferably 11 to 337°C, and more preferably 20 to 30°C.

[0226]

- Reaction (contacting) time-

In the detection method of the present invention, reaction time of the complex pertaining to the present invention and the labelled primary antibody, or the primary antibody and the labelled secondary antibody, is usually 0.5 to 12 hours, preferably 1 to 4 hours, and more preferably 1 to 2 hours.

[0227]

It is possible to remove the unreacted labelled primary antibody, by the washing operation after subjecting the complex pertaining to the present invention and labelled primary antibody to a reaction, when the labelled primary antibody is used in the detection operation of the detection step in the detection method of the present invention. In addition, it is possible to remove the unreacted primary

antibody and the labelled secondary antibody, by the washing operation after
subjecting the complex pertaining to the present invention and the primary
antibody to a reaction, or after subjecting the complex pertaining to the present
invention and the complex of primary antibody and the labelled secondary
5 antibody to a reaction, when the primary antibody and the labelled secondary
antibody are used. As the washing method, a washing method usually used in
this field can be used, except for using the washing solution containing the
calcium ion, as described above. The washing solution containing the calcium
ion, to be used in the washing operation, may be any solution, as long as it
10 contains usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5
mM of the calcium ion, and does not inhibit binding of the extracellular membrane
vesicles or the viruses pertaining to the present invention in the complex, the Tim
protein pertaining to the present invention, and the carrier of the present invention,
and includes for example, a buffer solution containing usually 0.5 to 100 mM,
15 preferably 1 to 10 mM, and more preferably 2 to 5 mM of the calcium ion, and
having buffer action at pH 7.0 to 8.0, and preferably 7.2 to 7.6, and not
precipitating calcium (for example, TBS, HBS). It should be noted that the
phosphate buffer is not preferable, because it precipitates by binding with calcium.
In addition, buffer agent concentration in these buffer solutions is appropriately
20 selected from a range of usually 5 to 50 mM, and preferably 10 to 30 mM, and
NaCl concentration is appropriately selected from a range of usually 100 to 200
mM, and preferably 140 to 160 mM. This solution may contain, for example,
saccharides, salts such as NaCl, and the like, a surfactant, a preservative, a
protein, or the like, as long as in such an amount that does not inhibit binding of
25 the extracellular membrane vesicles or the viruses pertaining to the present
invention in the complex, the Tim protein pertaining to the present invention and
the carrier of the present invention. The surfactant includes, for example, Tween
20 (produced by Wako Pure Chemical Industries Co.), or the like, and surfactant
concentration in the washing solution is usually 0.00001 to 0.2 %, and preferably

0.0005 to 0.1 %. When the carrier pertaining to the present invention is the beads, it is usually 0.1 mL to 1000 mL, and preferably 0.1 mL to 500 mL, and more preferably 0.1 mL to 100 mL, relative to 1 mg of the carrier pertaining to the present invention. Amount of the washing solution to be used in 1 well is usually
5 100 μ L to 300 μ L, and preferably 200 μ L to 300 μ L, and the washing solution is removed after the addition, when the carrier pertaining to the present invention is the microplate. The washing operation may be repeated plural times, as needed.

[0228]

10 -Detection-

The labelled substance of the labelled primary antibody or the labelled secondary antibody includes peroxidase, alkali phosphatase, or the like, when the detection step in the detection method of the present invention is chromogenic detection. These labelled substances may be detected, according to the known
15 method per se, in response to each labelled substance.

[0229]

The chromogenic substrate solution in the chromogenic detection may be any one, as long as it is a chromogenic substrate solution usually used in this field, and includes, when peroxidase is used as the labelled substance, for example, a
20 TMB (tetramethyl benzidine) solution or an OPD (o-phenylene diaime) solution, and preferably includes the TMB solution.

[0230]

Amount of the chromogenic substrate in the chromogenic detection is usually 0.1 mL to 1000 mL, preferably 0.1 mL to 500 mL, and more preferably 0.1
25 mL to 100 mL, relative to 1 mg of the carrier pertaining to the present invention, when the carrier pertaining to the present invention is the beads, and it is usually 50 μ L to 300 μ L, preferably 50 μ L to 200 μ L, and more preferably 50 μ L to 100 μ L, relative to 1 well, when the carrier pertaining to the present invention is the microplate.

[0231]

Reaction time with the chromogenic substance is usually 5 minutes to 60 minutes, and preferably 10 minutes to 40 minutes, when the detection step in the detection method of the present invention is the chromogenic detection.

5 [0232]

Temperature of a reaction with the chromogenic substrate solution is usually 2°C to 37°C, and preferably 20°C to 30°C, when the detection step in the detection method of the present invention is the chromogenic detection.

[0233]

10 As a reaction stopping solution to stop the chromogenic reaction, a strong acid, such as usually 1 mol/L of hydrochloric acid, or 1 mol/L of sulfuric acid, or the like, is added in the same amount as the chromogenic substrate solution to stop the chromogenic reaction, when the detection step in the detection method of the present invention is the chromogenic detection.

15 [0234]

Fluorescence is measured by the addition of a fluorescence measurement solution to the complex of the complex pertaining to the present invention and the labelled primary antibody, or the complex of the complex pertaining to the present invention and the primary antibody and the labelled secondary antibody, when the
20 detection step in the detection method of the present invention is fluorescence detection, and a fluorescence substance is used as the labelled substance of labelled primary antibody or the labelled secondary antibody. Any of the fluorescence measurement solution usually used in this field (hereinafter, it may be abbreviated as “measuring solution”, in some cases) may be used, except for
25 using the calcium ion containing-fluorescence measurement solution, as the fluorescence measurement solution. The calcium ion-containing measurement solution to be used in the fluorescence measurement solution may be any one, as long as it contains usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably usually 2 to 5 mM of the calcium ion, and does not affect binding of the

extracellular membrane vesicle or the virus pertaining to the present invention in the complex, the Tim protein pertaining to the present invention, and the carrier of the present invention, and includes, for example, the buffer solution containing usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5mM of the calcium ion, and having buffer action at pH 7.0 to 8.0, and preferably 7.2 to 7.6, and not precipitating calcium (for example, TBS, HBS). It should be noted that the phosphate buffer is not preferable because it precipitates by binding with calcium. In addition, buffer agent concentration in these buffer solutions is appropriately selected from a range of usually 5 to 50mM, preferably 10 to 30 mM, and NaCl concentration is appropriately selected from a range of usually 100 to 200mM, preferably 140 to 160 mM. This solution may contain, for example, saccharides, salts, such as NaCl, and the like, a surfactant, a preservative, a protein, such as BSA, as long as in such an amount that does not inhibit binding of the extracellular membrane vesicle or the virus pertaining to the present invention in the complex, the Tim protein pertaining to the present invention, and the carrier of the present invention. The surfactant includes, for example, Tween 20 (produced by Wako Pure Chemical Industries Co.), or the like, and surfactant concentration in the washing solution is usually 0.00001 to 0.2%, and preferably 0.0005 to 0.1 %. Amount of the fluorescence measurement solution to be used, in 1 well, in the detection method of the present invention is usually 50 μ L to 300 μ L, and preferably 50 μ L to 200 μ L, when the detection method of the present invention is the ELISA method, and the carrier pertaining to the present invention is the microplate. It is usually 0.1 mL to 1000 mL, preferably 0.1 mL to 500 mL, more preferably 0.1 mL to 100 mL, relative to 1 mg of the carrier pertaining to the present invention, when the detection method pertaining to the present invention is the flow cytometry method, and the carrier pertaining to the present invention is the beads.

[0235]

-Specific example of detection step in detection method of the present invention-

When the detection step is carried out by the ELISA method, using, for example, the microplate, as the carrier pertaining to the present invention, after the complex formation step, and the complex separation step, as needed, and further after carrying out the washing operation, as needed, to each well of the microplate, on which the resulting Tim protein pertaining to the present invention is immobilized, usually 50 μ L to 300 μ L, preferably 50 μ L to 200 μ L, and more preferably 50 μ L to 100 μ L of a diluted solution, which was obtained by diluting a peroxidase labeled primary antibody or a unlabeled primary antibody, against the extracellular membrane vesicles or the viruses, using usually 10 times to 1000000 times, and preferably 1000 times to 100000 times of a diluent containing usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM of the calcium ion, is added relative to 1 well, and subjected to a reaction at usually 2 to 37°C, and preferably 11 to 37°C, for usually 0.5 to 12 hours, and preferably 1 to 4 hours, and next each well is washed using a washing buffer containing the calcium ion (a solution which contains usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM of the calcium ion, and does not influence binding of the extracellular membrane vesicles or the viruses pertaining the present invention in the complex, the Tim protein pertaining to the present invention, and the carrier of the present invention). In using the unlabeled primary antibody, each well is washed using usually 100 μ L to 300 μ L, and preferably 200 μ L to 300 μ L of the washing buffer containing the calcium ion (the solution which contains usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM of the calcium ion, and does not influence binding of the extracellular membrane vesicles or the viruses pertaining to the present invention in the complex, the Tim protein pertaining to the present invention, and the carrier of the present invention), after further subjecting the peroxidase labeled second antibody to a reaction with the primary antibody by the same method. Next, usually 50 μ L to 300 μ L, preferably 50 μ L to 200 μ L, and preferably 50 μ L to 100 μ L of a chromogenic substrate solution, such as a TMB solution, an OPD solution,

or the like, relative to 1 well, is added to each well and subjected them to a reaction at usually 2°C to 37°C, and preferably 20°C to 30°C, for usually 5 minutes to 60 hours, and preferably 10 minutes to 40 hours. After that, a reaction termination solution such as 1 mol/L hydrochloric acid or 1 mol/L sulfuric acid, or the like, is added in the same amount as the chromogenic substrate solution to terminate a color reaction, and measure absorbance using a microplate reader.

When the detection step is carried out by the flow cytometry method using, for example, the beads, as the carrier pertaining to the present invention, after the complex formation step, and the complex separation step, as needed, and further after carrying out the washing operation, as needed, to the beads, on which the resulting Tim protein pertaining to the present invention is immobilized, usually 0.1 mL to 1000 mL, preferably 0.1 mL to 500 mL, and more preferably 0.1 mL to 100 mL of the diluted solution, which was obtained by diluting a fluorescent labelled primary antibody, or a unlabeled primary antibody, using usually 10 times to 1000000 times, and preferably 1000 times to 100000 times of the diluent containing usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM of the calcium ion, is added, relative to 1 mg of the carrier pertaining to the present invention, and subjected them to a reaction at usually 2 to 37°C, and preferably 11 to 37°C, for usually 0.5 to 12 hours, and preferably 1 to 4 hours, and next the beads are washed using the washing buffer containing the calcium ion (the solution which contains usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM of the calcium ion, and does not influence binding of the extracellular membrane vesicles or the viruses pertaining to the present invention in the complex, the Tim protein pertaining to the present invention, and the carrier of the present invention). In using the unlabeled primary antibody, the beads are washed using the washing buffer containing the calcium ion (the solution which contains usually 0.5 to 100 mM, preferably 1 to 10 mM, and more preferably 2 to 5 mM of the calcium ion, and does not influence binding of the

extracellular membrane vesicles or the viruses pertaining to the present invention in the complex, the Tim protein pertaining to the present invention, and the carrier of the present invention), after further subjecting a fluorescent labelled second antibody to a reaction with the primary antibody by the same method. Next, after
5 suspending the beads by the addition of usually 0.1 mL to 1000 mL, preferably 0.1 mL to 500 mL, and preferably 0.1 mL to 100 mL of a fluorescence measurement solution, relative to 1 mg of the carrier pertaining to the present invention, fluorescence intensity is measured using a flow cytometer.

[0236]

10 Affinity of antibodies for antigens is generally said to have K_d at a level of 10 nM to 100 pM. On the other hand, binding strength of the Tim-4 protein and phosphatidylserine has been reported to be K_d = about 2 nM (Nature (Impact Factor: 41.46). 12/2007; 450 (7168): 435-9. DOI: 10.1038/nature 06307). It was
15 surprising that sensitivity of the detection method of the present invention for detecting the extracellular membrane vesicle or the virus, and the like, using the Tim protein pertaining to the present invention is higher as compared with a conventional method for detecting the extracellular membrane vesicle or the virus
20 using the antibodies, although affinity of antibodies against surface antigens of the extracellular membrane vesicle or the virus envelope membranes, and their surface antigens is comparable degree to affinity between phosphatidylserine on the surface of the extracellular membrane vesicle or the virus envelope membrane and the Tim protein of the present invention.

[0237]

25 The extracellular membrane vesicle or the virus obtained by the method of the present invention can be used for analyzing proteins and nucleic acids, such as microRNAs, which are present on the surface or inside of the particle, and for basic research of functional analysis of the extracellular membrane vesicle or the virus, or the like. In addition, it can also be utilized for diagnostic drugs, medicines, vaccines, or the like.

[0238]

<9. Kit for capturing extracellular membrane vesicle or the virus of the present invention>

5 The Kit for capturing the extracellular membrane vesicle or the virus of the present invention comprises, as components:

1. a reagent comprising the Tim protein pertaining to the present invention, and a reagent comprising the carrier pertaining to the present invention, or 2. a reagent comprising the Tim carrier of the present invention.

10 These kits may further contain at least one kind selected from the calcium ion-containing washing solution, the protein denaturing agent-containing solution, and the calcium ion chelating agent-containing solution. Specific examples of each component, preferable aspects, and the like, are as described above.

[0239]

15 In addition, in the reagents contained in these kits, there may be contained reagents usually used in this field, for example, the buffer agent, a sensitizer, a surfactant, a preservative (for example, sodium azide, salicylic acid, benzoic acid, or the like), a stabilizer (for example, albumin, globulin, water-soluble gelatin, the surfactant, saccharides, or the like), an activator, an effect avoidance agent of co-present substances, and the one usually used in this field, which does not
20 inhibit stability with co-present reagents, and does not inhibit a reaction or binding of the Tim protein and the carrier pertaining to the present invention, the Tim protein pertaining to the present invention bound to the carrier pertaining to the present invention and the extracellular membrane vesicle in the sample. In addition, concentration ranges, and the like, of these reagents, and the like, may
25 be used, according to appropriate selection of the usually used concentration ranges, and the like, to exert effect each of the reagents has.

[0240]

Furthermore, the kit of the present invention may contain description of the obtaining method of the present invention, the removing method of the present

invention, the detection method of the present invention, or the like. The “description” means an instruction manual, a package insert, a pamphlet (leaflet), or the like, of the kit, in which features, principles, operation procedures, determination procedures, and the like, of the method are substantially described
5 by documents or figures.

[0241]

Explanation will be given below on the present invention in more detail with reference to Experimental Examples, Examples and Comparative Examples, however, the present invention should not be limited at all by them.

10 It should be noted that the Tim protein of the present invention, and the T-cell immunoglobulin and mucin domain-containing molecule-2 (Tim-2) protein (hereinafter it may be abbreviated as “the Tim-2 protein”, in some cases) together may be abbreviated as “the Tim family protein”, in some cases.

15

EXAMPLES

[0242]

Experimental Example 1. Preparation of Fc tag fusion type Tim-4 protein

The Fc tag fusion type Tim-4 protein was prepared by the following
5 method.

[0243]

< (1) Vector construction and culture conditions >

First, a vector was constructed for expression of the Fc tag fusion type
Tim-4 protein in which a cDNA (SEQ ID NO: 26) encoding the N-terminal 1 to 273
10 amino acid region of a mouse-derived Tim-4 protein was incorporated into the
Sall-EcoRV site of a pEF-Fc vector (hereinafter it may be abbreviated as “the
pEF-Tim-4-Fc”, in some cases).

On the other hand, 293 T cells (RIKEN BRC) were each cultured for 1 day
using 25 sheets of 150 mm dishes for cell culture, using 20 mL of DMEM
15 (produced by Nacalai Tesque, Inc.) containing 10% FBS (produced by BioWest
Co., Ltd.). Thereafter, for each dish, 25 mL of DMEM containing 10% FBS was
replaced with 25 mL of FBS-free DMEM.

Thereafter, 20 µg of the pEF-Tim-4-Fc was transfected into each of 293 T
cells, using Polyethylenimine “MAX” (produced by Polysciences Inc.), according
20 to a usual method. After transfection, the 293 T cells after transfection were
each cultured for 4 days under condition at 37°C, and 5% CO₂.

[0244]

< (2) Purification >

The resulting culture of the transfected 293T cells was each subjected to
25 centrifugal separation treatment (800 × G, for 5 minutes) to recover and pool each
culture supernatant. The resulting culture supernatant was subjected to filtration
treatment using a Rapid Flow 0.2 µm filter unit (manufactured by Thermo Fisher
Scientific Inc.) to separate impurities and obtain a culture supernatant filtrate.

Subsequently, 500 mL of the resulting culture supernatant filtrate was

added to a poly prep column (manufactured by Bio-Rad Laboratories, Inc.) packed with 700 μ L of a nProtein A Sepharose 4 Fast Flow (produced by GE Healthcare Japan; Protein A has affinity for the Fc tag) washed with 20 mL of PBS, and the Fc tag fusion type Tim-4 protein in the culture supernatant filtrate was bound on the nProtein A Sepharose 4 Fast Flow. Then, the nProtein A Sepharose 4 Fast Flow was washed with 20 mL of PBS. Thereafter, using each 600 μ L of a 0.1 M glycine hydrochloride buffer solution (pH 3.0), elution was carried out 5 times, in 100 μ L of a 1 M Tris buffer solution (pH 8.0), as a neutralizing solution, to obtain each 600 μ L of five eluate fractions.

Absorbance at 280 nm was measured for each of the resulting five eluate fractions to determine presence or absence of a protein. Fractions containing the protein were mixed into one portion, and concentrated by ultrafiltration using an Amicon Ultra-0.5 mL, 10K centrifugal filter column (manufactured by Millipore Corp.), and then the solvent was replaced with 40 μ L of PBS using the same column. Then, amount of the protein in the eluate replaced with PBS was quantitated by a BCA method, then concentration of the protein was adjusted to 88 μ g/mL using PBS to obtain the PBS solution containing the Fc tag fusion type mouse-derived Tim-4 protein (it may be abbreviated as “the Fc tag fusion type mTim-4 protein”, in some cases) (the solution may be abbreviated as “the Fc tag fusion type mTim-4 protein-containing PBS solution”, in some cases).

[0245]

Experimental Example 2. Preparation of FLAG tag fusion type Tim-4 protein

The FLAG tag fusion type Tim-4 protein was prepared by the following method.

[0246]

< (1) Vector construction and culture conditions >

First, a FLAG tag fusion type mouse-derived Tim-4 protein cDNA (a cDNA encoding an amino acid sequence fused with 1 x FLAG at the C-terminal of the N-terminal 1 to 273 amino acid region of the mouse-derived Tim-4 protein, SEQ

ID NO: 33 (containing a stop codon (taa) and a nucleotide sequence encoding 1 × FLAG, in this regard, however, excluding the restriction enzyme site), produced by Fasmac Co., Ltd.), was incorporated in an XhoI/BamHI site of a pCAG-Neo vector (produced by Wako Pure Chemical Industries, Ltd.) to construct a vector for
5 expressing the FLAG tag fusion type Tim-4 protein (hereinafter it may be abbreviated as “the pCAG-Tim-4-FLAG”, in some cases).

On the other hand, the 293 T cells (RIKEN BRC) were cultured for 1 day using 50 mL DMEM (produced by Wako Pure Chemical Industries, Ltd.) containing 10% FBS (produced by Biosera) in a 225 cm² flask by seeding, so that
10 the cells grow to 70% to 90% at the time of transfection. Thereafter, 60 µg of the pCAG-Tim-4-FLAG was transfected into the 293 T cells cultured for 1 day using a Lipofectamine 2000 (produced by Thermo Fisher Scientific Inc.), according to a usual method. After transfection, the 293 T cells transfected were cultured for 1 day under condition at 37°C and 5% CO₂. Thereafter, the whole amount of the
15 culture solution was removed, the transfected 293 T cells were washed twice with 10 mL of PBS, and the culture solution was exchanged with 50 mL of an Opti-MEM (produced by Thermo Fisher Scientific Inc.) to culture for 3 days under condition at 37°C and 5% CO₂.

[0247]

20 < (2) Purification >

The culture solution of the 293 T cells transfected, after three days of culture, was subjected to centrifugal separation treatment (300 × G, for 5 minutes) to recover the culture supernatant. The recovered culture supernatant was further subjected to centrifugal separation treatment three times (first time: 300 ×
25 G, for 3 minutes, second time: 1200 × G, for 20 minutes, and third time: 10000 × G, for 20 minutes) to obtain a supernatant, where impurities were separated. The resulting supernatant was subjected to ultrafiltration using a Vivaspin (cut off molecular weight of 30,000, manufactured by GE Healthcare) to concentrate 10 times to obtain a concentrated culture supernatant solution. An ANTI-FLAG M2

affinity gel (500 μ L, 1/10 volume of the concentrated culture supernatant solution, produced by Sigma-Aldrich Co., Ltd.) washed with PBS was added to 5 mL of the resulting concentrated culture supernatant solution and mixed with inversion for 3 hours, and the FLAG tag fusion type Tim-4 protein in the concentrated culture supernatant solution and the ANTI-FLAG M2 affinity gel were subjected to a reaction to bind the FLAG tag fused Tim-4 protein to the ANTI-FLAG M2 affinity gel. Then, the ANTI-FLAG M2 affinity gel was washed three times with 5 μ L of PBS.

After that, 250 μ L (half volume of the ANTI-FLAG M2 affinity gel used) of a 200 μ g/mL FLAG peptide solution (a solution of a DYKDDDDK peptide (produced by Wako Pure Chemical Industries, Ltd.) diluted with PBS) was added to the ANTI-FLAG M2 affinity Gel, and mixed with inversion at 4°C for 30 minutes, and after centrifugal separation treatment (at 4°C, at 8000 $\times$ G, for 1 minute), the supernatant (eluate) was recovered. In order to remove the FLAG peptide in the recovered supernatant (eluate), 20 mL of PBS was added to the supernatant (eluate) and subjected to ultrafiltration to obtain a concentrated solution. PBS was added to the resulting concentrated solution, and volume of the solution was adjusted to 500 μ L to obtain the PBS solution containing the FLAG tag fusion type mouse-derived Tim-4 protein (it may be abbreviated as “the FLAG tag fusion type mTim-4 protein”, in some cases) (the solution may be abbreviated as “the FLAG tag fusion type mTim-4 protein-containing PBS solution”, in some cases) (Experimental Example 2).

[0248]

Experimental Example 3. Preparation of His tag fusion type Tim-4 protein

The His tag fusion type Tim-4 protein was prepared by the following method.

[0249]

< (1) Vector construction and culture conditions >

The His tag fusion type mouse-derived Tim-4 protein cDNA (a cDNA

encoding an amino acid sequence fused with 6 x His tag at the C-terminal of the N-terminal 1 to 273 amino acid region of the mouse-derived Tim-4 protein, SEQ ID NO: 34 (containing the stop codon (tga) and a cDNA encoding 6 x His tag) was incorporated in the XhoI/BamHI site of the pCAG-Neo vector (produced by Wako Pure Chemical Industries, Ltd.) to construct a vector for expressing the His tag fusion type Tim-4 protein (hereinafter it may be abbreviated as “the pCAG-Tim-4-His”, in some cases).

On the other hand, the 293 T cells (RIKEN BRC) were cultured for 1 day using 50 mL of DMEM (manufactured by Wako Pure Chemical Industries, Ltd.) containing 10% FBS (produced by Biosera) in a 225 cm² flask. Thereafter, 60 µg of the pCAG-Tim-4-His was transfected into the 293 T cells using Lipofectamine 2000 (produced by Thermo Fisher Scientific Inc.), according to a usual method. After transfection, the 293 T cells transfected were cultured for 1 day under condition at 37°C and 5% CO₂. Thereafter, the whole amount of the culture solution was removed, the transfected 293 T cells were washed twice with 10 mL of PBS, and the culture solution was exchanged with 50 mL of the Opti-MEM (manufactured by Thermo Fisher Scientific Inc.) and cultured for 3 days under condition at 37°C and 5% CO₂.

[0250]

< (2) Purification >

The culture solution of the 293 T cells transfected after three days of culture was subjected to centrifugal separation treatment (300 × G, for 5 minutes) to recover the culture supernatant. The recovered culture supernatant was further subjected to centrifugal separation treatment three times (the first time: 300 × G, for 3 min, the second time: 1200 × G, for 20 min, and the third time: 10000 × G, for 20 min) to separate impurities, and obtain the supernatant. The resulting supernatant was subjected to ultrafiltration using the Vivaspin (cut off molecular weight 30,000, manufactured by GE Healthcare) and concentrated 10 times to obtain a concentrated culture supernatant solution.

Ni Sepharose 6 Fast Flow (2.7 mL, produced by GE Healthcare) was prepared according to a protocol attached to the Ni Sepharose 6 Fast Flow, and transferred to a column. A binding buffer (50 mM Tris-HCl, 500 mM NaCl, 20 mM imidazole) was added to the column at a flow rate of about 1 mL/min, while measuring an OD 280 nm until absorbance at 280 nm was stabilized. After the addition of 5 mL of the resulting concentrated culture supernatant solution to the column, the binding buffer was sufficiently added and washed until the absorbance was stabilized. Subsequently, an elution buffer (50 mM Tris-HCl, 500 mM NaCl, 300 mM imidazole) was added to the column, and each 1 mL of the eluate fractions was recovered by 10 fractions.

[0251]

< (3) Electrophoresis and silver staining >

Each 15 µL aliquot of the eluted fractions was fractionated and mixed with 5 µL of 4 × sample buffer solution (produced by Wako Pure Chemical Industries, Ltd.), and incubated at 98°C for 5 minutes to obtain each 20 µL of a sample for electrophoresis. Each 15 µL of the sample for electrophoresis was loaded on a Super Sep Ace 5-20% gel (produced by Wako Pure Chemical Industries, Ltd.), and subjected to electrophoresis at 25 mA for 65 minutes.

The gel was stained with Silver Stain II Kit Wako (manufactured by Wako Pure Chemical Industries, Ltd.) to select and pool (put together) five fractions containing a target protein. Then, to remove imidazole contained in the eluate, 20 mL of PBS was added and ultrafiltration was carried out using the Vivaspin (cut off molecular weight 30,000, produced by GE Healthcare) to obtain a concentrated solution. PBS was added to the resulting concentrated solution, and volume of the solution was adjusted to 500 µL to obtain the PBS solution containing the His tag fusion type mouse-derived Tim-4 protein (it may be abbreviated as “the His tag fusion type mTim-4 protein”, in some cases) (the solution may be abbreviated as “the His tag fusion type mTim-4 protein-containing PBS solution”, in some cases).

[0252]

Examples 1 to 8. Obtaining of extracellular membrane vesicles using Tim-4 carrier of the present invention (obtaining method of the present invention)

The Tim-4 carrier of the present invention was prepared as follows, and the
5 extracellular membrane vesicles pertaining to the present invention were obtained using this.

[0253]

< (1) Preparation of calcium ion-containing culture supernatant sample >

A human chronic myelogenous leukemia cell strain K562, 1×10^7 cells,
10 secreting the extracellular membrane vesicle, was cultured for 3 days under condition at 37°C and 5% CO₂, using 80 mL of the X-VIVO 15 medium (produced by Lonza AG). Then the cells were subjected to centrifugal separation treatment (300 × G, for 5 minutes) to precipitate the cells, and remove the supernatant. The precipitated cells were suspended in 60 mL of the X-VIVO 15 medium
15 containing 10 μM monensin sodium (produced by MP Biomedicals Co., Ltd.) and cultured for 24 hours under condition at 37°C and 5% CO₂.

Thereafter, the culture solution was subjected to centrifugal separation treatment (300 × G, for 5 minutes) to recover the culture supernatant. The recovered culture supernatant (60 mL) was further subjected to centrifugal
20 separation treatment three times (the first time, 300 × G, for 3 minutes, the second time, 1200 × G, for 20 minutes, and the third time, 10000 × G, for 20 minutes) to separate impurities and obtain the supernatant. The resulting supernatant was subjected to ultrafiltration using the Vivaspin (cut off molecular weight 30,000, produced by GE Healthcare) until volume attained 6 mL or less to obtain the
25 concentrated solution. The X-VIVO 15 medium containing 10 μM monensin sodium (manufactured by MP Biomedicals Co., Ltd.) was added to the resulting concentrated solution to adjust liquid volume to 6 mL to obtain the 10 times concentrated K562 cell culture concentrated solution sample (hereinafter it may be abbreviated as “the culture supernatant sample”, in some cases).

In addition, CaCl_2 was added to the resulting culture supernatant sample, so as to attain the final concentration of 2 mM to obtain the K562 cell culture supernatant concentrated sample containing 2 mM CaCl_2 (hereinafter it may be abbreviated as “the calcium ion-containing culture supernatant sample”, in some cases).

[0254]

< (2) Biotin labeling of Fc tag fusion type mouse-derived Tim-4 protein >

For 114 μL of the PBS solution containing the Fc tag fusion type mTim-4 protein (containing 10 μg of the Fc tag fusion type mTim-4 protein) prepared by the same method as in Experimental Example 1, the NH_2 -group of the Fc tag fusion type mTim-4 protein was labeled with biotin, using the Biotin Labeling Kit- NH_2 (manufactured by Dojindo Molecular Technologies, Inc.), according to a protocol attached to the kit to obtain 100 μL of the PBS solution containing 3.8 μg of the NH_2 -group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein (it may be abbreviated as “the NH_2 -group biotin-labeled Fc tag fusion type mTim-4 protein”, in some cases) (the solution may be abbreviated as “the NH_2 -group biotin-labeled Fc tag fusion type mTim-4 protein-containing PBS solution”, in some cases).

In addition, for 114 μL of the Fc tag fusion type mTim-4 protein- containing PBS solution (containing 10 μg of the Fc tag fusion type mouse-derived Tim-4 protein) prepared by the same method as in Experimental Example 1, the SH-group of the Fc tag fusion type mouse-derived Tim-4 protein was labeled with biotin, using a Biotin Labeling Kit-SH manufactured by Dojindo Molecular Technologies, Inc.), according to a protocol attached to the kit to obtain 100 μL of the PBS solution containing 5.9 μg of the SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein (it may be abbreviated as “the SH-group biotin-labeled Fc tag fusion type mTim-4 protein”, in some cases) (the solution may be abbreviated as “the SH-group biotin-labeled Fc tag fusion type mTim-4 protein-containing PBS solution”, in some cases).

[0255]

< (3) Dilution of Fc tag fusion type mouse-derived Tim-4 protein- containing PBS solution >

The Fc tag fusion type mTim-4 protein-containing PBS solution (11.4 μ L),
5 prepared by the same method as in Experimental Example 1, was mixed with
188.6 μ L of PBS to obtain 200 μ L of the PBS solution containing 1 μ g of the
biotin-unlabeled Fc tag fusion type mTim-4 protein.

The NH₂-group biotin-labeled Fc tag fusion type mTim-4 protein- containing
PBS solution (26.3 μ L) prepared above (containing 1 μ g of the NH₂-group
10 biotin-labeled Fc tag fusion type mTim-4 protein) was mixed with 173.7 μ L of PBS
to obtain 200 μ L of the PBS solution containing 1 μ g of the NH₂-group
biotin-labeled Fc tag fusion type mTim-4 protein.

In addition, 16.9 μ L of the SH-group biotin-labeled Fc tag fusion type
mTim-4 protein-containing PBS solution prepared above (containing 1 μ g of the
15 SH-group biotin-labeled Fc tag fusion type mTim-4 protein) was mixed with 183.1
 μ L of PBS to obtain 200 μ L of the PBS solution containing 1 μ g of the SH-group
biotin-labeled Fc tag fusion type mTim-4 protein.

[0256]

< (4) Washing of beads>

20 A PBS-T solution (20 μ L) containing a 30 μ g/ μ L Dynabeads Protein G
(produced by Thermo Fisher Scientific Inc.) (containing 0.6 mg of the Dynabeads
Protein G) was dispensed into each of three 1.5 mL tubes (manufactured by BM
Equipment Co., Ltd.). Next, 500 μ L of PBS was added to each of the 1.5 mL
tubes, and after stirring, each of the 1.5 mL tubes were loaded on a magnet stand,
25 and the Dynabeads Protein G was collected on the tube wall using magnetic force,
and the solution in the 1.5 mL tube was discarded with a pipette (hereinafter it may
be abbreviated as “the washing operation”, in some cases).

In addition, 60 μ L of the PBS solution containing a 10 μ g/ μ L Dynabeads
M-270 Streptavidin C1 (produced by Thermo Fisher Scientific Inc.) (containing 0.6

mg of the Dynabeads M-270 Streptavidin C1) was dispensed into the 1.5 mL tube (manufactured by BM Instruments co., Ltd), and the washing operation was carried out in the same method as above using 500 μ L of PBS.

[0257]

5 < (5) Immobilization of Fc tag fusion type mouse-derived Tim-4 protein on beads >

For one of the three 1.5 mL tubes containing the Dynabeads Protein G (0.6 mg), 200 μ L of the PBS solution containing 1 μ g of the biotin-unlabeled Fc tag fusion type mTim-4 protein prepared above was added in its entirety, and subjected to a reaction at 8°C for 1 hour to obtain 200 μ L of the PBS solution
10 containing the carrier on which the biotin-unlabeled Fc tag fusion type mTim-4 protein was bound (mTim-4 carrier).

For one of the remaining two 1.5 mL tubes containing the Dynabeads Protein G (0.6 mg), 200 μ L of the PBS solution containing 1 μ g of the NH₂-group biotin-labeled Fc tag fusion type mTim-4 protein prepared above was added in its
15 entirety, and subjected to a reaction at 8°C for 1 hour to obtain 200 μ L of the PBS solution containing the carrier on which the NH₂-group biotin-labeled Fc tag fusion type mTim-4 protein was bound (mTim-4 carrier).

In addition, for one tube, 200 μ L of the PBS solution containing 1 μ g of the SH-group biotin-labeled Fc tag fusion type mTim-4 protein prepared above was
20 added in its entirety, and subjected to a reaction at 8°C for 1 hour to obtain 200 μ L of the PBS solution containing the carrier on which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound (mTim-4 carrier).

For one of 1.5 mL tube containing the Dynabeads M-270 Streptavidin C1, 200 μ L of the PBS solution containing 1 μ g of the SH-group biotin-labeled Fc tag
25 fusion type mTim-4 protein prepared by the same method as above was added, and subjected to a reaction at 8°C for 1 hour to obtain 200 μ L of the PBS solution containing the carrier on which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound (mTim-4 carrier).

In this way, 200 μ L of the PBS solution containing 0.6 mg of each of the

four types of the mTim-4 carriers shown in the following Table 1 was obtained.

[0258]

Table 1

		1	2	3	4
Mouse-derived Tim-4 carrier	Fc tag fusion type mouse-derived Tim-4 protein	Unlabeled	Biotin labeled (NH ₂ -group)	Biotin labeled (SH-group)	
	Carrier	Protein G beads			Streptavidin beads

[0259]

- 5 < (6) Obtaining of extracellular membrane vesicles by obtaining method of the present invention>

The resulting 0.6 mg of the four types of the mTim-4 carriers above, described in Table 1, was subjected to the washing operation each three times with 500 μ L of PBS, and then 200 μ L of the calcium ion-containing culture
10 supernatant sample prepared in the (1) was added to each of the mTim-4 carriers in a pellet state and subjected them to a reaction at 8°C for 3 hours.

The mTim-4 carrier after the reaction was subjected to the washing operation 3 times with 500 μ L each of TBS-T containing 2 mM CaCl₂ (Tris buffer, 0.05% Tween 20, 2 mM CaCl₂). At the third time of the washing operation, each
15 250 μ L of the 4 types of the mTim-4 carriers was dispensed into two 1.5 mL tubes.

Each 20 μ L of the 1% SDS aqueous solution or the 1 mM EDTA aqueous solution was added, as the eluent, to each 0.3 mg of the four types of the mTim-4 carriers in a pellet state, and then they were mixed at room temperature for 10 seconds using a vortex mixer and spun down. Each 1.5 mL tube was loaded on
20 a magnet stand, and the mTim-4 carrier was collected on the tube wall using magnetic force to recover the supernatant (eluate).

It should be noted that, the types of the mTim-4 proteins, the carriers and the eluents used to obtain the extracellular membrane vesicles from the mTim-4 carrier, used in each Example, and the lane numbers in Western blotting to be
25 described later are shown in the following Table 2.

[0260]

Table 2

		Example 1	Example 2	Example 3	Example 4	Example 5	Example 6	Example 7	Example 8
Mouse-derived Tim-4 carrier	Fc tag fusion type mouse-derived Tim-4 protein	Unlabeled		Biotin labeled (NH ₂ -group)		Biotin labeled (SH-group)			
	Carrier								
		Protein G beads						Streptavidin beads	
Eluent		1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA
Lane number in Fig.1		1	2	3	4	5	6	7	8

[0261]

< (7) Western blotting >

5 To each 7.5 μ L of the supernatants (eluates) obtained in Examples 1 to 8, 2.5 μ L of the 4 $\times$ sample buffer (produced by Wako Pure Chemical Industries, Ltd.) was added and incubated at 98°C for 5 minutes to obtain each sample for Western blotting. Each 10 μ L of the sample for Western blotting was loaded on the Super Sep Ace 5-20% gel (produced by Wako Pure Chemical Industries, Ltd.),
10 and subjected to electrophoresis at 25 mA for 65 minutes. The resulting electrophoresis gel was transcribed onto a PVDF membrane (produced by Millipore Corporation) under 1 mA/cm² for 60 minutes using a semi-dry blotter and a discontinuous buffer (Anode buffer 1: 0.3 M Tris / 20% methanol, Anode buffer 2: 0.025 M Tris / 20% methanol, Cathode buffer: 0.025 M Tris / 0.04 M
15 aminocaproic acid / 20% methanol).

To the PVDF membrane, 3% skimmed milk diluted with PBS-T (the PBS buffer, 0.1% Tween 20) was added and subjected to a reaction at room temperature for 1 hour for blocking, and 2 mL of an anti-human Lamp-1 mouse monoclonal antibody diluted 250-fold with PBS-T (produced by BD Biosciences,
20 hereinafter it may be abbreviated as “the anti-human Lamp-1 antibody”, in some cases) was subjected to a reaction at 8°C overnight.

After that, the PVDF membrane after the reaction was washed three times with PBS-T, and then subjected to a reaction with a secondary antibody {anti-mouse IgG (H + L), rabbit, IgG fraction, peroxidase-conjugated antibody}

(produced by Wako Pure Chemical Industries, Ltd.) diluted 10,000-fold with PBS-T at room temperature for 1 hour. After washing it 5 times with PBS-T, ImmunoStar Zeta (produced by Wako Pure Chemical Industries, Ltd.) was added to detect a luminescent signal using LAS-4000 (manufactured by General Electric Company). It should be noted that the anti-human Lamp-1 antibody is an antibody against Lamp-1 which is one of the marker proteins of exosome.

[0262]

<Results>

The results of Western blotting obtained are shown in Fig. 1. In Fig. 1, each lane is as follows:

Lane 1: Results of Example 1 (results of the case of using the mTim-4 carrier in which the biotin-unlabeled Fc tag fusion type mTim-4 protein was bound on the Protein G beads, and using the 1% SDS aqueous solution as the eluent);

Lane 2: Results of Example 2 (the results of the case of using the mTim-4 carrier in which the biotin-unlabeled Fc tag fusion type mTim-4 protein was bound on the Protein G beads, and using the 1 mM EDTA solution as the eluent);

Lane 3: Results of Example 3 (the results of the case of using the mTim-4 carrier in which the NH₂-group biotin-labeled Fc tag fusion type mTim-4 protein was bound on the Protein G beads, and using the 1% SDS aqueous solution as the eluent);

Lane 4: Results of Example 4 (the results of the case of using the mTim-4 carrier in which the NH₂-group biotin-labeled Fc tag fusion type mTim-4 protein was bound on the Protein G beads, and using the 1 mM EDTA solution as the eluent);

Lane 5: Results of Example 5 (the results of the case of using the mTim-4 carrier in which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound on the Protein G beads, and using the 1% SDS aqueous solution as the eluent);

Lane 6: Results of Example 6 (the results of the case of using the mTim-4

carrier in which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound on the Protein G beads, and using the 1 mM EDTA solution as the eluent);

Lane 7: Results of Example 7 (the results of the case of using the mTim-4 carrier in which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound to the streptavidin beads, and using the 1% SDS aqueous solution as the eluent);

Lane 8: Results of Example 8 (the results of the case of using the mTim-4 carrier in which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound to the streptavidin beads, and using the 1 mM EDTA solution as the eluent).

[0263]

From Fig. 1, it has been revealed that the extracellular membrane vesicles including exosome can be obtained, according to the obtaining method of the present invention, from the fact that a band of Lamp-1, which is an exosome marker, was recognized at the vicinity of 100 kDa in any of Examples 1 to 8 (Examples 1 to 8: the lanes 1 to 8).

In particular, from comparison among Examples 2, 4, 6, and 8, it has been revealed that, when the calcium ion chelating agent is used as the eluent, the one in which the Tim-4 protein and the carrier are bound via the SH-group of the Tim-4 protein (Example 8: the lane 8) is possible to obtain more extracellular membrane vesicles, as compared with the one bound via the NH₂-group (Example 4: the lane 4) or those bound via the affinity tag (Example 2: lane 2, Example 6: the lane 6) (Example 2: lane 2, Example 4: lane 4, Example 6: lane 6, Example 8: the lane 8).

[0264]

Examples 9 to 16. Obtaining of extracellular membrane vesicles using Tim-4 carrier of the present invention (obtaining method of the present invention)

The Tim-4 carrier of the present invention was prepared as follows, and the extracellular membrane vesicles pertaining to the present invention were obtained using the same.

[0265]

< (1) Preparation of culture supernatant sample >

Preparation of the culture supernatant sample was carried out in the same method as in “(1) preparation of culture supernatant sample” of Examples 1 to 8.

5 [0266]

< (2) Biotin labeling of Fc tag fusion type mouse-derived Tim-4 protein >

For 114 μ L of the PBS solution containing the Fc tag fusion type mTim-4 protein (containing 10 μ g of the Fc tag fusion type mTim-4 protein), prepared by the same method as in “(2) Biotin labeling of Fc tag fusion type mouse-derived Tim-4 protein” of Experimental Example 1, the SH-group of the Fc tag fusion type mTim-4 protein was labeled with biotin by the same method as in Example 1 to obtain 100 μ L of the PBS solution containing 3.9 μ g of the SH-group biotin-labeled Fc tag fusion type mTim-4 protein (hereinafter it may be abbreviated as “the SH-group biotin-labeled Fc tag fusion type mTim-4 protein-containing PBS solution”, in some cases).

[0267]

< (3) Biotin labeling of FLAG tag fusion type mouse-derived Tim-4 protein >

For 99 μ L of the PBS solution containing the FLAG tag fusion type mTim-4 protein prepared by the same method as in Experimental Example 2 (containing 10 μ g of the FLAG tag fusion type mTim-4 protein), the SH-group of the FLAG tag fusion type mTim-4 protein was labeled with biotin using the Biotin Labeling Kit-SH (manufactured by Dojindo Molecular Technologies, Inc.), according to a protocol attached to the kit to obtain 100 μ L of the PBS solution containing 4.6 μ g of the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein (hereinafter it may be abbreviated as “the PBS solution containing the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein”, in some cases).

[0268]

< (4) Biotin labeling of His tag fusion type mouse-derived Tim-4 protein >

For 54 μ L of the PBS solution containing the His tag fusion type mTim-4

protein prepared by the same method as in Experiment Example 3 (containing 10 µg of the His tag fusion type mTim-4 protein), the SH-group of the His tag fusion type mTim-4 protein was labeled with biotin using the Biotin Labeling Kit-SH (manufactured by Dojindo Molecular Technologies, Inc.), according to a protocol
5 attached to the kit to obtain 100 µL of the PBS solution containing 7.2 µg of the SH-group biotin-labeled His tag fusion type mTim-4 protein (hereinafter it may be abbreviated as “the PBS solution containing the SH-group biotin-labeled His tag fusion type mTim-4 protein”, in some cases).

[0269]

10 < (5) Dilution of tag fusion type mouse-derived Tim-4 protein >

The Fc tag fusion type mTim-4 protein-containing PBS solution (11.4 µL), prepared by the same method as in Experimental Example 1 (containing 1 µg of the Fc tag fusion type mouse-derived Tim-4 protein), was mixed with 188.6 µL of PBS to obtain 200 µL of the PBS solution containing 1 µg of biotin-unlabeled Fc
15 tag fusion type mouse-derived Tim-4 protein.

The SH-group biotin-labeled Fc tag fusion type mTim-4 protein-containing PBS solution (16.9 µL), prepared in the (2) (containing 1 µg of the SH-group biotin-labeled Fc tag fusion type mTim-4 protein), was mixed with 183.1 µL of PBS to obtain 200 µL of the PBS solution containing 1 µg of the SH-group
20 biotin-labeled Fc tag fusion type mTim-4 protein.

In addition, 21.6 µL of the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein-containing PBS solution, prepared in the (3) (containing 1 µg of the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein), was mixed with 178.4 µL of PBS to obtain 200 µL of the PBS solution containing 1 µg of the
25 SH-group biotin-labeled FLAG tag fusion type mTim-4 protein.

The SH-group biotin-labeled His tag fusion type mTim-4 protein-containing PBS solution (13.9 µL), prepared in the (4) (containing 1 µg of the SH-group biotin-labeled His tag fusion type mTim-4 protein), was mixed with 186.1 µL of PBS to obtain 200 µL of the PBS solution containing 1 µg of the SH-group

biotin-labeled His tag fusion type mTim-4 protein.

[0270]

< (6) Washing of beads >

The PBS-T solution (20 μ L) containing 30 μ g/ μ L of the Dynabeads Protein
5 G (produced by Thermo Fisher Scientific, Inc.) (containing 0.6 mg of the
Dynabeads Protein G) was dispensed into one 1.5 mL tube (manufactured by BM
Equipment Co., Ltd.), and the washing operation was carried out using 500 μ L of
PBS in the same method as in “(4) washing of beads” in Examples 1 to 8.

In addition, 60 μ L of the PBS solution containing the 10 μ g/ μ L Dynabeads
10 M-270 Streptavidin (produced by Thermo Fisher Scientific Inc.) (containing 0.6 mg
of the Dynabeads M-270 Streptavidin) was dispensed into each of the three 1.5
mL tubes (manufactured by BM Equipment Co., Ltd.), and the washing operation
was carried out using each 500 μ L of PBS in the same method as in “(4) washing
of beads” in Examples 1 to 8.

15 [0271]

< (7) Immobilization of tag-fused mouse-derived Tim-4 protein on beads >

Subsequently, 200 μ L of the PBS solution containing 1 μ g of the
biotin-unlabeled Fc tag fusion type mTim-4 protein was added in its entirety to the
1.5 mL tube containing 0.6 mg of the Dynabeads Protein G in a pellet state, after
20 the washing operation, and subjected to a reaction at 8°C for 1 hour to obtain 200
 μ L of the PBS solution containing the carrier on which the biotin-unlabeled Fc tag
fusion type mTim-4 protein was bound (the mTim-4 carrier).

Furthermore, for one of the three 1.5 mL tubes containing 0.6 mg of the
Dynabeads M-270 Streptavidin in a pellet state, after the washing operation, 200
25 μ L of the PBS solution containing 1 μ g of the SH-group biotin-labeled Fc tag
fusion type mTim-4 protein prepared above was added in its entirety and
subjected to a reaction at 8°C for 1 hour to obtain 200 μ L of the PBS solution
containing the carrier on which the SH-group biotin-labeled Fc tag fusion type
mTim-4 protein was bound (the mTim-4 carrier).

For one of the remaining two 1.5 mL tubes containing 0.6 mg of the Dynabeads M-270 Streptavidin in a pellet state, after the washing operation, 200 μ L of the PBS solution containing 1 μ g of the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein prepared above was added in its entirety, and subjected to a reaction at 8°C for 1 hour to obtain 200 μ L of the PBS solution containing the carrier on which the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein was bound (the mTim-4 carrier).

In addition, for one tube, 200 μ L of the PBS solution containing 1 μ g of the SH-group biotin-labeled His tag fusion type mTim-4 protein prepared above was added in its entirety, and subjected to a reaction at 8°C for 1 hour to obtain 200 μ L of the PBS solution containing the carrier on which the SH-group biotin-labeled His tag fusion type mTim-4 protein was bound (the mTim-4 carrier).

In this way, 200 μ L of the PBS solutions containing 0.6 mg of each of the four types of mTim-4 carriers shown in the following Table 3 were obtained.

[0272]

Table 3

		1	2	3	4
Mouse-derived Tim-4 carrier	Type of tag	Fc tag		FLAG tag	His tag
	Tag fusion type mouse-derived Tim-4 protein	Unlabeled	Biotin labeled (SH-group)		
	Carrier	Protein G beads	Streptavidin beads		

[0273]

< (8) Obtaining of extracellular membrane vesicles by obtaining method of the present invention >

Each supernatant (eluate) was obtained by carrying out the same method as in “(6) Obtaining of extracellular membrane vesicles by obtaining method of the present invention” of Examples 1 to 8, except for using “0.6 mg of the four kinds of the mTim-4 carriers shown in Table 3” instead of “0.6 mg of the four kinds of the mTim-4 carrier shown in Table 1”. It should be noted that the type of the mTim-4 proteins, the carriers, and the eluents used to obtain the extracellular membrane

vesicles from the mTim-4 carrier, used in each Example, and the lane numbers in Western blotting to be described later are shown in the following Table 4.

[0274]

Table 4

		Example 9	Example 10	Example 11	Example 12	Example 13	Example 14	Example 15	Example 16
Mouse-derived Tim-4 carrier	Type of tag	Fc tag				FLAG tag		His tag	
	Tag fusion type mouse-derived Tim-4 protein	Unlabeled		Biotin labeled (SH-group)					
	Carrier	Protein G beads		Streptavidin beads					
Eluent		1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA
Lane number in Fig.2		1	2	3	4	5	6	7	8

5

[0275]

< (7) Western blotting >

Western blotting was carried out by the same method as in “(7) Western blotting” of Examples 1 to 8, except for using “7.5 μ L of each supernatant (eluate) obtained in Examples 9 to 16 (above (8)), instead of “7.5 μ L of each supernatant (eluate) obtained in Examples 1 to 8”.

10

[0276]

<Results>

The results of Western blotting obtained are shown in Fig. 2. In Fig. 2, each lane is as follows:

15

Lane 1: Results of Example 9 (the results of the case of using the mTim-4 carrier in which the biotin-unlabeled Fc tag fusion type mTim-4 protein was bound on the Protein G beads, and using the 1% SDS aqueous solution as the eluent);

Lane 2: Result of Example 10 (the results of the case of using the mTim-4 carrier in which the biotin-unlabeled Fc tag fusion type mTim-4 protein was bound on the Protein G beads, and using the 1 mM EDTA solution as the eluent);

20

Lane 3: Results of Example 11 (the results of the case of using the mTim-4 carrier in which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound on the streptavidin beads, and using the 1% SDS aqueous solution as the

eluent);

Lane 4: Results of Example 12 (the results of the case of using the mTim-4 carrier in which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound on the streptavidin beads, and using the 1 mM EDTA solution as the eluent);

Lane 5: Results of Example 13 (the results of the case of using the mTim-4 carrier in which the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein was bound on the streptavidin beads, and using the 1% SDS aqueous solution as the eluent);

Lane 6: Results of Example 14 (the results of the case of using the mTim-4 carrier in which the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein was bound on the streptavidin beads, and using the 1 mM EDTA solution as the eluent);

Lane 7: Results of Example 15 (the results of the case of using the mTim-4 carrier in which the SH-group biotin-labeled His tag fusion type mTim-4 protein was bound on the streptavidin beads, and using the 1% SDS aqueous solution as the eluent);

Lane 8: The results of Example 16 (the results of the case of using the mTim-4 carrier in which the SH-group biotin-labeled His tag fusion type mTim-4 protein was bound on the streptavidin beads, and using the 1 mM EDTA solution as the eluent).

From Fig. 2, it has been revealed that the extracellular membrane vesicles including exosome can be obtained, by using the obtaining method of the present invention, because of the fact that a band of Lamp-1, which is a marker protein of exosome, was detected at the vicinity of 100 kDa, in any of Examples 9 to 16 (Example 9 to 16: the lanes 1 to 8).

In addition, it has been revealed that the extracellular membrane vesicles can be obtained by using the Tim-4 carrier of the present invention, irrespective of the type, length, and presence or absence of the tags (Examples 9 to 16: the

lanes 1 to 8).

From comparison among Examples 10, 12, 14, and 16, it has been revealed that when EDTA, which is the calcium ion chelating agent, is used as the eluent, those on which the Tim-4 protein and the carrier are bound via the SH-group of the Tim-4 protein (Example 12: the lane 4, Example 14: the lane 6, Example 16: the lane 8) are possible to obtain more extracellular membrane vesicles as compared with the one bound via the affinity tag (Example 10: the lane 2).

[0277]

10 Examples 17 to 18. Obtaining of extracellular membrane vesicles using Tim-4 carrier of the present invention (obtaining method of the present invention)

The Tim-4 carrier of the present invention was prepared as follows, and the extracellular membrane vesicles pertaining to the present invention were obtained using the same.

15 [0278]

< (1) Preparation of culture supernatant sample >

Preparation of culture supernatant sample was carried out in the same method as in “(1) Preparation of culture supernatant sample” of Examples 1 to 8.

[0279]

20 < (2) Dilution of biotin-unlabeled FLAG tag fusion type mouse-derived Tim-4 protein >

The PBS solution (47 μ L) containing 5 μ g of the biotin-unlabeled FLAG tag fusion type mTim-4 protein, prepared by the same method as in Experimental Example 2 (the biotin-unlabeled FLAG tag fusion type mTim-4 protein-containing PBS solution) was mixed with 153 μ L of PBS to obtain 200 μ L of the PBS solution containing 5 μ g of the biotin-unlabeled FLAG tag fusion type mTim-4 protein.

25

[0280]

< (3) Washing of beads >

A 50% glycerol TBS solution (50 μ L) containing 10 μ g/ μ L of

anti-DYKDDDDK tag antibody magnetic beads (containing 0.5 mg of the anti-DYKDDDDK tag antibody magnetic beads) (produced by Wako Pure Chemical Industries, Ltd.) was dispensed into the 1.5 mL tube (manufactured by BM Equipment Co., Ltd.), and the washing operation was carried out using 500 μ L of PBS.

[0281]

< (4) Immobilization of FLAG tag fusion type mouse-derived Tim-4 protein on carrier >

Subsequently, 200 μ L of the PBS solution containing 5 μ g of the FLAG tag fusion type mTim-4 protein was added in its entirety to the anti-DYKDDDDK tag antibody magnetic beads in a pelleted state, after the washing operation, and subjected to a reaction at 8°C for 1 hour to obtain 200 μ L of the PBS solution containing the mTim-4 carrier.

In this way, 200 μ L of the PBS solution containing 0.5 mg of the mTim-4 carrier shown in the following Table 5 was obtained.

[0282]

Table 5

		1
Mouse-derived Tim-4 carrier	Type of tag	FLAG tag
	Tag fusion type mouse-derived Tim-4 protein	Biotin-unlabeled
	Carrier	Anti-DYKDDDDK tag antibody beads

[0283]

< (5) Obtaining of extracellular membrane vesicles by obtaining method of the present invention >

Each supernatant (eluate) was obtained by carrying out the same method as in “(6) Obtaining of extracellular membrane vesicles by the obtaining method of the present invention” of Examples 1 to 8, except for using “0.5 mg of the mTim-4 carrier described in Table 5”, instead of “0.6 mg of the four kinds of the mTim-4 carrier described in Table 1”.

It should be noted that the types of the mTim-4 protein, the carrier and the eluent used to obtain the extracellular membrane vesicles from the mTim-4 carrier, used in each Example, and the lane numbers in Western blotting to be described later are shown in the following Table 6.

5 [0284]

[Table 6]

		Example 17	Example 18
Mouse-derived Tim-4 carrier	Type of tag	FLAG tag	
	Tag fusion type mouse-derived Tim-4 protein	Biotin-unlabeled	
	Carrier	Anti-DYKDDDDK tag antibody beads	
Eluent		1% SDS	1 mM EDTA
Lane number in Fig. 3		1	2

[0285]

< (6) Western blotting >

Western blotting was carried out by the same method as in “(7) Western blotting” of Examples 1 to 8, except for using “7.5 μ L of each supernatant (eluate) obtained in Examples 17 to 18 (above (5)) instead of “7.5 μ L of each supernatant (eluate) obtained in Examples 1 to 8”.

[0286]

<Results>

15 The results of Western blotting obtained are shown in Fig. 3. In Fig. 3, each lane is as follows:

Lane 1: Results of Example 17 (the results of the case of using the mTim-4 carrier in which the biotin-unlabeled FLAG tag fusion type mTim-4 protein was bound on the anti-DYKDDDDK antibody beads, and using the 1% SDS aqueous solution as the eluent);

20 Lane 2: Result of Example 18 (the results of the case of using the mTim-4 carrier in which the biotin-unlabeled FLAG tag fusion type mTim-4 protein was bound on the anti-DYKDDDDK antibody beads, and using the 1 mM EDTA solution as the eluent).

From Fig. 3, it has been revealed that the extracellular membrane vesicles including exosome can be obtained, according to the obtaining method of the present invention, when the carrier on which the Tim-4 protein is immobilized via the anti-tag antibody, from the fact that a band of Lamp-1, which is an exosome marker, was observed at the vicinity of 100 kDa, in any case of Examples 17 to 18 (Examples 17 to 18: the lanes 1 to 2).

[0287]

Examples 19 to 20 and Comparative Examples 1 to 3. Comparison of purity of extracellular membrane vesicles obtained by the obtaining method of the present invention and conventional method

As described below, comparison was carried out on purity of the extracellular membrane vesicles obtained by each of the obtaining method of the present invention by SDS elution (Example 19), the obtaining method of the present invention by EDTA elution (Example 20), the ultracentrifugal separation method (Comparative Example 1), Exo Quick (Comparative Example 2), and Total Exosome Isolation (Comparative Example 3).

[0288]

< Obtaining of extracellular membrane vesicles by the obtaining method of the present invention (Examples 19 and 20)>

The mTim-4 protein where the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein was bound to the Dynabeads M-270 Streptavidin C1 (produced by Thermo Fisher Scientific Inc.) and the extracellular membrane vesicles in the calcium ion-containing culture supernatant sample were subjected to a reaction by the same method as in Examples 13 to 14, and the extracellular membrane vesicles were each eluted with the 1% SDS aqueous solution or 1 mM EDTA aqueous solution, as the eluent, to obtain each of the supernatants (eluates) except for using “500 μ L of the calcium ion-containing culture supernatant sample”, instead of “200 μ L of the calcium ion-containing culture supernatant sample”, “50 μ L of the 1% SDS aqueous solution”, instead of “20 μ L

of the 1% SDS aqueous solution” as an eluent, and using “50 μ L of the 1 mM EDTA aqueous solution”, instead of “20 μ L of the 1 mM EDTA aqueous solution,.

Each of the resulting supernatants (eluates) was defined as Sample 1 (when eluted with the 1% SDS aqueous solution), and Sample 2 (when eluted with the 1 mM EDTA aqueous solution).

It should be noted that the type of the mTim-4 protein, the carrier and the eluents used to obtain the extracellular membrane vesicles from the mTim-4 carrier, used in Examples 19 and 20, are shown in the following Table 7.

[0289]

Table 7

		Example 19	Example 20
Mouse-derived Tim-4 carrier	Type of tag	FLAG tag	
	Tag fusion type mouse-derived Tim-4 protein	Biotin-labeled (SH-group)	
	Carrier	Streptavidin beads	
Eluent		1% SDS	1 mM EDTA

[0290]

<Obtaining of extracellular membrane vesicles by ultracentrifugal separation method (Comparative Example 1)>

The culture supernatant sample (1 mL), prepared by the same method as in Example 1, was subjected to centrifugal separation treatment (20,000 $\times$ G, for 30 minutes) to separate impurities and obtain the supernatant. Then, 1 mL of the resulting supernatant was subjected to ultracentrifugal separation treatment (110,000 $\times$ G, for 70 minutes) to obtain a precipitate fraction. Thereafter, the resulting precipitate fraction was suspended in 1 mL of PBS. The suspension of the precipitate fraction was subjected to ultracentrifugal separation treatment again (110,000 $\times$ G, for 70 minutes), and then the resulting precipitate fraction was suspended in 50 μ L of PBS. The resulting suspension was referred to as Sample 3 (Comparative Example 1).

[0291]

<Obtaining of extracellular membrane vesicles by centrifugal separation method using commercially available reagent (obtaining of extracellular membrane vesicles by ExoQuick) (Comparative Example 2)>

The culture supernatant sample (1 mL), prepared by the same method as in Example 1, was subjected to centrifugal separation treatment (20,000 × G, for 30 minutes) to separate impurities and obtain the supernatant. Then, 1 mL of the resulting supernatant was mixed with 0.2 mL of the ExoQuick-TC Reagent (produced by System Biosciences, Inc.) and the mixture solution was allowed to stand overnight at 8°C. Thereafter, the mixture solution that had been allowed to stand overnight was subjected to centrifugal separation treatment (1,500 × G, for 30 minutes), and the resulting precipitate fraction was suspended in 100 µL of PBS. The resulting suspension solution was referred to as Sample 4 (Comparative Example 2).

[0292]

<Obtaining of extracellular membrane vesicles by centrifugal separation method using commercially available reagent (obtaining of extracellular membrane vesicles by Total Exosome Isolation) (Comparative Example 3)>

The K562 cell culture supernatant concentrated solution sample (1 mL), prepared by the same method as in Example 1, was subjected to centrifugal separation treatment (20,000 × G, for 30 minutes) to separate impurities and obtain the supernatant. Subsequently, 1 mL of the resulting supernatant was mixed with 0.5 mL of the Total Exosome Isolation Reagent (produced by Thermo Fisher Scientific Inc.) and allowed to stand at 8°C for 1 day. The precipitate fraction obtained by centrifugal separation treatment (10,000 × G, for 1 hour) of the mixed solution was suspended in 100 µL of PBS. The resulting suspension solution was referred to as Sample 5 (Comparative Example 3).

It should be noted that the methods used in each Example and Comparative Example, the resulting samples, and the lane numbers in Western blotting and silver staining to be described later are shown in the following Table 8.

[0293]

Table 8

	Example 19	Example 20	Comparative Example 1	Comparative Example 2	Comparative Example 3
Method	Method of the present invention (elution by 1% SDS)	Method of the present invention (elution by 1 mM EDTA)	Ultra-centrifugation method	Exo Quick	Total Exosome Isolation
Sample number	Sample 1	Sample 2	Sample 3	Sample 4	Sample 5
Lane number in Fig. 4	1	2	3	4	5

[0294]

<Western blotting>

5 Amounts of the proteins in the resulting Samples 1 to 5 by each method were measured by the BCA method, and based on the measurement result, and using the amounts of the proteins as standard amounts of electrophoresis, Western blotting was carried out. That is, 37.5 μ L of the PBS solution containing 0.25 μ g of each of the proteins in Samples 1 to 5, and 12.5 μ L of the 4 $\times$ sample
10 buffer solution (produced by Wako Pure Chemical Industries, Ltd.) were mixed, and incubated at 98°C for 5 minutes to obtain 50 μ L of each sample for Western blotting.

 Subsequently, each 20 μ L of the resulting sample for Western blotting was loaded on two sheets of the Super Sep Ace 5-20% gel (produced by Wako Pure
15 Chemical Industries, Ltd.), and subjected to electrophoresis at 25 mA for 60 minutes. One of the resulting two sheets of the gels was transcribed onto the PVDF membrane (produced by Millipore Corporation) at 1 mA/cm² for 60 minutes, using the semi-dry blotter and the discontinuous buffer (Anode Buffer 1: 0.3 M Tris / 20% Methanol, Anode Buffer 2: 0.025 M Tris / 20% Methanol, Cathode Buffer:
20 0.025 M Tris / 0.04 M aminocaproic acid / 20% methanol). The 3 % skimmed milk, diluted with PBS-T, was added to the PVDF membrane and subjected to a reaction at room temperature for 1 hour for blocking, and then 2 mL of the anti-human Lamp-1 mouse monoclonal antibody (produced by BD Biosciences), diluted 250-fold with PBS-T, was subjected to a reaction at room temperature for 1

hour. After washing 3 times with PBS-T, the membrane was subjected to a reaction with the secondary antibody {anti-mouse IgG (H + L), rabbit, the IgG fraction, the peroxidase-conjugated antibody (produced by Wako Pure Chemical Industries, Ltd.)}, diluted 10,000-fold with PBS-T, at room temperature for 1 hour.

5 After washing five times with PBS-T, an ECL prime (produced by General Electric Company) was added, and each luminescent signal was detected using the LAS-4000 (manufactured by General Electric Company).

In addition, the other one gel was silver stained using a Silver staining II kit Wako (manufactured by Wako Pure Chemical Industries, Ltd.).

10 [0295]

<Results>

The results of Western blotting obtained, and the results of silver staining are shown in Fig. 4-A and Fig. 4-B, respectively. In Fig. 4-A and Fig. 4-B, each lane is as follows:

15 Lane 1: Results of Example 19 (the results of the case where the method of the present invention was carried out using the mTim-4 carrier where the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein was bound on the streptavidin beads, and using the 1% SDS aqueous solution as the eluent);

20 Lane 2: Results of Example 20 (the results of the case where the method of the present invention was carried out using the mTim-4 carrier where the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein was bound on the streptavidin beads, and using the 1 mM EDTA solution as the eluent);

25 Lane 3: Results of Comparative Example 1 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by the ultracentrifugal separation method);

Lane 4: Results of Comparative Example 2 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by ExoQuick);

Lane 5: Results of Comparative Example 3 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by Total

Exosome Isolation).

From Fig. 4-A, it has been revealed that the extracellular membrane vesicles including exosome can be obtained, according to the obtaining method of the present invention, from the fact that a band of Lamp-1, which is an exosome marker, was observed at the vicinity of 100 kDa in any of Examples 19 and 20, which are the obtaining method of the present invention (Examples 19 to 20: the lanes 1 to 2).

On the other hand, from Fig. 4-A, a band of Lamp-1, which is an exosome marker, was only slightly observed in any of the conventional methods (the ultracentrifugal separation method (Comparative Example 1), Exo Quick (Comparative Example 2) and Total Exosome Isolation (Comparative Example 3)) (Comparative Examples 1 to 3: the lanes 3 to 5).

In addition, from Fig. 4-B, the bands derived from contaminating proteins and the like were found fewer in the obtaining method of the present invention (Examples 19 and 20), as compared with in any of the conventional methods (ultracentrifugal separation method (Comparative Example 1), Exo Quick (Comparative Example 2), and Total Exosome Isolation (Comparative Example 3)), (Examples 19 and 20: lanes 1 and 2, Comparative Examples 1 to 3: lanes 3 to 5).

[0296]

From the above results, it has been revealed that the extracellular membrane vesicles can be obtained in good purity, by the obtaining method of the present invention (Examples 19 and 20), as compared with any of the conventional methods (the ultracentrifugal separation method (Comparative Example 1), Exo Quick (Comparative Example 2), and Total Exosome Isolation (Comparative Example 3)) (the lanes 1 to 5).

[0297]

Example 21. Electron microscopic observation of extracellular membrane vesicles obtained by obtaining method of the present invention

In order to investigate states of the extracellular membrane vesicles obtained by the obtaining method of the present invention, observation was carried out with an electron microscope.

[0298]

5 < (1) Preparation of mouse macrophage culture supernatant sample >

In order to obtain peritoneal macrophage, 2 mL of a 3% thioglycolate solution (produced by Fluka) was injected intraperitoneally to 6 female C57BL/6J mice, 8 weeks old (purchased from Japan SLC, Inc.). After 3 days, macrophages were recovered from the peritoneal cavity, and the recovered
10 macrophages were cultured for 2 days in 4 pieces of 150 mm dishes for cell culture, using 80 mL of DMEM (produced by Nacalai Tesque, Inc.) containing 10% FBS (produced by BioWest Co., Ltd.), then the culture supernatant was recovered to obtain the mouse macrophage culture supernatant sample.

[0299]

15 < (2) Preparation of Tim-4 carrier >

The mTim-4 carrier, where the SH-group biotin-labeled Fc tag fusion type mTim-4 protein is bound on the Dynabeads MyOne Streptavidin C1, was prepared by the same method as in Examples 11 to 12, except for using 1 mg of the Dynabeads MyOne Streptavidin C1 (produced by Thermo Fisher Scientific
20 Inc.), instead of 0.6 mg of the Dynabeads MyOne Streptavidin C1 (produced by Thermo Fisher Scientific Inc.), using 100 μ L of the PBS solution containing 100 μ g of the SH-group biotin labeled Fc tag fusion type mTim-4 protein, instead of 200 μ L of the PBS solution containing 1 μ g of the SH-group biotin labeled Fc tag fusion type mTim-4 protein, and setting reaction time of the PBS solution containing the
25 Dynabeads and the SH-group biotin labeled Fc tag fusion type mTim-4 protein to 2 hours instead of 1 hour.

[0300]

< (3) Obtaining of extracellular membrane vesicles using Tim-4 carrier >

The mouse macrophage culture supernatant sample (32 mL) was

subjected to centrifugal separation treatment (first time: $800 \times G$, for 10 minutes, second time: $12,000 \times G$, for 30 minutes) to obtain the supernatant. After CaCl_2 was added to the resulting supernatant, so as to attain the final concentration of 2 mM, 1 mg of the mTim-4 carrier prepared above was added, and mixed while stirring at room temperature for 1 hour. Subsequently, the mTim-4 carrier, mixed under stirring at room temperature for 1 hour, was recovered, then subjected to the washing operation three times with 5 mL of TBS-T containing 2 mM CaCl_2 as the final concentration, and further subjected to the washing operation twice with 1 mL thereof, and then eluted three times with 100 μL of TBS containing 1 mM EDTA to obtain 300 μL of the extracellular membrane vesicles fraction.

Subsequently, in order to surely recover the extracellular membrane vesicles in the mouse macrophage culture supernatant sample, the extracellular membrane vesicles were recovered again by the following method, from the mouse macrophage culture supernatant sample after eluting three times with 100 μL of TBS containing 1 mM EDTA to obtain 300 μL of the extracellular membrane vesicles fraction. That is, CaCl_2 was added to the mouse macrophage culture supernatant sample, after three times of the elutions with 100 μL of TBS containing 1 mM EDTA, so as to attain the final concentration of 2 mM, then 1 mg of the mTim-4 carrier, after the elution of three times with 100 μL of TBS containing 1 mM EDTA, was added and mixed while stirring at room temperature for 1 hour. Subsequently, the mTim-4 carrier, mixed under stirring at room temperature for 1 hour, was recovered, and subjected to the washing operation three times with 5 mL of TBS-T containing 2 mM CaCl_2 at the final concentration, and further subjected to the washing operation twice with 1 mL thereof, and then eluted three times with 100 μL of TBS containing 1 mM EDTA to obtain 300 μL of the extracellular membrane vesicles fraction.

Thereafter, in order to more surely recover the extracellular membrane vesicles in the mouse macrophage culture supernatant sample, the above operation was carried out again, and the extracellular membrane vesicles were

recovered from the mouse macrophage culture supernatant sample, after the elution of six times in total with 100 μ L of TBS containing 1 mM EDTA to obtain 300 μ L of the extracellular membrane vesicles fraction.

Total 900 μ L of the extracellular membrane vesicles, obtained by nine times of the elution operations, was concentrated to 60 μ L using an Amicon Ultra-0.5 mL 10K centrifugal filter column to obtain a sample for observation with an electron microscope.

[0301]

< (4) Observation of extracellular membrane vesicles obtained by obtaining method of the present invention, with electron microscope >

The sample (10 μ L) for observation with the electron microscope was adsorbed on a grid, and the excessive sample for observation with the electron microscope was suctioned with a filter paper. Subsequently, the grid was washed with water, and stained twice with a uranium acetate aqueous solution, and then observation by a negative staining method was carried out with a transmission electron microscope.

It should be noted that the type of the mTim-4 protein, the carrier, and the eluent used for obtaining the extracellular membrane vesicles from the mTim-4 carrier, used in Example 21, are shown in the following Table 9.

[0302]

Table 9

		Example 21
Mouse-derived Tim-4 carrier	Type of tag	Fc tag
	Tag fusion type mouse-derived Tim-4 protein	Biotin-labeled (SH-group)
	Carrier	Streptavidin beads
Eluent		TBS containing 1 mM EDTA

[0303]

<Results>

The resulting observation image with the electron microscope is shown in

Fig. 5. From Fig. 5, it has been revealed that the extracellular membrane vesicles, having a diameter of about 50 to 150 nm, can be obtained, while maintaining a spherical shape, according to the obtaining method of the present invention.

5 [0304]

From the above, it has been revealed that the extracellular membrane vesicles can be obtained in an intact state, according to the obtaining method of the present invention.

[0305]

10 Examples 22 to 25. Obtaining of extracellular membrane vesicles by Tim-4 carrier of the present invention (obtaining method of the present invention)

The extracellular membrane vesicles pertaining to the present invention was obtained using the carrier where the human-derived Tim-4 protein was immobilized on the beads (hereinafter it may be abbreviated as “the hTim-4 carrier”, in some cases), and the mTim-4 carrier.

15

[0306]

< (1) Preparation of culture supernatant sample >

Preparation of the culture supernatant sample was carried out in the same method as in “(1) preparation of culture supernatant sample” of Examples 1 to 8.

20

[0307]

< (2) Dilution of Fc tag fusion type Tim-4 protein >

The PBS solution containing 100 µg/mL of the biotin-unlabeled Fc tag fusion type human-derived Tim-4 protein was prepared by dissolving, in 1 mL of PBS, 100 µg of a freeze-dried product of the biotin-unlabeled Fc tag fusion type human-derived Tim-4 protein (produced by Wako Pure Chemical Industries, Ltd., SEQ ID NO: 7 (the human-derived Tim-4 protein in which Fc tag was fused to the N-terminal 25 to 315 amino acid region of the human-derived Tim-4 protein (GenBank NP_612388.2)). The PBS solution (200 µL) containing 1 µg of the biotin-unlabeled Fc tag fusion type hTim-4 protein was obtained by mixing 10 µL

25

of the PBS solution containing the biotin-unlabeled Fc tag fusion type hTim-4 protein, and 190 μ L of PBS.

In addition, the PBS solution containing 100 μ g/mL of the biotin-unlabeled Fc tag fusion type mTim-4 protein was prepared by dissolving, in 1 mL of PBS, 100 μ g of the freeze-dried product of the biotin-unlabeled Fc tag fusion type mouse-derived Tim-4 protein (produced by Wako Pure Chemical Industries, Ltd., SEQ ID NO: 6 (the mTim-4 protein in which the Fc tag was fused to N-terminal 22 to 279 amino acid region of the mouse-derived Tim-4 protein (GenBank NP_848874.3)). The PBS solution (200 μ L) containing 1 μ g of the biotin-unlabeled Fc tag fusion type mTim-4 protein was obtained by mixing 10 μ L of the PBS solution containing the biotin-unlabeled Fc tag fusion type mTim-4 protein, and 190 μ L of PBS.

< (3) Washing of beads >

The PBS-T solution (20 μ L) containing the 30 μ g/ μ L Dynabeads Protein G (produced by Thermo Fisher Scientific Inc.) (containing 0.6 mg of the Dynabeads Protein G) was dispensed into each of two 1.5 mL tubes (manufactured by BM Equipment Co., Ltd.) to carry out the washing operation using 500 μ L of PBS.

< (4) Immobilization of biotin-unlabeled Fc tag fusion type Tim-4 protein on beads >

For one of two 1.5 mL tubes containing the Dynabeads Protein G (0.6 mg), 200 μ L of the PBS solution containing 1 μ g of the biotin-unlabeled Fc tag fusion type hTim-4 protein, prepared above, was added in its entirety, and subjected to a reaction at 8°C for 1 hour to obtain 200 μ L of the PBS solution containing the carrier on which the biotin-unlabeled Fc tag fusion type hTim-4 protein was bound (the hTim-4 carrier).

For remaining one 1.5 mL tube containing the Dynabeads Protein G (0.6 mg), 200 μ L of the PBS solution containing 1 μ g of the biotin-unlabeled Fc tag fusion type mTim-4 protein prepared above was added in its entirety, and subjected to a reaction at 8°C for 1 hour to obtain 200 μ L of the PBS solution

containing the carrier on which the biotin-unlabeled Fc tag fusion type mTim-4 protein was bound (mTim-4 carrier).

< (5) Obtaining of extracellular membrane vesicles by obtaining method of the present invention>

5 After subjecting each 0.6 mg of the resulting hTim-4 carrier and the mTim-4 carrier above to the washing operation with 500 μ L of PBS three times, 200 μ L of the calcium ion-containing culture supernatant sample was added to each of the hTim-4 carrier and the mTim-4 carrier, in a pellet state, and subjected to a reaction each at 8°C for 3 hours. Thereafter, the hTim-4 carrier and the
10 mTim-4 carrier after the reaction were each subjected to the washing operation three times with 500 μ L of 2 mM CaCl_2 -containing TBS-T.

 At the third time of washing, the hTim-4 carrier and the mTim-4 carrier each 250 μ L, (0.3 mg of the carrier) were dispensed into two 1.5 mL tubes. To each 0.3 mg of the mTim-4 carrier and the hTim-4 carrier, in a pellet state, 20 μ L of the
15 1% SDS aqueous solution, or the 1 mM EDTA aqueous solution was added, as the eluent, and then they were mixed at room temperature for 10 seconds using a vortex mixer and spun down. The 1.5 mL tubes were each loaded on a magnet stand, and the hTim-4 carrier and the mTim-4 carrier were collected on the tube wall by magnetic force to recover each supernatant (eluate).

20 It should be noted that the types of the Tim-4 proteins, the carrier used, and the eluates used for obtaining the extracellular membrane vesicles from the Tim-4 carrier, in Examples 22 to 25, and the lane numbers in Western blotting to be described later are shown in the following Table 10.

[0308]

Table 10

		Example 22	Example 23	Example 24	Example 25
Mouse-derived Tim-4 carrier or Human-derived Tim-4 carrier	Tim-4 protein	Fc tag fusion type human-derived Tim-4 protein (Biotin-unlabeled)		Fc tag fusion type mouse-derived Tim-4 protein (Biotin-unlabeled)	
	Carrier	Dynabeads Protein G beads			
Eluent		1% SDS	1 mM EDTA	1% SDS	1 mM EDTA
Lane number in Fig. 6		1	2	3	4

[0309]

< (6) Western blotting >

- 5 Western blotting was carried out by the same method as in “(7) Western blotting” of Examples 1 to 8, except for using “7.5 μ L of each supernatant (eluate) obtained in Examples 22 to 25 (above (5))”, instead of “7.5 μ L of each supernatant (eluate) obtained in Examples 1 to 8”.

[0310]

10 <Results>

The results of Western blotting obtained are shown in Fig. 6. In Fig. 6, each lane is as follows:

- Lane 1: Results of Example 22 (the results of the case of using the hTim-4 carrier where the biotin-unlabeled Fc tag fusion type hTim-4 protein was bound on the Protein G beads, and using the 1% SDS aqueous solution as the eluent);

Lane 2: Results of Example 23 (the results of the case of using the hTim-4 carrier where the biotin-unlabeled Fc tag fusion type hTim-4 protein was bound on the Protein G beads, and using the 1 mM EDTA aqueous solution as the eluent);

- Lane 3: Results of Example 24 (the results of the case of using the mTim-4 carrier where the biotin-unlabeled Fc tag fusion type mTim-4 protein was bound on the Protein G beads, and using the 1% SDS aqueous solution as the eluent);

Lane 4: Results of Example 25 (the results of the case of using the mTim-4 carrier where the biotin-unlabeled Fc tag fusion type mTim-4 protein was bound

on the Protein G beads, and using the 1 mM EDTA aqueous solution as the eluent).

From Fig. 6, it has been revealed that the extracellular membrane vesicles including exosome can be obtained, according to the obtaining method of the present invention, from the fact that a band of Lamp-1, which is an exosome marker, was observed at the vicinity of 100 kDa in any case of Examples 22 to 25 (Example 22 to 25: the lanes 1 to 4).

[0311]

In addition, it has been revealed that the Tim-4 protein can be used for the Tim-4 carrier of the present invention and the obtaining method of the present invention, regardless of organism species of origin.

[0312]

Examples 26 to 27 and Comparative Examples 4 to 9. Comparison of obtained amount of extracellular membrane vesicles by Tim-4 carrier and carrier on which PS protein was immobilized

Obtaining of the extracellular membrane vesicles pertaining to the present invention was carried out using the Tim-4 carrier and the carrier where PS proteins (human origin Annexin V, human MFG-E8, and mouse derived MFG-E8) were each immobilized on the beads.

[0313]

< (1) Dilution of PS protein-containing PBS solution >

The His tag fusion type human-derived Annexin V (20 µg, produced by Creative BioMart Co., Ltd., it may be abbreviated as “the His tag fusion type hAnnexin V”, in some cases) was dissolved in 100 µL of PBS, so as to attain 200 µg/mL to prepare the His tag fusion type hAnnexin V-containing PBS solution. Then, 5 µL of the PBS solution containing 1 µg of the His tag fusion type hAnnexin V protein and 195 µL of PBS were mixed for dilution.

The His tag fusion type human-derived MFG-E8 (50 µg, produced by R & D Systems Co., Ltd., it may be abbreviated as “the His tag fusion type hMFG-E8”)

was dissolved in 500 μ L of PBS, so as to attain 100 μ g/mL to prepare the His tag fusion type hMFG-E8-containing PBS solution. Then, 10 μ L of the PBS solution containing 1 μ g of the His tag fusion type hMFG-E8 protein, and 190 μ L of PBS were mixed for dilution. The His tag fusion type mouse-derived MFG-E8 (50 μ g, produced by R & D Systems Co., Ltd., it may be abbreviated as “the His tag fusion type mMFG-E8”) was dissolved in 500 μ L of PBS, so as to attain 100 μ g/mL to prepare the His tag fusion type mMFG-E8-containing PBS solution. Then, 10 μ L of the PBS solution containing 1 μ g of the His tag fusion type mouse-derived MFG-E8 protein, and 190 μ L of PBS were mixed for dilution.

10 [0314]

< (2) Preparation of anti-His tag antibody-immobilized beads >

A solution (100 μ L) containing 30 μ g/ μ L Dynabeads M-270 Carboxylic Acid (produced by Thermo Fisher Scientific Inc.) (containing 3 mg of the Dynabeads M-270 Carboxylic Acid) was dispensed into the 1.5 mL tube (manufactured by BM Equipment Co., Ltd.), and the washing operation was carried out using a reaction buffer (0.1 M MES, pH 5.0).

Subsequently, 60 μ L of a solution of a 6 $\times$ His antibody (produced by Wako Pure Chemical Industries, Ltd.) (containing 60 μ g of the 6 $\times$ His antibody), diluted with 490 μ L of the reaction buffer, was added and mixed with inversion at room temperature for 30 minutes, then 50 μ L of 6 mg/mL WSC (produced by Dojindo Molecular Technologies, Inc.) was added and mixed with inversion at room temperature for 4 hours. The Dynabeads M-270 Carboxylic Acid after mixing by inversion was subjected to the washing operation with TBS-T, and diluted with 100 μ L of PBS to obtain 3 mg of the anti-His tag antibody-immobilized beads.

25 [0315]

< (3) Preparation of Tim-4 carrier and carrier on which various PS proteins were immobilized >

Subsequently, 100 μ L of the PBS solution containing the resulting anti-His tag antibody-immobilized beads (containing 3 mg of the anti-His tag

antibody-immobilized beads) was dispensed into each of four 1.5 mL tubes (manufactured by BM Equipment Co., Ltd.) in an amount of each 20 μ L (containing 0.6 mg of the anti-His tag antibody-immobilized beads), and the washing operation was each carried out with 500 μ L PBS.

5 After that, for one of the four 1.5 mL tubes containing 0.6 mg of the anti-His tag antibody-immobilized beads in a pellet state, after the washing operation, 200 μ L of the His tag fusion type mTim-4 protein-containing PBS solution prepared above (containing 1 μ g of the His tag fusion type mTim-4 protein) was added and subjected to a reaction at 8°C for 1 hour.

10 Further, for one tube, 200 μ L of the His tag fusion type hAnnexin V-containing PBS solution prepared above (containing 1 μ g of the His tag fusion type hAnnexin V) was added and subjected to a reaction at 8°C for 1 hour.

For one tube, 200 μ L of the His tag fusion type hMFG-E8-containing PBS solution prepared above (containing 1 μ g of the His tag fusion type hMFG-E8) was added and subjected to a reaction at 8°C for 1 hour.

For one tube, 200 μ L of the His tag fusion type mMFG-E8-containing PBS solution prepared above (containing 1 μ g of the His tag fusion type mMFG-E8) was added and subjected to a reaction at 8°C for 1 hour.

In this way, 200 μ L of the PBS solutions each containing 0.6 mg of each of the four types of the carriers shown in the following Table 11 were obtained.

[0316]

Table 11

		1	2	3	4
Mouse-derived Tim-4 carrier or Phosphatidylserine bound protein-immobilized carrier	Phosphatidylserine bound protein	His tag fusion type mouse-derived Tim-4 protein	His tag fusion type human-derived Annexin V	His tag fusion type human-derived MFG-E8	His tag fusion type mouse-derived MFG-E8
	Carrier	Anti-His tag antibody-immobilized beads			

[0317]

< (4) Obtaining of extracellular membrane vesicles >

25 The PBS solution (200 μ L) each containing 0.6 mg of each of the resulting

4 types of carriers above was subjected to the washing operation three times with 500 μ L of PBS, then 200 μ L of the calcium ion-containing culture supernatant sample, prepared by the same method as in Examples 1 to 8, was added to each of 5 types of the carriers in a pellet state, and subjected to a reaction at 8°C for 3 hours.

Thereafter, 4 types of the carriers, which were subjected to a reaction with the calcium ion-containing culture supernatant sample, were subjected to the washing operation three times each with 500 μ L of TBS-T containing 2 mM CaCl_2 .

At the third time of washing, each 250 μ L of 4 types of the carriers was dispensed into two 1.5 mL tubes. The 1% SDS aqueous solution or the 1 mM EDTA aqueous solution (each 20 μ L) was added, as the eluent, to each 0.3 mg of 4 types of the carriers in a pellet state, and then spun down using a vortex mixer at room temperature for 10 seconds. Each 1.5 mL of the tube was loaded on a magnet stand, and the resulting 4 types of the carriers were collected on the tube wall using magnetic force to recover the supernatant (eluate).

It should be noted that types of the PS proteins, the carriers, and the eluates used for obtaining the extracellular membrane vesicles from the carriers, used in each Example, and the lane numbers in Western blotting to be described later are shown in the following Table 12.

[0318]

Table 12

		Example 26	Example 27	Compa- rative Example 4	Compa- rative Example 5	Compa- rative Example 6	Compa- rative Example 7	Compa- rative Example 8	Compa- rative Example 9
Mouse-derived Tim-4 carrier or PS protein- immobilized carrier	PS protein	His tag fusion type mouse-derived Tim-4 protein		His tag fusion type human-derived Annexin V		His tag fusion type human-derived MFG-E8		His tag fusion type mouse-derived MFG-E8	
	Carrier	Anti-His tag antibody-immobilized beads							
Eluent		1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA
Lane number in Fig. 7		1	2	3	4	5	6	7	8

[0319]

< (5) Western blotting>

Western blotting was carried out by the same method as in “(7) Western blotting” of Examples 1 to 8, except for using “7.5 μ L of each supernatant (eluate) obtained in Examples 26 to 27, Comparative Examples 4 to 9 (above (4))”, instead of “7.5 μ L of each supernatant (eluate) obtained in Examples 1 to 8”.

[0320]

<Results>

The results of Western blotting obtained are shown in Fig. 7. In Fig. 7, each lane is as follows:

Lane 1: Results of Example 26 (the results of the case of using the carrier where the His tag fusion type mTim-4 protein was bound on the anti-His tag antibody-immobilized beads, and using the 1% SDS aqueous solution as the eluent);

Lane 2: Results of Example 27 (the results of the case of using the carrier where the His tag fusion type mTim-4 protein was bound on the anti-His tag antibody-immobilized beads, and using the 1 mM EDTA aqueous solution as the eluent);

Lane 3: Results of Comparative Example 4 (the results of the case of using the carrier where the His tag fusion type hAnnexin V was bound on the anti-His tag antibody-immobilized beads, and using the 1% SDS aqueous solution as the eluent);

Lane 4: Results of Comparative Example 5 (Results in a case of using the carrier where the His tag fusion type hAnnexin V was bound on the anti-His tag antibody-immobilized beads, and using the 1 mM EDTA aqueous solution as the eluent);

Lane 5: Results of Comparative Example 6 (the results of the case of using the carrier where the His tag fusion type hMFG-E8 was bound on the anti-His tag antibody-immobilized beads, and using the 1% SDS aqueous solution as the eluent);

Lane 6: Results of Comparative Example 7 (the results of the case of using the carrier where the His tag fusion type hMFG-E8 was bound on the anti-His tag antibody-immobilized beads, and using the 1 mM EDTA aqueous solution as the eluent);

5 Lane 7: Results of Comparative Example 8 (the results of the case of using the carrier where the His tag fusion type mMFG-E8 was bound on the anti-His tag antibody-immobilized beads and using the 1% SDS aqueous solution as the eluent);

10 Lane 8: Results of Comparative Example 9 (the results of the case of using the carrier where the His tag fusion type mMFG-E8 was bound on the anti-His tag antibody-immobilized beads, and using the 1 mM EDTA aqueous solution as the eluent).

15 From Fig. 7, it has been revealed that the extracellular membrane vesicles including exosome can be obtained, according to the obtaining method of the present invention, from the fact that a band of Lamp-1, which is an exosome marker, was observed at the vicinity of 100 kDa in any case of Examples 26 to 27 (Example 26 to 27: the lanes 1 to 2).

On the other hand, from Fig. 7, it has been revealed that the extracellular membrane vesicles including exosome cannot be obtained by the carriers on which the PS proteins other than the Tim-4 protein (Annexin V, MFG-E8) were immobilized, from the fact that the band of Lamp-1 was not observed at the vicinity of 100 kDa in any case of Comparative Examples 4 to 9 (Comparative Example 4 to 9: the lanes 3 to 8).

[0321]

25 Examples 28 to 33. Obtaining of extracellular membrane vesicles by obtaining method of the present invention (examination of complex formation step)

The extracellular membrane vesicles were obtained by each of the obtaining methods of the present invention as described below.

In Examples 28 to 29, after the SH-group biotin-labeled FLAG tag fusion

type mouse-derived Tim-4 protein, prepared by the same method as in Examples 13 to 14, was subjected to a reaction with the carrier pertaining to the present invention, the sample was further added thereto to obtain the extracellular membrane vesicles pertaining to the present invention.

5 In Examples 30 to 31, after the SH-group biotin-labeled FLAG tag fusion type mouse-derived Tim-4 protein, prepared by the same method as in Examples 13 to 14, was subjected to a reaction with the sample, the carrier pertaining to the present invention was further added thereto to obtain the extracellular membrane vesicles pertaining to the present invention.

10 In Examples 32 to 33, the SH-group biotin-labeled FLAG tag fusion type mouse-derived Tim-4 protein, prepared by the same method as in Examples 13 to 14, the sample, and the carrier pertaining to the present invention were added at the same time to obtain the extracellular membrane vesicles pertaining to the present invention.

15 [0322]

<Washing of beads>

Each 60 μL of the PBS solution containing the 10 $\mu\text{g}/\mu\text{L}$ Dynabeads M-270 Streptavidin C1 (produced by Thermo Fisher Scientific Inc.) (containing 0.6 mg of the Dynabeads M-270 Streptavidin C1) was dispensed into three 1.5 mL tubes (manufactured by BM Equipment Co., Ltd.), and the washing operation was carried out each using 500 μL of PBS.

[0323]

25 The His tag fusion type mTim-4 protein-containing PBS solution (270 μL) (containing 50 μg of the His tag fusion type mTim-4 protein) was labeled with biotin by the same method as in Examples 13 to 14 to obtain 200 μL of the PBS solution containing 39.2 μg of the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein. Into 5.1 μL of the PBS solution containing 1 μg of the resulting SH-group biotin-labeled FLAG tag fusion type mTim-4 protein, 194.9 μL of the PBS solution was added to obtain 200 μL of the PBS solution containing 1 μg of

the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein.

[0324]

<The case of subjecting the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein and the carrier pertaining to the present invention to a reaction, followed by further subjecting the extracellular membrane vesicles in the sample pertaining to the present invention to a reaction (Examples 28 to 29)>

The PBS solution (200 μ L) containing 1 μ g of the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein was added to the 1.5 mL tube containing 0.6 mg of the pellet-like Dynabeads M-270 Streptavidin C1 which had been subjected to the washing operation, and the Dynabeads M-270 Streptavidin C1, and the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein were brought into contacted and subjected to a reaction at 8°C for 1 hour to obtain the mTim-4 carrier. Subsequently, the resulting mTim-4 carrier was subjected to the washing operation three times with 500 μ L of PBS, and 200 μ L of the calcium ion-containing culture supernatant sample, prepared by the same method as in Example 1, was added to the 1.5 mL tube containing 0.6 mg of the mTim-4 carrier after washing, and subjected to a reaction at 8°C for 3 hours. After that, the mTim-4 carrier which had been subjected to a reaction with the calcium ion-containing culture supernatant sample was subjected to the washing operation three times with 500 μ L of TBS-T added with 2 mM CaCl_2 as the final concentration. At the third time of washing, each 250 μ L of the mTim-4 carrier was dispensed into two 1.5 mL tubes. After the addition of 20 μ L of the 1% SDS aqueous solution or the 1 mM EDTA aqueous solution, as the eluent, to each 0.3 mg of the mTim-4 carrier in a pellet state, they were mixed at room temperature for 10 seconds using a vortex mixer and spun down. Each of the 1.5 mL tubes was loaded on a magnet stand, and the mTim-4 carrier was collected on the tube wall using magnetic force to recover each supernatant (eluate).

[0325]

<The case of subjecting SH-group biotin-labeled FLAG tag fusion type mTim-4

protein and sample pertaining to the present invention to a reaction, followed by further subjecting the carrier pertaining to the present invention to a reaction (Examples 30-31)>

The calcium ion-containing culture supernatant sample (200 μ L) prepared
5 by the same method as in Example 1 was dispensed into the 1.5 mL tube, and 5.1 μ L of the PBS solution containing 1 μ g of the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein was added, and the extracellular membrane vesicles in the calcium ion-containing culture supernatant sample, and the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein were brought into contacted
10 and subjected to a reaction at 8°C for 3 hours.

The complex of the extracellular membrane vesicles and the mTim-4 carrier was obtained by the addition of the solution after subjecting the extracellular membrane vesicles in the calcium ion-containing culture supernatant sample, and the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein to
15 a reaction at 8°C for 3 hours, to the 1.5 mL tube containing 0.6 mg of the pellet-like Dynabeads M-270 Streptavidin C1 after the washing operation, and subjecting them to a reaction at 8°C for 1 hour. Thereafter, the resulting complex of the extracellular membrane vesicles and the mTim-4 carrier was subjected to the washing operation three times with 500 μ L of TBS-T added with 2 mM CaCl_2 as
20 the final concentration. At the third time of washing, each 250 μ L of the complex with the mTim-4 carrier was dispensed into the two 1.5 mL tubes. After the addition of 20 μ L of the 1% SDS aqueous solution or the 1 mM EDTA aqueous solution, as the eluent, to each 0.3 mg of the complex with the mTim-4 carrier in a pellet state, they were mixed using a vortex mixer at room temperature for 10
25 seconds and spun down. Each of the 1.5 mL tubes was loaded on a magnet stand, and the mTim-4 carrier was collected on the tube wall using magnetic force to recover each supernatant (eluate).

[0326]

< The case of subjecting the SH-group biotin-labeled FLAG tag fusion type

mTim-4 protein, sample pertaining to the present invention, and carrier pertaining to the present invention to reaction simultaneously (Examples 32 to 33)>

The calcium ion-containing culture supernatant sample (200 μ L) prepared by the same method as in Example 1, and 5.1 μ L of the PBS solution containing 1 μ g of the SH-group biotin-labeled FLAG tag fusion type mTim-4 protein were added to the 1.5 mL tube containing 0.6 mg of the pellet-like Dynabeads M-270 Streptavidin C1 after the washing operation, and subjected to a reaction at 8°C for 4 hours. The Dynabeads M-270 Streptavidin C1 in a pellet state after the reaction was subjected to the washing operation three times with 500 μ L of TBS-T containing 2 mM CaCl_2 as the final concentration. At the third time of washing, each 250 μ L of the mTim-4 carrier was dispensed into the two 1.5 mL tubes, and 20 μ L of the 1% SDS aqueous solution or the 1 mM EDTA aqueous solution was added, as the eluate, to each 0.3 mg of the mTim-4 carrier, and then they were mixed using a vortex mixer at room temperature for 10 seconds and spun down. Each of the 1.5 mL tubes was loaded on a magnet stand, and the Dynabeads M-270 Streptavidin C1 was collected on the tube wall using magnetic force to recover each supernatant (eluate).

It should be noted that, the order of bringing into contacted the carrier, the mTim-4 protein, and the calcium ion-containing culture supernatant sample, and the types of the eluents used for obtaining the extracellular membrane vesicles from the carrier, in each Example, are shown in the following Table 13.

[0327]

Table 13

	Order of contact	Eluent
Example 28	(1) Contacting carrier with mouse-derived Tim-4 protein	1% SDS
Example 29	(2) Further contacting with calcium ion-containing cell culture supernatant sample	1% EDTA
Example 30	(1) Contacting mouse-derived Tim-4 protein with calcium ion-containing cell culture supernatant sample	1% SDS
Example 31	(2) Further contacting with carrier	1% EDTA
Example 32	(1) Contacting carrier, calcium ion-containing cell culture supernatant sample, and mouse-derived Tim-4 protein at the same time	1% SDS
Example 33		1% EDTA

[0328]

<Western blotting>

Western blotting was carried out by the same method as in “(7) Western blotting” of Examples 1 to 8, except for using “7.5 μ L of each supernatant (eluate) obtained in Examples 28 to 33 (above (5))”, instead of “7.5 μ L of each supernatant (eluate) obtained in Examples 1 to 8”.

[0329]

<Results>

The results of Western blotting obtained are shown each in Fig. 8. In Fig. 8, each lane is as follows:

Lane 1: Results of Example 28 (the results of the case of obtaining the extracellular membrane vesicles by the method for bringing into contacted the carrier with the mTim-4 protein, further bringing into contacted with the calcium ion-containing cell culture supernatant sample, and using the 1% SDS aqueous solution as the eluent);

Lane 2: Results of Example 29 (the results of the case of obtaining the extracellular membrane vesicles by the method for bringing into contacted the carrier with the mTim-4 protein, further bringing into contacted with the calcium ion-containing cell culture supernatant sample, and using the 1 mM EDTA aqueous solution was used as an eluent);

Lane 3: Results of Example 30 (the results of the case of obtaining the extracellular membrane vesicles by the method for bringing into contacted the mTim-4 protein and the calcium ion-containing cell culture supernatant sample, further bringing into contacted with the carrier, and using the 1% SDS aqueous solution was used as an eluent);

Lane 4: Results of Example 31 (the results of the case of obtaining the extracellular membrane vesicles by the method for bringing into the mTim-4 protein with the calcium ion-containing cell culture supernatant sample, further bringing into contacted with the carrier, and using the 1 mM EDTA aqueous solution was used as an eluent);

Lane 5: Results of Example 32 (the results of the case of obtaining the extracellular membrane vesicles by the method for bringing into contacted the carrier, the calcium ion-containing cell culture supernatant sample, and the mTim-4 protein at the same time, and using the 1% SDS aqueous solution as the eluent),

Lane 6: Results of Example 33 (the results of the case of obtaining the extracellular membrane vesicles by the method for bringing into contacted the carrier, the calcium ion-containing cell culture supernatant sample, and the mTim-4 protein at the same time, and using the 1 mM EDTA aqueous solution as the eluent).

As shown in Fig. 8, a band of Lamp-1, which is an exosome marker, was obtained at the vicinity of 100 kDa in any case of Examples 28 to 33 (Examples 28 to 33: the lanes 1 to 6).

In addition, from the results of Examples 28 to 33, it has been revealed that the step for forming the complex of the Tim-4 protein bound to the carrier and the extracellular membrane vesicles in the sample (complex formation step) may be any step, as long as the complex of the mTim-4 protein bound to the carrier and the extracellular membrane vesicles in the sample is accordingly formed, regardless of the order of contact among the Tim-4 protein pertaining to the present invention, the carrier pertaining to the present invention, and the extracellular membrane vesicles in the sample.

[0330]

Examples 34 to 35, Comparative Examples 10 to 13. Comparison between obtaining methods of the present invention and conventional method

As described below, the extracellular membrane vesicles were obtained by the obtaining method of the present invention by elution with SDS (Example 34), by the obtaining method of the present invention by elution with EDTA (Example 35), by the anti-CD 63 antibody immobilization method (Comparative Examples 10 to 11), and by Exosome-Human CD63 Isolation/Detection (Comparative

Examples 12 to 13).

[0331]

< Immobilization of Tim-4 protein on carrier >

5 The solution (15 μ L) containing the 10 μ g/ μ L Dynabeads M-270 Streptavidin (produced by Thermo Fisher Scientific Inc.) (containing 1×10^7 particles of the Dynabeads M-270 Streptavidin) was dispensed into the 1.5 mL tube (manufactured by BM Equipment Co., Ltd), and subjected to the washing operation.

10 Subsequently, 200 μ L of the PBS solution containing 0.25 μ g of the SH-group biotin-labeled FLAG tag fusion type mouse-derived Tim-4 protein, prepared by the same method as in Examples 11 to 12, was added in its entirety to the 1.5 mL tube containing the Dynabeads M-270 Streptavidin after the washing operation, and subjected to a reaction under refrigeration for 1 hour to obtain the PBS solution containing the mTim-4 carrier.

15 [0332]

<Preparation of anti-CD63 antibody (H5C6)-immobilized carrier>

20 The solution (50 μ L) containing the 30 μ g/ μ L Dynabeads M-270 Carboxylic Acid (produced by Thermo Fisher Scientific, Inc.) (containing 1×10^8 particles of the Dynabeads M-270 Carboxylic Acid) was dispensed into the 1.5 mL tube (manufactured by BM Equipment Co., Ltd), and subjected to the washing operation using the reaction buffer (0.1 M MES, pH 5.0).

On the other hand, 30 μ g (60 μ L) of the anti-CD63 antibody (H5C6) (produced by BD Pharmingen) was diluted with 490 μ L of the reaction buffer (0.1 M MES, pH 5.0) to obtain a reaction buffer-diluted anti-CD 63 antibody solution.

25 Subsequently, 550 μ L of the reaction buffer-diluted anti-CD 63 antibody solution was added to the 1.5 mL tube containing the Dynabeads M-270 Carboxylic Acid, after the washing operation, and mixed with inversion at room temperature for 30 minutes. Thereafter, further 50 μ L of 3 mg/mL WSC (produced by Dojindo Molecular Technologies, Inc.) was added and mixed with

inversion at room temperature for 4 hours, and after the washing operation with TBS-T, dilution was carried out with 50 μ L PBS to obtain the PBS solution containing the anti-CD63 antibody (H5C6) carrier.

In this way, two kinds of the carriers shown in the following Table 14 were obtained.

[0333]

Table 14

	1	2
Protein or antibody to be immobilized on carrier	Biotin-labeled (SH-group) FLAG tag fusion type mouse-derived Tim-4 protein	Anti-CD63 antibody (H5C6)
Carrier	Dynabeads M-270 Streptavidin	Dynabeads M-270 Carboxylic Acid

<Obtaining of extracellular membrane vesicles by obtaining method of the present invention>

The resulting mTim-4 carrier-containing PBS solution (200 μ L) above (containing 1×10^7 particles of the mTim-4 carriers) was subjected to the washing operation three times with 500 μ L of PBS, and then 50 μ L of the calcium ion-containing culture supernatant sample, prepared by the same method as in Examples 1 to 8, was added to the mTim-4 carrier in a pellet state, and subjected to a reaction at 8°C for 3 hours.

Thereafter, the mTim-4 carrier after the reaction was subjected to the washing operation three times with 500 μ L of TBS-T containing 2 mM CaCl_2 . At the third time of washing, each 250 μ L of the mTim-4 carrier was dispensed into the two 1.5 mL tubes. Each 20 μ L of the 1% SDS aqueous solution or the 1 mM EDTA aqueous solution was added, as the eluent, to each 0.3 mg of the mTim-4 carrier in a pellet state, and they were mixed using a vortex mixer at room temperature for each 10 seconds and spun down. Each of the 1.5 mL tubes was loaded on a magnet stand, and the mTim-4 carrier was collected on the tube wall using magnetic force to recover the supernatant (eluate).

[0334]

< Obtaining of extracellular membrane vesicles by anti-CD 63 antibody

immobilization method >

The extracellular membrane vesicles in the calcium ion-containing culture supernatant sample was obtained in the same method as in the <Obtaining of extracellular membrane vesicles by obtaining method of the present invention>, except for using “5 μ L of the anti-CD63 antibody (H5C6) carrier-containing PBS solution (containing 1×10^7 particles of the carrier)”, instead of “200 μ L of the mTim-4 carrier-containing PBS solution”, and by eluting the extracellular membrane vesicles with the 1% SDS aqueous solution or the 1 mM EDTA aqueous solution to recover the supernatant (eluate).

[0335]

<Obtaining of extracellular membrane vesicles by Exosome-Human CD 63 Isolation/Detection>

The extracellular membrane vesicles in the calcium ion-containing culture supernatant sample was obtained by the same method as in the <Obtaining of extracellular membrane vesicles by obtaining method of the present invention>, except for using “1 mL of the Exosome-Human CD 63 Isolation/Detection (produced by Thermo Fisher Scientific Inc.) (containing 1×10^7 particles of the carrier)”, instead of “200 μ L of the mTim-4 carrier- containing PBS solution”, and by eluting the extracellular membrane vesicles with the 1% SDS aqueous solution or the 1 mM EDTA aqueous solution to recover the supernatant (eluate).

It should be noted that, the types of the carriers, and the eluents used to obtain the extracellular membrane vesicles from the carrier, used in each Example and Comparative Example, and the lane numbers in Western blotting to be described later are shown in the following Table 15.

[0336]

Table 15

	Example 34	Example 35	Comparative Example 10	Comparative Example 11	Comparative Example 12	Comparative Example 13
Method	Obtaining method of the present invention		Anti-CD63 antibody method		Exosome-Human CD63 Isolation/Detection	
Protein or antibody to be immobilized to carrier	FLAG tag fusion type mouse-derived Tim-4 protein (Biotin-labeled SH-group)		Anti-CD63 antibody (H5C6)		Anti-CD63 antibody	
Carrier	Dynabeads M-270 Streptavidin		Dynabeads M-270 Carboxylic Acid		—	
Eluent	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA
Lane number in Fig. 9	1	2	3	4	5	6

[0337]

<Western blotting>

- 5 Western blotting was carried out by the same method as in “(7) Western blotting” of Examples 1 to 8, except for using “7.5 μ L of each supernatant (eluate) obtained in Examples 34 to 35 and Comparative Examples 10 to 13”, instead of “7.5 μ L of each supernatant (eluate) obtained in Examples 1 to 8”.

[0338]

- 10 <Results>

The results of Western blotting obtained are shown in Fig. 9. In Fig. 9, each lane is as follows:

- Lane 1: Result of Example 34 (the results of the case where the extracellular membrane vesicles were obtained by the obtaining method of the present invention, and the 1% SDS aqueous solution was used as the eluent);

Lane 2: Result of Example 35 (the results of the case where the extracellular membrane vesicles were obtained by the obtaining method of the present invention, and the 1 mM EDTA aqueous solution was used as the eluent);

- Lane 3: Results of Comparative Example 10 (the results of the case where the extracellular membrane vesicles were obtained by the anti-CD63 antibody method, and the 1% SDS aqueous solution was used as the eluent);

Lane 4: Results of Comparative Example 11 (the results of the case where

the extracellular membrane vesicles were obtained by the anti-CD63 antibody method, and the 1 mM EDTA aqueous solution was used as the eluent);

Lane 5: Result of Comparative Example 12 (the results of the case where the extracellular membrane vesicles were obtained by Exosome-Human CD63 Isolation/Detection, and the 1% SDS aqueous solution was used as the eluent);

Lane 6: Result of Comparative Example 13 (the results of the case where the extracellular membrane vesicles were obtained by Exosome-Human CD63 Isolation/Detection, and the 1 mM EDTA aqueous solution was used as the eluent).

As shown in Fig. 9, a band of CD63, which is one of exosome markers, was observed at the vicinity of 25 to 60 kDa in Examples 34 to 35, wherein obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention (Examples 34 to 35: lanes 1 to 2).

On the other hand, as shown in Fig. 9, the band of CD63 was observed only slightly at the vicinity of 25 to 60 kDa (Comparative Examples 10 to 13: the lanes 3 to 6), in Comparative Examples 10 to 11 wherein obtaining of the extracellular membrane vesicles was carried out by the anti-CD63 antibody method, and in Comparative Examples 12 to 13 wherein obtaining of the extracellular membrane vesicles was carried out by the Exosome-Human CD63 Isolation/Detection.

From the above, it has been revealed that more extracellular membrane vesicles can be recovered, according to the obtaining method of the present invention, as compared with the method for obtaining the extracellular membrane vesicles by affinity of the surface antigen protein and the antibody, using the antibody against the surface antigen protein of the extracellular membrane vesicles in, such as the anti-CD63 antibody method, or Exosome-Human CD63 Isolation/Detection, or the like.

[0339]

Examples 36 to 38. Obtaining of residual extracellular membrane vesicles from

the ultracentrifugal separation-treated sample by obtaining method of the present invention

As described below, the obtaining method of the present invention was carried out for the sample from which the extracellular membrane vesicles had been removed and obtained by the ultracentrifugal separation method which is a conventional method (hereinafter it may be abbreviated as ultracentrifugal separation treatment, in some cases).

[0340]

< (1) Removal of extracellular membrane vesicles by ultracentrifugal separation method >

FBS (15 mL, produced by Corning Inc.) was subjected to centrifugal separation treatment ($10,000 \times G$, for 20 minutes) to separate impurities, and the supernatant was transferred to a new tube to obtain the centrifugal separation treated FBS. Next, each 5 mL of the resulting centrifugal separation treated FBS was subjected to ultracentrifugal separation treatment ($110,000 \times G$, overnight) or ultracentrifugal separation treatment ($450,000 \times G$, overnight), and the supernatant was transferred to a new tube to obtain each 5 mL of the ultracentrifugal separation-treated ($110,000 \times G$) FBS and ultracentrifugal separation treated ($450,000 \times G$) FBS.

[0341]

< (2) Washing of beads >

The PBS solution (180 μ L) containing the 10 μ g/ μ L Dynabeads MyOne Streptavidin C1 (produced by Thermo Fisher Scientific Inc.) (containing 1.8 mg of the Dynabeads MyOne Streptavidin C1) was dispensed into each of three tubes. Next, each 1500 μ L of PBS was added to the tube, and after stirring, each tube was loaded on a magnet stand, the Dynabeads MyOne Streptavidin C1 was collected on the tube wall by using magnetic force, and the solution in the tube was discarded with a pipette (hereinafter it may be abbreviated as the washing operation, in some cases).

[0342]

< (3) Immobilization of Fc tag fusion type mouse-derived Tim-4 protein on beads>

The PBS solution (1500 μ L) containing 3 μ g of the SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein was each added to 1.8 mg of the pellet-like Dynabeads MyOne Streptavidin C1 after the washing operation, and
5 subjected to a reaction at 8°C for 10 minutes to obtain each 1500 μ L of the PBS solution containing the carrier on which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound (mTim-4 carrier).

[0343]

10 < (4) Obtaining of extracellular membrane vesicles by obtaining method of the present invention>

The resulting mTim-4 carrier (1.8 mg) was subjected to the washing operation each three times with 1500 μ L of PBS to obtain the mTim-4 carrier in a pellet state. Thereafter, each 5 mL of the centrifugal separation treated FBS, the
15 ultracentrifugal separation treated FBS (110,000 x G) and the ultracentrifugal separation treated FBS (450,000 x G) was dispensed into three 15 mL centrifuge tubes (manufactured by Corning Inc.), then 1.8 mg of the mTim-4 carrier in a pellet state was added and subjected to a reaction at 8°C for 2 hours. After the reaction, the 15 mL centrifuge tubes were loaded on a magnet stand, and the
20 mTim-4 carrier was collected on the tube wall using magnetic force, and each supernatant (each FBS) was recovered in each of new 15 mL centrifuge tubes. The pellet-like mTim-4 carrier remained in the centrifuge tube was each subjected to the washing operation with 3 mL of TBS-T containing 2 mM CaCl_2 (Tris buffer, 0.0005% Tween 20, 2 mM CaCl_2), and then each 1 mL of TBS-T containing 2 mM
25 CaCl_2 was added to the mTim-4 carrier in a pellet state and suspended, and the entire amount of the suspension was transferred to the 1.5 mL tube, followed by subjecting to the washing operation each twice.

Each 50 μ L of the TBS solution containing 1 mM EDTA, as the eluent, was added to 1.8 mg of the pellet-like mTim-4 carrier, and they were mixed at room

temperature for 10 seconds using a vortex mixer and spun down. Each of the 1.5 mL tubes was loaded on a magnet stand, and the mTim-4 carrier was collected on the tube wall using magnetic force to recover the eluate. The TBS solution (50 μ L) containing 1 mM EDTA was added again to recover the eluate in the same method using the mTim-4 carrier used above.

Thereafter, the beads, used when the eluate was recovered twice, were again added to each supernatant (each FBS) recovered in the 15-mL centrifuge tube, and the operation for recovering the extracellular membrane vesicles in each supernatant (each FBS) was repeated further twice by the same method as described above to obtain each eluate.

[0344]

< (5) Western blotting >

The resulting each eluate (100 μ L) was ultrafiltrated with the VIVASPIN 500 (MVCO 10,000) (manufactured by Sartorius AG), so as to attain 30 μ L. Five μ L of the 4 $\times$ sample buffer solution (produced by Wako Pure Chemical Industries, Ltd.) was added to each 15 μ L of the ultrafiltrated eluate, and incubated at 98°C for 5 minutes to obtain each sample for Western blotting. Each 20 μ L of the sample for Western blotting was loaded on the Super Sep Ace 5-20% gel (produced by Wako Pure Chemical Industries Ltd.), and subjected to electrophoresis at 25 mA for 65 minutes. The resulting electrophoresis gel was transcribed onto the PVDF membrane (produced by Millipore Corporation) at 1 mA/cm² for 60 minutes using the semi-dry blotter and the discontinuous buffer (Anode buffer 1: 0.3 M Tris / 20% methanol, Anode buffer 2: 0.025 M Tris / 20% methanol, Cathode buffer: 0.025 M Tris / 0.04 M aminocaproic acid / 20% methanol). The 3% skimmed milk, diluted with PBS-T (PBS buffer, 0.1% Tween 20), was added to the post-transcription PVDF membrane, and subjected to a reaction at room temperature for 1 hour for blocking, and 2 mL of the anti-bovine CD9 antibody (produced by Novus Biologicals LLC, hereinafter it may be abbreviated as “the anti-bovine CD9 antibody”, in some cases), diluted 1000-fold

with PBS-T, was added and subjected to a reaction at room temperature for 1 hour. The PVDF membrane, after the reaction, was washed three times with PBS-T, and the secondary antibody {anti-mouse IgG (H + L), rabbit, IgG fraction, peroxidase-conjugated antibody} (produced by Wako Pure Chemical Industries Ltd.), diluted 10,000-fold with PBS-T, was subjected to a reaction at room temperature for 1 hour. After washing 5 times with PBS-T, the ImmunoStar Basic (produced by Wako Pure Chemical Industries, Ltd.) was added to a membrane, which had been subjected to a reaction with the anti-bovine CD9 antibody, and the ImmunoStar Zeta (produced by Wako Pure Chemical Industries, Ltd.) was added to a membrane, which had been subjected to a reaction with the anti-Flotillin-2 antibody, and a luminescent signal was detected using the LAS-4000 (manufactured by GE Healthcare). It should be noted that, the anti-bovine CD9 antibody and the anti-Flotillin-2 antibody are the antibodies recognizing CD9 and Flotillin-2, which are marker proteins of exosome, respectively.

[0345]

< (6) Measurement of average particle number and average particle size >

Each 100 μ L of the resulting eluate was treated with a centrifugal filter (0.45 μ m, PVDF) (manufactured by Millipore Corporation), and diluted 5-fold with water, and then particles contained in the diluted solution were measured three times using a NanoSight LM 10 (manufactured by NanoSight Ltd.), according to a manual of the NanoSight, and the average particle number (Particles) and the average particle size (Mean Size) were examined.

It should be noted that, the method for treating the samples, and the method for obtaining the extracellular membrane vesicles remaining in the sample, used in each Example, are shown in the following Table 16.

[0346]

Table 16

		Example 36	Example 37	Example 38
Treatment method of sample	Ultracentrifugal separation method (gravity in ultracentrifugal separation method)	—	○ (110000 × g)	○ (450000 × g)
+				
Obtaining of extracellular membrane vesicles remaining in a sample by the method of the present invention	Obtaining method of the present invention	○	○	○
Lane number in Fig. 10		1	2	3

[0347]

<Results>

5 The results of Western blotting obtained, and the measurement results of average particle number and average particle size by the NanoSight are shown in Fig. 10 and Table 17, respectively. In Fig. 10, each lane shows the following result:

10 Lane 1: Result of Example 36 (the results of the case where the sample was centrifugal separation treated and obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention);

15 Lane 2: Results of Example 37 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation treatment and ultracentrifugal separation treatment at 110,000 × G);

 Lane 3: Results of Example 38 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation treatment and ultracentrifugal separation treatment at 450,000 × G).

20 [0348]

 From Fig. 10, it has been revealed that bands of CD9 and Flotillin-2 which are the exosome markers were confirmed, and the extracellular membrane

vesicles contained in the sample could not be removed (obtained) completely by the ultracentrifugal separation treatment, and a large quantity of the extracellular membrane vesicles remained in the sample, also in the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation treatment, and ultracentrifugal separation treatment at $110,000 \times G$ or at $450,000 \times G$ (Examples 37 to 38), (Examples 37 to 38: Lanes 2 to 3). Furthermore, it has been revealed that the extracellular membrane vesicles remained in the sample, which were not removed (obtained) completely by these ultracentrifugal separation methods, can be obtained (removed) by the obtaining method of the present invention (Examples 37 to 38: Lanes 2 to 3).

[0349]

From Table 17, it was confirmed that size (particle size) of the extracellular membrane vesicles obtained was almost the same between the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation treatment and ultracentrifugal separation treatment at $110,000 \times G$ or at $450,000 \times G$ (Examples 37 to 38), and the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation treatment (Example 36). Thus, it has been revealed that the extracellular membrane vesicles remaining in the sample, which could not be removed completely by the ultracentrifugal separation method, were not fragmented and was present as particles.

[0350]

Table 17

		Particles	Mean size (nm)
Example 36	① Untreated	2.04×10^9	155
Example 37	② $110,000 \times g$	1.36×10^9	162
Example 38	③ $450,000 \times g$	1.20×10^9	159

[0351]

Examples 39 to 40. Obtaining of remaining extracellular membrane vesicles by obtaining method of the present invention from sample after treatment by Total Exosome Isolation (polymer precipitation)

5 As described below, the obtaining method of the present invention was carried out for the sample, from which the extracellular membrane vesicles contained had been removed (obtained) by Total Exosome Isolation (polymer precipitation), which is a conventional method (hereinafter it may be abbreviated as “the polymer precipitation treatment”, in some cases).

10 [0352]

< (1) Removal of extracellular membrane vesicles by Total Exosome Isolation (polymer precipitation) method>

FBS (10 mL, produced by Corning Inc.) was subjected to centrifugal separation treatment ($10,000 \times G$, for 20 minutes) to separate impurities and
15 obtain the centrifugal separation treated FBS. Subsequently, 1 mL of the Total Exosome Isolation (from serum) (produced by Thermo Fisher Scientific Inc.) was added to 5 mL of the resulting centrifugal separation treated FBS, and allowed to stand under refrigeration for 30 minutes, and centrifugal separation treated ($10,000 \times G$, for 20 minutes), then the supernatant was recovered to obtain 6 mL
20 of FBS treated with the Total Exosome Isolation.

[0353]

< (2) Washing of beads>

The PBS solution (180 μ L) containing the 10 μ g/ μ L Dynabeads MyOne Streptavidin C1 (produced by Thermo Fisher Scientific Inc.) (containing 1.8 mg of
25 the Dynabeads MyOne Streptavidin C1) was dispensed into each of the two tubes. Next, 1500 μ L of PBS was added to each of the tubes, and after stirring, each tube was loaded on a magnet stand, the Dynabeads MyOne Streptavidin C1 was collected on the tube wall by using magnetic force, and the solution in the tube was discarded with a pipette (hereinafter it may be abbreviated as the washing

operation, in some cases).

[0354]

< (3) Immobilization of Fc tag fusion type mouse-derived Tim-4 protein on beads>

The PBS solution (1500 μ L) containing 3 μ g of the SH-group biotin-labeled
5 Fc tag fusion type mouse-derived Tim-4 protein, prepared by the same method as
in Examples 5 to 8, was added to 1.8 mg of the Dynabeads MyOne Streptavidin
C1, in a pellet state, after the washing operation, and subjected to a reaction at
8°C for 10 minutes to obtain each 1500 μ L of the PBS solution containing the
carrier on which the SH-group biotin-labeled Fc tag fusion type mouse-derived
10 Tim-4 protein was bound (the mTim-4 carrier).

[0355]

< (4) Obtaining of extracellular membrane vesicles by obtaining method of the
present invention>

The resulting mTim-4 carrier (1.8 mg) was washed each three times with
15 1500 μ L of PBS to obtain the mTim-4 carrier in a pellet state. Thereafter, each
1.8 mg of the mTim-4 carrier in a pellet state was added to 5 mL of the centrifugal
separation-treated FBS or 6 mL of the Total Exosome Isolation-treated FBS which
had been dispensed into 15 mL centrifuge tubes (produced by Corning Inc.), and
subjected to a reaction at 8°C for 2 hours.

20 After the reaction, each of the 15 mL centrifuge tubes were loaded on a
magnet stand, and the mouse-derived Tim-4 carrier was collected on the tube wall
by magnetic force to recover each supernatant (each FBS) in new 15 mL
centrifuge tubes. The pellet-like mTim-4 carrier remained in the centrifuge tubes
was subjected to the washing operation each with 3 mL of TBS-T containing 2 mM
25 CaCl_2 (Tris buffer, 0.0005% Tween 20, 2 mM CaCl_2), and then each 1 mL of
TBS-T containing 2 mM CaCl_2 was added to the pellet-like mTim-4 carrier and
suspended, and after the entire amount of the suspension was transferred to the
1.5 mL tube, the washing operation was each carried out twice.

The TBS solution (50 μ L) containing 1 mM EDTA, as the eluent, was added

to each 1.8 mg of the mTim-4 carrier in a pellet state, and then they were mixed using a vortex mixer at room temperature for 10 seconds and spun down. Each 1.5 mL tube was loaded on a magnet stand, and the mTim-4 carrier was collected on the tube wall using magnetic force to recover the eluate. The TBS solution
5 (50 μ L) containing 1 mM EDTA was added again to recover the eluate in the same method using the mTim-4 carrier used above.

Thereafter, the mTim-4 carrier (beads) used in recovering the eluate twice was added again to each supernatant (each FBS) recovered in the 15 mL-centrifuge tube, and by the same method as described above, the procedure
10 of recovering the extracellular membrane vesicles in each supernatant (each FBS) was repeated further twice to obtain each eluate.

[0356]

< (5) Western blotting >

Each 300 μ L of the resulting eluate was ultrafiltrated with the VIVASPIN 500
15 (MVCO 10,000) (produced by Sartorius AG), so as to attain 30 μ L. Each 10 μ L of the 4 $\times$ sample buffer (produced by Wako Pure Chemical Industries, Ltd.) was added to 30 μ L of each ultrafiltrated eluate, and incubated at 98°C for 5 minutes to obtain each sample for Western blotting. Each 20 μ L of the sample for Western blotting was loaded at each 2 places on the Super Sep Ace 5-20% gel (produced
20 by Wako Pure Chemical Industries, Ltd.) and subjected to electrophoresis at 25 mA for 65 minutes. The resulting electrophoresis gel was transcribed onto the PVDF membrane (produced by Millipore Corporation) at 1 mA/cm² for 60 minutes using the semi-dry blotter and the discontinuous buffer (Anode buffer 1: 0.3 M Tris / 20% methanol, Anode buffer 2: 0.025 M Tris / 20% methanol, Cathode buffer:
25 0.025 M Tris / 0.04 M aminocaproic acid / 20% methanol). The 3% skimmed milk, diluted with PBS-T (PBS buffer, 0.1% Tween 20), was added to the post-transcription PVDF membrane, and subjected to a reaction at room temperature for 1 hour for blocking, and 2 mL of the anti-bovine CD9 antibody (produced by Novus Biologicals LLC, hereinafter it may be abbreviated as “the

anti-bovine CD9 antibody”, in some cases), diluted 1000-fold with PBS-T, or the anti-human Flotillin-2 antibody (produced by BD Biosciences, hereinafter it may be abbreviated as “the anti-human Flotillin-2 antibody”, in some cases), diluted 250-fold with PBS-T, was added and subjected to a reaction at room temperature for 1 hour. After the reaction, the PVDF membrane was washed three times with PBS-T, and the secondary antibody {anti-mouse IgG (H + L), rabbit, IgG fraction, peroxidase-conjugated antibody} (produced by Wako Pure Chemical Industries Ltd.), diluted 10,000-fold with PBS-T, was subjected to a reaction at room temperature for 1 hour. After washing 5 times with PBS-T, the ImmunoStar Basic (produced by Wako Pure Chemical Industries, Ltd.) was added to a membrane, which had been subjected to a reaction with the anti-bovine CD9 antibody, and the ImmunoStar Zeta (produced by Wako Pure Chemical Industries, Ltd.) was added to a membrane, which had been subjected to a reaction with the anti-Flotillin-2 antibody, and a luminescent signal was detected using the LAS-4000 (manufactured by GE Healthcare). It should be noted that, the anti-bovine CD9 antibody is an antibody against CD9 which is one of the marker proteins of exosome, and the anti-human Flotillin-2 antibody is an antibody against Flotillin-2 which is one of the marker proteins of exosome.

[0357]

It should be noted that, the method for treating the sample, and the methods of obtaining the extracellular membrane vesicles remaining in the sample, used in each Example, and the lane number in Western blotting are shown in the following Table 18.

[0358]

Table 18

		Example 39	Example 40
Treatment method of sample	Total Exosome Isolation (PEG precipitation) method	—	○
+			
Obtaining of extracellular membrane vesicles remaining in a sample by the method of the present invention	Obtaining method of the present invention	○	○
Lane number in Fig. 11		1	2

[0359]

<Results>

5 The results of Western blotting obtained are shown in Fig. 11. In Fig. 11, each lane represents the following result.

 Lane 1: Results of Example 39 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation
10 treatment);

 Lane 2: Results of Example 40 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation treatment and polymer precipitation treatment).

15

[0360]

From Fig. 11, it has been revealed that also in the case where obtaining of the extracellular membrane vesicles were carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation treatment, and the polymer precipitation (Example 40), the extracellular membrane vesicles contained in the sample could not be removed (obtained) completely by the Total Exosome Isolation (polymer precipitation) method, and a large quantity of the extracellular membrane vesicles remained in the sample, from the fact that bands of CD9 and Flotillin-2, which are the exosome markers, were confirmed (Example 40: Lane 2).

Furthermore, it has been revealed that the extracellular membrane vesicles remained in the sample that were not removed (obtained) completely by the Total Exosome Isolation (polymer precipitation) method can be obtained by the obtaining method of the present invention (Example 40: Lane 2).

[0361]

Examples 41 to 47. Obtaining (removal) of extracellular membrane vesicles from sample by removing method of the present invention and/or conventional method (ultracentrifugation method, Total Exosome Isolation (polymer precipitation) method)

As described below, the extracellular membrane vesicles were obtained (removed) from the sample by the removing method of the present invention and/or the conventional method (ultracentrifugation method, Total Exosome Isolation (polymer precipitation) method).

[0362]

< (1) Removal of extracellular membrane vesicles by ultracentrifugal separation method >

FBS (28 mL, produced by Corning Inc.) was subjected to centrifugal separation treatment ($10,000 \times G$, for 20 minutes) to separate impurities and obtain centrifugal separation treated FBS (hereinafter it may be abbreviated as

“the removed sample-1”, in some cases). Subsequently, 12 mL of the resulting centrifugal separation treated FBS (“the removed sample-1”) was subjected to ultracentrifugal separation treatment ($110,000 \times G$, overnight) to obtain ultracentrifugal separation treated FBS ($110,000 \times G$) (hereinafter it may be abbreviated as “the removed sample-2”, in some cases).

[0363]

< (2) Removal of extracellular membrane vesicles by Total Exosome Isolation (polymer precipitation) method >

Subsequently, 1.6 mL of Total Exosome Isolation (from serum) (produced by Thermo Fisher Scientific Inc.) was added to 8 mL of the centrifugal separation treated FBS (“the removed sample-1”), and allowed to stand under refrigeration for 30 minutes, and centrifugal separation treated ($10,000 \times G$, for 20 minutes), then each supernatant was recovered to obtain 9.6 mL of Total Exosome Isolation treated FBS (hereinafter it may be abbreviated as “the removed sample-3”, in some cases).

In addition, 0.8 mL of Total Exosome Isolation was added to 4 mL of the ultracentrifugal separation treated ($110,000 \times G$) FBS (“the removed Sample-2”), and allowed to stand under refrigeration for 30 minutes, and centrifugal separation treated ($10,000 \times G$, 20 minutes) to recover each supernatant and obtain 4.8 mL of ultracentrifugal separation treated ($110,000 \times G$) / Total Exosome Isolation treated FBS (hereinafter it may be abbreviated as “the removed sample-4”, in some cases).

[0364]

< (3) Washing of beads >

The PBS solution (240 μ L) containing the 10 μ g/ μ L Dynabeads MyOne Streptavidin C1 (produced by Thermo Fisher Scientific Inc.) (containing 2.4 mg of the Dynabeads MyOne Streptavidin C1) was dispensed into each of three tubes. Next, 2000 μ L of PBS was added to each of the tubes, and after stirring, each tube was loaded on a magnet stand, the Dynabeads MyOne Streptavidin C1 was

collected on the tube wall using magnetic force, and the solution in the tube was discarded with a pipette (hereinafter it may be abbreviated as “the washing operation”, in some cases).

[0365]

5 < (4) Immobilization of Fc tag fusion type mouse-derived Tim-4 protein on beads >

The PBS solution (2000 μ L) containing 4 μ g of the SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein was added to each 2.4 mg of the Dynabeads MyOne Streptavidin C1 in a pellet state, after the washing operation, and subjected to a reaction at 8°C for 10 minutes to obtain each 2000 μ L of the
10 PBS solution containing the carrier on which the SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein was bound (the mTim-4 carrier).

[0366]

< (5) Removal of extracellular membrane vesicles >

The resulting 2.4 mg of the mTim-4 carrier was subjected to the washing
15 operation three times with each 2000 μ L of PBS to obtain the mTim-4 carrier in a pellet state.

Thereafter, each 4 mL of centrifugal separation treated FBS (“the removed sample-1”), 4 mL of ultracentrifugal separation treated (110,000 $\times$ G) FBS (“the removed sample-2”), or 4. 8 mL of Total Exosome Isolation treated FBS (“the
20 removed sample-3”) was dispensed into each tube and subjected to a reaction at 8°C for 1 hour. After the reaction, each of the tubes was loaded on a magnet stand, and the mTim-4 carrier was collected on the tube wall using magnetic force to recover supernatant (each FBS) in a new tube.

The mTim-4 carrier in a pellet state remaining in the tube was subjected to
25 the washing operation three times with each 4 mL of TBS-T (Tris buffer, 0.0005% Tween 20), and then each supernatant (each FBS) was added again, and each of the operations from the reaction to washing was repeated five times in total. After the fifth time reaction, each supernatant (each FBS) was transferred to a new tube and centrifugal separation treated (10,000 $\times$ G, for 20 minutes), then the

supernatant was recovered to obtain 4 mL of ultracentrifugal separation treated (110,000 × G) / Tim-4 treated FBS (hereinafter it may be abbreviated as “the removed sample-5”, in some cases), 4.8 mL of Total Exosome Isolation treated / Tim-4 treated FBS (hereinafter it may be abbreviated as “the removed sample-6”, in some cases), and 4 mL of the Tim-4 treated FBS (hereinafter it may be abbreviated as “the removed sample-7”, in some cases).

[0367]

< (6) Obtaining of extracellular membrane vesicles by obtaining method of the present invention>

Seven 0.6 mg mTim-4 carriers were newly prepared by the same way as the above method, and each was subjected to the washing operation. The removed sample described in the following Table 19 was added to 0.6 mg of the mTim-4 carrier in a pellet state, in each addition amount to the mouse-derived Tim-4 carrier of the removed sample, and each was subjected to a reaction at 8°C for 3 hours.

[0368]

Table 19

		Example 41	Example 42	Example 43	Example 44	Example 45	Example 46	Example 47
Name of sample obtained in each Example		Removed sample-5	Removed sample-6	Removed sample-4	Removed sample-2	Removed sample-3	Removed sample-7	Removed sample-1
Centrifugal separation treatment		○	○	○	○	○	○	○
Treatment method of sample	Ultracentrifugal separation Method (gravity in ultracentrifugation method)	○ (110,000 x g)	—	○ (110,000 x g)	○ (110,000 x g)	—	—	—
	Total Exosome Isolation (PEG precipitation) method	—	○	○	—	○	—	—
	Removing method of the present invention	○	○	—	—	—	○	—
Addition amount of removed sample to mouse-derived Tim-4 carrier		1 mL	1.2 mL	1.2 mL	1 mL	1.2 mL	1 mL	1 mL

After the reaction, each 1.5 mL tube was loaded on a magnet stand, and the mTim-4 carrier was collected on the tube wall by magnetic force, and each supernatant (each FBS) was recovered to obtain the mTim-4 carrier in a pellet state.

The resulting mTim-4 carrier in a pellet state was subjected to the washing

operation three times with each 1 mL of TBS-T containing 2 mM CaCl_2 (Tris buffer, 0.0005% Tween 20, 2 mM CaCl_2), and then each 50 μL of the TBS solution containing 1 mM EDTA, as the eluent, was added to each 0.6 mg of the mTim-4 carrier in a pellet state, and they were mixed using a vortex mixer at room
5 temperature for 10 seconds, and spun down. Each 1.5 mL tube was loaded on a magnet stand, and the mTim-4 carrier was collected on the tube wall using magnetic force to recover each eluate. The TBS solution (50 μL) containing 1 mM EDTA was added again to recover each eluate in the same method.

[0369]

10 < (7) Western blotting >

In the resulting eluate, 100 μL was ultrafiltrated, so as to attain 30 μL with the VIVASPIN 500 (MVCO 10,000) (produced by Sartorius AG). To each 30 μL of the ultrafiltrated eluate, 10 μL of the 4 × sample buffer (produced by Wako Pure Chemical Industries, Ltd.) was added and incubated at 98°C for 5 minutes to
15 obtain each sample for Western blotting. The sample for Western blotting (each 20 μL) was loaded, by two places, on the Super Sep Ace 5-20% gel (produced by Wako Pure Chemical Industries, Ltd.), and subjected to electrophoresis at 25 mA for 65 minutes. The resulting electrophoresis gel was transcribed onto the PVDF membrane (produced by Millipore Corporation) under 1 mA/cm^2 for 60 minutes
20 using the semi-dry blotter and the discontinuous buffer (Anode buffer 1: 0.3 M Tris / 20% methanol, Anode buffer 2: 0.025 M Tris / 20% methanol, Cathode buffer: 0.025 M Tris / 0.04 M aminocaproic acid / 20% methanol). To the PVDF membrane after transcription, the 3% skimmed milk diluted with PBS-T (the PBS buffer, 0.1% Tween 20) was added and subjected to a reaction at room
25 temperature for 1 hour for blocking, and 2 mL of the anti-bovine CD9 antibody (produced by Novus Biologicals LLC, hereinafter it may be abbreviated as “the anti-bovine CD9 antibody”, in some cases) diluted 1000-fold with PBS-T, or the anti-human Flotillin-2 antibody (produced by BD Biosciences, hereinafter it may be abbreviated as “the anti-human Flotillin-2 antibody”, in some cases), diluted

250-fold with PBS-T, was subjected to a reaction at room temperature for 1 hour. After the reaction, the PVDF membrane was washed three times with PBS-T, and the secondary antibody {anti-mouse IgG (H + L), rabbit, IgG fraction, peroxidase-conjugated antibody} (produced by Wako Pure Chemical Industries Ltd.), diluted 10,000-fold with PBS-T, was subjected to a reaction at room temperature for 1 hour. After washing five times with PBS-T, the ImmunoStar Basic (produced by Wako Pure Chemical Industries, Ltd.) was added to the membrane after being subjected to a reaction with the anti-bovine CD9 antibody, and the ImmunoStar Zeta (produced by Wako Pure Chemical Industries, Ltd.) was added to the membrane after being subjected to a reaction with the anti-Flotillin-2 antibody, and a luminescent signal was detected using the LAS-4000 (manufactured by GE Healthcare). It should be noted that the anti-bovine CD9 antibody is an antibody against CD9, which is one of the marker proteins of exosome, and the anti-human Flotillin-2 antibody is an antibody against Flotillin-2, which is one of the marker proteins of exosome.

[0370]

It should be noted that, the method for treating the sample, the method for obtaining (removing) the extracellular membrane vesicles remaining in the sample, used in each Example, and the lane numbers in Western blotting to be described later are shown in the following Table 20.

[0371]

Table 20

		Example 41	Example 42	Example 43	Example 44	Example 45	Example 46	Example 47
Name of sample obtained in each Example		Removed sample-5	Removed sample-6	Removed sample-4	Removed sample-2	Removed sample-3	Removed sample-7	Removed sample-1
Centrifugal separation treatment		○	○	○	○	○	○	○
Treatment method of sample	Ultracentrifugal separation method (gravity in ultracentrifugation method)	○ (110,000 x g)	—	○ (110,000 x g)	○ (110,000 x g)	—	—	—
	Total Exosome Isolation (PEG precipitation) method	—	○	○	—	○	—	—
	Removing method of the present invention	○	○	—	—	—	○	—
Addition amount of removed sample to mouse-derived Tim-4 carrier		1 mL	1.2 mL	1.2 mL	1 mL	1.2 mL	1 mL	1 mL
		+						
Obtaining of extracellular membrane vesicles remaining in the sample by the obtaining method of the present invention		○	○	○	○	○	○	○
Lane number in Fig. 12		1	2	3	4	5	6	7

[0372]

<Results>

5 The results of Western blotting obtained are shown in Fig. 12. In Fig. 12, each lane shows the following result.

 Lane 1: Results of Example 41 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation
10 treatment, ultracentrifugal separation treatment, and further treatment with the removing method of the present invention);

 Lane 2: Results of Example 42 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation
15 treatment, polymer precipitation treatment, and further treatment with the removing method of the present invention);

 Lane 3: Results of Example 43 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation
20 treatment, ultracentrifugal separation treatment, and further polymer precipitation

treatment);

Lane 4: Results of Example 44 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation treatment, and ultracentrifugal separation treatment);

Lane 5: Results of Example 45 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation treatment, and polymer precipitation treatment);

Lane 6: Results of Example 46 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation treatment, and treatment with the removing method of the present invention);

Lane 7: Results of Example 47 (the results of the case where obtaining of the extracellular membrane vesicles was carried out by the obtaining method of the present invention, after subjecting the sample to centrifugal separation treatment).

[0373]

From Fig. 12, it has been revealed that the extracellular membrane vesicles contained in the sample cannot be removed completely, and a large quantity of the extracellular membrane vesicles remain in the sample, from the fact that the bands of exosome markers CD9 and Flotillin-2 are observed, in the ultracentrifugation method and Total Exosome Isolation (polymer precipitation) method, which are the conventional methods (Examples 44 to 45: lanes 4 to 5).

In addition, it has been revealed that the extracellular membrane vesicles contained in the sample cannot be removed sufficiently, and resulted in to remain, from the fact that the bands of CD9 and Flotillin-2 are observed, even if these conventional methods are combined (Example 43: lane 3). On the other hand, it has been revealed that the extracellular membrane vesicles in the sample, which

cannot be removed only by the conventional methods, can be removed (obtained) by combining the ultracentrifugation method or Total Exosome Isolation (polymer precipitation) method, which are the conventional methods, with the removing method of the present invention, from the fact that the bands of CD9 and Flotillin-2 are not confirmed (Examples 41 to 42: lanes 1-2). Furthermore, it has been revealed that the extracellular membrane vesicles in the sample can be removed sufficiently, even with the method of the present invention alone (Example 46: lane 6). In addition, it has been suggested that the viruses can also be removed similarly as the extracellular membrane vesicles, according to the removing (obtaining) method of the present invention.

[0374]

Examples 48 to 55. Reutilization of Tim carrier of the present invention in removing method of the present invention

The removing method of the present invention was repeated using the Tim carrier of the present invention as follows.

[0375]

< (1) Preparation of sample >

One mL of FBS (produced by Corning Inc.) was subjected to centrifugal separation treatment ($10,000 \times G$, for 20 minutes) to separate impurities to obtain 1 mL of the centrifugal separation treated FBS.

[0376]

< (2) Washing of beads >

The PBS solution (60 μ L) containing the 10 μ g/ μ L Dynabeads MyOne Streptavidin C1 (produced by Thermo Fisher Scientific Inc.) (containing 0.6 mg of the Dynabeads MyOne Streptavidin C1) was dispensed into the 1.5 mL tube (manufactured by BM Equipment Co., Ltd.). Next, 500 μ L of PBS was added to each 1.5 mL tube, and after stirring, the 1.5 mL tube was loaded on a magnet stand, the Dynabeads MyOne Streptavidin C1 was collected on the tube wall using magnetic force, and the solution in the 1.5 mL tube was discarded with a

pipette (hereinafter it may be abbreviated as the washing operation, in some cases).

[0377]

< (3) Immobilization of Fc tag fusion type mouse-derived Tim-4 protein on beads>

5 The PBS solution (500 μ L) containing 1 μ g of the SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein was added to 0.6 mg of the Dynabeads MyOne Streptavidin C1, in a pellet state, after the washing operation, and subjected to a reaction at 8°C for 10 minutes to obtain 500 μ L of the PBS solution containing the carrier on which the SH-group biotin-labeled Fc tag fusion
10 type mouse-derived Tim-4 protein was bound (the mTim-4 carrier).

[0378]

< (4) Removal of extracellular membrane vesicles by removing method of the present invention>

15 The 1.5 mL tube was loaded on a magnet stand and the mTim-4 carrier was collected on the tube wall using magnetic force, and the solution in the 1.5 mL tube was discarded with a pipette, and then the mTim-4 carrier was subjected to the washing operation three times with each 500 μ L of PBS to obtain the mTim-4 carrier in a pellet state. Thereafter, 1 mL of the centrifugal separation treated FBS was added to the mTim-4 carrier in a pellet state, and subjected to a reaction
20 at 8°C for 1 hour.

After the reaction, the 1.5 mL tube was loaded on a magnet stand, the mTim-4 carrier was collected on the tube wall using magnetic force to recover the supernatant (FBS) in a new 1.5 mL tube (referred to as supernatant-1). The mTim-4 carrier in a pellet state was subjected to the washing operation three
25 times with 500 μ L of TBS-T containing 2 mM CaCl_2 (Tris buffer, 0.0005% Tween 20, 2 mM CaCl_2).

The TBS solution (50 μ L) containing 1 mM EDTA as the eluent was added to 0.6 mg of each mTim-4 carrier in a pellet state, and then they were mixed using a vortex mixer at room temperature for 10 seconds, and spun down. The 1.5 mL

tube was loaded on a magnet stand, and the mTim-4 carrier was collected to the tube wall using a magnetic force to recover the eluate (referred to as the eluate-1). The TBS solution (50 μ L) containing 1 mM EDTA was added again to the mTim-4 carrier to recover the eluate by the same method (referred to as eluate-2). The resulting eluate-1 and eluate-2 were mixed to obtain a removed sample-8.

The supernatant-1 was added again to the mTim-4 carrier after the elution operation (after the elution operation to obtain the eluate-2) and the operation of recovering the extracellular membrane vesicles in the supernatant-1 was repeated eight times in total to obtain each eluate.

The resulting removed samples and the lane numbers in Western blotting to be described later are as shown in the following Table 21.

[0379]

Table 21

	Example 48	Example 49	Example 50	Example 51	Example 52	Example 53	Example 54	Example 55
Name of sample	Removed sample 8	Removed sample 9	Removed sample 10	Removed sample 11	Removed sample 12	Removed sample 13	Removed sample 14	Removed sample 15
Mouse-derived Tim-4 carrier and number of times sample reutilized	0 (unused)	1	2	3	4	5	6	7
Lane numbers in Fig. 13	1	2	3	4	5	6	7	8

[0380]

< (5) Western blotting >

Each 100 μ L of the resulting eluate was ultrafiltrated, so as to attain 30 μ L with the VIVASPIN 500 (MVCO 10,000) (manufactured by Sartorius AG). To each 15 μ L of the ultrafiltrated eluate, 5 μ L of the 4 $\times$ sample buffer (produced by Wako Pure Chemical Industries, Ltd.) was added and incubated at 98°C for 5 minutes to obtain each sample for Western blotting. Each 20 μ L of the sample for Western blotting was loaded on the Super Sep Ace 5-20% gel (produced by Wako Pure Chemical Industries, Ltd.) and subjected to electrophoresis at 25 mA for 65 minutes. The resulting electrophoresis gel was transcribed onto the PVDF

membrane (produced by Millipore Corporation) at 1 mA/cm² for 60 minutes using the semi-dry blotter and the discontinuous buffer (Anode buffer 1: 0.3 M Tris / 20% methanol, Anode buffer 2: 0.025 M Tris / 20% methanol, Cathode buffer: 0.025 M Tris / 0.04 M aminocaproic acid / 20% methanol). The 3% skimmed milk, diluted with PBS-T (PBS buffer, 0.1% Tween 20), was added to the post-transcription PVDF membrane, and subjected to a reaction at room temperature for 1 hour for blocking, and 2 mL of the anti-bovine CD9 antibody (produced by Novus Biologicals LLC, hereinafter it may be abbreviated as “the anti-bovine CD9 antibody”, in some cases), diluted 1,000-fold with PBS-T, was subjected to a reaction at room temperature for 1 hour. The PVDF membrane after the reaction was washed three times with PBS-T, and the secondary antibody {anti-mouse IgG (H + L), rabbit, IgG fraction, peroxidase-conjugated antibody} (produced by Wako Pure Chemical Industries Ltd.), diluted 10,000-fold with PBS-T, was subjected to a reaction at room temperature for 1 hour. After washing five times with PBS-T, the ImmunoStar Zeta (produced by Wako Pure Chemical Industries, Ltd.) was added, and a luminescent signal was detected using the LAS-4000 (manufactured by GE Healthcare). It should be noted that, the anti-bovine CD9 antibody is an antibody against CD9, which is one of the marker proteins of exosome.

[0381]

<Results>

The results of Western blotting obtained are shown in Fig. 13. In Fig. 13, each lane shows the following result.

Lane 1: Results of Example 48 (the results of the case where the extracellular membrane vesicles in the sample were removed by the obtaining/removing method of the present invention using the unused Tim-4 carrier of the present invention);

Lane 2: Results of Example 49 (the results of the case where the extracellular membrane vesicles in the sample used once were removed by the obtaining/removing method of the present invention using the Tim-4 carrier of the

present invention used once);

Lane 3: Results of Example 50 (the results of the case where the extracellular membrane vesicles in the sample used twice were removed by the obtaining/ removing method of the present invention using the Tim-4 carrier of the present invention used twice);

Lane 4: Results of Example 51 (the results of the case where the extracellular membrane vesicles in the sample used 3 times were removed by the obtaining/ removing method of the present invention using the Tim-4 carrier of the present invention used 3 times);

Lane 5: Results of Example 52 (the results of the case where the extracellular membrane vesicles in the sample used 4 times were removed by the obtaining/ removing method of the present invention using the Tim-4 carrier of the present invention used 4 times);

Lane 6: Results of Example 53 (the results of the case where the extracellular membrane vesicles in the sample used 5 times were removed by the obtaining/ removing method of the present invention using the Tim-4 carrier of the present invention used 5 times);

Lane 7: Results of Example 54 (the results of the case where the extracellular membrane vesicles in the sample used 6 times were removed by the obtaining/ removing method of the present invention using the Tim-4 carrier of the present invention used 6 times);

Lane 8: Results of Example 55 (the results of the case where the extracellular membrane vesicles in the sample used 7 times were removed by the obtaining/ removing method of the present invention using the Tim-4 carrier of the present invention used 7 times).

[0382]

From Fig. 13, it has been revealed that the extracellular membrane vesicles can be removed more reliably, by utilizing the Tim-4 carrier of the present invention repeatedly, from the fact that when the removal operation is carried out

by repeatedly using the Tim-4 carrier of the present invention, amount of exosome recovered from the sample decreases. In addition, it has been revealed that the Tim-4 carrier of the present invention is reusable, by separating the extracellular membrane vesicles from the complex of the Tim-4 protein bound to the carrier and the extracellular membrane vesicle in the sample, using EDTA, which is the calcium ion chelating agent.

[0383]

Examples 56 to 67, Comparative Examples 14 to 15. Obtaining of extracellular membrane vesicles by carrier on which Tim family protein is immobilized

As described below, obtaining of the extracellular membrane vesicles pertaining to the present invention was carried out by using the carrier in which the Tim-1 protein, the Tim-3 protein, or the Tim-4 protein, which is the Tim family, was each immobilized on the beads.

[0384]

< (1) Preparation of calcium ion-containing culture supernatant (stock solution) >

The human chronic myelogenous leukemia cell strain K562, 1×10^7 cells, secreting the extracellular membrane vesicles, was cultured for three days under condition at 37°C and 5% CO₂, using 80 mL of the X-VIVO15 medium (produced by Lonza AG), then the cells were precipitated by centrifugal separation treatment (300 × G, for 5 minutes) to remove the supernatant. The precipitated cells were suspended in 60 mL of the X-VIVO 15 medium containing 10 μM monensin sodium (produced by MP Biomedicals Co., Ltd) and cultured for 24 hours under condition at 37°C and 5% CO₂.

Thereafter, the culture solution was subjected to centrifugal separation treatment (300 × G, for 5 minutes) to recover the culture supernatant. The recovered culture supernatant (60 mL) was further subjected to centrifugal separation treatment three times (the first time: 300 × G, for 3 minutes, the second time: 1,200 × G, for 20 minutes, the third time: 10,000 × G, for 20 minutes) to separate impurities to obtain the supernatant (hereinafter it may be abbreviated as

“the culture supernatant (stock solution)”, in some cases).

In addition, CaCl_2 was added to the resulting culture supernatant stock solution, so as to attain the final concentration of 2 mM to obtain a sample of K562 cell culture supernatant concentrated solution containing 2 mM CaCl_2 (hereinafter it may be abbreviated as “the calcium ion-containing culture supernatant (stock solution)”, in some cases).

[0385]

< (2) Washing of beads >

The PBS-T solution (20 μL) containing the 30 $\mu\text{g}/\mu\text{L}$ Dynabeads Protein G (produced by Thermo Fisher Scientific Inc.) (containing 0.6 mg of the Dynabeads Protein G) was dispensed into seven 1.5 mL tubes (manufactured by BM Equipment Co., Ltd.), and each subjected to the washing operation.

[0386]

< (3) Immobilization of Fc tag fusion type Tim protein on beads >

Each 200 μL of the TBS solution containing 1 μg of the Fc tag fusion type mouse-derived Tim-1 protein, the Fc tag fusion type mouse-derived Tim-3 protein, the Fc tag fusion type mouse-derived Tim-4 protein, the Fc tag fusion type human-derived Tim-1 protein, the Fc tag fusion type human-derived Tim-3 protein, or the Fc tag fusion type human-derived Tim-4 protein (all produced by Wako Pure Chemical Industries, Ltd.) was added to the 1.5 mL tubes containing 0.6 mg of Dynabeads Protein G respectively, and subjected to a reaction at 8°C for 1 hour to obtain each of the carrier on which the Fc tag fusion type mTim-1 protein was bound, the carrier on which the Fc tag fusion type mTim-3 protein was bound, the carrier on which the Fc tag fusion type mTim-4 protein-bound carrier, the carrier on which the Fc tag fusion type hTim-1 protein was bound, the carrier on which the Fc tag fusion type hTim-3 protein was bound, and the carrier on which the Fc tag fusion type hTim-4 protein was bound. It should be noted that, the resulting these six types of carriers are shown in the following Table 22. They may be abbreviated collectively as “the Tim protein-bound carrier”, in some cases.

[0387]

Table 22

		1	2	3	4	5	6
Tim protein-bound carrier	Carrier	Dynabeads Protein G beads					
	Fc tag fusion type Tim protein	Human-derived Tim-1	Mouse-derived Tim-1	Human-derived Tim-3	Mouse-derived Tim-3	Human-derived Tim-4	Mouse-derived Tim-4

[0388]

< (4) Obtaining of extracellular membrane vesicles by method of the present invention>

The resulting 6 types of the Tim protein-bound carriers above were each subjected to the washing operation three times with 500 μ L of TBS-T (Tris buffer, 0.1% Tween 20) and twice with 500 μ L of TBS to obtain the Tim protein-bound carriers in a pellet state. Subsequently, 1 mL of the calcium ion-containing culture supernatant (stock solution) prepared in the (1) was added to each of the Tim protein-bound carriers in a pellet state, and the Dynabeads Protein G which had been subjected to only the washing operation (hereinafter it may be abbreviated as “the Tim protein non-bound carrier”, in some cases), and each subjected to a reaction at 8°C for 3 hours.

Thereafter, the Tim protein-bound carrier or the Tim protein non-bound carrier, after the reaction, was subjected to the washing operation three times with each 500 μ L of the calcium ion-containing TBS-T (Tris buffer, 0.0005% Tween 20, 2 mM CaCl_2). At the third time of the washing operation, 500 μ L of the CaCl_2 -containing TBS-T solution containing the Tim protein-bound carrier or the Tim protein non-bound carrier was dispensed into each of the two 1.5 mL tubes, by each 250 μ L aliquot, and after the tube was loaded on a magnetic stand, the washing solution was removed.

50 μ L of 1% SDS aqueous solution or the TBS solution (25 μ L) containing 1 mM EDTA, as the eluent, was added to each of 0.3 mg of the pellet-like Tim protein-bound carrier, or the Tim protein non-bound carrier, and they were mixed using a vortex mixer at room temperature for 10 seconds and spun down. The

TBS solution (25 μ L) containing 1 mM EDTA was added again to the tube to which EDTA had been added and the same operation was carried out to obtain each supernatant (eluate).

[0389]

5 < (5) Western blotting >

The 4 $\times$ sample buffer (3.75 μ L, produced by Wako Pure Chemical Industries, Ltd.) was added to 11.25 μ L of the resulting each supernatant (each eluate) in the (4), and incubated at 95°C for 3 minutes to obtain each sample for Western blotting. Each 15 μ L of the sample for Western blotting was loaded on
10 the Super Sep Ace 5-20% gel (produced by Wako Pure Chemical Industries, Ltd.), and subjected to electrophoresis at 30 mA for 60 minutes. The resulting electrophoresis gel was transcribed onto the PVDF membrane (produced by Millipore Corporation) at 1 mA/cm² for 60 minutes using the semi-dry blotter and the discontinuous buffer (Anode buffer 1: 0.3 M Tris / 20% methanol, Anode buffer
15 2: 0.025 M Tris / 20% methanol, Cathode buffer: 0.025 M Tris / 0.04 M aminocaproic acid / 20% methanol). The five % skimmed milk, diluted with TBS-T (TBS buffer, 0.1% Tween 20), was added to the transcribed PVDF membrane and subjected to a reaction at room temperature for 1 hour for blocking, and then 2 mL of the anti-human Lamp-1 antibody (produced by BD Biosciences),
20 diluted 250-fold with PBS-T, or the 250-fold diluted anti-human Flotillin-2 antibody (produced by BD Biosciences) were subjected to a reaction at room temperature for 1 hour. The PVDF membrane after the reaction was washed three times with TBS-T, and subjected to a reaction with the secondary antibody {anti-mouse IgG (H + L), rabbit, IgG fraction, peroxidase-conjugated antibody} (produced by Wako
25 Pure Chemical Industries Ltd.), diluted 5,000-fold with PBS-T, at room temperature for 1 hour. After washing five times with TBS-T, the ImunoStar Zeta (produced by Wako Pure Chemical Industries, Ltd.) was added to the PVDF membrane, after subjected to a reaction with each antibody, and a luminescent signal was detected using the LAS-4000 (manufactured by GE Healthcare).

It should be noted that the types of Tim proteins, the carrier and the eluents used for obtaining the extracellular membrane vesicles from the Tim protein-bound (non-bound) carrier, used in each Example and Comparative Example, are shown in the following Table 23.

5 [0390]

Table 23

		Comparative Example		Example											
		14	15	56	57	58	59	60	61	62	63	64	65	66	67
Tim protein-(non-)bound carrier	Carrier	Dynabeads Protein G beads													
	Fc tag fusion type Tim protein	—		Human-derived Tim-1		Mouse-derived Tim-1		Human-derived Tim-3		Mouse-derived Tim-3		Human-derived Tim-4		Mouse-derived Tim-4	
Eluent		1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA
Lane numbers in Fig 14		1	2	3	4	5	6	7	8	9	10	11	12	13	14

[0391]

<Results>

10 The results of Western blotting obtained are shown in Fig. 14. In Fig. 14, each lane is as follows.

Lane 1: Results of Comparative Example 14 (the results of the case where the carrier of only the magnetic beads of the Dynabeads protein G was used, and the 1% SDS aqueous solution was used as the eluent);

15 Lane 2: Results of Comparative Example 15 (the results of the case where the carrier of only the magnetic beads of the Dynabeads protein G was used and the TBS solution containing 1 mM EDTA was used as the eluent);

Lane 3: Results of Example 56 (the results of the case of using the carrier in which the human-derived Tim-1 protein was bound to the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

20 Lane 4: Results of Example 57 (the results of the case of using the carrier in which the human-derived Tim-1 protein was bound to the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

Lane 5: Results of Example 58 (the results of the case of using the carrier

in which the mouse-derived Tim-1 protein was bound to the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

Lane 6: Result of Example 59 (the results in a case of using the carrier in which the mouse-derived Tim-1 protein was bound to the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

Lane 7: Results of Example 60 (the results of the case of using the carrier on which the human-derived Tim-3 protein was bound to the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

Lane 8: Results of Example 61 (the results of the case of using the carrier in which the human-derived Tim-3 protein was bound to the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

Lane 9: Results of Example 62 (the results of the case of using the carrier in which the mouse-derived Tim-3 protein was bound to the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

Lane 10: Results of Example 63 (the results of the case of using the carrier in which the mouse-derived Tim-3 protein was bound to the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

Lane 11: Results of Example 64 (the results of the case of using the carrier in which the human-derived Tim-4 protein was bound to the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

Lane 12: Results of Example 65 (the results of the case of using the carrier in which the human-derived Tim-4 protein was bound to the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

Lane 13: Results of Example 66 (the results of the case of using the carrier in which the mouse-derived Tim-4 protein was bound to the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

Lane 14: Results of Example 67 (the results in a case of using the carrier in which the mouse-derived Tim-4 protein was bound to the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent).

From Fig. 14, it has been revealed the extracellular membrane vesicles can be obtained by using the carrier on which the Tim-1 protein, the Tim-3 protein or the Tim-4 protein is bound (the Tim protein-bound carrier), regardless of the origin of the protein or the elution method, from the fact that a band of Lamp-1 or Flotillin-2, which is exosome marker protein, was observed in lanes 3 to 14.

In addition, it has been revealed that, in the case of eluting with SDS, more extracellular membrane vesicles can be obtained in the order of the Tim-4 protein-bound carrier > the Tim-1 protein-bound carrier > the Tim-3 protein-bound carrier.

[0392]

Examples 68 to 79. Obtaining of extracellular membrane vesicles by carrier on which Tim protein is immobilized

Obtaining of the extracellular membrane vesicles pertaining to the present invention was carried out, using the carriers on which each of the biotin-labeled Tim-1 protein, the biotin-labeled Tim-3 protein or the biotin-labeled Tim-4 protein was immobilized.

[0393]

< (1) Preparation of culture supernatant sample >

The calcium ion-containing culture supernatant (stock solution) was obtained by the same method as in “(1) preparation of calcium ion-containing culture supernatant (stock solution)” in Examples 50 to 67, and Comparative Examples 14 to 15.

[0394]

< (2) Biotin labeling of SH-group of Fc tag fusion type Tim-1 protein >

For 200 μ L of the PBS solution containing the Fc tag fusion type mouse-derived Tim-1 protein (produced by Wako Pure Chemical Industries, Ltd.) (containing 20 μ g of the Fc tag fusion type mouse-derived Tim-1 protein), the SH-group of the Fc tag fusion type mouse-derived Tim-1 protein was labeled with biotin using the Biotin Labeling Kit-SH (produced by Dojindo Molecular

Technologies, Inc.), according to a protocol attached to the kit to obtain 200 μ L of the PBS solution containing the SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-1 protein.

[0395]

5 < (3) Biotin labeling of SH-group of Fc tag fusion type Tim-3 protein >

For 200 μ L of the PBS solution containing the Fc tag fusion type mouse-derived Tim-3 protein (produced by Wako Pure Chemical Industries, Ltd.) (containing 20 μ g of the Fc tag fusion type mouse-derived Tim-3 protein), the SH-group of the Fc tag fusion type mouse-derived Tim-3 protein was labeled with
10 biotin using the Biotin Labeling Kit-SH (produced by Dojindo Molecular Technologies, Inc.), according to a protocol attached to the kit to obtain 200 μ L of the PBS solution containing the SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-3 protein.

[0396]

15 < (4) Biotin labeling of SH-group of Fc tag fusion type Tim-4 protein >

For 100 μ L of the PBS solution containing the Fc tag fusion type mouse-derived Tim-4 protein (produced by Wako Pure Chemical Industries, Ltd.) (containing 10 μ g of the Fc tag fusion type mouse-derived Tim-4 protein), the SH-group of the Fc tag fusion type mouse-derived Tim-4 protein was labeled with
20 biotin using the Biotin Labeling Kit-SH (produced by Dojindo Molecular Technologies, Inc.), according to a protocol attached to the kit to obtain 100 μ L of the PBS solution containing the SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein.

[0397]

25 < (5) Dilution of tag-fused Tim protein >

The PBS solution (10 μ L) containing the Fc tag fusion type mTim-1 protein (produced by Wako Pure Chemical Industries, Ltd.) (containing 1 μ g of the Fc tag fusion type mTim-1 protein) was mixed with 190 μ L of TBS to obtain 200 μ L of a solution containing 1 μ g of the biotin-unlabeled Fc tag fusion type mTim-1 protein.

The TBS solution (11.5 μ L) containing the SH-group biotin-labeled Fc tag fusion type mTim-1 protein prepared in the (2) (containing 1 μ g of the SH-group biotin-labeled Fc tag fusion type mTim-1 protein) was mixed with 188.5 μ L of TBS to obtain 200 μ L of a solution containing 1 μ g of the biotin-labeled Fc tag fusion type mTim-1 protein.

The PBS solution (10 μ L) containing the Fc tag fusion type mTim-3 protein (produced by Wako Pure Chemical Industries, Ltd.) (containing 1 μ g of the Fc tag fusion type mTim-3 protein) was mixed with 190 μ L of TBS to obtain 200 μ L of a solution containing 1 μ g of the biotin-unlabeled Fc tag fusion type mTim-3 protein.

The TBS solution (9.0 μ L) containing the SH-group biotin-labeled Fc tag fusion type mTim-3 protein prepared in the (3) (containing 1 μ g of the SH-group biotin-labeled Fc tag fusion type mTim-3 protein) was mixed with 191.0 μ L of TBS to obtain 200 μ L of a solution containing 1 μ g of the biotin-labeled Fc tag fusion type mTim-3 protein.

The PBS solution (10 μ L) containing the Fc tag fusion type mTim-4 protein (produced by Wako Pure Chemical Industries, Ltd.) (containing 1 μ g of the Fc tag fusion type mTim-4 protein) was mixed with 190 μ L of TBS to obtain 200 μ L of a solution containing 1 μ g of the biotin-unlabeled Fc tag fusion type mTim-4 protein.

The TBS solution (10 μ L) containing the SH-group biotin-labeled Fc tag fusion type mTim-4 protein prepared in the (4) (containing 1 μ g of the SH-group biotin-labeled Fc tag fusion type mTim-4 protein) was mixed with 190 μ L of TBS to obtain 200 μ L of a solution containing 1 μ g of the biotin-labeled Fc tag fusion type mTim-4 protein.

[0398]

< (6) Washing of beads >

The PBS-T solution (20 μ L) containing 30 μ g/ μ L of the Dynabeads Protein G (produced by Thermo Fisher Scientific Inc.) (containing 0.6 mg of the Dynabeads Protein G) was transferred into six 1.5 mL tubes (manufactured by BM Equipment Co., Ltd.), and each subjected to the washing operation.

In addition, 60 μ L of PBS solution containing the 10 μ g/ μ L Dynabeads M-270 Streptavidin C1 (produced by Thermo Fisher Scientific Inc.) (containing 0.6 mg of the Dynabeads M-270 Streptavidin C1) was dispensed into each of the 1.5 mL tubes (manufactured by BM Equipment Co., Ltd.), and the washing operation
5 was carried out by the same method as above using 500 μ L of TBS.

[0399]

< (7) Immobilization of Fc tag fusion type Tim protein on beads >

The solution (200 μ L) containing 1 μ g of the SH-group biotin-unlabeled Fc tag fusion type mTim-1 protein, 200 μ L of the solution containing 1 μ g of the
10 SH-group biotin-unlabeled Fc tag fusion type mTim-3 protein, or 200 μ L of the solution containing 1 μ g of the SH-group biotin-unlabeled Fc tag fusion type mTim-4 protein was each added to six 1.5 mL tubes containing the 0.6 mg of pellet-like Dynabeads Protein G, after the washing operation, and subjected to a reaction at 8°C for 1 hour to obtain each of the carrier on which the SH-group
15 biotin-unlabeled Fc tag fusion type mTim-1 protein was bound (it may be abbreviated as “the biotin-unlabeled Fc tag fusion type mTim-1 carrier”, in some cases), the carrier on which the SH-group biotin-unlabeled Fc tag fusion type mTim-3 protein was bound (it may be abbreviated as “the biotin-unlabeled Fc tag fusion type mTim-3 carrier”, in some cases), and the carrier on which the
20 SH-group biotin-unlabeled Fc tag fusion type mTim-4 protein was bound (it may be abbreviated as “the biotin-unlabeled Fc tag fusion type mTim-4 carrier”, in some cases).

In addition, 200 μ L of the solution containing 1 μ g of the SH-group biotin-labeled Fc tag fusion type mTim-1 protein, 200 μ L of a solution containing 1
25 μ g of the SH-group biotin-labeled Fc tag fusion type mTim-3 protein, or 200 μ L of a solution containing 1 μ g of the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was added to the 1.5 mL tube containing 0.6 mg of the pellet-like Dynabeads M270 Streptavidin C1, after the washing operation, to bind on the beads by the same method as above to prepare each of the carrier on which the

SH-group biotin-labeled Fc tag fusion type mTim-1 protein was bound (it may be abbreviated as “the biotin-labeled Fc tag fusion type mTim-1 carrier”, in some cases), the carrier on which the SH-group biotin-labeled Fc tag fusion type mTim-3 protein was bound (it may be abbreviated as “the biotin-labeled Fc tag fusion type mTim-3 carrier”, in some cases), and the carrier on which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound (it may be abbreviated as “the biotin-labeled Fc tag fusion type mTim-4 carrier”, in some cases).

It should be noted that, the resulting these six types of the carriers may be abbreviated collectively as “the Tim protein-bound carrier” in some cases.

[0400]

< (8) Obtaining of extracellular membrane vesicles by obtaining method of the present invention >

The resulting these Tim protein-bound carriers above were subjected to the washing operation three times with 500 μ L of TBS-T (Tris buffer, 0.1% Tween 20), and twice with 500 μ L of TBS to obtain the Tim protein-bound carrier in a pellet state. Subsequently, 1 mL of the calcium ion-containing culture supernatant (stock solution) was added to each of the resulting six pellet-like Tim protein-bound carriers, and each subjected to a reaction at 8°C for 3 hours. After that, the Tim protein-bound carriers after the reaction were subjected to the washing operation 3 times with each 500 μ L of the calcium ion-containing TBS-T (Tris buffer, 0.0005% Tween 20, 2 mM CaCl_2). At the third time of the washing operation, 500 μ L of the CaCl_2 -containing TBS-T solution containing the Tim protein-bound carrier was dispensed into each of the two 1.5 mL tubes in an amount of each 250 μ L, and the tubes were loaded on a magnetic stand, and then the washing solution was removed.

50 μ L of 1% SDS aqueous solution or 25 μ L of the TBS solution containing 1 mM EDTA, as the eluent, was added to each 0.3 mg of the 6 types of the Tim protein-bound carriers in a pellet state, and they were mixed using a

vortex mixer at room temperature for 10 seconds, and spun down. To the tube to which EDTA had been added, 25 μ L of the TBS solution containing 1 mM EDTA was added again, and the same operation was carried out to obtain the eluate.

It should be noted that the types of Tim proteins, the carriers, and the Tim protein-(un) bound carriers, used in each Example, are shown in the following Table 24.

[0401]

Table 24

		Example											
		68	69	70	71	72	73	74	75	76	77	78	79
Tim protein-bound carrier	Carrier	Dynabeads Protein G beads		Streptavidin beads		Dynabeads Protein G beads		Streptavidin beads		Dynabeads Protein G beads		Streptavidin beads	
	Fc tag fusion type Tim protein	Biotin-unlabeled mouse-derived Tim-1		SH-group biotin-labeled mouse-derived Tim-1		Biotin-unlabeled mouse-derived Tim-3		SH-group biotin-labeled mouse-derived Tim-3		Biotin-unlabeled mouse-derived Tim-4		SH-group biotin-labeled mouse-derived Tim-4	

[0402]

< (9) Western blotting >

Western blotting was carried out by the same method as in “(5) Western blotting” in Examples 56 to 67, except for using 11.25 μ L of the resulting each eluate in the (6), instead of “11.25 μ L of the resulting each eluate in (4)”, in <(5) Western blotting> of Examples 56 to 67, and using, as the secondary antibody, {anti-mouse IgG (H + L), donkey, IgG fraction, peroxidase-conjugated antibody}(produced by Jackson Immuno Research Inc.), diluted 30,000-fold with TBS-T, instead of “the secondary antibody {anti-mouse IgG (H + L), rabbit, IgG fraction, peroxidase-conjugated antibody}(produced by Wako Pure Chemical Industries, Ltd.).

It should be noted that the types of Tim proteins, carriers, and the eluents used for obtaining the extracellular membrane vesicles from the Tim protein-bound (non-bound) carrier, used in each Example, and the lane numbers in Western blotting are shown in the following Table 25.

[0403]

Table 25

		Example											
		68	69	70	71	72	73	74	75	76	77	78	79
Tim protein- bound carrier	Carrier	Dynabeads Protein G beads		Streptavidin beads		Dynabeads Protein G beads		Streptavidin beads		Dynabeads Protein G beads		Streptavidin beads	
	Fc tag fusion type Tim protein	Biotin- unlabeled mouse-derived Tim-1		SH-group biotin-labeled mouse-derived Tim-1		Biotin- unlabeled mouse-derived Tim-3		SH-group biotin-labeled mouse-derived Tim-3		Biotin- unlabeled mouse-derived Tim-4		SH-group biotin-labeled mouse-derived Tim-4	
Eluent		1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA
Lane numbers in Fig. 15		1	2	3	4	5	6	7	8	9	10	11	12

[0404]

<Results>

5 The results of Western blotting obtained are shown in Fig. 15. In Fig. 15, each lane is the result of the following.

 Lane 1: Results of Example 68 (the results of the case of using the carrier in which the SH-group biotin-unlabeled Fc tag fusion type mTim-1 protein was bound on the Dynabeads protein G, and using the 1% SDS aqueous solution as
10 the eluent);

 Lane 2: Results of Example 69 (the results of the case of using a carrier in which the SH-group biotin-unlabeled Fc tag fusion type mTim-1 protein was bound on the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

15 Lane 3: Results of Example 70 (the results of the case of using a carrier in which the SH-group biotin-labeled Fc tag fusion type mTim-1 protein was bound on the Dynabeads M270 Streptavidin, and using the 1% SDS aqueous solution as the eluent);

 Lane 4: Results of Example 71 (the results of the case of using a carrier in
20 which the SH-group biotin-labeled Fc tag fusion type mTim-1 protein was bound on the Dynabeads M270 Streptavidin, and using the TBS solution containing 1 mM EDTA as the eluent);

 Lane 5: Results of Example 72 (the results of the case of using a carrier in

which the SH-group biotin-unlabeled Fc tag fusion type mTim-3 protein was bound on the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

5 Lane 6: Results of Example 73 (the results of the case of using a carrier in which the SH-group biotin-unlabeled Fc tag fusion type mTim-3 protein was bound on the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

10 Lane 7: Results of Example 74 (the results of the case of using a carrier in which the SH-group biotin-labeled Fc tag fusion type mTim-3 protein was bound on the Dynabeads M270 Streptavidin, and using the 1% SDS aqueous solution as the eluent);

15 Lane 8: Results of Example 75 (the results of the case of using a carrier in which the SH-group biotin-labeled Fc tag fusion type mTim-3 protein was bound on the Dynabeads M270 Streptavidin, and using the TBS solution containing 1 mM EDTA as the eluent);

Lane 9: Results of Example 76 (the results of the case of using a carrier in which the SH-group biotin-unlabeled Fc tag fusion type mTim-4 protein was bound on the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

20 Lane 10: Results of Example 77 (the results of the case of using a carrier in which the SH-group biotin-unlabeled Fc tag fusion type mTim-4 protein was bound on the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

25 Lane 11: Results of Example 78 (the results of the case of using a carrier in which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound on the Dynabeads M270 Streptavidin, and using the 1% SDS aqueous solution as the eluent);

Lane 12: Results of Example 79 (the results of the case of using a carrier in which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound

on the Dynabeads M270 Streptavidin, and using the TBS solution containing 1 mM EDTA as the eluent).

From Fig. 15, it has been revealed that the extracellular membrane vesicles can be obtained, by using the carrier on which the Tim-1, the Tim-3, or the Tim-4 was bound (the Tim protein-bound carrier), from the fact that a band of Lamp-1, which is a marker protein of exosome, was observed in any of the lanes 1 to 12.

In addition, it has been revealed that more extracellular membrane vesicles can be obtained in the order of the Tim-4 protein-bound carrier > the Tim-1 protein-bound carrier > the Tim-3 protein-bound carrier. It has been revealed that when eluting with the calcium chelating agent, more extracellular membrane vesicles can be obtained by immobilization on the beads (carriers) via the SH group of the Tim4 protein, as compared with immobilizing via the tag (lanes 9 to 12).

[0405]

Examples 80 to 83, Comparative Examples 16 to 19. Obtaining of extracellular membrane vesicles by carrier on which Tim family protein was immobilized

Obtaining of the extracellular membrane vesicles pertaining to the present invention was carried out using the carrier in which the Tim-1 protein, the Tim-2 protein, or the Tim-4 protein was immobilized, as the Tim family protein, on the beads.

[0406]

< (1) Preparation of calcium ion-containing culture supernatant sample >

The calcium ion-containing culture supernatant sample was obtained by the same method as in “(1) Preparation of culture supernatant sample” of Examples 1 to 8.

[0407]

< (2) Washing of beads >

The PBS-T solution (20 μ L) containing the 30 μ g/ μ L Dynabeads Protein G

(produced by Thermo Fisher Scientific Inc.) (containing 4.8 mg of the Dynabeads Protein G) was dispensed into each of the four 1.5 mL tubes (manufactured by BM Equipment Co., Ltd.), and each was subjected to the washing operation.

[0408]

5 < (3) Immobilization of 6×His tag fusion type Tim family protein on beads>

The TBS solution (100 μ L) containing 4 μ g of the anti-6×His antibody (clone No. 28 to 75, produced by Wako Pure Chemical Industries, Ltd.) was added to each of the four 1.5 mL tubes containing 0.6 mg of the Dynabeads Protein G, in a pellet state, after the washing operation, and subjected to a
10 reaction at 8°C for 30 minutes to obtain 100 μ L of the TBS solution containing the carrier on which the anti-6×His antibody was bound. These carriers on which the anti-6×His antibody was bound were subjected to the washing operation three times with each 250 μ L of TBS-T (Tris buffer, 0.1% Tween 20), and then subjected to the washing operation twice with each 250 μ L of TBS.

15 Next, 100 μ L of the TBS solution containing 1 μ g of the 6×His tag fusion type mouse-derived Tim-1 protein (produced by R & D Systems Inc.), 100 μ L of the TBS solution containing 1 μ g of the 6×His tag fusion type mouse-derived Tim-2 protein (produced by R & D Systems Inc.), or 100 μ L of the TBS solution containing 1 μ g of the 6×His tag fusion type mouse-derived Tim-4 protein
20 (produced by R & D Systems Inc.) was each added to the anti-6×His antibody-bound Dynabeads Protein G carrier after the washing operation and subjected to a reaction at 8°C for 1 hour to obtain each of the carrier on which the Tim-1 protein was bound via the anti-6×His antibody (it may be abbreviated as “the 6×His tag fusion type mTim-1 protein-bound carrier”, in some cases), the
25 carrier on which the Tim-2 protein was bound (it may be abbreviated as “the 6×His tag fusion type mTim-2 protein-bound carrier”), and the carrier on which the Tim-4 protein was bound (it may be abbreviated as “the 6×His tag fusion type mTim-4 protein-bound carrier”, in some cases).

It should be noted that the resulting 6×His fusion type mTim-1

protein-bound carrier, and the 6×His fusion type mTim-4 protein-bound carrier may be abbreviated collectively as “the Tim protein-bound carrier” in some cases.

The types of the Tim proteins, the carrier and the Tim family protein-(non-)bound carriers, used in each Example, are shown in the following

5 Table 26.

[0409]

Table 26

		Comparative Example 16	Comparative Example 17	Example 80	Example 81	Comparative Example 18	Comparative Example 19	Example 82	Example 83
Tim family protein- (non-)bound carrier	Carrier	Anti-6xHis tag antibody-bound Dynabeads Protein G carrier							
	Tim family protein	—	—	6xHis tag fusion type mouse-derived Tm-1 protein		6xHis tag fusion Type mouse-derived Tm-2 protein		6xHis tag fusion type mouse-derived Tm-4 protein	

[0410]

< (4) Obtaining of extracellular membrane vesicles by obtaining method of the
10 present invention>

The resulting anti-6×His antibody-bound Dynabeads Protein G carrier, the 6×His tag fusion type mTim-1 protein-bound carrier, the 6×His tag fusion type mTim-2 protein-bound carrier, the 6×His tag fusion type mTim-2 protein-bound carrier in the (3) were each subjected to the washing operation three times with
15 250 μL of TBS-T (Tris buffer, 0.1% Tween 20) and twice with 250 μL of TBS to obtain each carrier in a pellet state. Thereafter, 200 μL of the calcium ion-containing culture supernatant sample was added to each carrier in a pellet state, and subjected to a reaction at 8°C for 3 hours. Each carrier after the reaction was subjected to the washing operation three times with 500 μL of the
20 calcium ion-containing TBS-T (Tris buffer, 0.0005% Tween 20, 2 mM CaCl₂). At the third time of the washing operation, 500 μL of the CaCl₂-containing TBS-T solution containing each carrier was dispensed into two 1.5 mL tubes in an amount of each 250 μL, and after loading the tube on a magnetic stand, the washing solution was removed.

25 50 μL of the 1% SDS aqueous solution or 25 μL of the TBS solution

containing 1 mM EDTA, as the eluent, was added to each 0.3 mg of the carrier in a pellet state, and they were mixed using a vortex mixer at room temperature for 10 seconds, and spun down. To the tube to which EDTA had been added, 25 μ L of the TBS solution containing 1 mM EDTA was added again, and the same operation was carried out to obtain the eluate.

[0411]

< (5) Western blotting >

Western blotting was carried out by the same method as in “(7) Western blotting” in Examples 68 to 79, except for using 11.25 μ L of the resulting each eluate in the (4).

It should be noted that the types of the Tim family proteins, the carrier, and the eluents used for obtaining the extracellular membrane vesicles from the Tim protein-bound (non-bound) carrier, used in each Example, and the lane numbers in Western blotting are shown in the following Table 27.

[0412]

Table 27

		Comparative Example 16	Comparative Example 17	Example 80	Example 81	Comparative Example 18	Comparative Example 19	Example 82	Example 83
Tim family protein- (non-)bound carrier	Carrier	Anti-6xHis tag antibody-bound Dynabeads Protein G carrier							
	Tim family protein	—	—	6xHis tag fusion type mouse-derived Tm-1 protein		6xHis tag fusion Type mouse-derived Tm-2 protein		6xHis tag fusion type mouse-derived Tm-4 protein	
Eluent		1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA
Lane numbers in Fig. 16		1	2	3	4	5	6	7	8

[0413]

<Results>

The results of Western blotting obtained are shown in Fig. 16. In Fig. 16, each lane shows the following result.

Lane 1: Results of Comparative Example 16 (the results of the case of using the carrier in which the anti-6xHis antibody was bound on the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

Lane 2: Results of Comparative Example 17 (the results of the case of using the carrier in which the anti-6×His antibody was bound to the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

5 Lane 3: Results of Example 80 (the results of the case of using the carrier in which the 6×His tag fusion type mTim-1 protein was bound on the Dynabeads protein G via the anti-6×His antibody, and using the 1% SDS aqueous solution as the eluent);

10 Lane 4: Results of Example 81 (the results of the case of using the carrier in which the 6×His tag fusion type mTim-1 protein was bound on the Dynabeads protein G via the anti-6×His antibody, and using the TBS solution containing 1 mM EDTA as the eluent);

15 Lane 5: Results of Comparative Example 18 (the results of the case of using the carrier in which the 6×His tag fusion type mTim-2 protein was bound on the Dynabeads protein G via the anti-6×His antibody, and using the 1% SDS aqueous solution as the eluent);

Lane 6: Results of Comparative Example 19 (the results of the case of using the carrier in which the 6×His tag fusion type mTim-2 protein was bound on the Dynabeads protein G via the anti-6×His antibody, and using the TBS solution containing 1 mM EDTA as the eluent);

20 Lane 7: Results of Example 82 (the results of the case of using the carrier in which the 6×His tag fusion type mTim-4 protein was bound on the Dynabeads protein G via the anti-6×His antibody, and using the 1% SDS aqueous solution as the eluent);

25 Lane 8: Result of Example 83 (the results of the case of using the carrier in which the 6×His tag fusion type mTim-4 protein was bound on the Dynabeads protein G via the anti-6×His antibody, and using the TBS solution containing 1 mM EDTA as the eluent).

From Fig. 16, in the case of binding the 6×His tag fusion type Tim-2 protein, a band of Lamp-1, which is a marker protein of exosome, was not observed in any

of the elution methods (lanes 5 to 6). On the other hand, in the case of the carrier on which the 6×His tag fusion type Tim-1 protein or the 6×His tag fusion type Tim-4 protein was bound, the band of anti-Lamp-1, which is a marker protein of exosome, was observed in any of the elution methods (lanes 3 to 4, lanes 7 to 8). From these results, it has been revealed that the extracellular membrane vesicles cannot be obtained, using the carrier on which the Tim-2 protein was immobilized.

In addition, it has been revealed that, when eluting by SDS, more extracellular membrane vesicles can be obtained in the order of the carrier on which the Tim-4 protein is bound > carrier on which the Tim-1 protein is bound.

[0414]

Examples 84 to 95, Comparative Examples 20 to 21. Obtaining of viruses by carrier on which Tim protein is immobilized

As described below, obtaining of the viruses pertaining to the present invention was carried out using the carrier on which the Tim-1 protein, the Tim-3 protein, or the Tim-4 protein, as Tim protein, was each immobilized on the beads.

[0415]

< (1) Preparation of co-transfection cell culture supernatant >

A PSFM-J1 medium (produced by Wako Pure Chemical Industries, Ltd.) containing about 2 µg of mouse IL23 expression vector DNA, 90 ng of Linear AcNPV DNA, and 3 µL of TransIT-Insect (produced by Mirus Bio LLC) was added to 1.0×10^6 cells of Sf9 cell seeded in a 25 cm² flask. After culturing for 7 days at 28°C, the culture supernatant (co-transfection solution) was recovered.

[0416]

< (2) Preparation of baculovirus-containing insect cell culture supernatant sample >

Sf9 cells diluted with the PSFM-J 1 medium, so as to attain 1.5×10^6 cells/mL (50 mL), were prepared. The co-transfection solution of 1/200 volume of the culture solution was added thereto, and cultured at 27°C under shaking at

130 rpm. After 72 hours, the cell culture solution was recovered, and subjected to centrifugal separation at 3,000 × G, for 30 minutes at 4°C, to fractionate into precipitate and supernatant. The resulting supernatant was used as a recombinant baculovirus solution expressing mouse IL-23 (hereinafter it may be abbreviated as “the baculovirus solution”, in some cases).

In addition, CaCl₂ was added to the resulting baculovirus solution, so as to attain the final concentration of 2 mM to obtain the baculovirus solution containing 2 mM CaCl₂ (hereinafter it may be abbreviated as “the calcium ion-containing baculovirus solution”, in some cases).

[0417]

< (3) Washing of beads >

Washing of the beads was carried out by the same method as in “(2) Washing of beads” of Examples 56 to 67 and Comparative Examples 14 to 15.

[0418]

< (4) Immobilization of Fc tag Fusion Type Tim Protein on Beads >

As shown in the following Table 28, 6 types of the Tim protein-bound carriers were obtained by the same method as in “(3) Immobilization of Fc tag fusion type Tim protein on beads” of Examples 56 to 67 and Comparative Examples 14 to 15.

[0419]

Table 28

		1	2	3	4	5	6
Tim protein-bound carrier	Carrier	Dynabeads Protein G beads					
	Fc tag fusion type Tim protein	Human-derived Tim-1	Mouse-derived Tim-1	Human-derived Tim-3	Mouse-derived Tim-3	Human-derived Tim-4	Mouse-derived Tim-4

[0420]

< (5) Obtaining of baculovirus by method of the present invention >

Each eluate was obtained by carrying out similarly as in “(4) Obtaining of extracellular membrane vesicles by method of the present invention” in Examples 56 to 67 and Comparative Examples 14 to 15, except for using “1 mL of the

calcium ion-containing baculovirus solution prepared in the (2)", instead of "1 mL of the calcium ion-containing culture supernatant".

[0421]

< (6) Western blotting >

5 Western blotting was carried out by the same method as in "(5) Western blotting" of Examples 56 to 67 and Comparative Examples 14 to 15, except for using "the anti-baculovirus gp64 antibody (produced by Novus Biologicals LLC), diluted 500-fold with TBS-T", instead of "2 mL of the anti-human Lamp-1 antibody, or diluted 250-fold with TBS-T (produced by BD Biosciences), and 2 mL of the
10 250-fold diluted anti-human Flotillin-2 antibody (produced by BD Biosciences)".

It should be noted that the types of Tim proteins, carrier, and the eluents used for obtaining the extracellular membrane vesicles from the Tim protein-bound (non-bound) carrier, used in each Example and Comparative Example, and the lane numbers in Western blotting are shown in the following
15 Table 29.

[0422]

Table 29

		Comparative Example		Example											
		20	21	84	85	86	87	88	89	90	91	92	93	94	95
Tim protein- (non-)bound carrier	Carrier	Dynabeads Protein G beads													
	Fc tag fusion type Tim protein	—		Human-Derived Tim-1 (hTim-1)		Mouse-derived Tim-1 (mTim-1)		Human-Derived Tim-3 (hTim-3)		Mouse-derived Tim-3 (mTim-3)		Human-Derived Tim-4 (hTim-4)		Mouse-derived Tim-4 (mTim-4)	
Eluent		1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA
Lane numbers in Fig 17		1	2	3	4	5	6	7	8	9	10	11	12	13	14

[0423]

<Results>

20 The results of Western blotting obtained are shown in Fig. 17. In Fig. 17, each lane shows the following result.

Lane 1: Results of Comparative Example 20 (the results of the case where only the magnetic beads carrier of the Dynabeads protein G was used, and the

1% SDS aqueous solution was used as the eluent);

Lane 2: Results of Comparative Example 21 (the results of the case where only the magnetic beads carrier of the Dynabeads protein G was used, and the TBS solution containing 1 mM EDTA was used as the eluent);

5 Lane 3: Results of Example 84 (the results of the case of using the carrier in which the hTim-1 protein was bound on the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

 Lane 4: Results of Example 85 (the results of the case of using the carrier in which the hTim-1 protein was bound on the Dynabeads protein G, and using the
10 TBS solution containing 1 mM EDTA as the eluent);

 Lane 5: Results of Example 86 (the results of the case of using the carrier in which the mTim-1 protein was bound on the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

 Lane 6: Results of Example 87 (the results of the case of using the carrier
15 in which the mTim-1 protein was bound on the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

 Lane 7: Results of Example 88 (the results of the case of using the carrier in which the hTim-3 protein was bound on the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

20 Lane 8: Results of Example 89 (the results of the case of using the carrier in which the hTim-3 protein was bound on the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

 Lane 9: Results of Example 90 (the results of the case of using the carrier in which the mTim-3 protein was bound on the Dynabeads protein G, and using
25 the 1% SDS aqueous solution as the eluent);

 Lane 10: Results of Example 91 (the results of the case of using the carrier in which the mTim-3 protein was bound on the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

 Lane 11: Results of Example 92 (the results of the case of using the carrier

in which the hTim-4 protein was bound on the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

Lane 12: Results of Example 93 (the results of the case of using the carrier in which the hTim-4 protein was bound to the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

Lane 13: Results of Example 94 (the results of the case of using the carrier in which the mTim-4 protein was bound on the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

Lane 14: Results of Example 95 (the results of the case of using the carrier in which the mTim-4 protein was bound on the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent).

From Fig. 17, it has been revealed that the baculovirus can be obtained by using the carrier on which the Tim-1 protein, the Tim-3 protein or the Tim-4 protein is bound (the Tim protein-bound carrier), regardless of the origin of the Tim protein and the elution method, from the fact that a band of baculovirus marker protein gp64 was observed in the lanes 3 to 14.

In addition, it has been revealed that, when eluting by SDS, more viruses can be obtained in the order of the carrier on which the Tim3 protein is bound and the carrier on which the Tim-4 protein is bound in the same level, next the carrier on which the Tim-1 protein is bound.

It has been revealed that, when eluting using the calcium ion chelating agent, more viruses can be obtained in the order of the carrier on which the Tim-3 protein is bound, followed by the carrier on which the Tim-1 protein is bound, and the carrier to which the Tim-4 protein is bound.

[0424]

Examples 96 to 99, Comparative Examples 22-25. Obtaining of viruses by carrier on which Tim family protein is immobilized

As described below, obtaining of the viruses pertaining to the present invention was carried out using the carrier in which each of the Tim-1 protein, the

Tim-2 protein, or the Tim-4 protein, as the Tim family protein, was immobilized on the beads.

[0425]

< (1) Preparation of co-transfection cell culture supernatant >

5 Preparation of the co-transfected cell culture supernatant was carried out similarly as in “(1) Preparation of co-transfection cell culture supernatant” of Examples 84 to 95 and Comparative Examples 20 to 21.

[0426]

10 < (2) Preparation of calcium ion-containing and baculovirus-containing insect cell culture supernatant sample >

 The calcium ion-containing baculovirus solution was obtained by the same method as in “(2) Preparation of baculovirus-containing insect cell culture supernatant sample” of Examples 84 to 95 and Comparative Examples 20 to 21.

[0427]

15 < (3) Washing of beads >

 The PBS-T solution (20 μ L) containing the 30 μ g/ μ L Dynabeads Protein G (produced by Thermo Fisher Scientific Inc.) (containing 4.8 mg of the Dynabeads Protein G) was dispensed into four 1.5 mL tubes (produced by BM Equipment Co., Ltd.), and each was subjected to the washing operation.

20 [0428]

< (4) Immobilization of 6 $\times$ His tag fusion type Tim family protein on beads >

25 The carrier on which the 6 $\times$ His tag fusion type mTim-1 protein is bound, the carrier on which the 6 $\times$ His tag fusion type mTim-2 protein is bound, and the carrier on which the 6 $\times$ His tag fusion type mTim-4 protein is bound were each obtained by carrying out similarly as in “(3) Immobilization of 6 $\times$ His tag fusion type Tim family protein on beads” of Examples 80 to 83 and Comparative Examples 16 to 19.

 The types of the Tim family proteins, the carrier and the Tim family protein-(non-)bound carrier, used in each Example, are shown in the following

Table 30.

[0429]

Table 30

		Comparative Example 22	Comparative Example 23	Example 96	Example 97	Comparative Example 24	Comparative Example 25	Example 98	Example 99
Tim family protein- bound carrier	Carrier	Anti-6xHis tag antibody-bound Dynabeads Protein G carrier							
	Tim family protein	—	—	6xHis tag fusion type mouse-derived Tim-1 protein	6xHis tag fusion Type mouse-derived Tim-2 protein	6xHis tag fusion type mouse-derived Tim-4 protein			

[0430]

5 < (5) Obtaining of baculovirus by obtaining method of the present invention>

An eluate was obtained by carrying out the same method as in “(4) Obtaining of extracellular membrane vesicles by obtaining method of the present invention” of Examples 80 to 83 and Comparative Examples 16 to 19, except for using “200 μ L of the calcium ion-containing baculovirus solution” prepared in the
10 (2), instead of “200 μ L of the calcium ion-containing cell culture supernatant sample”.

[0431]

< (6) Western Blotting>

Western blotting was carried out by the same method as in “(5) Western
15 blotting” in Examples 80 to 83 and Comparative Examples 16 to 19, except for “adding 1 μ L of the 4 $\times$ sample buffer (produced by Wako Pure Chemical Industries, Ltd.) to 3 μ L of the resulting each eluate obtained by the (5) Obtaining of baculovirus by obtaining method of the present invention”, instead of “3.75 μ L of the 4 $\times$ sample buffer (produced by Wako Pure Chemical Industries, Ltd.) to 11.25
20 μ L of the resulting each eluate”, using “4 μ L of each sample for Western blotting”, instead of “15 μ L of each sample for Western blotting”, and using “the anti-baculovirus gp64 antibody” instead of “the anti-Lamp-1 antibody”.

It should be noted that the types of Tim family proteins, carrier and the eluents used to obtain the extracellular membrane vesicles from the Tim family
25 protein-(non-)bound carriers, used in each Example, and the lane numbers in

Western blotting are shown in the following Table 31.

[0432]

Table 31

		Comparative Example 22	Comparative Example 23	Example 96	Example 97	Comparative Example 24	Comparative Example 25	Example 98	Example 99
Tim family protein- bound carrier	Carrier	Anti-6xHis tag antibody-bound Dynabeads Protein G carrier							
	Tim protein	—	—	6xHis tag fusion type mouse-derived Tim-1 protein		6xHis tag fusion Type mouse-derived Tim-2 protein		6xHis tag fusion type mouse-derived Tim-4 protein	
Eluent		1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA
Lane numbers in Fig. 18		1	2	3	4	5	6	7	8

[0433]

5 <Results>

The results of Western blotting obtained are shown in Fig. 18. In Fig. 18, each lane shows the following result.

Lane 1: Results of Comparative Example 22 (the results of the case of using the carrier in which the anti-6xHis tag antibody was bound on the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

Lane 2: Results of Comparative Example 23 (the results of the case of using the carrier in which the anti-6xHis tag antibody was bound on the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

Lane 3: Results of Example 96 (the results of the case of using a carrier in which the 6xHis tag fusion type mTim-1 protein was bound on the Dynabeads protein G via the anti-6xHis tag antibody, and using the 1% SDS aqueous solution as the eluent);

Lane 4: Result of Example 97 (the results of the case of using the carrier in which the 6xHis tag fusion type mTim-1 protein was bound on the Dynabeads protein G via the anti-6xHis tag antibody, and using the TBS solution containing 1 mM EDTA as the eluent);

Lane 5: Result of Comparative Example 24 (the results of the case of using

the carrier in which the 6×His tag fusion type mTim-2 protein was bound on the Dynabeads protein G via the anti-6×His tag antibody, and using the 1% SDS aqueous solution as the eluent);

Lane 6: the result of Comparative Example 25 (the results of the case of using the carrier in which the 6×His tag fusion type mTim-2 protein was bound on the Dynabeads protein G via the anti-6×His tag antibody, and using the TBS solution containing 1 mM EDTA as the eluent);

Lane 7: Results of Example 98 (the results of the case of using the carrier in which the 6×His tag fusion type mTim-4 protein was bound on the Dynabeads protein G via the anti-6×His tag antibody, and using the 1% SDS aqueous solution as the eluent);

Lane 8: Results of Example 99 (the results of the case of using the carrier in which the 6×His tag fusion type mTim-4 protein was bound on the Dynabeads protein G via the anti-6×His tag antibody, and using the TBS solution containing 1 mM EDTA as the eluent).

From Fig. 18, when the Tim-2 protein was bound, no gp64 band of baculovirus marker protein was observed by any of the elution methods (lanes 5 to 6). On the other hand, the gp64 band was observed in any of the elution methods for the carrier on which the Tim-1 protein or the Tim-4 protein was bound (lanes 3 to 4, lanes 7 to 8).

From this result, it has been revealed that it was impossible to obtain the baculovirus with the carrier on which the Tim-2 protein was immobilized.

[0434]

Examples 100 to 105, Comparative Examples 26 to 33. Comparison of sensitivity in detection of extracellular membrane vesicles by ELISA using PS protein

As described below, the extracellular membrane vesicles derived from the K562 cell culture supernatant was detected by carrying out sandwich ELISA using a plate (well) on which an antibody against the PS protein or an exosome surface marker protein (hereinafter it may be abbreviated as “the marker protein”, in some

cases) is immobilized, and using the HRP-labeled anti-CD63 antibody, as a detection antibody.

[0435]

< (1) Preparation of culture supernatant (stock solution)>

5 The human chronic myelogenous leukemia cell strain K562, 1×10^7 cells, secreting the extracellular membrane vesicles, was cultured using 80 mL of the X-VIVO 15 medium (produced by Lonza AG) for 3 days under condition at 37°C and 5% CO₂. Then the cells were precipitated by centrifugal separation treatment (300 × G, for 5 minutes) to remove the supernatant. The precipitated
10 cells were suspended in 60 mL of the X-VIVO 15 medium containing 10 μM monensin sodium (produced by MP Biomedicals Co., Ltd) and cultured for 24 hours under condition at 37°C and 5% CO₂.

 Thereafter, the culture solution was subjected to centrifugal separation treatment (300 × G, for 5 minutes) to recover the culture supernatant. The
15 recovered culture supernatant (60 mL) was further subjected to centrifugal separation treatment three times (the first time: 300 × G, for 3 minutes, the second time: 1,200 × G, for 20 minutes, the third time: 10,000 × G, for 20 minutes) to separate impurities and obtain a supernatant (hereinafter it may be abbreviated as “the culture supernatant (stock solution)”, in some cases).

20 [0436]

< (2) Preparation of dilution series of ultracentrifugation precipitate fraction of calcium ion-containing K562 cell culture supernatant>

 The resulting culture supernatant stock solution (10 mL) in the (1) was subjected to centrifugal separation treatment (10,000 × G, for 20 minutes) to
25 separate impurities, and the supernatant was transferred to a new tube to obtain 10 mL of a centrifugal separation treated K562 cell culture supernatant. Next, 10 mL of the resulting centrifugal separation treated K562 cell culture supernatant was subjected to ultracentrifugal separation treatment (110,000 × G, for 70 minutes), the supernatant was removed, and then 10 mL of TBS was added to the

precipitate and suspended. The suspension was subjected to ultracentrifugal separation treatment ($110,000 \times G$, for 70 minutes), supernatant was removed, and then 200 μ L of TBS was added to the precipitate, and suspended to obtain an ultracentrifugation precipitate fraction of K562 cell culture supernatant. Protein concentration of the ultracentrifugation precipitate fraction of K562 cell culture supernatant was measured using a Protein Assay BCA Kit (produced by Wako Pure Chemical Industries, Ltd.), according to a protocol attached to the kit. The dilution series of the ultracentrifugation precipitate fraction of the calcium ion-containing K562 cell culture supernatant was prepared by dilution with TBS containing 2 mM CaCl_2 , so as to attain a protein concentration of each 125, 250, 500, 1000, and 2000 ng/mL.

[0437]

< (3) Preparation of HRP-labeled anti-CD63 mouse monoclonal antibody >

The anti-CD63 mouse monoclonal antibody H5C6 (100 μ L, 50 μ g) (produced by BD Biosciences) was labeled with HRP using a Peroxidase Labeling Kit-NH₂ (manufactured by Dojindo Molecular Technologies, Inc.), according to a protocol attached to the kit to obtain 200 μ L of the HRP-labeled anti-CD63 mouse monoclonal antibody. Glycerol (200 μ L) was added to and mixed with the resulting labeled antibody, and stored at -20°C as the HRP-labeled anti-CD63 mouse monoclonal antibody stock solution. The HRP-labeled anti-CD63 mouse monoclonal antibody stock solution was diluted 2,000-fold with the 2 mM CaCl_2 -containing TBS to prepare a diluted solution of the HRP-labeled anti-CD63 mouse monoclonal antibody.

[0438]

< (4) Preparation of immobilizing solutions of PS protein and anti-marker protein antibody >

Immobilizing solutions of various PS proteins and the anti-marker protein antibodies were prepared as follows. The anti-CD9 mouse monoclonal antibody M-L 13 (16 μ L, 8 μ g) (produced by BD Biosciences) and 784 μ L of a 50 mM

MOPS (pH 7.5) solution were mixed to prepare 800 μ L of the anti-CD9 antibody immobilizing solution. The anti-CD 63 mouse monoclonal antibody H5C6 (16 μ L, 8 μ g) (produced by BD Biosciences) and 784 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 800 μ L of the anti-CD 63 antibody immobilizing
5 solution. The anti-CD81 mouse monoclonal antibody JS-81 (16 μ L, 8 μ g) (produced by BD Biosciences) and 784 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 800 μ L of the anti-CD81 antibody immobilizing solution. The His tag fusion type mouse MFG-E8 protein (80 μ L, 8 μ g) (produced by R & D Systems Inc.) and 720 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to
10 prepare 800 μ L of the mMFG-E8 immobilizing solution. The His tag fusion type human MFG-E8 protein (80 μ L, 8 μ g) (produced by R & D Systems Inc.) and 720 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 800 μ L of the hMFG-E8 immobilizing solution. The His tag fusion type human Annexin V protein (40 μ L, 8 μ g) (produced by Creative BioMart) and 760 μ L of the 50 mM
15 MOPS (pH 7.5) solution were mixed to prepare 800 μ L of the hAnnexin V immobilizing solution. The Fc tag fusion type mouse Tim-1 protein (32 μ L, 8 μ g) (produced by Wako Pure Chemical Industries, Ltd.) and 768 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 800 μ L of the mTim-1 immobilizing solution. The His tag fusion type mouse Tim-2 protein (80 μ L, 8 μ g) (produced
20 by R & D Systems Inc.) and 720 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 800 μ L of the mTim-2 immobilizing solution. The Fc tag fusion type mouse Tim-3 protein (32 μ L, 8 μ g) (produced by Wako Pure Chemical Industries, Ltd.) and 768 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 800 μ L of the mTim-3 immobilizing solution. The Fc tag fusion type
25 mTim-4 protein (32 μ L, 8 μ g) (produced by Wako Pure Chemical Industries, Ltd.) and 768 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 800 μ L of the mTim-4 immobilizing solution. The Fc tag fusion type human Tim-1 protein (32 μ L, 8 μ g) (produced by Wako Pure Chemical Industries, Ltd.) and 768 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 800 μ L of the hTim-1

immobilizing solution. The Fc tag fusion type human Tim-3 protein (32 μ L, 8 μ g) (produced by Wako Pure Chemical Industries, Ltd.) and 768 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 800 μ L of the hTim-3 immobilizing solution. The Fc tag fusion type human Tim-4 protein (32 μ L, 8 μ g) (produced by Wako Pure Chemical Industries, Ltd.) and 768 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 800 μ L of the hTim-4 immobilizing solution.

[0439]

< (5) ELISA measurement >

The PS protein immobilizing solution or the anti-marker protein antibody immobilizing solution was dispensed into six wells, by 100 μ L per well for one type of a protein, to an Immuno-plate Maxisorp C96 (manufactured by Nunc A/S), and allowed to stand at 8°C overnight. After removing the dispensed solution, a blocking solution (TBS containing 25% Block Ace) was added to each well in each amount of 300 μ L, and subjected to a reaction at room temperature for 1 hour, while mixing at 500 rpm using a plate mixer. After the blocking solution was removed, for the wells on which the resulting PS protein or anti-marker protein antibody was immobilized, each 100 μ L of the dilution series of the calcium ion-containing K562 cell culture supernatant ultracentrifugation precipitate fraction, having each a protein concentration of 125, 250, 500, 1000, or 2000 ng/mL, was added to each of 5 wells, and 100 μ L of TBS containing 2 mM CaCl_2 was each added, as a blank, to 1 well, and the mixture was subjected to a reaction at room temperature for 1 hour, while mixing at 500 rpm using the plate mixer. After washing three times with 300 μ L of TBS-T containing 2 mM CaCl_2 , 100 μ L of the diluted HRP-labeled anti-CD63 mouse monoclonal antibody solution was added to each well, and the mixture was subjected to a reaction at room temperature for 1 hour, while mixing at 500 rpm using the plate mixer. After washing five times with 300 μ L of TBS-T containing 2 mM CaCl_2 , 100 μ L of the TMB solution (produced by Wako Pure Chemical Industries, Ltd.) was added to each well, and subjected to a standing reaction at room temperature for 30 minutes. After

stopping the reaction by the addition of 100 μ L of 1 M HCl, absorbance at 450 nm was measured with a microplate reader Tecan Ultra (produced by Tecan Ltd.).

It should be noted that the proteins immobilized on the plate and possibility of detection (results), in each Example and Comparative Example, are shown in the following Table 32.

[0440]

Table 32

	Comparative Example 26	Comparative Example 27	Comparative Example 28	Comparative Example 29	Comparative Example 30	Comparative Example 31	Comparative Example 32
Protein immobilized on a plate	—	Anti-CD9	Anti-CD63	Anti-CD81	His tag fusion type mouse-derived MFG-E8	His tag fusion type human-derived MFG-E8	His tag fusion type human-derived hAnnexin V
Capability of detection	X	Δ	Δ	Δ	Δ	Δ	Δ
Name of lanes in Fig. 19	Blank	Anti-CD9	Anti-CD63	Anti-CD81	mMFG-E8	hMFG-E8	hAnnexin V

	Example 100	Comparative Example 33	Example 101	Example 102	Example 103	Example 104	Example 105
Protein immobilized on a plate	Fc tag fusion type mouse-derived Tim-1 protein	Fc tag fusion type mouse-derived Tim-2 protein	Fc tag fusion type mouse-derived Tim-3 protein	Fc tag fusion type mouse-derived Tim-4 protein	Fc tag fusion type human-derived Tim-1 protein	Fc tag fusion type human-derived Tim-3 protein	Fc tag fusion type human-derived Tim-4 protein
Capability of detection	○	Δ	○	⊙	○	○	⊙
Name of lanes in Fig. 19	mTim-1	mTim-2	mTim-3	mTim-4	hTim-1	hTim-3	hTim-4

[0441]

10 <Results>

The results of the ELISA measurement obtained are shown in Fig. 19. Fig. 19 shows each of detection signals (absorbance at 450 nm) derived from the HRP-labeled anti-CD63 mouse monoclonal antibody bound to exosomes contained in each protein concentration dilution series of the calcium ion-containing K562 cell culture supernatant ultracentrifugation precipitate fraction in the wells on which the PS protein or the anti-marker protein antibody was immobilized. The horizontal axis shows the type of the PS protein or the anti-marker protein antibody immobilized on the well, and in the detection results for the wells on which the same PS protein or the like was immobilized, protein

concentration in the calcium ion-containing K562 cell culture supernatant ultracentrifugation precipitate fraction used is 0, 125, 250, 500, 1000, 2000 ng/mL in the order from the left. In addition, the vertical axis shows the detection signal derived from the HRP-labeled anti-CD63 mouse monoclonal antibody bound to the exosome contained in each protein concentration dilution series of the K562 cell culture supernatant ultracentrifugation precipitate fraction.

In the wells, on which each of the Tim-1 protein, the Tim-3 protein, or the Tim-4 protein was immobilized, the extracellular membrane vesicles are detectable in higher sensitivity (Examples 100 to 105), as compared with the wells on which the anti-CD9 antibody, the anti-CD63 antibody or the anti-CD81 antibody, which is the anti-marker protein antibody, was each immobilized, the wells on which the MFG-E8 or the Annexin V, which is a PS protein, was each immobilized, and the well on which the Tim-2 protein, which is the Tim family protein, was immobilized (Comparative Examples 27 to 33). That is, it has been revealed that the detection method of the present invention, using the Tim protein pertaining to the present invention, is capable of detecting the extracellular membrane vesicles in higher sensitivity, as compared with the conventional methods. In particular, it has been revealed that the extracellular membrane vesicles can be detected in particularly high sensitivity by using the Tim-4 protein among the Tim proteins.

[0442]

Examples 106 to 109. Comparison of sensitivity in detection of extracellular membrane vesicles by ELISA by difference in Tim protein immobilization method

As described below, detection sensitivity of the extracellular membrane vesicles was compared in the case where the Tim-1 protein or the Tim-4 protein was each immobilized directly on a plate, with the case where the SH-group biotin-labeled Tim-1 protein or the SH-group biotin-labeled Tim-4 protein was each immobilized on the plate via streptavidin.

[0443]

< (1) Preparation of ultracentrifugation precipitate fractions of K562 cell culture

supernatant>

The dilution series of the ultracentrifugation precipitate fractions of the calcium ion-containing K562 cell culture supernatant was prepared by the same method as in “(2) Preparation of ultracentrifugation precipitate fraction of calcium ion-containing K562 cell culture supernatant” of Examples 100 to 105 and Comparative Examples 26 to 33, except for “diluting the ultracentrifugation precipitate fraction of the calcium ion-containing K562 cell culture supernatant with TBS containing 2 mM CaCl_2 , so as to attain a protein concentration of each 500, 1000 ng/mL”, instead of “diluting the ultracentrifugation precipitate fraction of the calcium ion-containing K562 cell culture supernatant with TBS containing 2 mM CaCl_2 , so as to attain a protein concentration of each 125, 250, 500, 1000, 2000 ng/mL”.

[0444]

< (2) Preparation of HRP-labeled anti-CD63 mouse monoclonal antibody>

The diluted solution of the HRP-labeled anti-CD63 mouse monoclonal antibody was prepared by the same method as in “(3) Preparation of HRP-labeled anti-CD63 mouse monoclonal antibody” of Examples 100 to 105 and Comparative Examples 26 to 33.

[0445]

< (3) Preparation of biotin-labeling and immobilizing solution of Tim-1 protein and Tim-4 protein>

The Fc tag fusion type mouse-derived Tim-1 protein 40 μL , (10 μg) (produced by Wako Pure Chemical Industries, Ltd.), and 40 μL (10 μg) of the Fc tag fusion type mouse-derived Tim-4 protein (produced by Wako Pure Chemical Industries Ltd.) were each labeled with biotin using the Biotin Labeling Kit-SH (produced by Dojindo Molecular Technologies, Inc.), according to a protocol attached to the kit to obtain the SH-group biotin-labeled Fc tag fusion type mTim-1 protein, and the SH-group biotin-labeled Fc tag fusion type mTim-4. Protein concentrations of the SH-group biotin-labeled Fc tag fusion type mTim-1 protein,

and the SH-group biotin-labeled Fc tag fusion type mTim-4 protein were each measured using the Protein Assay BCA Kit (produced by Wako Pure Chemical Industries, Ltd.), according to a protocol attached to the kit. The SH-group biotin-labeled Fc tag fusion type mTim-1 protein solution and the SH-group biotin-labeled Fc tag fusion type mTim-4 protein solution were each prepared by diluting these with TBS, so as to attain a protein concentration of 5 µg/mL.

The Fc tag fusion type mouse-derived Tim-1 protein (produced by Wako Pure Chemical Industries, Ltd.), or the Fc tag fusion type mouse-derived Tim-4 protein (8 µL, (2 µg) (produced by Wako Pure Chemical Industries Ltd.), and 392 µL of the 50 mM MOPS (pH 7.5) solution were mixed to prepare each of 400 µL of the mTim-1 protein immobilizing solution or the mTim-4 protein immobilizing solution.

In addition, 2 µL (10 µg) of streptavidin (produced by Wako Pure Chemical Industries, Ltd.), and 998 µL of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 1000 µL of the streptavidin immobilizing solution.

[0446]

< (4) Immobilization >

Each of the protein immobilizing solutions was added to three wells by each 100 µL (0.5 µg) per well of the Immuno-plate Maxisorp C96 (manufactured by Nunc A/S), and the plate was allowed to stand at 8°C overnight. After removal of the added solution, a blocking solution (TBS containing 25% Block Ace) was added to each well each 300 µL, and the mixture was subjected to a reaction at room temperature for 1 hour, while mixing at 500 rpm using the plate mixer.

In addition, the streptavidin immobilizing solution was added to six wells by each 100 µL (0.5 µg) per well of the Immuno-plate Maxisorp C96 (produced by Nunc A/S), and the plate was allowed to stand at 8°C overnight. After removal of the added solution, the blocking solution (TBS containing 25% Block Ace) was added to each well each 300 µL, and the mixture was subjected to a reaction at

room temperature for 1 hour while mixing at 500 rpm using the plate mixer. After removal of the blocking solution, the SH-group biotin-labeled Fc tag fusion type mTim-1 protein solution and the SH-group biotin-labeled Fc tag fusion type mTim-4 protein solution were added to 3 wells by each 100 μ L (0.5 μ g) per well, and the mixture was subjected to a reaction at room temperature for 1 hour, while mixing at 500 rpm using the plate mixer.

[0447]

< (5) ELISA measurement >

The ELISA measurement was carried out by the same method as in Examples 100 to 105 and Comparable Examples 26 to 33, except for each adding “each 100 μ L of the calcium ion-containing dilution series of the ultracentrifugation precipitate fraction of the K562 cell culture supernatant, having a protein concentration of 500 or 1000 ng/mL, to each well of two wells on which each protein was immobilized,” instead of each adding “for the wells on which the resulting PS protein or anti-marker protein antibody was immobilized, each 100 μ L of the dilution series of the calcium ion-containing K562 cell culture supernatant ultracentrifugation precipitate fraction, having each a protein concentration of 125, 250, 500, 1000, or 2000 ng/mL, was added to each of 5 wells”.

It should be noted that the proteins immobilized on the plate, the methods for immobilizing the protein on the plate, and possibility of detection (result), in each Example and Comparative Example, are shown in the following Table 33. Possibility of detection in Table 33 is each comparison between Examples 106 and 107, and between Examples 108 and 109.

[0448]

Table 33

	Example 106	Example 107	Example 108	Example 109
Immobilized protein	Fc tag fusion type mouse-derived Tim-1 protein	SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-1 protein	Fc tag fusion type mouse-derived Tim-4 protein	SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein
Immobilization method	Direct immobilization	Biotin-streptavidin binding	Direct immobilization	Biotin-streptavidin binding
Possibility of detection	○	◎	○	◎
Name of lane in Fig. 20	mTim-1	bmTim-1/SA	mTim-4	bmTim-4/SA

The results of the ELISA measurement obtained are shown in Fig. 20. Fig. 20 shows detection signals (absorbance at 450 nm) derived from the HRP-labeled anti-CD63 mouse monoclonal antibody bound to exosomes contained in each protein concentration dilution series of the ultracentrifugation precipitate fraction of the calcium ion-containing K562 cell culture supernatant, in the wells on which the mTim-1 protein was directly immobilized on a plate, the wells on which the mTim-4 protein was directly immobilized on a plate, the wells on which the mTim-1 protein was immobilized by biotin-streptavidin binding, and the wells on which the mTim-4 protein was immobilized by biotin-streptavidin binding.

The horizontal axis shows the type of the Tim proteins immobilized on the well. In addition, the vertical axis shows detection signal derived from the HRP-labeled anti-CD63 mouse monoclonal antibody bound to the exosome contained in each protein concentration dilution series of the ultracentrifugation precipitate fraction of the calcium ion-containing K562 cell culture supernatant.

From Fig. 20, it has been revealed that the extracellular membrane vesicles in the sample can be detected, according to ELISA using the Tim-1 protein or the Tim-4 protein, irrespective of the immobilization method of the Tim protein on the plate (Examples 106 to 109). In particular, the extracellular membrane vesicles can be detected in higher sensitivity in the wells on which the Tim protein was immobilized via streptavidin (Example 107, wherein the plate and the Tim protein were bound by binding of biotin of the SH-group of the mTim-1

and streptavidin, and Example 109, wherein the plate and the Tim protein were bound by binding of biotin of the SH-group of the mTim-4 and streptavidin), as compared with the wells in which the Tim protein was immobilized directly on the plate (Example 106, wherein the mTim-1 was immobilized directly to the plate, and Example 108, wherein the mTim-4 was immobilized directly on the plate).

Therefore, it has been revealed that, as the binding form between the Tim protein and a solid phase, such a case is more preferable where the plate and the Tim protein are bound by binding of biotin of the SH-group of the Tim protein and streptavidin.

[0449]

Examples 110 to 115. Comparative Example 34 to 39. Comparison of sensitivity in detection of viruses by ELISA using PS protein

As described below, baculovirus in the baculovirus-containing insect cell culture supernatant sample was detected by carrying out a sandwich ELISA using a plate on which various PS proteins or the antibody against baculovirus surface marker protein gp64 was immobilized, and using the HRP-labeled anti-gp64 antibody as a detection antibody.

[0450]

< (1) Preparation of co-transfection cell culture supernatant >

Co-transfection cell culture supernatant was prepared by the same method as in “(1) Preparation of co-transfection cell culture supernatant” of Examples 84 to 95 and Comparative Examples 20 to 21.

[0451]

< (2) Preparation of calcium ion-containing and baculovirus-containing insect cell culture supernatant sample >

The calcium ion-containing baculovirus solution was obtained similarly as in “(2) Preparation of baculovirus-containing insect cell culture supernatant sample” of Examples 84 to 95 and Comparative Examples 20 to 21.

[0452]

< (3) Preparation of dilution series of baculovirus-containing insect cell culture supernatant sample >

The baculovirus-containing insect cell culture supernatant sample (50 μ L) and 4950 μ L of the PSFM-J1 medium were mixed to prepare a 100-fold diluted solution, then 2.0 mL of the 100-fold diluted solution and 2.0 mL of the PSFM-J1 medium were mixed to prepare 4.0 mL of the 200-fold diluted solution, then 2.0 mL of the 200-fold diluted solution and 2.0 mL of the PSFM-J1 medium were mixed to prepare 4.0 mL of a 400-fold diluted solution, and then 2.0 mL of the 400-fold diluted solution and 2.0 mL of the PSFM-J1 medium were mixed to prepare 4.0 mL of a 800-fold diluted solution.

[0453]

< (4) Preparation of HRP-labeled anti-gp64 mouse monoclonal antibody>

The anti-gp64 mouse monoclonal antibody AcV1 200 μ L, (100 μ g) (produced by Novus Biologacals LLC) was labeled with HRP using the Peroxidase Labeling Kit-NH₂ (produced by Dojindo Molecular Technologies, Inc.), according to a protocol attached to the kit to obtain 200 μ L of the HRP-labeled anti-gp64 mouse monoclonal antibody solution. The HRP-labeled anti-gp64 mouse monoclonal antibody solution was diluted 1,000-fold with TBS containing 2 mM CaCl₂ to prepare a diluted solution of the HRP-labeled anti-gp64 mouse monoclonal antibody.

[0454]

< (5) Preparation of immobilizing solutions of PS protein and anti-gp64 antibody>

As described below, the immobilizing solutions of various PS proteins and marker proteins were prepared. The anti-gp64 mouse monoclonal antibody AcV1 (12 μ L, 6 μ g) (produced by Novus Biologicals LLC) and 588 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 600 μ L of the anti-gp64 antibody immobilizing solution. The His tag fusion type mouse-derived MFG-E8 protein (60 μ L, 6 μ g) (produced by R & D Systems Inc.) and 540 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 600 μ L of the mMFG-E8

immobilizing solution. The His tag fusion type human-derived MFG-E8 protein (60 μ L, 6 μ g) (produced by R & D Systems Inc.) and 540 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 600 μ L of the hMFG-E8 immobilizing solution. The His tag fusion type human-derived Annexin V protein (30 μ L, 6 μ g) (produced by Creative BioMart) and 570 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 600 μ L of the hAnnexin V immobilizing solution. The Fc tag fusion type mouse-derived Tim-1 protein (24 μ L, 6 μ g) (produced by Wako Pure Chemical Industries, Ltd.) and 576 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 600 μ L of the mTim-1 immobilizing solution. The His tag fusion type mouse-derived Tim-2 protein (60 μ L, 6 μ g) (produced by R & D Systems Inc.) and 540 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 600 μ L of the mTim-2 immobilizing solution. The Fc tag fusion type mouse-derived Tim-3 protein (24 μ L, 6 μ g) (produced by Wako Pure Chemical Industries, Ltd.) and 576 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 600 μ L of the mTim-3 immobilizing solution. The Fc tag fusion type mouse-derived Tim-4 protein (24 μ L, 6 μ g) (produced by Wako Pure Chemical Industries, Ltd.) and 576 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 600 μ L of mTim-4 immobilizing solution. The Fc tag fusion type human-derived Tim-1 protein (24 μ L, 6 μ g) (produced by Wako Pure Chemical Industries, Ltd.) and 576 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 600 μ L of the hTim-1 immobilizing solution. The Fc tag fusion type human-derived Tim-3 protein (24 μ L, 6 μ g) (produced by Wako Pure Chemical Industries, Ltd.) and 576 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 600 μ L of the hTim-3 immobilizing solution. The Fc tag fusion type human-derived Tim-4 protein (24 μ L, 6 μ g) (produced by Wako Pure Chemical Industries, Ltd.) and 576 μ L of the 50 mM MOPS (pH 7.5) solution were mixed to prepare 600 μ L of the hTim-4 immobilizing solution.

[0455]

< (6) ELISA measurement >

The PS protein immobilizing solution or anti-gp64 antibody immobilizing solution was dispensed into the Immuno-plate Maxisorp C96 (produced by Nunc A/S), each five wells for one type of a protein, by 100 μ L per well, and allowed to stand at 8°C overnight. After removing the dispensed solution, each 300 μ L of a blocking solution (TBS containing 25% Block Ace) was added to each well, and subjected to a reaction at room temperature for 1 hour, while mixing at 500 rpm using the plate mixer. After removal of the blocking solution, for the resulting wells on which the PS protein or the anti-gp64 antibody was immobilized, each 100 μ L of the calcium ion-containing and baculovirus-containing insect cell culture supernatant sample dilution series (100-fold diluted, 200-fold diluted, 400-fold diluted, 800-fold diluted) prepared in (3) was added to each well of 4 wells, and 100 μ L of the PMSF-J1 medium as a blank was added to 1 well, and the mixture was subjected to a reaction at room temperature for 1 hour, while mixing at 500 rpm using the plate mixer. After washing three times with 300 μ L of the 2 mM CaCl_2 -containing TBS-T, 100 μ L of the HRP-labeled anti-gp64 mouse monoclonal antibody diluted solution was added to each well, and the mixture was subjected to a reaction at room temperature for 1 hour, while mixing at 500 rpm using the plate mixer. After washing five times with 300 μ L of the 2 mM CaCl_2 -containing TBS-T, 100 μ L of the TMB solution (produced by Wako Pure Chemical Industries, Ltd.) was added to each well, and subjected to a standing reaction at room temperature for 30 minutes. After stopping the reaction by the addition of 100 μ L of 1 M HCl, absorbance at 450 nm was measured with the microplate reader Tecan Ultra (produced by Tecan Ltd.).

It should be noted that proteins immobilized on the plate, and possibility of detection (results), in each Example and Comparative Example, are shown in the following Table 34.

[0456]

Table 34

	Comparative Example 34	Comparative Example 35	Comparative Example 36	Comparative Example 37	Comparative Example 38	Example 110
Protein immobilized on a plate	—	Anti-gp64 antibody	His tag fusion type mouse-derived MFG-E8	His tag fusion type human-derived MFG-E8	His tag fusion type human-derived Annexin V	Fc tag fusion type mouse-derived Tim-1 protein
Capability of detection	X	Δ	Δ	Δ	Δ	○
Name of lanes in Fig. 21	Blank	Anti-gp64	mMFG-E8	hMFG-E8	hAnnexin V	mTim-1

	Comparative Example 39	Example 111	Example 112	Example 113	Example 114	Example 115
Protein immobilized on a plate	His tag fusion type mouse-derived Tim-2 protein	Fc tag fusion type mouse-derived Tim-3 protein	Fc tag fusion type mouse-derived Tim-4 protein	Fc tag fusion type human-derived Tim-1 protein	Fc tag fusion type human-derived Tim-3 protein	Fc tag fusion type human-derived Tim-4 protein
Capability of detection	Δ	○	⊙	○	○	⊙
Name of lanes in Fig. 21	mTim-2	mTim-3	mTim-4	hTim-1	hTim-3	hTim-4

[0457]

5 <Results>

The results of the ELISA measurement obtained are shown in Fig. 21. Fig. 21 shows detection signal (absorbance at 450 nm) derived from the HRP-labeled anti-gp64 mouse monoclonal antibody bound to exosomes contained in each dilution series of the calcium ion-containing and baculovirus-containing insect cell culture supernatant in the wells, on which various PS proteins or the anti-gp64 antibody was immobilized. The horizontal axis shows the types of the PS proteins or the anti-marker protein antibody immobilized on the well, and the detection results for the wells, on which the same PS protein or the like was immobilized, were shown in the order from left, blank, 800-fold dilution, 400-fold dilution, 200-fold dilution, and 100-fold dilution, in the dilution series of the calcium ion-containing and baculovirus-containing insect cells culture supernatant sample used. In addition, the vertical axis shows detection signal (absorbance at 450 nm) derived from the HRP-labeled anti-gp64 mouse monoclonal antibody.

In the wells, on which the Tim-1 protein, the Tim-3 protein, or the Tim-4

protein was each immobilized, viruses were detectable in higher sensitivity (Examples 110 to 115), as compared with the wells, on which the anti-gp64 antibody which is an antibody against a surface marker protein of baculovirus was immobilized, the wells on which the PS protein MFG-E8, or the Annexin V was
5 immobilized was immobilized, and the well, on which the Tim family Tim-2 protein was immobilized (Comparative Example 34 to 39). That is, it has been revealed that the detection method of the present invention using the Tim protein pertaining to the present invention is capable of detecting viruses in higher sensitivity, as compared with the conventional methods. In particular, it has been revealed that
10 the viruses can be detected in particularly higher sensitivity by using the Tim-4 protein among the Tim proteins.

[0458]

Examples 116 to 119. Obtaining of viruses by carrier on which Tim protein is immobilized

15 Obtaining of the viruses pertaining to the present invention was carried out using the carrier on which the biotin-labeled Tim-4 protein was immobilized.

[0459]

< (1) Preparation of co-transfection cell culture supernatant >

The co-transfection cell culture supernatant was prepared similarly as in
20 “(1) Preparation of co-transfection cell culture supernatant” of Examples 84 to 95 and Comparative Examples 20 to 21.

[0460]

< (2) Preparation of calcium ion-containing and baculovirus-containing insect cell culture supernatant sample >

25 The calcium ion-containing and baculovirus-containing insect cell culture supernatant sample was obtained by carrying out similarly as in “(2) Preparation of baculovirus-containing insect cell culture supernatant sample” of Examples 84 to 95 and Comparative Examples 20 to 21.

[0461]

< (3) Preparation of diluted solution of baculovirus-containing insect cell culture supernatant sample >

The calcium ion-containing and baculovirus-containing insect cell culture supernatant sample (100 μ L) was mixed with 800 μ L of the PSFM-J1 medium to
5 prepare 900 μ L of a nine-fold diluted solution.

[0462]

< (4) Biotin labeling of SH-group of Tim-4 protein>

For 100 μ L of the PBS solution containing the Fc tag fusion type mouse-derived Tim-4 protein (produced by Wako Pure Chemical Industries, Ltd.)
10 (containing 10 μ g of the Fc tag fusion type mouse-derived Tim-4 protein), the SH-group of the Fc tag fusion type mouse-derived Tim-4 protein was labeled with biotin using the Biotin Labeling Kit-SH (produced by Dojindo Molecular Technologies, Inc.), according to a protocol attached to the kit to obtain 100 μ L of the PBS solution containing the SH-group biotin-labeled Fc tag fusion type
15 mTim-4 protein.

[0463]

< (5) Dilution of tag fused Tim protein>

The PBS solution (5 μ L) containing the Fc tag fusion type mTim-4 protein (produced by Wako Pure Chemical Industries, Ltd.) (containing 0.5 μ g of the Fc tag fusion type mouse-derived Tim-4 protein) was mixed with 95 μ L of TBS to
20 obtain 100 μ L of a solution containing 0.5 μ g of the biotin-unlabeled Fc tag fusion type mTim-4 protein.

The PBS solution (5 μ L) containing the SH-group biotin-labeled Fc tag fusion type mTim-4 protein prepared in the (4) (containing 0.5 μ g of the SH-group biotin-labeled Fc tag fusion type mTim-4 protein) was mixed with 95 μ L of TBS to
25 obtain 100 μ L of a solution containing 1 μ g of the biotin-labeled Fc tag fusion type mTim-4 protein.

[0464]

< (6) Washing of beads>

The PBS-T solution containing 30 µg/µL Dynabeads Protein G (5 µL) (produced by Thermo Fisher Scientific Inc.) (containing 0.3 mg of the Dynabeads Protein G) was transferred to a 1.5 mL tube (manufactured by BM Equipment Co., Ltd.), and after washing twice with 500 µL of TBS-T (TBS, 0.0005% Tween 20),
5 the tube was loaded on a magnetic stand, and the washing solution was removed.

In addition, 30 µL of the PBS solution containing a MagCapture Tamavidin 2-REV (produced by Wako Pure Chemical Industries, Ltd.) (containing 0.3 mg of the beads) was transferred to the 1.5 mL tube (manufactured by BM Equipment Co., Ltd.), and after washing twice with 500 µL of TBS-T (TBS, 0.0005% Tween
10 20), the tube was loaded on a magnetic stand to remove the washing solution.

[0465]

< (7) Immobilization of Tim protein on beads >

A solution (100 µL) containing 0.5 µg of the SH-group biotin-unlabeled Fc tag fusion type mTim-4 protein was added to the 1.5 mL tube containing 0.3 mg of
15 the Dynabeads Protein G, in a pellet state, after the washing operation, and subjected to a reaction at 8°C for 1 hour, under 1200 rpm using a thermomixer to obtain the carrier on which the SH-group biotin-unlabeled Fc tag fusion type mTim-4 was bound (it may be abbreviated as “the biotin-unlabeled Fc tag fusion type mTim-4 carrier”, in some cases).

In addition, 100 µL of a solution containing 0.5 µg of the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was added to the 1.5 mL tube containing 0.3 mg of the MagCapture Tamavidin 2-REV after the washing operation, and allowed to bind on the beads similarly as above to obtain the
20 carrier on which the SH-group biotin-labeled Fc tag fusion type mTim-4 was bound (it may be abbreviated as “the biotin-labeled Fc tag fusion type mTim-4 carrier”, in some cases).

It should be noted that, the resulting these two types of carriers may be abbreviated collectively as “the Tim protein-bound carrier” in some cases.

[0466]

< (8) Obtaining of baculovirus by obtaining method of the present invention>

The resulting these Tim protein-bound carriers above were subjected to the washing operation three times with 250 μ L of TBS-T (TBS, 0.0005% Tween 20) to obtain the Tim protein-bound carrier in a pellet state. Subsequently, 100 μ L of the diluted solution of the calcium ion-containing and baculovirus-containing insect cell culture supernatant prepared in the (3) was added to each of the resulting two kinds of Tim protein-bound carriers, in pellet state, and the mixture was subjected to a reaction at 8°C, for 12 hours under 1200 rpm using a thermomixer. Thereafter, the Tim protein-bound carrier after the reaction was subjected to the washing operation three times with each 250 μ L of the calcium ion-containing TBS-T (Tris buffer, 0.0005% Tween 20, 2 mM CaCl_2). At the third time of the washing operation, 250 μ L of the CaCl_2 -containing TBS-T solution containing the Tim protein-bound carrier was each dispensed into two 1.5 mL tubes by 125 μ L, and the tubes were loaded on a magnetic stand and then the washing solution was removed.

The 1% SDS aqueous solution (50 μ L) or 25 μ L of the TBS solution containing 1 mM EDTA, each as the eluent, was added to 0.15 mg of two kinds of the Tim protein-bound carriers, in a pellet state, and then they were mixed using a vortex mixer for 10 seconds and spun down. The TBS solution containing 1 mM EDTA (25 μ L) was added again to the tube to which EDTA had been added, and the same operation was carried out to obtain the eluate.

It should be noted that the types of Tim proteins, carriers, and the Tim protein-(non) bound carriers, used in each Example, are shown in the following Table 35.

[0467]

Table 35

		Example			
		116	117	118	119
Tim protein-bound carrier	Carrier	Dynabeads protein G	Dynabeads protein G	MagCapture Tamavidin REV-2	MagCapture Tamavidin REV-2
	Tim protein	Biotin-unlabeled mouse-derived Tim-4 protein	Biotin-unlabeled mouse-derived Tim-4 protein	SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein	SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein

[0468]

< (9) Western blotting >

- 5 Western blotting was carried out by the same method as in “(5) Western blotting” of Examples 80 to 83 and Comparative Examples 16 to 19, except for “adding 15 μ L of the 4 $\times$ sample buffer (produced by Wako Pure Chemical Industries, Ltd.) to each 15 μ L of the eluate obtained in the (8) “Obtaining of baculovirus by obtaining method of the present invention”, instead of “adding 3.75
- 10 μ L of the 4 $\times$ sample buffer (produced by Wako Pure Chemical Industries, Ltd.) to each 11.25 μ L of the resulting eluate”, and using “the anti-baculovirus gp64 antibody” instead of “the anti-Lamp-1 antibody”.

It should be noted that the types of Tim proteins, carriers, and the eluents used for obtaining viruses from the Tim protein-bound carriers, used in each

15 Example, and the lane numbers in Western blotting are shown in the following Table 36.

[0469]

Table 36

		Example			
		116	117	118	119
Tim protein-bound carrier	Carrier	Dynabeads protein G	Dynabeads protein G	MagCapture Tamavidin REV-2	MagCapture Tamavidin REV-2
	Tim protein	Biotin-unlabeled mouse-derived Tim-4 protein	Biotin-unlabeled mouse-derived Tim-4 protein	SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein	SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein
Eluent		1% SDS	1 mM EDTA	1% SDS	1 mM EDTA
Lane numbers in Fig. 22		1	2	3	4

[0470]

<Results>

The results of Western blotting obtained are shown in Fig. 22. In Fig. 22, each lane is the result of the following:

5 Lane 1: Results of Example 116 (the results of the case of using the carrier in which the SH-group biotin-unlabeled Fc tag fusion type mTim-4 protein was bound on the Dynabeads protein G, and using the 1% SDS aqueous solution as the eluent);

10 Lane 2: Results of Example 117 (the results of the case of using the carrier in which the SH-group biotin-unlabeled Fc tag fusion type mTim-4 protein was bound on the Dynabeads protein G, and using the TBS solution containing 1 mM EDTA as the eluent);

15 Lane 3: Results of Example 118 (the results of the case of using the carrier in which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound on the MagCapture Tamavidin REV-2, and using the 1% SDS aqueous solution as the eluent);

20 Lane 4: Results of Example 119 (the results of the case of using the carrier in which the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was bound on the MagCapture Tamavidin REV-2, and using the TBS solution containing 1 mM EDTA as the eluent).

From Fig. 22, it has been revealed that the viruses cannot be obtained by using the carrier on which the SH-group biotin-unlabeled or labeled Tim-4 protein was bound, from the fact that a band of gp64, which is a marker protein of baculovirus, was observed in any cases of the lanes 1 to 4.

25 In addition, it has been revealed that more viruses can be obtained in immobilization on beads (carrier) via the SH-group of the Tim protein than immobilization via the tag, in the case where the elution is carried out with the calcium chelating agent, from comparison between lane 2 and lane 4

[0471]

Examples 120 to 121, Comparative Examples 40 to 41. Comparison of detection sensitivity of extracellular membrane vesicles by flow cytometer

As described below, the extracellular membrane vesicles derived from the K562 cell culture supernatant was detected by the flow cytometer, using the carrier on which the Tim-4 protein or the antibody against CD63 of a surface marker protein of exosome was immobilized, and the PE-labeled anti-CD63 antibody as the detection antibody.

[0472]

< (1) Preparation of calcium ion-containing culture supernatant (stock solution) >

The human chronic myelogenous leukemia cell strain K562, 1×10^7 cells, secreting the extracellular membrane vesicles, was cultured for 3 days under condition at 37°C and 5% CO₂, using 80 mL of the X-VIVO 15 medium (produced by Lonza AG). Then the cells were precipitated by centrifugal separation treatment (300 × G, for 5 minutes) to remove the supernatant. The precipitated cells were suspended in 60 mL of the X-VIVO 15 medium containing 10 μM monensin sodium (produced by MP Biomedicals Co., Ltd) and cultured for 24 hours under condition at 37°C and 5% CO₂.

Thereafter, the culture solution was subjected to centrifugal separation treatment (300 × G, for 5 minutes) to recover the culture supernatant. The recovered culture supernatant (60 mL) was further subjected to centrifugal separation treatment three times (the first time: 300 × G, for 3 minutes, the second time: 1,200 × G, for 20 minutes, the third time: 10,000 × G, for 20 minutes) to separate impurities and obtain a supernatant (hereinafter it may be abbreviated as “the culture supernatant (stock solution)”, in some cases).

In addition, CaCl₂ was added to the resulting culture supernatant stock solution, so as to attain the final concentration of 2 mM, to obtain the 2 mM CaCl₂-containing K562 cell culture supernatant concentrated solution sample (hereinafter it may be abbreviated as “the calcium ion-containing culture supernatant (stock solution)”, in some cases).

[0473]

< (2) Preparation of diluted solution of culture supernatant sample >

The resulting calcium ion-containing culture supernatant (stock solution) (500 μ L), and 500 μ L of the X-VIVO 15 medium were mixed to prepare 1.0 mL of a 2-fold diluted solution, then 200 μ L of the 2-fold diluted solution and 800 μ L of the X-VIVO 15 medium were mixed to prepare 1.0 mL of a 10-fold diluted solution to obtain each of the 2-fold diluted calcium ion-containing culture supernatant solution (stock solution) and the 10-fold diluted calcium ion-containing culture supernatant solution (stock solution).

10 [0474]

< (3) Biotin labeling of SH-group of Tim-4 protein>

For 100 μ L of the PBS solution containing the Fc tag fusion type mouse-derived Tim-4 protein (produced by Wako Pure Chemical Industries, Ltd.) (containing 10 μ g of the Fc tag fusion type mouse-derived Tim-4 protein), the SH-group of the Fc tag fusion type mouse-derived Tim-4 protein was labeled with biotin, using the Biotin Labeling Kit-SH (produced by Dojindo Molecular Technologies, Inc.), according to a protocol attached to the kit to obtain 100 μ L of the PBS solution containing the SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein.

20 [0475]

< (5) Washing of beads>

An Exosome-Streptavidin Isolation/Detection Reagent (20 μ L) (containing the Dynabeads Streptavidin 4.5 μ m, 1×10^7 /mL) (produced by Thermo Fisher Scientific Inc.) was dispensed into each of two 1.5 mL tubes (manufactured by BM Equipment Co., Ltd.), and the washing operation was carried out using 200 μ L of TBS.

An Exosome-Human CD63 Isolation/Detection Reagent (20 μ L) (containing the Dynabeads Anti-CD63 antibody immobilized, 4.5 μ m, 1×10^7 /mL) (produced by Thermo Fisher Scientific Inc.) was dispensed into each of two 1.5

mL tubes (manufactured by BM Equipment Co., Ltd.), and the washing operation was carried out using 200 μ L of TBS.

[0476]

< (6) Immobilization of Tim-4 protein on beads >

5 A solution (100 μ L) containing 0.1 μ g of the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was added to two 1.5 mL tubes containing the Dynabeads Streptavidin, in a pellet state, after the washing operation, and subjected to a reaction at 8°C for 30 minutes under 1200 rpm using a thermomixer to obtain a solution containing the carrier on which the SH-group
10 biotin-labeled Fc tag fusion type mTim-4 (it may be abbreviated as “the biotin-labeled Fc tag fusion type mTim-4 carrier”, in some cases) was bound, (the solution may be abbreviated as “the solution containing biotin-labeled Fc tag fusion type mTim-4 carrier”, in some cases).

[0477]

15 < (7) Reaction with extracellular membrane vesicles >

 The resulting solution (100 μ L) containing the biotin-labeled Fc tag fusion type mTim-4 carrier above was loaded on a magnetic stand, and then the solution in the solution containing the biotin-labeled Fc tag fusion type mTim-4 carrier was removed. The biotin-labeled Fc tag fusion type mTim-4 carrier, in a pellet state,
20 and the Exosome-Human CD63 Isolation/Detection Reagent, in a pellet state, after the washing operation, were washed twice with 200 μ L of TBS containing 0.1% BSA to obtain carriers, in a pellet state. Subsequently, 100 μ L of the 2-fold diluted solution of the calcium ion-containing culture supernatant (stock solution), and the 10-fold diluted solution of the culture supernatant (stock solution)
25 prepared in the (2) were each added to each of the resulting pellet-like carriers and subjected to a reaction at 8°C for 12 hours under 1,200 rpm using a thermomixer. After that, the carrier after the reaction was subjected to the washing operation once with each 300 μ L of TBS containing the calcium ion-the 0.1% BSA (TBS, 0.1% BSA, 2 mM CaCl_2), and once with 400 μ L of TBS

containing the calcium ion-0.1% BSA, and each carrier, in a pellet state, after the washing operation, was suspended in 300 μ L of TBS containing the calcium ion-the 0.1% BSA (TBS, 0.1% BSA, 2 mM CaCl_2) to obtain two types of suspension of the carriers described in the following Table 37.

5 [0478]

Table 37

	1	2
Carrier	Dynabeads Streptavidin	Exosome-Human CD63 Isolation/Detection Reagent
Tim protein	SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein	—

[0479]

< (8) Detection by PE-labeled anti-CD63 antibody >

The resulting suspension of two types of the carriers in the (7) was each
10 dispensed into two 1.5 mL tubes in each amount of 100 μ L, and pelletized by
magnetic separation, and then each 20 μ L of the PE-labeled anti-CD63 mouse
monoclonal antibody H5C6 (produced by BD Biosciences), or the PE-labeled
control mouse IgG (produced by BD Biosciences) was added and subjected to a
reaction 25°C for 1 hour under 1000 rpm using a thermomixer. Thereafter, the
15 washing operation was carried out twice with each 300 μ L of TBS containing the
calcium ion, and the 0.1% BSA (TBS, 0.1% BSA, 2 mM CaCl_2), and then the
carriers were suspended in 500 μ L of TBS containing the calcium ion, and the
0.1% BSA (TBS, 0.1% BSA, 2 mM CaCl_2). Thereafter, the filtrate filtered through
a Falcon Cell Strainer (produced by Corning Inc.) was recovered, and
20 measurement and analysis were carried out with a flow cytometer Gallios
(manufactured by Beckman Coulter, Inc.). It should be noted that laser
wavelength at the time of measurement was 488 nm, and detection wavelength
was 575 nm.

It should be noted that the types of Tim proteins, carriers and the samples,
25 used in each Example, are shown in the following Table 38.

[0480]

Table 38

	Example 120	Example 121	Comparative Example 40	Comparative Example 41
Carrier	Dynabeads Streptavidin	Dynabeads Streptavidin	Exosome-Human CD63 Isolation/Detection Reagent	Exosome-Human CD63 Isolation/Detection Reagent
Tim protein	SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein	SH-group biotin-labeled Fc tag fusion type mouse-derived Tim-4 protein	—	—
Sample	2-fold diluted calcium ion-containing culture supernatant (stock solution)	10-fold diluted calcium ion-containing culture supernatant (stock solution)	2-fold diluted calcium ion-containing culture supernatant (stock solution)	10-fold diluted calcium ion-containing culture supernatant (stock solution)

[0481]

<Results>

5 The results of the flow cytometer measurement are shown in Fig. 23. Fig. 23 shows ratio of a signal detected exosomes captured using the biotin-labeled Fc tag fusion type mTim-4 carrier and the anti-CD63 antibody carrier from the calcium ion-containing culture supernatant (stock solution), diluted at each magnification by the PE-labeled anti-CD63 mouse monoclonal antibody, and a

10 noise detected the same by the PE-labeled control mouse IgG (Signal/Noise ratio). The horizontal axis shows dilution magnification of the calcium ion-containing culture supernatant (stock solution) used, and the vertical axis shows ratio of the signal detected by the PE-labeled anti-CD63 mouse monoclonal antibody and the noise detected by the PE-labeled control mouse IgG.

15 From Fig. 23, it has been revealed that the extracellular membrane vesicles can be detected by using the carrier on which the Tim protein pertaining to the present invention is bound. In addition, it has been shown that the flow cytometer measurement can be carried out in higher Signal/Noise ratio (detection sensitivity) by using the carrier on which the Tim-4 is immobilized, as compared

20 with using the carrier on which the anti-CD63 antibody is immobilized. That is, it has been revealed that the extracellular membrane vesicles can be detected in higher sensitivity by performing the flow cytometric analysis using the Tim carrier pertaining to the present invention, as compared with the conventional method.

[0482]

Examples 122 to 123, Comparative Example 42 to 43. Obtaining of viruses by carrier on which Tim protein is immobilized

Obtaining of the viruses pertaining to the present invention was carried out
5 using the carrier on which the Tim protein was immobilized.

[0483]

< (1) Biotin labeling of SH-group in Fc tag fusion type mTim-4 protein >

The SH-group of the Fc tag fusion type mouse-derived Tim-4 protein in 100
μL of the PBS solution containing the Fc tag fusion type mouse-derived Tim-4
10 protein (produced by Wako Pure Chemical Industries, Ltd.) (containing 10 μg of
the Fc tag fusion type mouse-derived Tim-4 protein) was labeled with biotin using
the Biotin Labeling Kit-SH (produced by Dojindo Molecular Technologies, Inc.),
according to a protocol attached to the kit to obtain 100 μL of the PBS solution
containing the SH-group biotin-labeled Fc tag fusion type mTim-4 protein.

15 [0484]

< (2) Dilution of SH-group biotin-labeled Fc tag fusion type mTim-4 protein >

The SH-group biotin-labeled Fc tag fusion type mTim-4 protein- containing
TBS solution (10 μL) prepared in the (1) (containing 1 μg of the SH-group
biotin-labeled Fc tag fusion type mTim-4 protein) was mixed with 190 μL of TBS to
20 obtain 200 μL of a solution containing 1 μg of the SH-group biotin-labeled Fc tag
fusion type mTim-4 protein.

[0485]

< (3) Washing of beads >

The PBS solution (60 μL) containing the MagCapture Tamavidin 2-REV
25 (produced by Wako Pure Chemical Industries, Ltd.) (containing 0.6 mg of the
MagCapture Tamavidin 2-REV) was transferred to two 1.5 mL tubes
(manufactured by BM Equipment Co., Ltd.), and after washing each twice with
500 μL of TBS-T (TBS, 0.0005% Tween 20), the tube was loaded on a magnetic
stand to remove the washing solution.

[0486]

< (4) Immobilization of SH-group biotin-labeled Fc tag fusion type mTim-4 protein on beads>

The solution (200 μ L) containing 1 μ g of the SH-group biotin-labeled Fc tag fusion type mTim-4 protein, or 200 μ L of TBS was added to the two 1.5 mL tubes containing 0.6 mg of the MagCapture Tamavidin 2-REV, after the washing operation, and each was subjected to a reaction at 8°C for 1 hour at 1200 rpm using a thermomixer to obtain the carrier on which the SH-group biotin-labeled Fc tag fusion type mTim-4 was bound (it may be abbreviated as “the biotin-labeled Fc tag fusion type mTim-4-bound carrier”, in some cases), and the carrier on which SH-group biotin-unlabeled Fc tag fusion type mTim-4 was bound (it may be abbreviated as “the biotin-labeled Fc tag fusion type mTim-4-non-bound carrier”, in some cases). It should be noted that, the Tim protein-bound carrier and the Tim protein-non-bound carrier may be abbreviated collectively as “the Tim protein-(non-)bound carrier” in some cases.

[0487]

< (5) Obtaining of influenza virus by obtaining method of the present invention>

The resulting 2 types of the Tim protein-(non-)bound carriers above were subjected to the washing operation three times with each 500 μ L of TBS-T (Tris buffer, 0.0005% Tween 20). An influenza A virus solution (60 μ L) (H1N1 A/WS/33 strain) (ATCC Code: VR-825), containing the calcium ion added with calcium chloride at the final concentration of 2 mM, was added to each of the two types of the Tim protein-(non-)bound carriers after the washing operation, and subjected to a reaction at 8°C for 2 hours at 1200 rpm using a thermomixer. The two types of the Tim protein-(non-bound-)carriers after the reaction were subjected to the washing operation three times with each 500 μ L of the calcium ion-containing TBS-T (Tris buffer, 0.0005% Tween 20, 2 mM CaCl_2). After the third time of the washing operation, 500 μ L of the calcium ion-containing TBS-T (Tris buffer, 0.0005% Tween 20, 2 mM CaCl_2) was added to each of the two types

of the Tim protein-(non-)bound carriers and suspended to obtain each 500 μ L of suspension. The suspension was dispensed by 250 μ L into each of the two 1.5 mL tubes, and after the tubes were loaded on a magnetic stand, the washing solution was removed to obtain each Tim protein-(non-)bound carrier in a pellet state.

It should be noted that the types of the carriers and the Tim protein, used in each Example and Comparative Example, are shown in the following Table 39.

[0488]

Table 39

	Comparative Example 42	Comparative Example 43	Example 122	Example 123
Carrier	MagCapture Tamavidin2-REV	MagCapture Tamavidin2-REV	MagCapture Tamavidin2-REV	MagCapture Tamavidin2-REV
Tim protein	—	—	Biotin-labeled Fc tag fusion type Tim-4 protein	Biotin-labeled Fc tag fusion type Tim-4 protein

[0489]

Among the four 1.5 ml tubes containing the resulting 0.3 mg of the Tim protein-(non-)bound carrier in a pellet state, for one 1.5 mL tube containing the Tim protein-bound carrier, and one 1.5 mL tube containing the Tim protein-non-bound carrier, each 20 μ L of the 1% SDS aqueous solution was added as the eluent, then they were mixed using a vortex mixer at room temperature for 10 seconds, and spun down to obtain each eluate.

In addition, among the four 1.5 ml tubes containing 0.3 mg of the Tim protein-(non-)bound carrier in the pellet state, for one 1.5 mL tube containing the Tim protein-bound carrier and one 1.5 mL tube containing the Tim protein-non-bound carrier, each 10 μ L of the TBS solution containing 50 mM EDTA as the eluent was added, and they were mixed using a vortex mixer at room temperature for 10 seconds, and spun down. The TBS solution containing 50 mM EDTA was again added to each of the tubes after spun down, and they were mixed using a vortex mixer at room temperature for 10 seconds, and spun down to obtain each eluate.

The TBS solution (2.2 μ L) containing 10% β -propiolactone was added to each 20 μ L of the resulting four types of the eluates, and they were mixed using a vortex mixer and left to stand on ice for 3 hours to obtain four types of 22.2 μ L of β -propiolacton-treated eluates.

5 [0490]

< (6) Western blotting >

The TBS solution (3.3 μ L) containing 10% β -propiolactone was added to 30 μ L of the calcium ion-containing influenza A virus solution (H1N1 A/WS/33 strain) (ATCC Code: VR-825) and they were mixed using a vortex mixer. Then,
10 11.1 μ L of the 4 $\times$ sample buffer (produced by Wako Pure Chemical Industries, Ltd.) was added to the solution which had been left to stand on ice for 3 hours, and incubated at 95°C for 3 minutes to obtain an input sample for Western blotting (44.4 μ L in total). In addition, 7.4 μ L of the 4 $\times$ sample buffer (produced by Wako Pure Chemical Industries, Ltd.) was added to each 22.2 μ L of the 4 types of the
15 eluates treated with β -propiolactone, and incubated at 95°C for 3 minutes to obtain each of the eluate samples for Western blotting (29.6 μ L in total). The input sample (20 μ L) for Western blotting and each 20 μ L of the eluate sample for Western blotting were loaded on the Super Sep Ace 5-20% gel (produced by Wako Pure Chemical Industries, Ltd.), and subjected to electrophoresis at 30 mA
20 for 60 minutes. The resulting electrophoresis gel was transcribed onto the PVDF membrane (produced by Millipore Corporation) at 1.2 mA/cm² for 60 minutes using the semi-dry blotter and the discontinuous buffer (Anode buffer 1: 0.3 M Tris / 20% methanol, Anode buffer 2: 0.025 M Tris / 20% methanol, Cathode buffer: 0.025 M Tris / 0.04 M aminocaproic acid / 20% methanol). The 5 % skimmed
25 milk, diluted with TBS-T (TBS buffer, 0.1% Tween 20), was added to the post-transcription PVDF membrane, and subjected to a reaction at room temperature for 1 hour for blocking, and then subjected to a reaction at room temperature for 1 hour, with 2 mL of the anti-influenza A virus Nucleoprotein antibody C43 (produced by Abcam plc), diluted 300-fold with TBS-T. The PVDF

membrane after the reaction was washed three times with TBS-T, and reacted with the secondary antibody {anti-mouse IgG (H + L), donkey, IgG fraction, peroxidase-conjugated antibody} (produced by Jackson Immuno Research Laboratories, Inc.), diluted 30,000-fold with TBS-T at room temperature for 1 hour.

- 5 After washing 5 times with TBS-T, the ImmunoStar Zeta (produced by Wako Pure Chemical Industries, Ltd.) was added to the PVDF membrane after being subjected to a reaction with each antibody, and a luminescent signal was detected using the LAS-4000 (manufactured by GE Healthcare).

10 It should be noted that the types of carriers, Tim protein, and the eluents for elution from the carrier, used in each Example, are shown in the following Table 40.

[0491]

Table 40

	Comparative Example 42	Comparative Example 43	Example 122	Example 123
Carrier	MagCapture Tamavidin2-REV	MagCapture Tamavidin2-REV	MagCapture Tamavidin2-REV	MagCapture Tamavidin2-REV
Tim protein	—	—	Biotin-labeled Fc tag fusion type Tim-4 protein	Biotin-labeled Fc tag fusion type Tim-4 protein
Eluent	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA
Lane numbers in Fig. 24	2	3	4	5

[0492]

15 <Results>

The results of Western blotting obtained are shown in Fig. 24. In Fig. 24, each lane is the result of the following.

Lane 1: Results of electrophoresis of influenza A virus;

20 Lane 2: Results of Comparative Example 42 (the results of the case of using the biotin-labeled Fc tag fusion type mTim-4-non-bound carrier, and using the 1% SDS solution as the eluent);

Lane 3: Results of Comparative Example 43 (the results of the case of using the biotin-labeled Fc tag fusion type mTim-4-non-bound carrier, and using

the TBS solution containing 50 mM EDTA as the eluent);

Lane 4: Results of Example 122 (the results of the case of using the biotin-labeled Fc tag fusion type mTim-4-bound carrier, and using the 1% SDS solution as the eluent);

5 Lane 5: Results of Example 123 (the results of the case of using the biotin-labeled Fc tag fusion type mTim-4-bound carrier, and using the TBS solution containing 50 mM EDTA as the eluent).

From Fig. 24, it has been revealed that the influenza virus can be obtained by using the carrier on which the Tim protein was bound, from the fact that no
10 band of the Nucleoprotein, which is a marker protein of influenza A virus, was observed in any of the cases in lanes 2 to 3 (in the case where the biotin-labeled Fc tag fusion type mTim-4-non-bound carrier was used), whereas the band of the Nucleoprotein, which is a marker protein of influenza A virus, was observed in any
15 of the cases in the lanes 4 to 5 (in the case where the biotin-labeled Fc tag fusion type mTim-4-bound carrier was used).

In addition, it has been revealed that the influenza virus can be obtained efficiently by using the carrier on which the Tim protein is bound, from comparison between the lane 1 (the result of electrophoresis of the influenza A virus) and the
lanes 4 to 5 (results of using the biotin-labeled Fc tag fusion type mTim-4-bound
20 carrier).

[0493]

Examples 124 to 125, Comparative Examples 44 to 45. Obtaining of viruses by carrier on which Tim protein is immobilized

Obtaining of the viruses pertaining to the present invention was carried out
25 using the carrier on which the Tim protein was immobilized.

[0494]

< (1) Preparation of RS virus-containing HEp-2 cell culture supernatant sample >

A 10% FBS-containing D-MEM high glucose medium (20 mL) (produced by Wako Pure Chemical Industries, Ltd.) containing 1.5×10^6 cells of the HEp-2 cells

was added to a 75 cm² flask and cultured for 4 days under condition at 37°C and 5% CO₂. The supernatant was removed from the culture solution after the culture, and 5 mL of the E-MEM medium containing 2% FBS and 5.3 × 10⁵ TCID₅₀/mL RS virus (ATCC, Code: VR-26) was added, and allowed to stand for 1 hour under condition at 36°C and 5% CO₂. Additional 20 mL of the E-MEM medium containing 2% FBS was added and cultured for 3 days under condition at 36°C and 5% CO₂. The supernatant was removed from the culture solution after the culture, and 20 mL of the E-MEM medium containing 2% FBS was added to culture the cells for 2 days under condition at 36°C and 5% CO₂. Thereafter, the cells were released from the flask by pipetting, recovered together with the culture supernatant into a 50 mL centrifuge tube, and centrifuged at 1,500 rpm for 10 minutes to recover only the culture supernatant. Calcium chloride was added to the resulting culture supernatant, so as to attain the final concentration of 2 mM, and used it as “the calcium-containing RS virus solution”.

[0495]

< (2) Biotin labeling of SH-group in Fc tag fusion type mTim-4 protein >

The PBS solution (100 µL) containing the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was obtained by carrying out the same method as in < (1) Biotin labeling of SH-group in Fc tag fusion type mTim-4 protein > of Examples 122 to 123 and Comparative Example 42 to 43.

[0496]

< (3) Dilution of SH-group biotin-labeled Fc tag fusion type mTim-4 protein >

The solution (200 µL) containing 1 µg of the SH-group biotin-labeled Fc tag fusion type mTim-4 protein was obtained by carrying out the same method as in < (2) Dilution of SH-group biotin-labeled Fc tag fusion type mTim-4 protein > of Examples 122 to 123 and Comparative Examples 42 to 43.

[0497]

< (4) Washing of beads >

The MagCapture Tamavidin 2-REV, after carrying out the washing

operation, was obtained by carrying out the same method as in < (3) Washing of beads> of Examples 122 to 123 and Comparative Examples 42 to 43.

[0498]

< (5) Immobilization of SH-group biotin-labeled Fc tag fusion type mTim-4 protein on beads>

The biotin-labeled Fc tag fusion type mTim-4 protein-bound carrier, and the biotin-labeled Fc tag fusion type mTim-4 protein-(non)-bound carrier were each obtained by carrying out the same method as in < (4) Immobilization of SH-group biotin-labeled Fc tag fusion type mTim-4 protein on beads> of Examples 122 to 123 and Comparative Examples 42 to 43.

It should be noted that the biotin-labeled Fc tag fusion type mTim-4 protein-bound carrier and the biotin-labeled Fc tag fusion type mTim-4 protein-non-bound carrier may be abbreviated collectively as “the Tim protein-non-bound carrier”, in some cases.

[0499]

< (6) Obtaining of RS virus by obtaining method of the present invention>

Each 22.2 μ L of the β -propiolacton-treated eluate was obtained by carrying out the same method as in < (5) Obtaining of influenza virus by obtaining method of the present invention> of Examples 122 to 123 and Comparative Examples 42 to 43, except for using “120 μ L of the calcium ion-containing RS virus solution prepared in the (1)”, instead of “60 μ L of the influenza A virus solution (H1N1 AWS/33 strain) (ATCC Code: VR - 825) containing the calcium ion added with calcium chloride at the final concentration of 2 mM”.

It should be noted that the types of carriers and the Tim protein, used in each Example, are shown in the following Table 41.

[0500]

Table 41

	Comparative Example 44	Comparative Example 45	Example 124	Example 125
Carrier	MagCapture Tamavidin2-REV	MagCapture Tamavidin2-REV	MagCapture Tamavidin2-REV	MagCapture Tamavidin2-REV
Tim protein	—	—	Biotin-labeled Fc tag fusion type Tim-4 protein	Biotin-labeled Fc tag fusion type Tim-4 protein

[0501]

< (7) Western blotting >

- 5 Western blotting was carried out by the same method as in < (6) Western blotting > of Examples 122 to 123 and Comparative Examples 42 to 43, except for using “30 μ L of the calcium ion-containing RS virus solution” instead of “30 μ L of the calcium ion-containing influenza A virus solution (H1N1 A/WS/33 strain) (ATCC Code: VR-825)”, and using “2 mL of the anti-RS virus F protein antibody
- 10 2F7 (produced by Abcam plc), diluted 500-fold with TBS-T”, instead of “2 mL of the anti-influenza A virus nucleoprotein antibody C43 (produced by Abcam plc), diluted 300-fold with TBS-T”, and a luminescent signal was detected

It should be noted that the types of the carriers, the Tim protein, and the eluents from the carriers, used in each Example, are shown in the following Table

15 42.

[0502]

Table 42

	Comparative Example 44	Comparative Example 45	Example 124	Example 125
Carrier	MagCapture Tamavidin2-REV	MagCapture Tamavidin2-REV	MagCapture Tamavidin2-REV	MagCapture Tamavidin2-REV
Tim protein	—	—	Biotin-labeled Fc tag fusion type Tim-4 protein	Biotin-labeled Fc tag fusion type Tim-4 protein
Eluent	1% SDS	1 mM EDTA	1% SDS	1 mM EDTA
Lane numbers in Fig. 25	2	3	4	5

[0503]

<Results>

- 20 The results of Western blotting obtained are shown in Fig. 25. In Fig. 25,

each lane is the result of the following.

Lane 1: Results of electrophoresis of the RS virus;

Lane 2: Results of Comparative Example 44 (the results of the case of using the biotin-labeled Fc tag fusion type mTim-4-non-bound carrier, and using
5 the 1% SDS solution as the eluent);

Lane 3: Results of Comparative Example 45 (the results of the case of using the biotin-labeled Fc tag fusion type mTim-4-non-bound carrier, and using the TBS solution containing 50 mM EDTA as the eluent);

Lane 4: Results of Example 124 (the results of the case of using the
10 biotin-labeled Fc tag fusion type mTim-4-bound carrier, and using the 1% SDS solution as the eluent);

Lane 5: Results of Example 125 (the results of the case of using the biotin-labeled Fc tag fusion type mTim-4-bound carrier, and using the TBS solution containing 50 mM EDTA as the eluent).

15 From in Fig. 25, it has been revealed that the RS virus can be obtained by using the carrier on which the Tim protein is bound, from the fact that no band of the F protein, which is a marker protein of the RS virus, was observed in any of the cases in the lanes 2 to 3 (in the case where the biotin-labeled Fc tag fusion type mTim-4-non-bound carrier was used), whereas a band of the F protein,
20 which is a marker protein of RS virus, was observed in any of the cases in the lanes 4 to 5 (in the case where the biotin-labeled Fc tag fusion type mTim-4-bound carrier was used).

In addition, it has been revealed that the RS virus can be obtained efficiently by using the carrier on which the Tim protein is bound, from comparison
25 between the lane 1 (the result of electrophoresis of the RS virus) and the lanes 4 to 5 (result of using the biotin-labeled Fc tag fusion type mTim-4-bound carrier).

INDUSTRIAL APPLICABILITY

[0504]

The Tim protein-bound carrier of the present invention, an obtaining method and a removing method for the extracellular membrane vesicle and virus using the carrier, and the kit comprising the carrier are capable of obtaining or removing the extracellular vesicle and virus present in the sample in higher purity or in a more intact state, as well as more easily and efficiently, as compared with conventional methods for obtaining the extracellular membrane vesicle and virus, and the kit comprising the antibody or the like to be used for the obtaining method.

The Tim protein-bound carrier of the present invention, and the obtaining method of the present invention are useful, since the extracellular membrane vesicle obtained by the obtaining method of the present invention are utilized as pharmaceuticals and the like, and the obtained virus are utilized as vaccines, or vectors, and the like.

The Tim protein-bound carrier of the present invention and the removing method of the present invention are the useful ones, since the samples from which the extracellular membrane vesicle or virus is removed by the removing method of the present invention are those prevented from contamination of biological extracellular membrane vesicle or enveloped virus, and are utilized for research, or the like, using the sample.

The Tim protein-bound carrier of the present invention, the detection method for the extracellular membrane vesicle and the virus using the carrier are capable of detecting the extracellular membrane vesicle and the virus in higher sensitivity, as compared with the conventional detecting methods for detecting the extracellular membrane vesicle and virus.

The Tim protein-bound carrier of the present invention and the detection method of the present invention are useful, because according to the detection method of the present invention, even in the case of detecting a trace amount of the extracellular membrane vesicle and virus in the specimen, it is possible to carry out the measurement as it is without concentration or purification of the specimen.

CLAIMS

1. A carrier (a Tim carrier) on which a protein (a Tim protein), selected from a T-cell immunoglobulin and mucin domain-containing molecule-4 (a Tim-4) protein, a T-cell immunoglobulin and mucin domain-containing molecule-3 (a Tim-3) protein,
5 and a T-cell immunoglobulin and mucin domain-containing molecule-1 (a Tim-1) protein, is bound.
2. The Tim carrier according to claim 1, which is for capturing an extracellular membrane vesicle or a virus.
3. The Tim carrier according to claim 1, wherein the Tim protein comprises an IgV
10 domain.
4. A method for obtaining an extracellular membrane vesicle or a virus in a sample, comprising the following steps:
 - (1) a step for forming a complex of a Tim protein bound to a carrier, and the extracellular membrane vesicle or the virus in a sample, in the presence of a
15 calcium ion (complex formation step),
 - (2) a step for separating the complex and the sample (complex separation step),
 - (3) a step for separating the extracellular membrane vesicle or the virus from the complex to obtain the extracellular membrane vesicle or the virus (obtaining step).
5. The method according to claim 4, wherein the complex formation step is a step
20 for forming the complex of the Tim protein bound to the carrier, and the extracellular membrane vesicle or the virus in the sample, by contacting the Tim carrier and the extracellular membrane vesicle or the virus in the sample, in the presence of the calcium ion.
6. The method according to claim 4, wherein the complex formation step is a step
25 for forming the complex of the Tim protein bound to the carrier, and the extracellular membrane vesicle or the virus in the sample, by contacting the Tim protein, the carrier and the extracellular membrane vesicle or the virus in the sample, in the presence of the calcium ion.
7. The method according to claim 4, wherein the obtaining step is carried out

using a protein denaturing agent.

8. The method according to claim 4, wherein the obtaining step is carried out using a calcium ion chelating agent.

9. The method according to claim 4, wherein the Tim protein comprises an IgV domain.

10. A method for removing an extracellular membrane vesicle or a virus in a sample, comprising the following steps:

(1) a step for forming a complex of a Tim protein bound to a carrier, and the extracellular membrane vesicle or the virus in a sample, in the presence of a calcium ion (complex formation step),

(2) a step for separating the complex and the sample (complex separation step).

11. The method according to claim 10, wherein the complex formation step is a step for forming the complex of the Tim protein bound to the carrier, and the extracellular membrane vesicle or the virus in the sample, by contacting the Tim carrier and the extracellular membrane vesicle or the virus in the sample, in the presence of the calcium ion.

12. The method according to claim 10, wherein the Tim protein comprises an IgV domain.

13. A method for detecting an extracellular membrane vesicle or a virus in a sample, comprising the following steps:

(1) a step for forming a complex of a Tim protein bound to a carrier, and the extracellular membrane vesicle or the virus in the sample, in the presence of a calcium ion (complex formation step),

(2) a step for detecting the complex (detection step).

14. The method according to claim 13, wherein the method for detecting the extracellular membrane vesicle or the virus is an ELISA method or a flow cytometry method.

15. The method according to claim 13, wherein the Tim protein comprises an IgV domain.

16. The method according to claim 13, wherein the carrier binds to the Tim protein via an SH-group of the Tim protein.

17. A kit for capturing an extracellular membrane vesicle or a virus comprising a Tim carrier.

5 18. A kit for capturing an extracellular membrane vesicle or a virus comprising a reagent containing a Tim protein and a reagent containing a carrier.